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Recently, cholesterol metabolism has been shown to modulate the infection of 
several viruses and there is growing evidence that inflammatory response to infection 
also modulates lipid metabolism. 
However little is known about the role of inflammatory processes in modulating lipid 
metabolism and their consequences for the viral infection. 
This study investigates host-lipid viral interaction pathways using mouse 
cytomegalovirus, a large double-stranded DNA genome, which represents one of the 
few models for a natural infection of its natural host. 
In this study, transcriptomic and lipidomic profiling of macrophages shows that  
there is a specific coordinated regulation of the sterol pathways upon viral infection 
or treatment with IFN or  (but not TNFα, IL1 or IL6) resulting in the decrease of 
free cellular cholesterol. 
Furthermore, we show that pharmacological and RNAi inhibition of the sterol 
pathway augments protection against infection in vitro and in vivo and we identified 
that the prenylation branch of the sterol metabolic network was involved in the 
protective response. 
Finally, we show that genetic knock out of IFN results in a partial reduction while 
genetic knock out of Ifnar1 completely abolishes the reduction of the sterol 
biosynthetic activity upon infection. 
Overall these results support a role for part of the sterol metabolic network in 
protective immunity and show that type 1 IFN signalling is both necessary and 
sufficient for reducing the sterol metabolic network upon infection; thereby linking 
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1 Chapter 1: Introduction 
1.1 Characteristics of Cytomegalovirus 
1.1.1 Overview of the Herpes virus family 
The family of the Herpesviridae contains 8 human-pathogenic members, e.g. the 
Herpes Simplex viruses 1 and 2 (HSV1 and HSV2), the Varizella Zoster virus 
(VZV), the cytomegalovirus (CMV), the Epstein-Barr virus (EBV), and the Karposi-
Sarcoma virus (KHSV). The illnesses caused by Herpes virus infections have been 
known since antiquity, mainly that of the HSV1, an infection which causes small 
skin lesions known as cold sores. The term “Herpes” is based on the Greek 
expression for 'to creep' and reflects that Herpes viral infections spread mainly from 
cell to cell by direct cell contact. 
The Herpesviridae family (www.ictvonline.org/virusTaxonomy.asp?version=2009) 
contains in total more than 100 members, which infect a large spectrum of different 
species such as mammals, birds, reptiles and molluscs. Most of these viruses show a 
strict species specificity (Davison, Eberle et al. 2009). Members of the Herpesviridae 
share many structural properties, while differences in their biological properties 
allow a classification into three subfamilies, the alpha (α), beta- (β) and gamma- (γ) 
Herpesviridae. The classification of the families depends on their structural and 
genetic characteristics (Roizman, Carmichael et al. 1981; Pellet 2007). 
Structural properties common to all Herpes viruses: 
 The virion consists of a nucleoprotein core, which contains a linear double 
stranded DNA genome (125–290 kbp), protected by an icosahedral T-16 type 
capsid composed of 162 caspomeres. The size of the virion varies among 
species, being between 130 and 300 nm.  
 The capsid is then surrounded by an amorphous layer of viral proteins, called 
the tegument. So far, more than 30 different viral proteins are known to form 
the tegument.  
 The virion is surrounded by a lipid bilayer envelope, derived from cellular 
membranes spiked with viral proteins. 
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All Herpes viruses (except γ-herpes viruses) share also certain biological properties: 
 The genome of herpes viruses is composed of a unique long (Ul) and a 
unique short (Us) region, bounded by inverted repeats.  
 Around 70 core genes are functionally conserved between all viruses. 
 They encode a large number of enzymes involved in nucleic acid metabolism 
and protein processing. 
 The DNA synthesis and assembly of the viral capsid occurs in the cell 
nucleus. 
 Production of progeny virus results in host cell destruction 
 Herpes viruses establish a lifelong latency in their hosts. (Ds: Double 
stranded) 
 
However, millions of years of co-evolution with their host have led to specific 
properties of each Herpes virus-host system. The three subfamilies of the 
Herpesviridae are distinguished by their specific biological properties in e.g. cell 
tropism, replication time and host spectrum. 
 
The α-Herpes viruses display a broad host spectrum and a short replication time in 
cell culture. This subfamily contains the pathogens HSV1 and HSV2 and VZV. 
HSV1 and HSV2 are ubiquitously present in the human population, HSV1 is 
transmitted by contact during an acute infection and causes oral Herpes and usually 
Figure 1-1: Structure of herpes virion and genomes 
Ds:  Double stranded, HSV: Herpes simplex virus, VZV: Varizella Zoster virus, CMV: 
cytomegalovirus, UL: Unique Long, US: Unique Short. 
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infects the mucosa in the mouth causing cold sores. HSV2 or genital Herpes 
infections occur mainly as the results of sexual contact and are the cause of 
congenital Herpes infections in newborns. Both HSV1 and 2 establish latency in 
ganglia, HSV1 preferably in sensory ganglia of the face and HSV2 in the genital 
tract. VZV infection causes Varicella or Chicken Pox. During outbreaks, the virus is 
transmitted by contact or airborne droplets of respiratory mucosal fluids and finally 
VZV establishes latency in the dorsal root ganglia. The reactivation of latent virus 
then can cause Herpes Zoster or Shingles. 
 
The β-Herpes viruses are defined by a strict species specificity and cell tropism. In 
contrast to α and γ Herpes viruses, they show a slow replication rate in cell culture. 
Infection with β-Herpes viruses is characterised by enlargement of the infected cells. 
The beta Herpes virus subfamily includes the mouse and human cytomegalovirus 
(mCMV; hCMV) and human Herpesviruses 6 and 7 (HHV6 and HHV7). HHV6 and 
HHV7 are ubiquitous in the human population. HHV7 has been shown to cause 
exanthema subitum, whereas so far no disease has been linked with HHV6. 
 
The γ-Herpes viruses also display species specificity and are lymphotropic as they 
mainly infect B and T-cells (However they also have been showed to infect 
endothelial and epithelia cells). Furthermore γ-Herpes viruses are characterised by 
their short replication cycle in cell culture. This subfamily include the 
lymphocryptoviruses (γ-1) e.g. EBV and the Rhadinoviruses (γ-2) e.g.  (Karposi’s 
sarcoma associated virus (KSHV), Rhesus monkey Rhadinovirus (RRV), Equine 
Herpesevirus 2 (EHV-2) and Murine Herpes virus 68 (MHV68). 
EBV is transmitted mainly through the exchange of saliva and is the causative agent 
for Mononucleosis. One of the main characteristics of the γ-Herpes viruses is that 
their infection is oncogenic. EBV has been shown to be associated with Hodgkin’s 
Lymphoma, Nasopharyngeal carcinoma and some forms of gastric cancer arising 





1.1.2 Characteristics of the Herpes virus life cycle 
All Herpes viruses have very similar life cycles which can be divided in three phases; 
1: virus attachment and entry, and transportation of the capsid to the nucleus; 2: viral 
gene transcription and translation and synthesis of viral DNA; 3: assembly of new 
virion, enveloping and egress. 
 
1. Attachment, penetration and transport to the nucleus. 
The attachment of the virion to a cellular receptor mediated by viral glycoprotein 
complexes gH/gL/gO and gB/gB, triggers the fusion of the virus to the cell 
membrane and the penetration of the nucleocapsid inside the cytoplasm. Tegument 
proteins associate with the cytoskeleton and transport the capsid to nuclear pores, 
where it penetrates and releases the linear viral DNA-genome by a so far unknown 
mechanism. 
  
2. Viral gene transcription, translation and synthesis of viral DNA. 
In the nucleus, viral DNA utilises the host RNA polymerase II to initiate the 
transcription of viral genes. The expression of Herpes virus genes is tightly regulated 
and can be divided in three temporal phases: immediate early, early and late.  
The transcription of the viral immediate early genes starts within minutes after 
penetration of the virus and is independent of protein synthesis, for it occurs even 
under a cycloheximide-block of protein synthesis. The major function of the 
immediate early genes is to promote and enhance the expression of early and late 
genes. The induction of the transcription of the early genes is dependent on the 
cooperation of viral immediate early (IE) proteins and cellular transcription factors. 
Most of the early genes encode proteins with enzymatic properties involved in the 
replication of the viral genome. All Herpes viruses encode for an early gene which 
serves as their own DNA polymerase. This viral protein replicates the viral genome 
by a rolling circle-mechanism. This is made possible by circularisation of the linear 
viral genome in the nucleus forming a structure called episome. This allows the 
synthesis of new viral genomes as concatemers that are cleaved upon integration into 
new assembled capsids. The late genes encode structural proteins, like capsid 
proteins and the glycoproteins and their expression is only triggered by onset of the 
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viral DNA synthesis. New viral capsids are assembled in the nucleus with 
components imported from the cytoplasm (Sears and Roizman 1990). 
 
3. Assembly of new virions, enveloping and egress. 
When the temporal expression cascade of viral genes is completed, the newly 
synthesized genomes are complexed with core-protein while they are packed inside 
the newly assembled capsids, receive their tegument and are then transported out of 
the host cell. The mechanisms involved in the egress of the viruses are still not fully 
understood. Exactly how capsids leave the nucleus and gain their tegument is not 
fully characterized. Two models of viral egress of HSV 1 capsids from the 
perinuclear space are discussed in the literature (Mettenleiter 2002):  
In the first model called the de-envelopment re-envelopment process, Herpes viruses 
acquire a first envelope from the nuclear inner membrane while entering the 
perinuclear space. Virions then translocate to the ER lumen where it loses its first 
envelope by fusion with the outer nuclear or the ER membrane. Viral capsids 
associate then with the tegument compounds while they cross the cytoplasmic space 
and bud then into large cytoplasmic vesicles. During that process they receive their 
final viral envelope. The viral glycoproteins that are necessary to form the final 
envelope are transported from the ER to the trans-Golgi network and the cytoplasmic 
vesicles, where they reside until virion formation. The assembly of fully enveloped 
virions with functional glycoproteins occurs in these vesicles while they are 
transported to the cell surface. The viral particles are then released by exocytosis. 
Recently a modification of this model, named the enlarged nuclear pore model, has 
been proposed: in this model the newly assembled capsids reach the cytoplasm by 
direct transport through enlarged nuclear pores and fuse directly to the Golgi 
apparatus to receive their envelope (Wild, Engels et al. 2005). 
In the second classical model, the nuclear virions attain their full tegument and 
envelope in the nucleus and then translocate directly to the Golgi apparatus through 
the ER where they acquire a second membrane. During the transit, the envelope 
proteins are modified in situ 
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Figure 1-2: Herpes virus life cycle 
All Herpes viruses have very similar life cycles which can be divided in three phases; 1: virus attachment and entry, and 
transportation of the capsid to the nucleus; 2: viral gene transcription and translation and synthesis of viral DNA; 3: assembly of new 























All Herpes viruses have the ability to establish latency in their hosts (Chakravarty 
2008). Latency is defined as the maintenance without assemblage of infectious 
virions of the viral genome in the absence of productive infection (Reddehase, 
Podlech et al. 2002) . During latency no viral replication and no infectious particles 
are detectable and consequently, viruses evade the immune surveillance. Latent 
infections occur in most organs but only in specific cell types that form reservoirs. 
For most Herpes viruses these cell types are still not identified. This is because the 
cell types that allow establishment of latency are normally different from those that 
support the primary productive infection. Reactivation mechanisms are still not 
understood. It is thought that external stimuli drive the virus out of latency, most 
likely in periodical manner. It was shown that general inflammatory signals or 
cellular differentiation events trigger reactivation of certain Herpes viruses such as 
CMV (Reddehase, Podlech et al. 2002). Latency is to be differentiated from 
persistent infection which is defined by at long-lasting virus production, which may 
occur at a low level (Reddehase, Simon et al. 2008). 
1.1.4 Immune evasion 
Another prominent biological property of the Herpes viruses is their highly 
developed ability to counteract the immune response. Their replication cycle and 
their ability to establish latency make it necessary to escape the immune system of 
their host. First, Herpes viruses have to overcome the intrinsic defence mechanisms 
of the host cell, such as shut down of viral gene expression or apoptosis. In human 
cytomegalovirus infections the viral tegument protein pp71 (UL82) and the 71kD 
IE1 protein prevent formation of a closed chromatin structure of the viral genome 
and the viral UL36 and UL37 gene products are strong inhibitors of apoptosis 
(McCormick, Skaletskaya et al. 2003). 
Each Herpes virus has adapted to its host and developed specific mechanisms to 
evade their innate and adaptive immune responses. Viral gene products and 
microRNAs interact with different aspects of the host immune response and are able 
8 
 
to control, block or inhibit immune signalling, release of cytokines, and recognition 
by immune cells. 
1.1.5  Biology of Cytomegalovirus 
The etymology of the name Cytomegalovirus comes from the Greek “cyto”: cell and 
“megalo”: large. Indeed CMV infection induces cytopathic effects that are 
characterised by nuclear and cytoplasmic inclusions and cell rounding. In 1904, 
Ribbert was the first to specifically describe the pathology of the cytomegalovirus 

















Figure 1-3: Typical Cytomegalovirus inclusion in monocytes in the lung. 
The central cell displays the dramatically enlarged nuclei characteristic of CMV.
Histopathology of lung shows cytomegalic pneumocyte containing characteristic
intranuclear inclusion. Source: Wikipedia, this is a file from the Wikimedia Commons. 
Commons is a freely licensed media file repository 
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1.1.5.1 Pathogenesis of cytomegalovirus infection 
hCMV infection is ubiquitous and affects 50 to 80% of the population depending of 
the socio economic and geographic conditions (Western vs. developing country).The 
primary infection usually occurs during early age, and requires an exchange of body 
fluids (mainly saliva) (Wong, Tan et al. 2000). Epidemiology studies suggest that the 
entry of the virus is consecutive to contact with mucosal surfaces (Sinzger and Jahn 
1996). Circulating leukocytes and endothelial cells are believed to disseminate the 
virus in the body of the host (Dankner, McCutchan et al. 1990; Gerna, Percivalle et 
al. 2000). hCMV has been shown to infect ubiquitously distributed cell types such as 
epithelial cells, fibroblasts, and endothelial cells. hCMV also infects leukocytes such 
as macrophages, denditric cells, T cells and also specialized parenchymal cells such 
as smooth muscle cells and hepatocytes. As a consequence, a wide range of organs is 
affected by CMV infection, such as salivary glands, lungs, kidneys, the spleen, the 
liver, but also neurons and astrocytes in the brain (Ho 1995; Campbell, Cavanaugh et 
al. 2008). hCMV infection in immunocompetent individuals is normally 
asymptomatic. In some cases a primary infection may induce mononucleosis like 
symptoms, but in rare cases it may lead to pneumonia, myocarditis, haemolytic 
anaemia and other complications (Landolfo, 2003). hCMV infection becomes a life 
threatening disease for immunodeficient patients. It is the most common congenital 
viral infection in developed countries affecting 1% of all new born babies (Demmler 
1991). Foetuses are mainly infected in utero or congenitally when the mother has 
either had a primary infection during pregnancy or a reactivation of the latent virus. 
5-10% of the infected newborns display CMV related pathology such as hearing loss, 
mental retardation or other neuronal abnormalities and around 0.25% of all new born 
baby will die from CMV infection during infancy (Bale, Blackman et al. 1990). 
Postnatal infection of newborns, originate most frequently from breast milk and, 
although of higher incidence, does not display the same severity as the congenital 
infection (Demmler 1991). 
hCMV infection is a life threatening disease for immunosuppressed adults: hCMV 
infection is the most frequent opportunistic infection associated with Acquired 
Immunodeficiency Syndrome (AIDS) although hCMV pathologies in AIDS patient 
have been reduced following the use of the “Highly Active Antiretroviral Therapy” 
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(HAART). However acute infection can lead to the development of pneumonia in the 
lung, gastrointestinal and brain damage as well as retinitis leading to blindness 
(Ostrowski, Krakauer et al. 1998; Kovacs, Schluchter et al. 1999). hCMV has 
become a frequent infection in transplanted patients (Boeckh and Bowden 1995; 
Sagedal, Hartmann et al. 2005). Ultimately, patients may develop pathologies 
associated with hCMV infection, but rejection of the transplant caused by the 
inflammatory processes and the immune response to the hCMV infection or 
reactivation in the graft also occurs. hCMV infection has been associated with the 
development of atherosclerosis, although the contribution of hCMV remains 
controversial. Epidemiological and pathological studies suggested a link between 
hCMV infection and atherosclerosis (Adam, Melnick et al. 1987). Studies in cardiac 
transplant patients implicate hCMV infection as a significant factor in the 
development of coronary artery disease following transplantation (Danesh, Collins et 
al. 1997; Danesh and Appleby 1998). Since atherosclerosis is an inflammatory 
disease, it is difficult to differentiate if the effects of inflammation and disease cause 
the reactivation of hCMV or if hCMV infection triggers the inflammatory response 
and by doing so, cause the disease.  
1.1.5.2  Diagnosis and therapy for hCMV infection 
hCMV can be detected in blood, bronchial and throat washing, cerebrospinal fluid 
and urine. Several methods of detection exist to monitor hCMV particle numbers. 
The most accurate detection is the serological test using CMV specific pp65 
antibodies. PCR is also frequently used to monitor DNAemia, i.e. to detect viral 
genomes in the bloodstream. At this time there is no cure for hCMV infection, but 
antiviral drugs have been developed to slow the infection. Ganciclovir and foscarnet 
are the two main antiviral substances used nowadays against HCMV infections. 
Gancyclovir is phosphorylated by a viral kinase and inhibits the incorporation of 
dGTP by the viral DNA polymerase disrupting DNA synthesis. Foscarnet inhibits 
viral replication by blocking the docking site of the viral DNA polymerase. Several 
HCMV vaccines are in various stages of pre-clinical testing but none have been 




1.1.5.3 mCMV has a model for studying hCMV 
hCMV does not infect laboratory animals and human studies have obvious ethical 
limitations. mCMV, which shares 70 % homology of its genome as well as biological 
similarities (virion structure, life cycle and pathologies in the host), represents one of 
the few suitable mammalian models for an infection in its natural host. The mouse 
model has been extensively used to study the pathogenesis of acute, latent and 
recurrent viral infections since both mCMV and hCMV cause acute infection in 
immunocompromised hosts triggering the same clinical symptoms (Hamilton and 
Seaworth 1985; Reddehase, Balthesen et al. 1994). There are also many similarities 
in the host immune response to mCMV and hCMV infection (Mocarski and Kemble 
1996).  
1.1.5.4 mCMV characteristics 
mCMV share many characteristics with other Herpes viruses (See section 1). Mature 
virions have a diameter of 150 to 200 nm and are composed of a core, capsid, 
tegument and lipid membrane. More than 30 proteins have been purified and 
identified from the mCMV virion. The tegument is constituted of about 20 proteins 
with M83 (homolog of hCMV pp65) as major constitutive. The envelope includes 
two major Herpes virus conserved glycoprotein complexes composed of the 
glycoproteins gB, gH, gL and gO. mCMV has one of the longest genomes of the 
Herpes family composed of a linear double stranded DNA of 235 kb (Rawlinson, 
Farrell et al. 1996). mCMV virions contain a single unique sequence flanked by 
terminal repeats in contrast to the hCMV which has two unique regions (UL and US) 
(Chee, Bankier et al. 1990). 
To date no specific cellular receptor for CMV virions has been clearly identified. 
However, proteoglycan heparin sulphate has been shown to be important in the first 
step of the infection. Moreover glycoproteins gB and gH in combination with the 
epidermal growth factors receptor (EGFR) and α and β integrins have been shown to 
be important in the fusion of the viral membrane to the host (Wang, Huong et al. 
2003; Kinzler and Compton 2005).  
Like all Herpes viruses, after viral penetration and uncoating, mCMV nucleocapsids 
migrate to the nucleus and inject the viral genome into the nucleus, which then 
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circularises. The mCMV gene expression is also regulated in a strict temporal 
cascade composed of the three phases: Immediate early (IE), early (E) and late (L). 
The IE1 and IE3 gene products act as transcriptional activators of the viral and 
cellular gene expression (Keil, Ebeling-Keil et al. 1984). 
The IE gene expression is controlled by the major immediate early (MIE) enhancer. 
This enhancer contains binding sites for transcription factors such as CREB, AP1, 
NFKB and retinoic acid receptor (RAR) (Stinski and Isomura 2008). It is required 
for viral replication in vivo and in vitro. The enhancer is also thought to play a crucial 






1.2 Innate immune response to CMV infection 
1.2.1 Cells of the innate immune response to CMV infection 
After the physical barrier, innate immunity is the first defence against path. The 
innate immune system is found in fungi, plants and animals. It consists in the cells 
and mechanisms that recognize and provide immediate defence against infection 
with broad specificity. But, unlike the adaptive immune system, it does not confer 
long-lasting protective immunity against secondary infections to the host. The innate 
immune system in vertebrates assures several functions, such as the recruitment of 
immune cells to the sites of infection through the production of chemical factors 
(toxic proteins, chemokines, interleukin, cytokines etc..), the identification and 
removal of foreign substances, the activation of cells to trigger the activation of 
cellular defence mechanisms and also the promotion of clearance of dead cells and 
antibody complexes. Finally the innate immune system is able to activate the 
adaptive immune system though a process called antigen presentation. The cells of 
the innate immune system use receptors, such as the Toll like receptors (TLRs), that 
recognise molecular patterns present on a large spectrum of pathogens (pathogen 
associated patterns or PAMPs) (Gordon 2002; Akira and Takeda 2004; Beutler 
2009). Cells of the innate immune system comprise mast cells, phagocytic cells 
(macrophages, neutrophils and denditric cells (DC)), basophils, eosinophils and 
natural killer (NK) cells. These cells permanently sense the environment and are 
subdivided in many sub-cell types which have distinct functions and (micro) 
anatomical distribution. 
 
Three cell types of the innate immune system have been shown to be central for the 
control of CMV infection: NK cells, macrophages and DCs. 
NK cells are specialised cytotoxic cells involved in the elimination of viral infected 
or tumor cells (Gazit, Gruda et al. 2006). NK cells sense the neighbouring cells 
through inhibitory NK cell receptors which are specific for a cell-surface marker 
called MHC class I (major histocompatibility complex). When a compromised host 
cell presents decreased levels of MHC I, (such as tumor cells or virus-infected cells), 
it can activate NK cells due to decreased inhibitory signals consecutive to decreased 
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engagement of inhibitory receptors. Nk cells then kill the abnormal cells by secreting 
perforin and granzymes which trigger apoptosis. NK cells can also be activated and 
migrate to the site of infection in response to cytokines (IFNα/β, IL-2, IL-12, IL-15 
and IL-18) induced by infected cells. NK cells, when activated, are also able to 
secrete antiviral cytokines such as IFNγ and TNFα. NK cell functions are tightly 
regulated by the activities of both inhibitory and activating cell surface receptors that 
serve either to suppress or to activate their cytolytic function. NK cell inhibitory 
molecules include Ly49 receptors in rodents, killer cell Ig-like receptors (KIR) 
molecules in humans, and heterodimers of CD94 and NKG2A, which are found in 
both species. Whilst inhibitory NK cell receptors (NKR) are specific to MHC class I 
molecules, activating receptors use various ligand in addition to the MHC class I. 
These ligands are induced upon infection or cellular stress. NK cell activating 
receptors include KIRs in humans, Ly49H and Ly49D in mice, and NKGD, which is 
found in both species. 
Patients with NK cell defects are more susceptible for herpes viruses infections and 
particularly CMV (Biron, Byron et al. 1989). Furthermore, NK cells have been 
shown to be important in mCMV resistance (Welsh, Brubaker et al. 1991). The 
importance of NK cell in the protection of mCMV infection has been linked to the 
variation in Cmv1, a highly variable host resistance locus that regulates the efficacy 
of NK cell responsiveness. Cmv1 encodes for the receptor Ly49H, a C-type lectin-
like receptor which has been shown to recognise a mCMV protein (m157) expressed 
at the surface of infected cells. In fact, Balb/C mice lacking the NK cell receptor 
Ly49H are much more susceptible to mCMV infection than the C57Bl/6 mice that 
have it (Scalzo, Fitzgerald et al. 1990). Mice deficient in NK cells function or 
depleted of NK cell show a higher susceptibility to mCMV infection (Bukowski et 
al, 1984, Shanley 1990). However, NK cells are necessary but not sufficient in the 
control of CMV infection. 
 
Macrophages as well as DCs are professional antigen presenting cells (APC). Both 
cell types are able to display foreign antigens associated with major 
histocompatibility complex class I and II (MHC I and MHC II) on their surfaces. 
When an infection occurs, the ingestion of pathogens will result in the degradation of 
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the pathogens into peptides by specialised enzymes. The foreign peptides are then 
introduced in the MHC class II presentation pathway, which will trigger adaptive 
immune response. For the MHC class I presentation pathway, in most cells, peptides 
are generated by proteosomal degradation of endogenous cytosolic proteins and then 
transported to the ER where they are associated with the MHC class I complexes. For 
the MHC class II presentation pathway, peptides originate from endocytosed 
exogenous molecules and associate with MHC class II complexes in lysosomal 
compartments. MHC class I antigens are present in most cell and are recognised by 
CD8+ T cells while MHC class II antigens are recognized by CD4+ T cells which 
help to trigger the immune response. 
Macrophages arise from the differentiation of monocytes which circulate in blood 
and tissues. In response to inflammatory stimuli, monocytes will migrate to the site 
of inflammation and differentiate into mature macrophages. Macrophages have many 
functions in innate and adaptive immunity. First of all, macrophages act as scavenger 
cells, removing the necrotic cellular debris and pathogens by phagocytosis. The 
phagocytic function is mediated through, in one hand the Fc receptors present at the 
surface of macrophages which are able to bind antibody-coated microorganisms and 
in another hand by the TLRs which recognize a large spectrum of pathogen 
associated receptors (PAMPs) (Gordon 1998). In addition, in response to infection 
and inflammation, macrophages will produce a wide array of powerful chemical 
substances including enzymes, complement proteins, and regulatory factors such as 
cytokines (IL1β, IL6, IL12, and IL8). Particularly, macrophages will secret pro-
inflammatory cytokines such as TNFα and IL-1 which stimulate the activation of T 
cells and NK cells and trigger an antiviral response.  
Macrophages play also a role in mCMV pathogenesis. Indeed, intraperitoneal (IP) 
mCMV-infected mice induce an inflammatory response consisting largely of 
macrophages (Heise and Virgin 1995). These macrophages are activated and there is 
an increase of the expression of Fc receptors (Price, Winter et al. 1987), as well as 
MHC class II, MHC class I, and ICAM-1 (Heise and Virgin 1995). Moreover, one of 
the primary mediators of macrophage activation during MCMV infection is IFNγ 
(Heise and Virgin 1995). Macrophages are also able to produce type I interferon 
upon mCMV infection, although they are not the major contributors in response to 
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infection. Type I interferons production in macrophages in response to mCMV 
infection has been shown to be important in the expression of MHC class II 
molecules (Heise, Pollock et al. 1998). 
Macrophages and  monocytes are believed to be important in CMV dissemination of 
the virus in tissues and latency (Mitchell, Leung et al. 1996; Hanson, Slater et al. 
1999). Indeed monocytes are the predominant cell type infected in the blood but, 
when infected, monocytes are unable to start a proper viral replication cycle. Once 
activated by inflammatory signals, monocytes migrate to the loci of inflammation 
and differentiate into macrophages which allow the start of a productive infection. 
 
DCs are cells specialised in antigen presentation and link innate and adaptive 
immune response. At an immature stage of development, DCs act as sentinels in 
peripheral tissues, continuously sampling the antigenic environment. DCs are divided 
in two subtypes: Classical DC (cDC) and Plasmacytoid DCs (PDCs) which differ by 
their life span, their locations and there functions. DCs have the ability to endocytose 
a large variety of exogenous antigens for presentation via MHC class I molecules 
(Wilson and Villadangos 2005). This phenomenon is called cross-presentation and 
allows DCs to present viral antigens to CD8+ T cells without being infected 
themselves. Macrophages are also capable of cross presentation although not as 
efficient as DC. When infected or activated, DCs migration to the lymph nodes is 
increased and the adaptive immune response is triggered by the activation of T cells 
(Andrews, Andoniou et al. 2001). In the absence of microbial infections or other 
kind of stress, a small proportion of DCs migrate into lymphoid tissues. This helps to 
maintain a state of peripheral T-cell tolerance to self-antigens by elimination of the 
CD4+ and CD8+ cells expressing a self antigen. Activated DCs, mainly pDC, release 
antiviral cytokines such Type I interferon and IL12 (Dalod, Salazar-Mather et al. 
2002). These cytokines play a key role in antiviral defence. DCs, mainly cDC, have 
also the ability to activate NK cells by direct interaction in the site of infection or in 
the lymph nodes. Furthermore IL-2 secretion in association with direct cell contacts 
is necessary for the promotion by DC of NK cell IFNγ production  (Granucci, Zanoni 
et al. 2004).  
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DCs can be infected by CMV in vivo and in vitro (Dalod, Hamilton et al. 2003) and 
play a key role in the expansion of Ly49H NK cells (Andrews, Scalzo et al. 2003). 
Furthermore, during infection with mCMV, pDCs are the main producers of type I 
interferons and also contribute significantly to IL-12 and TNF-α production (Dalod, 
Hamilton et al. 2003; Zucchini, Bessou et al. 2008). 
In addition, cytokines have also been show to play a key role in the control of CMV 
infection. Studies with neutralizing antibodies or exogenous cytokine treatments 
have demonstrated the importance of  IFNγ, TNFα, IL-12, and IFNα/β in resistance 
to mCMV (Fennie, Lie et al. 1988; Heise and Virgin 1995; Orange, Wang et al. 
1995; Cousens, Orange et al. 1997). The section 1.2.4 of this chapter describe 




Figure 1-4: Initiation of the innate immune response to mCMV infection and major immune players involved in the control of 
mCMV infection. 
After a primary infection, mCMV viruses diffuse to the blood stream where they infect monocytes. Dissemination of the virus to 
tissues occurs through the activation of monocyte migration and differentiation into mature macrophages. DCs and macrophages 
secrete cytokines which induce an antiviral state and help to activate NK cells. Activated DC induce cytokines, principally Type I 
interferons, and migrate to the lymph node to induce the adaptive immune response by activating B and T cells. NK cells directly lyse 
infected cells and also exert some antiviral activities by secreting cytokines. 
NKR: NK cell receptor, TCR: T cell receptor  
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1.2.2 CMV interactions with innate immune cells 
Although the innate immune system possesses efficient mechanisms to fight viral 
infections, it is not sufficient to suppress both mCMV and hCMV primary infection. 
Indeed, mCMV has evolved with its host and developed mechanisms to counteract 
and evade the immune response by expressing a great diversity of proteins able to 
alter the immune response. The interplay between innate immune response and the 
ability of the virus to escape it, determine the success of the infection. 
mCMV virus has developed several immune evasion strategies against innate 
immune cells. Since antigen presentation is such a key aspect of the innate and 
adaptive immune response it is not surprising that many viral proteins interfere with 
this process. Both hMCV (UL18) and mCMV (m144) encodes for MHC class I 
homologs which act as ligand for NK cell receptors and inhibits their activation 
(Farrell, Vally et al. 1997; Reyburn, Mandelboim et al. 1997; Babic, Pyzik et al. 
2010). In addition, mCMV (gp34) and hCMV (UL40, US2, US3, US6 and US11) 
down regulates specific components of the MHC class I processing and presentation 
pathway to evade both CD8+ T and NK cell control (Alcami and Koszinowski 2000; 
Reddehase 2002). In macrophages, down regulation of MHC class II molecules has 
also been observed (Heise, Connick et al. 1998). Furthermore mCMV also induces 
the secretion of IL-10 which decreases the expression of MHC class II proteins 
(Redpath, Angulo et al. 1999) and hCMV produce an IL-10 homolog with 
immunosuppressive properties (Chang, Baumgarth et al. 2004). mCMV encode for a 
chemokine (MCK) that increase the recruitment of leukocytes to the site of infection 
which facilitate virus dissemination (Mocarski 2002). 
Moreover, CVM have developed in human and mouse many other mechanisms to 
alter the immune response to infection. For example, hCMV has been shown to 
perturb the DCs-T cells interaction by promoting the rapid disappearance of the co-
stimulatory molecule B7-1 (CD80) from the cell surface of DCs (Mintern, Klemm et 
al. 2006). hCMV alters the cytokine secretion of activated DCs especially IL-12 
(Chang, Baumgarth et al. 2004; Varani, Cederarv et al. 2007). hCMV protein UL16 
has been shown to block the interaction between NKG2D and its activating ligand 
(Cosman, Mullberg et al. 2001) while mCMV glycoprotein gp40 down modulates 
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expression of NKG2D ligand (Arase, Mocarski et al. 2002; Krmpotic, Busch et al. 
2002; Lenac, Arapovic et al. 2008). In addition, two hCMV proteins, gp68 and gp 
34, have been shown to interact with the Fc receptors which prevents the binding of 
antigen bound IgG antibodies (Lilley, Ploegh et al. 2001; Atalay, Zimmermann et al. 
2002).  
1.2.3  Initiation of the innate immune response 
Antigen presenting cells (APC) essentially express a range of pattern recognition 
receptors (PRRs) placed in different cellular locations and able to identify specific 
motifs of pathogens (Akira 2009). Once activated by the virus, these receptors 
initiate signalling cascade which in turn induces the transcription of inflammatory 
cytokines and chemokines, in particular type I interferon and TNFα (Akira and 
Takeda 2004). Coordination of intracellular, cytokines and chemokines response is 
essential for the early control of infection. In particular induction of type I interferon 
by DCs and macrophages stimulates and enhances the immune response and induces 
an antiviral state (Hornung, Rothenfusser et al. 2002). 
Toll like receptors (TLRs) are membrane receptors capable of sensing the viral 
infection by recognizing pathogen-associated molecular patterns (PAMPs) 
(Medzhitov and Janeway 1998; Kumar, Kawai et al. 2009).  
Among the TLRs receptors, TLR3, 7, 8 and 9, localized in endosomal vesicles, have 
been shown to recognize viral infections. TLR9 in particular is activated in response 
to DNA viruses such as Herpes viruses (Hemmi, Takeuchi et al. 2000). mCMV is 
detected by TLR9 in DCs (Krug, French et al. 2004; Tabeta, Georgel et al. 2004; 
Delale, Paquin et al. 2005). However TLR9 knockout mice still produce Ifnβ in 
response to mCMV infection, indicating that an alternative mechanism to sense the 
virus exists (Krug, French et al. 2004; Delale, Paquin et al. 2005). Several studies 
have recently shown that other TLRs (such as TLR2 and 3) play also a crucial role in 
the recognition of CMV infection but the mechanisms involved are not yet well 
identified (DeFilippis, Alvarado et al. ; Compton, Kurt-Jones et al. 2003; Tabeta, 
Georgel et al. 2004). It has also been recently demonstrated that TLR7 plays also a 




Specific activation of TLRs results in the activation of downstream proteins such as 
MyD88, IRAK1, IRAK4 or TRAF6. These proteins will then activate a complex 
composed of IRF3, NFκB, ATF2, CBP and p300. The complex will translocate to the 
nucleus where, in coordination with NFκB and IRF3, they will trigger an antiviral 
response by inducing cellular factors such as interferon inducible genes (ISGs) and 
the secretion of cytokines, in particular Ifnαs and β in an IRF3- and IRF7-dependent 
manner (Yoneyama, Suhara et al. 1998; Kawai and Akira 2006). If IRF3 is necessary 
for type I IFN responses in hCMV infected human fibroblasts (Sato, Suemori et al. 
2000), the expression of a subset of ISGs, such viperin (Grandvaux, Servant et al. 
2002) and ISG56 (Peters, Smith et al. 2002), can also take place in an IRF3-
dependent manner in the absence of IFN-mediated signalling. However, in pDC the 
major inducer of type I interferon in response to CMV infection, TLR7 has been 
shown to directly induce type I interferon genes expression without IRF3 activation 
(Kawai and Akira 2006; Zucchini, Bessou et al. 2008). 
 
Two cytoplasmic receptors: retinoic acid inducible I (RIG-I) and the melanoma 
differentiation associated 5 (MDA5) are also able to sense virus associated dsRNA. 
Once viral infection is recognized, these receptors activate the mitochondrial 
antiviral protein MAVS, through a CARD: CARD domain interaction. Although it 
recognises dsRNA, MAVS has been shown to be essential for IRF3 and IRF7 
activation by Herpes viruses (Scott 2009). This can be explained by the involvement 
of RNA polymerase III (POL3) to activate RIG-I. Indeed, POL3 converts ds DNA 
into dsRNA which contains 5’ triphosphate moiety (Chiu, Macmillan et al. 2009). 
Recently, a cytoplasmic dsDNA binding protein ZBP1 has been identified 
(Deigendesch, Koch-Nolte et al. 2006). ZBP1 activates Ifnβ production in HSV1 
infected cells (Chiu, Macmillan et al. 2009). However, induction of Ifnβ expression 
in response to infection can occur without the activation of ZBP1 (Lippmann, 







1.2.4 Type I Interferon response and CMV 
Type I interferon family is composed of 14 IFNαs, one IFNβ (Pinto and Hill 2005). 
Ifnβ is secreted in most cell types while secretion of IFNα is restricted to DCs, 
leukocytes and macrophages (Colonna, Krug et al. 2002; Diebold, Montoya et al. 
2003). Type I interferons plays a pivotal role in the control of innate and adaptive 
immune responses (Ruzek, Miller et al. 1997; Presti, Pollock et al. 1998; Redpath, 
Angulo et al. 1999; Andrews, Andoniou et al. 2001; Randolph-Habecker, Iwata et al. 
2002; Gamadia, Remmerswaal et al. 2003; Tang-Feldman, Wojtowicz et al. 2006; 
Fodil-Cornu and Vidal 2008). The synthesis and secretion of type I interferon is 
probably the earliest host antiviral reaction (around 8 hours post infection for mCMV 
(Schneider, Loewendorf et al. 2008)). Host defence against viral infections is 
strongly dependent on the early production of type I interferon, which promotes an 
antiviral state in adjacent non-infected cells as well as the activation of  cytotoxic 
lymphocytes (Biron 2001). pDCs, being the main producer of type I interferon in 
response to infection, play a major role in the establishment of a successful immune 
response against infection (Liu 2005; Swiecki, Gilfillan et al. 2010). 
As mentioned earlier, acute CMV infection triggers through the TLR signalling 
pathway specific intracellular responses, which activate the expression of ISGs and 
the release of inflammatory cytokines and chemokines such as type I interferons. A 
second pathway induced by MCMV infection, the lymphotoxin β receptor (LTβR) 
has been also shown to lead to the production of type I interferon (Banks, Rickert et 
al. 2005).  LTβR, expressed only by the stromal and myeloid cells binds LTαβ, a 
membrane bound heterodimer of lymphotoxin (LT) α and β. The expression of LTαβ 
is restricted to T and B cells and NK cells (Ware 2005). Basak and colleague have 
shown that LTβR signalling leads to the activation of NF-κB and type I IFN 
secretion (Basak, Kim et al. 2007). The secretion of type I interferon by the LTβR 
signalling has been shown to occur as early as 8 hours post infection and to be 
physiologically significant for the resistance to mCMV infection (Benedict, Banks et 
al. 2001; Schneider, Loewendorf et al. 2008). In contrast pDCs, major producer of 
type I interferons in response to mCMV, have been shown to produce large amount 
of type I interferon only starting around 36 hours after the initial start of the infection 
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(Dalod, Salazar-Mather et al. 2002; Delale, Paquin et al. 2005; Zucchini, Bessou et 
al. 2008; Swiecki, Gilfillan et al. 2010). 
 
Type I interferon secretion induces a cascade of transduction signals after binding to 
the type I interferon receptor. Type I interferon receptor is a transmembrane receptor 
composed of 2 subunits IFNAR1 and IFNAR2. After being activated by interferon 
binding, the two subunits dimerise and the complex phosphorylates Janus kinase 1 
(JAK1) and Tyrosine Kinase 2 (TYK2). Activation of JAK1/TYK2 results in 
tyrosine phosphorylation of signal transducer and activators of transcription 1 and 2 
(STAT1 and STAT2). Subsequently STAT1–STAT2 form a complex with IFN 
regulatory factor 9 (IRF9) known as ISGF3 (IFN-stimulated gene (ISG) factor 3) 
complexes. ISGF3 translocates to the nucleus and binds IFN-stimulated response 
elements (ISREs) contained in the promoter of interferon stimulated genes (ISG) to 
initiate genes transcription (Platanias 2005). 
There are more than one hundred ISGs identified. Once activated, ISG proteins will 
target many different stages of the virus life cycle such as cleavage of single stranded 
RNA (ssRNA), gene transcription, protein translation, trafficking and protein 
processing (Samuel 2001). The first wave of type I interferon response induces a 
positive feedback loop leading on to a second wave of type I interferon secretion, 
which contributes to the enhancement of the antiviral response (Tailor, Tamura et al. 
2007). Furthermore, in response to interferon signalling STAT1 can form alternative 
combinations with other STAT proteins: STAT1, 3, 4, 5, or 6. These dimers initiate 
the gene transcription of ISRE but also of IFN-activated sites (GAS) (Platanias 
2005).  In addition to the classical JAK-STAT pathway, multiple other JAK-kinase-
dependent signalling cascades are activated, like the IRS-PI 3-kinase pathway, the 
Crk-family proteins pathway (CRKL) or the phosphatidyl-inositol pathway (PI3K). 
Type I interferons also activate p38 mitogen-activated protein kinase (MAP kinase) 
to induce gene transcription in a STAT independent manner (Platanias 2005). 
Moreover, type I IFN also enhances DC maturation, NK cell cytotoxicity, and 
differentiation of virus-specific cytotoxic T lymphocytes (CD8+ T cells) (Dalod, 
Hamilton et al. 2003; Hahm, Trifilo et al. 2005), thus providing a link between innate 




Type I interferon plays a very important role in the control of mCMV infection. 
mCMV infection increases IFNβ and α levels at very early time point post infection 
in vivo (Schneider, Loewendorf et al. 2008; Zucchini, Bessou et al. 2008). Pre-
treatment of human fibroblasts with IFNβ limits plaque formation and mice lacking 
the Type I receptor or a downstream effecter (such asTYK2) are much more sensitive 
to mCMV infection (Presti, Pollock et al. 1998; Malmgaard, Salazar-Mather et al. 
2002; Sainz, LaMarca et al. 2005; Strobl, Bubic et al. 2005).  Treatment with 
subtypes of IFNα of mCMV infected mice led to a significant reduction in mCMV 
replication (Cull, Bartlett et al. 2002). However, in vitro studies reveal an only 
moderate reduction of mCMV replication following treatment with recombinant 
IFNα (Davignon, Castanie et al. 1996) which indicates that CMV interferes with the 
type I interferon response. 
Since type I interferon response plays a key role in the control of CMV infection, it is 
not surprising that the virus has developed mechanisms to counter its antiviral effect. 
First of all, there is evidence that CMV interfere with type I gene induction. hCMV 
infection selectively blocks the induction of ISGs including IFNβ  (Browne, Wing et 
al. 2001), however the precise molecular mechanisms of this inhibition remain to be 
identified.   
In addition, CMV has developed strategies to block the type I signalling pathway. 
hCMV blocks IFNα stimulated gene expression in fibroblasts and endothelial cells 
(Miller, Zhang et al. 1999; Paulus, Krauss et al. 2006) and induce the degradation of 
JAK1 and IRF9 proteins levels (Miller, Rahill et al. 1998). Human CMV IE1 protein 
binds to the ISGF3 complex to inhibit the interaction between STAT1 and STAT2 
(Paulus, Krauss et al. 2006). mCMV protein M27 is necessary and sufficient to block 
the induction of type I and II interferon. Le and colleagues have shown that mCMV 
inhibits IFNβ transcription by perturbing the formation of the enhanceosome (Le, 
Trilling et al. 2008). 
Both human and mouse CMV interferes with interferon induced effectors such as the 
activation of protein kinase R (PKR) and 2’-5’ oligoadenylate synthetase (RNaseL) 
























Figure 1-5: Induction of innate immune response by viral infection 
Toll-like receptor (TLR) signalling. Activation of TLRs by mCMV leads to the recruitment of kinases which catalyse the phosphorylation of IRF3 
and IRF7. TLRs engagement also results in the activation of nuclear factors such as NF-κB. Phosphorylated IRFs forms dimers, translocate into the 
nuclei and in collaboration with NF-κB and cofactors, bind to DNA and regulate the expression of type I interferons, inflammatory cytokines and ISG 
genes. IFN signalling. Endogenous IFNα/β bind to a common receptor expressed at the surface of target cells. Receptor engagement leads to the 
activation of STAT1 (signal transducer and activator of transcription 1) and STAT2, which, together with ISGF3G/IRF-9, bind IFN-stimulated 
response elements (ISREs) and activate ISG genes. PRRs: Pattern recognition receptors, ISG: Inteferons stimulated genes. 
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1.3 Adaptive immune response and CMV infection 
The adaptive immune response provides the vertebrate immune system the ability to 
specifically recognize and remember viral infections. Both innate and adaptive 
immune responses play a role in the control of human and mouse CMV infection. 
While innate immune response can contain the primary infection, the adaptive 
immune response is capable of clearing it. However, CMV have developed 
mechanisms to evade the immune system by establishing latency. (Koszinowski, 
Reddehase et al. 1991)  
The effector cells of the adaptive immune system are B lymphocytes, specialized in 
adaptive humoral response, CD8+ T lymphocytes (CD8+ T) or killer cells 
specialised in the elimination of the infected cells and CD4+T lymphocytes (CD4+ 
T) or helper cells which activate and maximize the immune response (Koszinowski, 
Reddehase et al. 1991).  
The activators of the T and B cells are the antigen presenting cells (APC) such as 
DCs and macrophages. Once activated by the viral infection APCs, mainly DCs, 
migrate to the lymph nodes where they present viral antigen epitope to the naive 
CD4+ T cells through the MHC class II pathway and to the naïve CD8+ T cells 
through the MHC class I pathway. Activated and differentiated T and B cells 
proliferate and migrate outside the lymph node. Chemo-attraction recruits T and B 
cells to the site of infection. B cells secrete antibodies against CMV such as Gb, Gl 
or pp65. Once enveloped by antibodies, virions or infected cells are degraded by the 
proteins of the complement. 
CD8+ T cells recognize infected cells through the antigen presentation of MHC class 
I and, in coordination with cytokines, when stimulated secrete perforin and 
granzymes to induce apoptosis of the infected cells. CD8+ T cells play a major role 
in the control of primary infection as well as latency (Reddehase, Weiland et al. 
1985; Reddehase, Mutter et al. 1987; Jonjic, Pavic et al. 1990; Simon, Holtappels et 
al. 2006). 
CD4+ T cell do not eliminate directly infected cells but their activation causes 
release of cytokines and other stimulatory signals such as Interleukins two and four 
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(Il2 and Il4) or Ifnγ, which stimulates the activity of macrophages, killer T and B 
cells. 
CD4+ T cells play  also a role in CMV clearance, especially in the salivary gland 
(Jonjic, Mutter et al. 1989). 
B cell secreted antibodies were found to have a protective role in mCMV infected 
mice. However, experiments in irradiated mice where activated B cells were re-
injected show that B cells are not sufficient to clear the infection although they 
contribute significantly (Klenovsek, Weisel et al. 2007). In humans, the transfer of 
antibodies from an hCMV seropositive mother to a newborn infant was shown to be 
protective against hCMV infection from seropositive blood transfusions (Wynn, 
Fulton et al. 2008). Jonjic and colleagues have shown that antibodies are not essential 
for the resolution of a primary infection but limit the dissemination of the virus 
(Jonjic, Pavic et al. 1994). 
 
CMV has developed strategies to counteract the adaptive immune response. 
Both human and mouse CMV interferes with the immunomodulatory functions of 
type I interferon response by decreasing the MHC class I expression and presentation 
as well as other proteins involved in the in antigen presentation (Mocarski 2002; 
Pinto and Hill 2005). Three mCMV proteins have been shown to interfere with MHC 
class I pathway. Gp34 forms complexes with MHC class I molecules in the ER that 
are then expressed at the cell surface (Kleijnen, Huppa et al. 1997). Gp34 co-operate 
with gp40 to prevent the recognition of infected cells by cytotoxic T cells 
(Kavanagh, Gold et al. 2001). Moreover, gp48 binds MHC class I complexes and 
induce their proteolytic destruction (Reusch, Muranyi et al. 1999). 
CMV reduces the ability of CD4 T cells to amplify the immune response by 
interfering with their ability to enhance the MHC class II antigen presentation in 
professional antigen presenting cells (APC). For example, hCMV produces a protein 
cmvIl10 mimicking the effect of interleukin 10 (IL10), an inhibitor of MHC class II 






1.3.1 Type II interferon response to mCMV infection 
Type II interferon (IFNγ) is produced by activated T cells and NK cells. Ifnγ binds to 
the Ifnγ receptor IFNGR, which is composed of two subunits IFNARG1 and 
IFNARG2. When activated by IFNγ binding, the two subunits dimerize and activate 
kinase JAK1 and JAK. Activated JAK1 will phosphorylate STAT1s and forms 
homodimers. These complexes will translocate into the nucleus and bind to Ifnγ-
activation site element (GAS), leading to the expression of Ifnγ inducible genes 
(Wesoly, Szweykowska-Kulinska et al. 2007). 
IFNγ plays a major role in immune response against CMV infection in mice and 
humans such as the activation of macrophages during infection (Heise and Virgin 
1995), the enhancement of MHC class I–dependent antigen presentation to CD8 T 
cells (Hengel, Lucin et al. 1994) and also the inhibition of mCMV replication and 
gene expression (Lucin, Jonjic et al. 1994). Furthermore it has been shown that 
injection of recombinant Ifnγ can protect against lethal infection (Fennie, Lie et al. 
1988). In addition, IFNγ plays a role in the regulation of latent infection although the 

















1.4 Cholesterol and host pathogen interaction 
Cellular lipids were considered to have only a structural role for a long time. 
However during the last decades, it became clearer that lipids were involved in much 
more active biological processes such as cell signalling, membrane trafficking, 
inflammation and immune response (Wenk 2005). 
It is not surprising, therefore, that lipids are involved in the life cycle of pathogens 
and especially that of viruses. Lipids play a key role in viral entry, viral replication 
and host pathogen interaction (Wenk 2006). 
Lipid content is modulated by pathogens for their own benefit. For instance, Munger 
and colleagues (Munger, Bennett et al. 2008) have shown that pyruvate metabolism 
and fatty acid flux production were changed in response to HCV infection. 
Among lipids, cholesterol has been identified as one of the most potent molecules. 
Not surprisingly cholesterol has been proven to be essential for almost every step of 
viral infection (from entry to egress). 
Furthermore, cholesterol pathways have been shown to be modulated by pro-
inflammatory signals and acute stress responses. In addition, several reports have 
shown that cytokines can modulate the serum cholesterol level. Changes in 
cholesterol pathways have also been shown to modulate the immune and 
inflammatory response. 
In conclusion, a body of evidence points to the pivotal role of cholesterol in the 
interplay between the virus and the host to modulate the infection and the immune 
response.  
However, the mechanisms involved in these processes are still not well understood. 
This section reviews the role of cholesterol in the life cycle of viruses and its 









1.4.1 Cholesterol metabolism 
1.4.1.1 Structure of cholesterol 
Cholesterol (Figure 1-6) is the most common steroid in mammalian biology. It is a 
complex molecule consisting of C27 H46 O with a molecular weight of 386.65 
grams per mole. It has weak amphipathic properties due to the polar nature of the 
hydroxyl group and the hydrophobic characteristics of the ring structure. In the cell, 
cholesterol is inserted into lipid bilayers of cell membranes, with the polar region 
interacting with the phospholipids segment of the bilayer and the hydrophobic 
portions oriented inward. In cell membranes, cholesterol has a stabilizing effect, 














Figure 1-6: molecular structure of cholesterol and its membrane organisation 
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1.4.1.2 Cholesterol synthesis and prenylation pathway 
Cholesterol synthesis occurs in the cytoplasm and ER and involves a cascade of 
enzymatic transformations (Goldstein and Brown 1990) (Figure 1-7). Firstly, acetyl-
CoAs are converted into 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by HMG-
CoA synthase 1 (HMGCS1). Then, HMG-CoA reductase (HMGCR), the rate-
limiting enzyme of the pathway converts HMG-CoA into mevalonate. Mevalonate is 
then transformed by three successive enzymatic phosphorylations into 5-
pyrophosphomevalonate (M5PP). After this step an ATP-dependent decarboxylation 
transforms the pyrophosphomevalonate in isopentenyl pyrophosphate, IsPP, an 
isoprenoid molecule. IsPP is in equilibrium with its isomer, dimethylallyl 
pyrophosphate (DMPP). Isopentenyl pyrophosphate (IDI1) condenses one molecule 
of IsPP with one molecule of DMPP to generate geranyl pyrophosphate (GPP). 
Farnesyl diphosphate synthase (FDPS) further condenses GPP with another IsPP 
molecule to become farnesyl pyrophosphate, FPP. Geranygeranyl pyrophosphate 
synthase (GGPS) convert one molecule of IPP and one of FPP into 
geranylgeranylpyrophsophate (GGPP). The main branch of these pathways leads to 
the formation of free cholesterol and is therefore named the sterol synthesis pathway. 
Squalene synthase (FDFT1) catalyzes the condensation of 2 molecules of FPP to 
form squalene. Squalene is then transformed into lanosterol by squalene epoxidase 
(Sqle) and lanosterol synthase (LSS) involving two-step cyclization. 19 additional 
reactions for lanosterol to be converted into free cholesterol are then required. The 
isoprenoid metabolites are not only metabolic precursors for the biosynthesis of 
cholesterol but also for alternative side pathways (Caraglia, Budillon et al. 2005). 
Protein prenylation is a posttranslational modification process occurring in the ER 
and involving the binding of a farnesyl or geranyl-geranyl molecules to the C 
terminal cysteine of a target protein. Ras and Ras-related small GTP-binding proteins 
(Rho, Rab, Rac and the γ subunit of the trimeric G proteins) are the main target for 
protein prenylation. Prenylated proteins play important roles in the regulation of 
apoptosis, signal transduction, cell differentiation, cell replication, cytoskeletal 
organization, vesicular trafficking and immune signalling. The enzymes that 
accomplish the prenylation of proteins in the cell are the farnesyltransferases type I 
(FNTA and FNTB), the geranylgeranyltransferase I (PGGT1B) and the Rab 
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geranylgeranyltransferase II (RABBGTA and RABGGTB). In addition, IsPPs are 






Figure 1-7: Schematic of the cholesterol synthesis pathway 
Grey boxes representing metabolites and enzymes regulating the pathway are 
indicated. GPP: Geranyl Pyrophospahte, FPP: Farnesyl pyrophosphate, GGPP: 




1.4.1.3 Regulation of the cholesterol synthesis 
Cholesterol homeostasis is regulated in vertebrate cells by transcriptional factors, 
which sense intra cellular cholesterol levels (Brown and Goldstein 1997; Osborne 
2000). These transcription factors are named sterol-regulatory element-binding 
proteins (SREBPs). In the nucleus SREBPs bind specifically to DNA sequences 
called sterol regulatory element (SRE) amplifying the expression of the genes 
containing these sequences. To date, more than 30 genes are known to contain SRE 
sequences including almost all the genes of the sterol synthesis pathway but also 
Hmgcr, Ldlr and Fasn (Horton 2002; Sun, Seemann et al. 2007). There are two genes 
encoding for three isoforms of SREBPs protein. Srefbf1 encodes for two splice 
variant proteins: SREBP1a and SREBP1c. SREBP-1a and SREBP-1c differ only by 
the first exon which encodes for a transactivator domain making SREBP1c less 
potent than SREBP-1a. SREBP-1a and -1c both activate genes involved in the 
synthesis of fatty acids and triglycerides and phospholipids. Srebf2 encodes for 
SREBP2, which preferentially activates genes responsible for cholesterol synthesis 
and the LDL receptor (Ldlr). 
The coordinate expression and translation of SREBPs allows for the control of the 
intracellular lipid homeostasis (Horton, Goldstein et al. 2002).  
SREBPs are regulated at the transcriptional level by transcription factors although 
the exact mechanisms remain unclear (Raghow, Yellaturu et al. 2008). SREBPs 
regulation also depends on the intra cellular cholesterol and oxysterol levels, which 
allow a feedback control mechanism for the cell to maintain and adjust the 
intracellular cholesterol concentration (see figure 1.7 and 1.8). Indeed, SREBPs are 
associated in the ER membrane with SREBP cleavage activating protein (SCAP) and 
Insulin induced gene 1 and 2 (Insig-1 and Insig-2). Cholesterol binds to the sterol-
sensing domain of SCAP. When bound to cholesterol molecules, SCAP binds to 
INSIGs proteins. This association causes the SREBP-SCAP complex to be retained 
within the ER. When the sterol concentration is low, SCAP and INSIGs do not 
interact together allowing the translocation of the complex SREBP-SCAP to the 
Golgi Apparatus (GA). In the GA, Protease S1P and S2P cleave the transmembrane 
domain of SREBPs precursor, releasing SREBP to the cytosol which then 




25-hydroxycholesterol binds to Insig-2 and blocks the translocation of the SREBP-
SCAP complex (Radhakrishnan, Ikeda et al. 2007).   
   
As mentioned before, HMGCR is the rate liming enzyme of the cholesterol synthesis 
pathway and its regulation is therefore crucial for the control of cholesterol synthesis. 
HMGCR activities are tightly controlled and involve several mechanisms apart from 
the SREBP2 transcriptional regulation. Indeed, HMGCR activity also depends on its 
post transcriptional regulation, phosphorylation state and degradation rates. HMGCR 
is most active in the dephosphorylated state. Phosphorylation is catalyzed by AMP-
activated protein kinase, AMPK, (used to be termed HMGR kinase), an enzyme 
whose activity is also regulated by phosphorylation. The phosphorylation state of 
HMGCR is additionally controlled by the cAMP signalling pathway. Increases in 
cAMP lead to dephosphorylation of HMGCR (Wang, Jones et al. 2006). 
The degradation of HMGCR occurs within the proteosome, a complex specialized in 
protein degradation. The primary signal directing proteins to the proteosome 
involved multiple ubiquitination. Although the mechanisms are still not well 
understood, sterol levels are involved in HMGCR degradation. A high level of free 
cholesterol increases the rate of HMGCR degradation. Long-term regulation involves 
Figure 1-8: SREBP regulation by SCAP and INSIGs proteins 
CT D: C terminus domain, W D: WD40 domain, bHLH:  basic Helix Loop Helix.  
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control of synthesis and degradation, while short-term regulation involves the 
phosphorylation state of the enzyme (Ness, Lopez et al. 1998). 
Hormones play also an important role in the regulation of HMGCR: insulin affects 
the post transational processing of HMGCR (Feramisco, Goldstein et al. 2004), 
thyroid hormones alter its expression and glucocorticoids act at the post-translational 
level (Geelen, Gibson et al. 1986; Ness, Lopez et al. 1998). 
1.4.1.4 Cholesterol homeostasis 
The concentration of intracellular cholesterol is tightly regulated by the cell. Apart 
from cholesterol synthesis, four mechanisms also regulate co-ordinately the 
intracellular concentration of cholesterol (Simons and Ikonen 2000):  Firstly, 
cholesterol uptake, where lipoprotein receptor Ldlr plays an important role in the 
uptake of cholesterol as it binds and internalises Low Density Lipoprotein (LDL), 
which comprises cholesterol ester rich particles. When they bind to the Ldlr, LDL 
particles are internalised in endosomes followed by lysososomal degradation. In the 
lysosome, LDL-cholesterol ester is hydrolysed to free cholesterol, with a resultant 
increase in intracellular levels. Secondly, bile acid and steroids synthesis; free 
cholesterol is converted in downstream steroids in the bile acids synthesis pathway. 
There are two pathways characterised for the synthesis of bile acids. In the liver, bile 
synthesis is initiated by cholesterol 7α-hydroxylase (CYP7A1). In other tissues, bile 
acid synthesis can be initiated by alternative pathway by 27-hydroxylase (CYP27A1) 
or 25 cholesterol hydroxylase: (encoded by Ch25h). Thirdly, cholesterol storage; 
cholesterol is stored in the cell as an ester a non bioactive form, formed by ACAT: 
cholesterol acyltransferase enzyme encoded by Soat1. The accumulation of 
cholesterol esters will form lipid droplets in the cell. Fourthly, cholesterol efflux; 
ABCs proteins facilitate the efflux of cellular cholesterol from the cell. 2 proteins 
have been mainly involved in the regulation of the efflux: ABCA1 and ABCG1. 
Abca1 KO mice have increased intracellular cholesterol concentrations. The cellular 
cholesterol is delivered to nascent HDL particles which then return cholesterol to the 
liver. One excreted lipoproteins rich in cholesterol are associated with APO 
proteins.APOE plays an important role in the reverse transport of cholesterol via 
APOE specific receptor. APOs are proteins present in lipoproteins such as VLDL, 
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HDL, and IDL. Among these Apoe has been shown to be important in the regulation 
of the cholesterol efflux, Apoe KO mice have an increase intracellular cholesterol 
concentration. 
Nuclear hormones receptors (McEwan 2009)  are a family that also plays an 
important role in the regulation of cholesterol metabolism. Members of this family 
are transcription factors characterized by their DNA binding domain and C terminal 
ligand binding. The main receptors of this family are the proliferator-activated 
receptors (PPARs), liver X receptors (LXRs), and farnesoid X receptors (FXR). 
Oxysterols, the oxidized form of cholesterol, act as ligands for these nuclear 
receptors. Hence receptors act as lipid sensors to coordinately regulating the changes 
in lipid metabolism (Chawla, Boisvert et al. 2001). All the nuclear receptors bind to 
the retinoid X receptors (RXRs) to form a dimer. LXRs regulate the cholesterol 
efflux (through the regulation of Abca1) and the synthesis of bile acid (through the 
regulation of Cyp27). LXRs have been directly linked to the regulation of SREBP1a 
although its relative contribution to the expression of SREBP is still in debate 


































Low cholesterol balance will trigger the up regulation of the cholesterol genes responsible for the entry and synthesis of cholesterol 
while the genes responsible of cholesterol storage and efflux will be down regulated. In the contrary excess level of cholesterol will 
decrease the expression of the genes controlling the entry and synthesis of cholesterol while the one responsible for the storage and 
efflux will be up regulated. ER: Endoplasmic Reticulum, SRE: Sterol regulatory elements, LXRE: LXR regulatory elements. 
Figure 1-9: Schematic representation of the intra-cellular regulation of cholesterol homeostasis 
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1.4.2 Involvement of cholesterol in viral lifecycle 
1.4.2.1 Cholesterol is essential for viral entry, assembly and budding of viruses 
The entry of many viruses in their host cell depends on cholesterol rich membrane 
structures called lipid rafts (LRs). LRs are specialised lipid-organised membrane 
domains rich in cholesterol, sphingolipids and marker proteins such as caveolin. The 
molecular composition of the lipid rafts confers a more rigid structure to the 
membrane that acts as an anchor for many proteins. In addition, LRs also contain 
viral receptors and co-receptors required for viral fusion and entry. Moreover, the 
entry of many enveloped and non-enveloped RNA and DNA viruses depends on LRs 
(Manie, de Breyne et al. 2000; Chawla, Boisvert et al. 2001; Ahn, Gibbons et al. 
2002; Bavari, Bosio et al. 2002; Marjomaki, Pietiainen et al. 2002; Norkin, Anderson 
et al. 2002; Reynolds, Maurer et al. 2004; Nishi and Saigo 2007; Raghu, Sharma-
Walia et al. 2007; Bader, Fazili et al. 2008; Desplanques, Nauwynck et al. 2008; Lee, 
Lin et al. 2008).  
LRs have also been involved in the assembly and budding of the viral particles. LRs 
seem to serve as a platform for clustering of viral proteins. LRs are involved in 
assembly of Influenza virus and VZV (Chazal and Gerlier, 2003). LRs are also 
involved in viral budding for Influenza virus, Measles virus, HIV-1, and Ebola virus 
(Chazal and Gerlier 2003). Finally LRs also contribute to the properties of the viral 












1.4.2.2  Role of cholesterol synthesis in viral replication 
The contribution of cholesterol synthesis to viral replication has been extensively 
studied using statins, drugs targeting the first enzyme HMGCR of the mevalonate 
pathway. Statin treatment of infected cells has antiviral properties in vitro and in vivo 
for RNA and DNA, enveloped and non enveloped viruses (except Novovirus), 
(Gower and Graham 2001; Horne, Muhlestein et al. 2003; Ye, Wang et al. 2003; del 
Real, Jimenez-Baranda et al. 2004; Potena, Frascaroli et al. 2004; Cohen 2005; Liu, 
Rodriguez et al. 2006; Ikeda and Kato 2007; Bader, Fazili et al. 2008; Mohan, 
Muller et al. 2008; Chang 2009; Robinzon, Dafa-Berger et al. 2009; Rothwell, 
Lebreton et al. 2009).  
The mechanisms involved in the antiviral effects of statins are not well understood. It 
is still unclear whether this effect is due to the reduction in cellular cholesterol 
concentrations or a change in some sterol intermediaries. Indeed, the antiviral effect 
of statins in vitro and in mice models has been often linked to a reduction in 
prenylated proteins (Bordier, Ohkanda et al. 2003; Einav and Glenn 2003; Glenn 
2006). For example, HCV has been shown to induce the prenylation of a cellular 
protein FBL2 critical for efficient replication (Wang, Gale et al. 2005). Although for 
most viruses, the mechanisms involving the reduction of viral replication and the 
prenylation pathway are not well understood, it is believed that apoptosis and cell 
cycle regulated by prenylated proteins may play a role in the antiviral properties of 
statins (McTaggart 2006).The antiviral effect of statins point at the crucial role of 
sterol synthesis in viral replication. Several trials have been started to evaluate the 
antiviral effect of statins in patients however the results so far are contradictory. 
Statins have an antiviral effect in HIV infected patients while they have no effect for 
HCV infection (O'Leary, Chan et al. 2007; Forde, Law et al. 2009; Montoya, Jaimes 









1.4.2.3 Viral infection manipulates intra cellular cholesterol metabolism 
Since cholesterol plays such an important role in viral replication, it is not surprising 
that viruses have developed strategies to hijack the cellular cholesterol metabolism 
for their own benefit. Indeed, viruses have developed strategies to use cholesterol 
metabolism, its biosynthetic and regulatory pathways as well as transport machinery 
for their own efficient assembly and egress.  
First of all, viruses exploit the cellular machinery involving the synthesis and 
transport of Lipid droplet (LD). LDs are ER-derived organelles composed of 
triacylglycerols and cholesterol esters surrounded by a phospholipids membrane. 
These organelles are specialised in storing intracellular neutral lipid and they 
dynamically move through the cytoplasm and interact with other organelles to 
facilitate the transport of lipids and proteins in the cell (Murphy 2001; Martin and 
Parton 2005). McLauchlan and others have demonstrated that HCV utilises the 
synthesis and the protein machinery of LD for assembly and egress of its own 
particles. (Miyanari, Atsuzawa et al. 2007; Boulant, Douglas et al. 2008; 
McLauchlan 2009). Furthermore, the Dengue virus capsid protein usurps lipid 
droplets for viral particle formation. These results may indicate that the hijacking of 
the LDs synthesis and machinery by viruses is a general viral strategy for assembly 
and egress. Pharmacological targeting of the LD formation is a promising therapeutic 
intervention as it drastically reduces the Dengue virus titre (Samsa, Mondotte et al. 
2009). 
Secondly, viruses have also developed mechanisms to modulate the transcription of 
the cholesterol metabolism regulatory genes and redistribute the intra cellular 
cholesterol pool. 
For example, HCV viral protein, HCV core and NS4b, indirectly increase the 
expression of the sterol synthesis regulating genes through the up-regulation of the 
gene expression and the proteic cleavage of SREBPS proteins (Waris, Felmlee et al. 
2007; Park, Jun et al. 2009). 
NEF, one of the HIV proteins, increases expression of the sterol biosynthesis 
pathways genes, as well as being able to bind directly to cholesterol. It is believed 
that NEF allows the redirection of cholesterol pool to LRs and newly synthesised 
viral particles (Zheng, Plemenitas et al. 2003).  
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Finally, West Nile virus infections increase cholesterol synthesis and redistribute 
intracellular cholesterol to newly formed viral membranes. This additionally disrupts 
the immune response to the infection by decreasing MHC class I and II presentation 
(Mackenzie, Khromykh et al. 2007). 
Furthermore, a very recent study has demonstrated that acute Measles virus infection 
induces the down regulation of almost the entire sterol biosynthetic pathway 
(Robinzon, Dafa-Berger et al. 2009). The authors of this study suggest that the down 
regulation of the gene expression in response to the viral infection may reduce the 
viral budding without providing convincing evidence. Moreover, Dengue virus can 
manipulate the intracellular cholesterol content and direct it to the site of the viral 
replication (Rothwell, Lebreton et al. 2009). 
1.4.2.4 Viral infection induced dyslipidemia in patient 
Viral infections are well known to induce dyslipidemia in patients. For example 
hepatitis B and C infection induces liver steatosis (Rubbia-Brandt et al 2003) and 
decreases cholesterol (LDL and HDL) concentrations in blood (Cicognani C et al, 
1997). Hypocholestemia is one of the symptoms of HIV infection (Zangerle et al, 
1994). Furthermore, several studies suggest that the level of cholesterol in blood can 
influence the reactivation of viral infection (Del Pozo 2010) 
The mechanisms leading to the dyslipidemia induced by viral infections are not well 
understood. In humans, a significant correlation has been made between the intensity 
of the acute phase response during sepsis and the reduction of cholesterol levels 
(Bentz and Magnette 1998; Chiarla, Giovannini et al. 2004) pointing at the 
involvement of a cytokine response in the reduction in cholesterol levels induced by 
infection.  
1.4.2.5 Herpes viruses and cholesterol metabolism 
The direct involvement of cholesterol on the life cycle of Herpes viruses has not been 
extensively studied and characterized. However there is some evidence that 
cholesterol plays an important role in Herpes virus infection. First of all, cholesterol 
has been shown to be critical for the viral entry of hCMV (Juckem, Boehme et al. 
2008), HSV1 (Bender, Whitbeck et al. 2003; Hannah, Cairns et al. 2009),VZV 
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(Hambleton, Steinberg et al. 2007), EBV(Ikeda and Longnecker 2007) and human 
Herpesvirus-6 (Tang, Kawabata et al. 2008). Additionally, Kawabata and colleagues 
have shown that human Herpesvirus-6 envelope component was enriched in 
cholesterol rich lipid rafts (Kawabata, Tang et al. 2009) suggesting an important role 
for cholesterol in viral budding. 
Furthermore, cholesterol synthesis has been shown to modulate Herpes virus gene 
expression. Indeed, pharmacological inhibition of the mevalonate pathway with 
statins have been reported to limit immediate early and late HCMV gene expression 
in endothelial cells (Potena, Frascaroli et al. 2004) 
Herpes viruses also induce the level of total cholesterol in infected patients (Del 
Pozo, van de Beek et al.). HSV1 infection results in the reduction of HDL cholesterol 
concentrations in infected patients (Vilkuna-Rautiainen, Pussinen et al. 2006). CMV 
infections have been shown to directly increase the level of cholesterol and 
cholesterol ester in smooth muscle cells in vitro and in the arterial wall in vivo of 
chickens (Abrahamsen, Clay et al. 1996; Melnick, Adam et al. 1996). Furthermore, 
mCMV infection has been show to increase oxidised LDL uptake mRNA expression 
in vascular smooth muscle cells (Zhou, Guetta et al. 1996). 
Hajjar and colleagues have shown that MVD infection of chicken smooth muscle 
cells increased sterol synthesis, decreased excretion of free cholesterol and increased 
cholesteryl ester synthetic activity (Hajjar, Falcone et al. 1985; Fabricant and 
Fabricant 1999). Infection of these cells also increased the internalisation of LDL and 
increased mRNA expression of Ldlr in the first hours post infection. The activity and 
expression of Hmgcr has been reported to be also increased by HSV infection in 
smooth muscle cells. In uninfected cells, mevalonic acid and 25-hydroxy cholesterol 
reduced the activity of Hmgcr but this effect was lost in the HSV-infected cells 
suggesting that the viruses interfere with the effects of oxysterols on cholesterol 
synthesis and uptake. Moreover this study suggests that a viral kinase (US3) is 
involved in this process (Hsu, Nicholson et al. 1995) 
Interestingly there is indirect evidence suggesting that there is interplay between 
cholesterol regulation, CMV infection and inflammation response. Indeed, hCMV 
has been considered as a risk factor for the development of atherosclerosis. 
Atherosclerosis is an inflammatory disease characterized by the development of fatty 
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deposit in the arterial wall, which will eventually lead to thromboses or strokes. 
Macrophage disregulation of cholesterol metabolism leads to foam cells formation 
and this process is believed to be one of the factors involved in the development of 
fatty deposit or atheroma in the artery wall. Although the causal relationship is still in 
debate and the mechanisms are not well understood, it is believed that CMV 
infection enhances the formation of fatty plaques.  
In fact, several studies have shown a significant relationship between Herpes virus 
infection, and an increasing risk of developing atherosclerosis, especially in hCMV 
infected patients (Alber, Powell et al. 2000; Georges, Rupprecht et al. 2003; Gomez, 
Laures et al. 2005). hCMV-seropositive individuals have endothelial dysfunction and 
an increased number of atherosclerotic plaques (Grahame-Clarke, Chan et al. 2003). 
Studies in apolipoprotein E-knockout mice also showed that mCMV infection 
increases lesion size (Hsich, Zhou et al. 2001). Moreover, mCMV infection increases 
the lesion T cell content and the levels of IFNγ and TNF in the arterial wall, which 
may contribute to the inflammatory process. Finally, mCMV reactivation has also 
been implicated in the development of atherosclerotic plaque (Vliegen, Duijvestijn et 
al. 2004).  
In addition recently, HSV infection has been linked with an increasing risk of 
developing Alzheimer disease and it is believed that disregulation of cholesterol 
efflux in neurones by HSV infection contribute to the disease process (Itabashi, Arai 














1.5 Innate immunity and cholesterol metabolism 
1.5.1 Cytokines and chemokines modulate cholesterol metabolism 
It is well documented that the acute phase response induces a decrease of total serum 
cholesterol levels in primates, and an increase in rodents’ cholesterol levels by 
stimulating hepatic de novo cholesterol synthesis, decreasing lipoprotein clearance, 
and decreasing the conversion of cholesterol into bile acids (Khovidhunkit, Kim et al. 
2004).  
Pro-inflammatory cytokines and LPS treatments have been reported to alter sterol 
blood levels.  LPS, TNF, IL-1, and Il-6 increase cholesterol levels in rodents.  
At the transcriptional level, in rodents, TNF, IL-1 and Il-6 stimulate hepatic 
cholesterol synthesis by increasing the transcription and activities of HMGCR 
(Khovidhunkit, Kim et al. 2004). The effect on the HMGCR activities and 
transcription occur 16 hrs after treatment. Furthermore, in rodents, TNFα has been 
shown to decrease specifically the transcription of SQLE. It is interesting to note that 
TNF and IL-1 in combination have synergistic effect on serum cholesterol and 
HMG-CoA reductase mRNA levels (Hardardottir, Moser et al. 1994). TNF may also 
affect cholesterol metabolism and excretion by inhibiting the expression and activity 
of cholesterol-7a-hydroxylase (CYP7A1), the rate-limiting enzyme in the classic 
pathway of bile acid synthesis (De Fabiani, Mitro et al. 2001). 
However, the effects of cytokines on cholesterol levels differ between rodents and 
primates. In primates, and humans TNFα, serum cholesterol levels do not change or 
decreases (Popa, Netea et al. 2007). In human hepatoma HepG2 cells IL-1 inhibits 
cholesterol synthesis and decreases cholesterol and apoB secretion. IL-6 increases 
cholesterol synthesis but decreases cholesterol secretion (Ettinger, Varma et al. 
1994).  
The role of IFN response in modulating the cholesterol synthesis is not clear and has 
not been extensively studied. In humans, high doses of IFNβ in Hella cells results in 
an increase of sterol synthesis (Pfeffer, Kwok et al. 1985) but IFNβ treatment 
decreases plasma cholesterol levels in multiple sclerosis patients (Morra, Coppola et 
al. 2004). Patients treated with IFNγ do not show changes in blood cholesterol level 
(Kurzrock, Rohde et al. 1986). Furthermore, IFNβ inhibits ApoE production at the 
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transcriptional level in a dose-dependent manner in patients (O'Toole and Love 
2002). IFNγ treated macrophages develop an unbalanced cellular cholesterol 
regulation leading to the increase of intracellular cholesterol esters, reduction of 
cholesterol efflux and ultimately in the formation of foam cells, which is an 
important step in the development of atherosclerosis (Reiss, Patel et al. 2004). 
Furthermore, IFNγ inhibits ApoE production at the post-transcriptional level in a 
human macrophage cell line (O'Toole and Love 2002). 
1.5.2 Cross talk between innate immunity and cholesterol metabolism: 
Involvement of TLRs and nuclear hormones receptor 
1.5.2.1 Innate immune response modulate cholesterol metabolism 
Emerging studies indicate that TLR signalling pathways are involved in the 
regulation of cholesterol metabolism. TLR activation promotes lipid accumulation in 
endothelial cells (Curtiss and Tobias 2009). The effect of TLRs on cholesterol 
metabolism seems to have an effect on mainly the cholesterol efflux through the 
modulation of the ABCs proteins. For example TLR agonists suppress the expression 
of ABCA1 and cholesterol efflux in macrophages and LPS treatment reduced the 
nuclear levels of RAR alpha and decreased ABCA1 expression and cholesterol efflux 
via IRAK activation in wild-type mice. TLRs activation has been reported to induce 
the increase of the oxysterol; 25 hydroxy-cholesterol (Bauman, Bitmansour et al. 
2009). The reduction of cholesterol efflux by TLRs activation is involved in the 
development of atherosclerosis as it leads to foam cell formation. 
Furthermore, Castrillo and colleagues have demonstrated that TLRs regulate 
expression of cholesterol efflux associated genes through IRF3 and the nuclear 
receptors LXR and RXRs, independently of IFNβ production. In this study, 
microbial ligand activation of the IRF3 pathway blocked the induction of LXR target 
genes such as ABCA1 and inhibited cholesterol efflux from macrophages (Castillo 
and Kowalik 2004). 
Although IFN treatment modulates cholesterol metabolism, little is known of the 
mechanisms and signalling pathway involved. Recently, Hao and colleagues have 
shown that the decrease in cholesterol efflux and in Abca1 expression induced by 
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IFNγ is LXR and STAT1 dependent in human macrophage-derived foam cells 
(Wang, Panousis et al. 2002; Hao, Cao et al. 2009). 
1.5.2.2 Cholesterol modulates innate immune response 
The cholesterol levels have also been demonstrated to modulate the innate response. 
For example, Prunet and colleagues have shown that oxysterol, (the oxidised form of 
cholesterol), initiates an inflammatory response in macrophages (Prunet, Montange 
et al. 2006) . 
Moreover, the level of intracellular cholesterol can modify the innate response. 
Increased cellular free cellular cholesterol enhances TLR signalling (Joseph, 
Castrillo et al. 2003; Naiki, Sorrentino et al. 2008) and enhances pro inflammatory 
cytokine response (Zhu, Lee et al. 2008)(Zhu 2008). In addition, Abca1 -/- mice 
show a reduction in IFN and ILl signalling in macrophages (Yvan-Charvet, Wang et 
al. 2010), indicating that cholesterol efflux is specifically involved in the regulation 
of the synthesis of inflammatory cytokines. 
1.5.2.3 Limitation of current studies 
It is worth noting that the interplay between innate immunity and cholesterol 
metabolism is generally studied using only two models. The first uses macrophage 
derived foam cells in the context of atherosclerosis. The second model uses hepatic 
cell. These 2 cell types are specifically involved in the regulation of lipid 
metabolism. They have probably a specific response to inflammatory stimuli, which 
differ from other cell type, such as fibroblasts or macrophages. Strikingly, very little 
is known about the interplay between innate immunity and cholesterol metabolism in 









1.6 Hypothesis and objectives of the thesis 
Today there is a body of evidence that suggests that viral infection depends on 
cholesterol metabolism and sterol biosynthesis especially. On the other hand, innate 
immunity cross reacts with the regulation of cholesterol metabolism through 
inflammatory cytokines and cellular signalling. However, the question remains open 
as to whether changes in cholesterol metabolism are also part of a protective immune 
regulation. The effect of mCMV infection on cholesterol metabolism and its 
consequences for the host and the virus are largely unknown. Nevertheless evidence 
suggests that cholesterol is involved in the CMV infection. 
These studies led us to hypothesise that the innate immune response plays a role in 
the regulation of cholesterol metabolism following mCMV infection. 
 
To test our hypothesis, 4 objectives were defined: 
 To characterise the regulation of cholesterol metabolism by mCMV infection. 
 To test whether these changes play a role in modulating the infection. 
 To investigate the role of the innate immunity in the changes of cholesterol 
metabolism induced by the infection. 
  To understand which signalling pathways triggered by the immune response 















2 Chapter 2: Materials and methods 
2.1 Tissue culture 
2.1.1 Cell lines 
NIH/3T3 cells and MEFs-P53 -/- cells were obtained from American Type Culture 
Collection (Manassas, VA.).  NIH/3T3 (ATCC CRL1658) cells are spontaneously 
immortalized fibroblast cells, derived from mouse embryonic origin. MEFs P53 -/- 
(ATCC CRL2645) was derived from mouse embryos that had null mutations in the 
p53 gene only.   
L929 cells were from Sigma (85011425, Poole, Dorset, UK). Cell line L929 is a 
subclone of the parental strain L, which was derived from normal subcutaneous 
areolar and adipose tissue. 
NIH-Bam25 cells were derived from NIH/3T3 cells by co-transfecting pBAMB25 (a 
plasmid containing the mCMV ie1 and ie3 genes by Angulo and colleagues (Angulo, 
Ghazal et al. 2000). 
All cell lines were cultured at 5% CO2, 95% humidity and at 37°C.  
2.1.2 Cell media and tissue culture consumable 
NIH/3T3 culture media: DMEM supplemented with 10% Calf Serum (CS) (v/v), 0.3 
mg/ml L-glutamine, 1.3% (w/v) streptomycin and 0.6% (w/v) penicillin. 
MEFs-P53 -/- culture media: DMEM supplemented with 10% (v/v) Fetal Calf Serum 
(FCS), 0.3 mg/ml L-glutamine, 1.3% (w/v) streptomycin and 0.6% (w/v) penicillin. 
L929 culture media: DMEM supplemented with 10% (v/v) FCS, 0.3 mg/ml L-
glutamine, 1.3% (w/v) streptomycin and 0.6% (w/v) penicillin. 
BMDMs culture media: DMEM-F12 supplemented with 10% (v/v) FCS, 10% L929 
conditioned media, 0.3 mg/ml L-glutamine, 1.3% (w/v) streptomycin and 0.6% (w/v) 
penicillin.  
Bam25 culture media: DMEM supplemented with 10% (v/v) FCS, 0.3 mg/ml L-
glutamine, 1.3% (w/v) streptomycin and 0.6% (w/v) penicillin. 
All tissue culture flasks and 96, 48 or 6-well were obtained from Nunc (Copenhagen, 
Denmark). DMEM was from Lonza (UK), DMEM-F12 was from Gibco (Paisley, 
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UK), L-glutamine, streptomycin and penicillin were from Invitrogen, trypsin/EDTA 
was from Lonza. 
2.1.3 Passaging cells 
Cell lines were expanded by passaging them 1:3 to 1:5 every 3 to 4 days when they 
reached 70 to 80% confluency. Cells were washed in phosphate-buffered saline 
(PBS) and incubated with trypsin/EDTA for a few minutes at room temperature (the 
volume of trypsin/EDTA depending of the size of the flask). 
After the cells started to detach from the flask, trypsin/EDTA was discarded and the 
cells were harvested and resuspended in an appropriate volume of medium.  
Cells were then centrifuged at 262 g-force for 5 minutes at room temperature, 
supernatant was discarded and the pellet was resuspended in medium to an 
appropriate volume. 
Low passage cells were used as much as possible for all experiments. 
2.1.4 Cell count with trypan blue exclusion assay 
Cells were trypsinised, resuspended in media and diluted (1/2 to 1/10) with trypan 
blue (0.4%). 
Ten µl of the solution was then injected by capillary in a haemocytometer and the 
viable cells counted in the 16 marked squares. The original numbers of viable cells 
per ml were estimated by using the following equation:  
 
Number of viable cells per ml = number of counted cell in the haemocytometer 
* 1*10-4 cm3* dilution factor. 
2.1.5 Cryopreservation of cells 
Cells were trypsinised as described previously, transferred to a plastic Falcon tube 
and centrifuged at 262 g-force for 5 min at room temperature. The cell pellets were 
resuspended in freezing medium (DMEM 40%, FCS 50%, dimethyl sulfoxide 
(DMSO) 10%) and stored into 1.8 ml cryovials (Corning, UK).  
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Cells were first frozen at –80°C overnight to avoid fast cooling and breaking of the 
cell membrane. After 24 hours cells were transferred to a liquid nitrogen container (-
170°C) for long-term storage. 
 
2.1.6 Thawing cells from liquid nitrogen 
Frozen cells from the liquid nitrogen container were transferred on ice and then 
thawed at 37°C. Cells were then transferred to a Falcon tube and culture medium was 
added to dilute the DMSO contained in the freezing medium. Cells were then 
centrifuged at 262 g-force for 5 min at room temperature. The supernatant was 
discarded and the cell pellet resuspended in normal medium and transferred to a 25 
cm2 tissue culture flask and grown as previously described. 
2.1.7 Sterility and cells contamination control 
The study of host/pathogens interactions and of the immune system requires strict 
control over the contamination of the cell lines by pathogens such as bacteria or 
fungi as these could dramatically affect the results of the experiments.  
To avoid cell contamination:  
 Cells were grown in media supplemented with antibiotics: 
penicillin/streptomycin. 
  Incubators and tissue culture hoods were weekly disinfected with antimicrobial 
agents. 
 Every 3 months, random samples of cells were grown in antibiotic free media to 
examine for the presence of mycoplasma and lymphotoxin contamination 
(SNBTS (Edinburgh, UK)). 
New cells brought to the tissue culture from other laboratories were placed in a 
quarantine incubator for a few days. Cells were then cultured in antibiotic free 







2.1.8 Seeding cell 
For each cell type, optimal seeding density was determined for every plate’s format. 
Table 2-1: Cell seeding density 
 96 well plates 48 well plates 24 well plates 6 well plates 
NIH/3T3 2 10^4 4 10^4 1 10^5 3 10^5 
MEFs-P53 -/- NA 2 10^4 4 10^4 3 10^5 
Bam25 2 10^4 4 10^4 1 10^5 3 10^5 
BMDMs 4 10^4 NA 2.5 10^5 1 10^6  
NA: Not applicable 
 
2.1.9 Preparation of L929 conditioned media 
L929 media was used as a source of Macrophage Colony Stimulating Factor 1 (M-
CSF1) to differentiate bone marrow hematopoietic stem cells into macrophages. 
M-CSF is a cytokine secreted by mesenchymal cells that stimulates survival, 
proliferation and differentiation of bone marrow hematopoietic stem cells into 
mature monocytes. Constant stimulation of monocytes by M-CSF leads ultimately to 
their differentiation into bone marrow macrophages (BMDMs). 
L929 cells were grown in a T175 tissue culture flask until 80% confluence. Cells 
were then trypsinised, split into 30 T175 flasks and grow for 14 days.  
The supernatant was then collected into 50 ml Falcon tubes and centrifuged at 262 g-
force to pellet the cell debris. Supernatant was then collected, aliquoted and stored at 










2.1.10 BMDMs culture 
2.1.10.1 Bone marrow primary cell isolation 
Bone marrow primary cells were extracted from 10-12 week old male BALB/c mice. 
Mice were sacrificed by cervical dislocation and femurs were gently extracted under 
sterile conditions. After removing excess tissue of the bones, both ends of each femur 
were cut off and the marrow cavity of the femur was flushed with DMEM-F12 
supplemented with 10% FCS and 10% L929 conditioned media. Cells were 
recovered in a 50 ml Falcon tube on ice and counted as previously described. 
2.1.10.2 Characterisation of BMDMs by FACS analysis 
Mature Macrophages, express specific proteins including CD14, CD11b, F4/80 
(mice), Lysozyme M, MAC-1/MAC-3 and CD68. The efficiency of the 
differentiation of the bone marrow cell into macrophages is assessed using 
fluorescence-activated cell sorting (FACS) analysis to measure the presence of these 
antigens on the surface of the cell. 
Freshly extracted bone marrow stem cells were plated on either 6- or 24- well plates 
and cultured for 7 days in DMEM-F12 containing 10% FCS and 10% L929 
conditioned media. Media was replaced every 3 days for 7 days to maintain constant 
stimulation with M-CSF1. To ensure that monocytes had developed fully into mature 
macrophages, the presence of F4/80 and CD11b protein at the surface of the 
macrophages was tested by flow cytometry analysis. Monocytes were cultured for 
seven days in the presence of M-CSF1 in order to mature into macrophages. At day 
seven, cells were washed with PBS twice, scraped off and transferred to a 
polystyrene FACS tubes (BD Falcon, UK). Tubes were then centrifuged at 1000 g 
for 5 minutes at 4 °C. After discarding the supernatant, the cells were washed with 
cold PBS and resuspended in 100 µl of blocking solution (10% mouse serum) for 30 
minutes on ice to avoid non-specific antibody binding. Allophycocyanin (APC) 
conjugated monoclonal rat-anti-mouse F4/80 (IgG2a·, Caltag Laboratories, UK) and 
fluorescein isothiocyanate (FITC) conjugated rat-anti-mouse CD11b (IgG2b·, 
eBiosciences, UK) and their isotype controls were then added to the cells  (1/100 
dilution in blocking solution) and incubated for further 30 minutes in the dark. Cells 
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were then washed with cold PBS, centrifuged and resuspended in 250 µl of cold 
PBS. 
A FACScan instrument (Becton Dickinson, UK) was used to perform FACS analysis 
of the samples and the data were analysed using Cell Quest software (Becton 
Dickinson, UK) or FlowJo software (Treestar, USA). Figure 2-1 shows that 93.1% of 
the cells were both F4/80 and CD11b antibody positive but not for their isotypes. 
These results indicate that our protocol for maturation of monocytes with M-CSF1 























The level of expression of surface proteins F4/80 and CD11b and their respective 
isotypes was analysed by flow cytometry. A. Dot blot showing the gating in forward 
scatter (FSC) and side scatter (SSC). B. Histograms for C. F4/80 and D. CD11b 
staining. Experiments were performed in collaboration with Dr Sara Rodriguez 
Martin from The Division of Pathway Medicine (Edinburgh University). 
 
 
Figure 2-1: Phenotypic characterisation of BMDMs by flow cytometry 
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2.2 General methods for virology 
2.2.1 Viruses 
C3X strain viral stock was generated from the recombinant bacterial artificial 
chromosome clone pSM3fr, originally derived from the mCMV strain MW97.01 
(Messerle, Hahn et al. 2000). 
PSM3fr-rev (called mCMV-GFP in this study) viral stock was generated from the 
recombinant virus originally named pSM3fr (Angulo, Ghazal et al. 2000) using 
homologous recombination in E. coli. mCMV-GFP recombinant viruses express the 
green fluorescent protein (GFP) marker inserted in front of the ie2 gene. 
C3X-IE3 KO virus originally named pSM3frdie3 and was generated by homologous 
recombination from the pSM3fr BAC(Angulo, Ghazal et al. 2000). C3X-IE3 virus is 
lacking the ie3 gene. 
Details of the genome structure of the viruses are presented in Figure 2-2. 
HSV and RSV viral stock were kindly provided by Diwakar S Kumar and Dr 
























Coding exons are shown as black rectangles. The blue box represents the mCMV 
enhancer ie1/ie3 promoter. The structures of the ie1 and ie3 transcripts are indicated 
below the genome representation. Starting with A: mCMV: the ie1 transcript of 
mCMV wild type viruses consists of exons 1 to 4, and the ie3 transcript is composed 
of exons 1 to 3 and 5. B, mCMV-GFP: GFP gene is shown (green box) and C, 
mCMV-IE3KO, the deletion of the fifth exon of the ie1 gene is marked by the delta. 
All viruses were generated by successive rounds of homologous recombination in E. 
coli (Angulo, Ghazal et al. 2000). 
 
 
Figure 2-2: Schematic representation of the immediate early gene coding region of mCMV, 
mCMV-GFP and mCMV-IE3KO viruses. 
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2.2.2 Viral stock propagation 
70 to 80% confluent cells in a tissue culture flask were infected with an MOI of 0.1 
in 3% serum media. The cells and the supernatant were harvested 5-7 days after 
infection when a nearly complete cytopathic effect (CPE) was observed. The 
supernatant was collected, spun at 1640 g-force for 15 minutes to remove cell debris 
and transferred to ice cold in 50 ml Falcon tubes. The concentrated viral stock was 
then stored at -70°C. 
In order to avoid or limit the risk of viral mutations occurring during multiple rounds 
of infection, viral stocks were generated in two steps. First a master stock was 
produced in a T25 tissue culture flask from the original viral stock (low passage 
number) and aliquots stored at -70°C. These aliquots were then used to generate 
working viral stocks in T175 tissue culture flasks. NIH/3T3 cells were used to grow 
C3X and CMV-GFP viral stock, while Bam25 cells were used to grow the IE3-KO 
viral stocks, as Bam25 cells express the ie3 gene. 
2.2.3 Concentrating viral stock 
In order to increase viral titre and to purify the viral particles, all the viral stocks 
were concentrated and resuspended in fresh media or PBS. 
Frozen viral stock were thawed in a 37oC water bath and stored on ice at 4oC. Ten ml 
of a 20% sorbitol - 0.01 M Tris-buffered saline (TBS) pH 7.8 solutions was added to 
centrifuge tubes (Sorvall) on ice. The viral stock (20 ml) was gently and slowly 
pipetted down the side of the tube so as not to disturb the sorbitol cushion and to 
ensure that separate layers form. The tubes were weighed and balanced within 0.5 of 
a gram and centrifuged at 26 000 x g for 70 minutes at 4oC to precipitate the viral 
particles. The supernatant was removed and pellets were resuspended in a small 
volume with DMEM, 10% FCS or PBS. Viral preparations were pooled together, 
aliquoted in a small volume (50 to 200 µl) and stored at -70 oC for further use.  
As a large percentage of viral particles were lost during the purification, 






2.2.4 Viral infection 
All cell types were infected with the mCMV viruses (C3X, mCMV-GFP, mCMV-
IE3) at a MOI of 1, unless specified. The viral inoculum was diluted to the 
appropriate concentration in fresh DMEM 3% CS (FCS for P53-/- and BMDMs), and 
penicillin/streptomycin. Cells were left for 1 hr adsorption with gentle shaking of the 
plate every 10 minutes at 37oC. After 1 hr absorption, inoculum was aspirated and 
cells washed twice with PBS. Fresh DMEM with either 10 % CS or FCS, and 
penicillin/streptomycin were then added to cells.  
2.2.4.1 Multiplicity of infection 
The multiplicity of infection or MOI has been defined has the ratio of infectious unit 
to cell. An infectious unit refers to the viral particles capable of producing an 
infection in a susceptible cell. 
In permissive cells, infection depends on the random collision of cells and virus 
particles and the distribution of virus particles per cell follows a Poisson distribution: 
 
 
Where m is the multiplicity of infection or MOI, k is the number of infectious agents 
that enter the infection target, and P(n) is the probability that an infection target (a 
cell) will get infected by n infectious agents. 
Consequently, when susceptible cells are mixed with a suspension of virus some 
cells are uninfected and other cells may receive one or more viral particles. Therefore 
a MOI=1 (1 infectious unit per cell) is not sufficient to infect the total cell 
population. Increasing the MOI number augment the number of infected cells: for 
example permissive cells infected at a MOI of 1 will results in the infection of 63.2% 
of the cell population while infection with a MOI of 5 will results in the infection of 
99.3%. 
In non or less permissive cells for a given virus (for example macrophages and 
mCMV), the infection of the cells does not depends only on the random collision of 
viruses and cells but also in the cellular factors affecting the viral entry and 
     e-mmk 
P(K) =  
         K! 
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replication. As a result, infection with a given MOI results in a smaller percentage of 
infected cells. 
2.2.5 Plaque assay and viral stock titration 
The Plaque assay is the gold standard technique to quantify the titre of infectious 
viruses in an infected sample. The principle of a plaque assay is based on the dilution 
of a solution of the virus, which is applied to a culture dish containing a layer of the 
host cells. The spreading of the infection is prevented by making the medium very 
viscous. After incubation the plaque forming units or PFUs (areas in which cells 
have been lysed), can be counted and the number of infective virus particles in the 
original suspension estimated. To minimize error, only the wells containing between 
10 and 100 plaques are counted. Low passage (less than 10) MEFs P53-/- were 
grown to reach 70 to 80% confluency, tryspinsed and plated (5x10^4 cells per well) in 
48 well plates.  
The following day, cells were infected as described before with 100 µl of the viral 
suspension (10-2 to 10-8 in DMEM supplemented with 3% FCS). After 1 hr 
absorption, cells were washed with DMEM and supplemented with 1 ml of DMEM 
supplemented with 3% FCS at 37 oC mixed with 2.5% melted agarose.  
Plates were placed in an incubator and after 3 to 4 days incubation. Plaques were 
counted in each well and the viral titres were expressed as plaque forming units per 





The kinetics growth of each virus was also quantified with a plaque assay for 5 days 
post infection at least in two independent assays with triplicate for each time point. 
 
 
                Number of plaques*dilution of viral stock    
Viral titre in PFU/ml= 
         Volume of viral inoculums (ml) 
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2.2.5.1 Growth kinetics of mCMV-C3X in NIH/3T3 fibroblasts and BMDMs 
Replication of the wild type virus mCMV-C3X was analysed in NIH/3T3 fibroblasts 
and BMDMs by performing single and multi step-growth curve characterisation. A 
single-step growth curve (high MOI) allows the study of the infection of the total 
population of cells simultaneously and displays information related to the burst and 
replication of the virus. The multi-step growth curve (low MOI resulting in multiple 
rounds of infection) displays information related to the budding and the cell to cell 
spread of the virus.  
NIH/3T3 fibroblasts and BMDMs were infected at low (0.1) and high (1) MOI for 
five days and the number of viral particles in the supernatant was estimated each day 
using a standard plaque assay technique (2.2.5). 
For the single-step growth analysis, fibroblast cultures that were infected with 10^5 
mCMV-C3X viral particles displayed rapid increases in the viral titres after two days 
of infection (around 1.5x10^5 PFU), followed by a continuous increase at day three 
and four (up to 4.10^6 PFU. At day 5 the number of viral particles levelled off or 
even decreased (1 10^6 PFU) reflecting the saturation and death of the infected cells 
(Figure 2-3A). 
For the multi-step growth analysis NIH/3T3 fibroblasts were infected with 10^4 PFU 
(MOI 0.1) resulting in a continuous increase of viral particles from day 2 (5.10^3 
PFU) up to day 5 (3.10^6 PFU), reflecting the increasing numbers of infected cells 
producing de novo viral particles (Figure 2-3A). 
Single step growth analysis with BMDMs infected with 10^5 PFU showed (Figure 
2-3B) a lower number of viral particles produced from day 2 (5.10^3 to day 5 (3.10^4) 
PFU) of infection compare to infected fibroblasts Multi-step growth analysis of 
BMDMs infected with 10^4 PFU also showed a lower production of viral particles 





Figure 2-3: Kinetics of mCMV-C3X in murine NIH/3T3 fibroblasts and 
BMDMs 
A: NIH/3T3 fibroblasts were infected at an MOI of 1 (Single step) or 0.1 PFU (Multi 
step) per cell with wild-type mCMV-C3X viruses. One experiment with three 
biological replicates was performed (n=3). Each data point represents the average 
and standard deviation from three independent wells. 
B: BMDMs from Balb/c mice were infected at an MOI of 1 (Single step) or 0.1 PFU 
(Multi step) per cell with wild-type mCMV-C3X viruses.   
At the indicated time points after infection supernatants from the infected cultures 
were harvested, and titres were determined by standard plaque assay on MEFs p53 -
/- cells. One experiment with three biological replicates was performed (n=3). Each 













2.2.6 Viral growth kinetics comparison of mCMV-C3X and mCMV-GFP in 
NIH/3T3 fibroblasts 
mCMV-GFP virus was used in this study to measure the replication of the virus upon 
treatment of NIH/3T3 live cells with siRNA or various drugs. The amount of 
fluorescence emitted from the infected cells was used to estimate viral replication 
(2.9). To ensure that mCMV-GFP and the wild type viruses had the same 
characteristics of replication, growth kinetic analysis of the 2 viruses in NIH/3T3 
fibroblastss was performed at low and high MOI. Results (Figure 2-4) show that the 
growth kinetics of the mCMV-GFP virus and the wild type were comparable at low 
and high MOI. These results are similar to those of the study done by Angulo and 
colleagues (Angulo, Ghazal et al. 2000). 
 
Figure 2-4: Growth kinetics comparison of mCMV-C3X and mCMV-GFP in 
NIH/3T3 fibroblastss 
A: Cells were infected at an MOI of one (Single step growth curve), or B:  0.1 PFU 
per cell (Multi step growth curve) with wild-type mCMV-C3X or the GFP tagged 
mCMV-GFP virus. At the indicated time, supernatants from the infected cultures 
were harvested, and titres were determined by standard plaque assay on MEFs p53 -
/- cells. For both graphs, one experiment with three biological replicates was 
performed (n=3). Each data point represents the average and standard deviation from 
three independent wells. 
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2.2.7 Viral growth kinetics comparison of mCMV-C3X and mCMV-IE3KO in 
BMDMs 
In this study, mCMV-IE3KO (2.2.1) was used to investigate the consequence of a 
non productive infection. To ensure that mCMV-IE3KO was not able to replicate in 
BMDMs, growth kinetic analysis of mCMV-IE3KO virus compared to mCMV-C3X 
was performed in BMDMs at low and high MOI. Results (Figure 2-5: Comparison of 
growth kinetics of mCMV-C3X and mCMV-IE3 in Figure 2-5) show that mCMV-
IE3KO infection of BMDMs in low and high MOI does not result in any plaque 
formation as seen with the wild type virus over 5 days of infection.  
 
Figure 2-5: Comparison of growth kinetics of mCMV-C3X and mCMV-IE3 in BMDMs 
BMDMs from C57bl6 were infected at an MOI of 1 (Single step growth curve) or 
0.1 (Multi step growth curve) PFU per cell with wild-type mCMV-C3X virus or the 
mutant mCMV-IE3KO virus. At the indicated time points after infection (dpi) 
supernatants from the infected cultures were harvested, and titres were determined by 
standard plaque assays on MEFs p53 -/- cells. For both graphs, one experiment with 
three biological replicates was performed (n=3). Each data point represents the 







2.3 Cytokines and pharmacological treatment  
IFNγ was from Boehinger Manheim Corp and IFNβ, IL6, TNF and IL1β were from 
Biosource International, USA. Each cytokine was dissolved in PBS and 0.1% 
albumin, aliquoted and stored at – 70oC 
 
Simvastatin (Sigma-Aldrich) was activated by hydrolysis of the lactone ring by 
adding 1 ml of 0.1 N NaOH, 96 % ethanol to 25 mg of simvastatin powder. 
After heating at 50 °C for 2 hrs the solution was neutralized with HCl to a pH of 7.2 
and sterilised by filtration through a 0.2 μM filter. 
The stock solution was diluted to the appropriate concentration in sterile PBS and the 
solution was aliquoted and stored at −20°C and used within a month.  
 
Mevalonate (Sigma-Aldrich, Germany) was resuspended in media to the appropriate 
concentration by vortexing the solution, sterilized by filtration through a 0.2 μm filter 
and stored at -20oC 
 
Geranylgeraniol, farnesol and squalene (Sigma-Aldrich) were dissolved to the 
appropriate stock concentration in DMSO, sterilised by filtration through a 0.2 μm 
filter and stored at -20°C. For tissue culture experiments geraniol and farnesol were 
diluted in media before use. 
 
Methyl-cyclodextrin was resuspended on the day of the experiment in media (with 
no serum) to the appropriate concentration by vortexing the solution and sterilised by 
filtration through a 0.2 μm filter.  
 
Gancyclovir (Cymevene, Hoffman-La Roche, UK) was resuspended in saline 
solution and sterilised by filtration through a 0.2 μm filter. Gancyclovir was then 





2.4 In vivo studies 
2.4.1 Mice and infection 
Mice were housed in the animal facilities at the University of Edinburgh under 
pathogen free conditions.  
All experiments and handling of the animals were carried out under appropriate 
personal and project licences (Prof P.Ghazal, University of Edinburgh) in accordance 
with the Home Office and the University of Edinburgh regulations.  
Mice (C57/BL6, Charles River, 12 weeks of age) were randomized into 2 groups of 
six animals a week prior to the experiment. 
After treatment with simvastatin (see below) at day 0, at day 1 of the experiment, 
mice were inoculated with 2 x 106 PFU by intraperitoneal injection (i.p) and 
monitored daily. At day 5, mice were sacrificed by cervical dislocation. This 
experiment was repeated twice independently. 
2.4.2 Simvastatin treatment 
Mice were given 50 mg/kg of activated simvastatin (Sigma) resuspended in 150 µl of 
PBS by gavage by a trained animal technician daily. 
The dosage of statins used in the present investigation was chosen according to the 
literature (Gower and Graham 2001) and was approved by the Home Office. No 
toxic effect in the mice during the course of the treatment was observed in response 
to simvastatin treatment 
2.4.3 Sample processing 
All the following procedures are performed on ice at 4oC in a class I cabinet. Spleen, 
liver, kidneys, lungs and hearts were removed and placed in 500 µl of PBS. Organs 
were weighed and resuspended in 10% (w/v) DMEM media under sterile condition. 
Tissues were homogenised with a tissue homogeniser and sonicated (1 pulse of 10 s, 
maximum power (800 W, Fisher Scientific) in order to free the viral particles from 
the cells. Samples were centrifuged to pellet the cell debris and supernatant was 
taken and kept at -70oC until further use. Viral titres were determined by standard 
plaque assay as mentioned above. 
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2.5 Molecular methods 
2.5.1 RNA extraction using Trizol® 
Cells were washed twice with PBS, and lysed with the appropriate volume of Trizol® 
reagent (Invitrogen, CA): 200 µl for 24 well-plates and 500 µl for 6 well-plates. 
After incubation for 5 minutes at room temperature, samples were transferred to a 1.5 
ml microfuge tube and stored at -70 ºC until further use. RNA was extracted after 
samples defrosted at room temperature by the addition of 1/5 of volume trizol. 
Samples were mixed gently by hand and incubated at room temperature for 1 minute 
and centrifuged (12000 g-force, 4 ºC for 15 minutes). The aqueous phase containing 
the RNA was collected carefully in a fresh tube in order to avoid proteic organic 
lower contamination. An equal volume of chloroform was added to the tubes to 
perform a second chloroform extraction as mentioned before. Finally, the upper 
aqueous layer was placed in a fresh tube and 0.1 volumes 3 M sodium acetate 
(NaOAc), 2.5 volumes ethanol (EtOH) were added to precipitate the RNA. Samples 
were incubated (-70 ºC, 1 hr) and then centrifuged (12000 g-force, 4ºC, 30 minutes). 
Supernatant was removed and the RNA pellets washed in 200 µl 70% (v/v) ethanol 
and centrifuged as before. This step was repeated twice. Samples were then DNAse 
(Sigma) treated to avoid any DNA contamination and RNA pellets were then 
resuspended in 50 µl RNAse-free H2O. 
2.5.2 RNA quantitation 
RNA quantity and purity was assayed using a spectrophotometer (Nanodrop ND-
1000 (Nanodrop Technologies, Germany). Ratio of the absorption at 260 and 280 nm 
(A260/A280) was used to assess the protein (optimal absorbance at 280nm) 
contamination of a DNA sample (optimal absorbance at 260 nm).  
Ratio A260/A230 was used to assess the organic (phenol, chloroform) contamination, 
which tends to have an optimal absorbance at 230 nm. 
Samples with a ratio A260/A230 ≥ 1.8 and a ratio A260/A280 ≥ 2 were selected for 
further quantitative PCR analysis. 
To assess the RNA integrity, a 2100 Bioanalyzer (Agilent) was used and the samples 
having a RNA integrity number (RIN number) of ≥ 9.0 were chosen.  
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2.5.3  Transcript quantification with real time quantitative PCR  
2.5.3.1 Principle 
Taqman primers probe/set contains 2 set of primers (forward and reverse) which are 
complementary oligonucleotides to the 5’ and 3’ area of the region of the cDNA to 
amplify. Taq polymerase will initiate the formation of the amplicon defined by the 2 
primers. TaqMan primers/probe set also contains a probe, which encloses 2 
fluorescent reporter dyes, 6 -carboxyfluorescein (FAM) and 6-carboxy-tetramethyl-
rhodamine (TAMRA).  FAM has its emission quenched due to the spatial proximity 
of TAMRA.  
During the extension phase of the PCR, the Taq polymerase cleaves the TaqMan 
probe, resulting in the release and accumulation of FAM no longer quenched by 
TAMRA. The amount of fluorescence will hence determine the initial concentration 
of RNA allowing quantification and therefore comparison. Because the PCR reaction 
is exponential until it reaches a plateau due to shortage of resources, the 
quantification of the fluorescence is done during the exponential phase of the PCR 
reaction using cycle threshold (Ct) value as a unit. Ct values represent the number of 
cycles requires for the fluorescence signal to reach a threshold of detection. Ct values 
are inversely proportional to the number of copies of the RNA targeted in the 
samples. The lower the Ct level the greater the amount of target RNA in the sample.  
2.5.3.2 Methods 
Commercially available “ready to use” Taqman primer probes set (Applied 
Biosystems, CA) was used for all Quantitative PCR experiments (QPCR).  
PCR reactions were performed using the Brilliant II QRT-PCR Master MixnKit 1 
step from Stratagene. Brilliant Master Mix contains the StrataScript® Reverse 
Transcriptase (RT), and enough oligonucleotides and magnesium to allow the 
formation of cDNA and its PCR amplification from the original mRNA in the same 
sample. 
For each sample QPCR was performed in 20 µl final volumes using MicroAmp 
Optical 96-well reaction plates and MicroAmp Optical Caps (Applied Biosystems).  
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Per reaction, 2 µl diluted RNA sample (~100 ng of RNA) was added to 10 µl 2 X 
Brilliant II master mixes, 1 µl Taqman primer/probe set for the gene of interest, 0.25 
µl StrataScript (Stratagene) and 6.25 µl double-distilled H2O. 
Data were collected using the Mx3000P instrument (Stratagene). 
After an initial incubation at 50 °C for 30 seconds to activate the RNA reverse 
transcriptase and allow cDNA synthesis, samples were then subject to 40 cycles 
under Taqman standard conditions: combined annealing and primer extension phase 
at 60 °C for 1 minute and a short denaturation  at 72 °C for 30 s.  
2.5.3.3 Analysis of the data 
Relative transcript quantification of the genes of interest was performed using the 
ΔΔct method(Livak and Schmittgen 2001) This method calculates the ratio of Ct 
value of the gene of interest to the Ct value of a housekeeping gene to give a 
‘normalised’ value. The normalised values are used to determine differential gene 
expression of the samples treated with various conditions.  
Gapdh was used as a housekeeping gene for each experiment. The stability of Gapdh 
expression with or without mCMV infection was checked in several micro array data 
sets (data not shown). 
Efficiency of the PCR reaction for each primers probe set was calculated by 
comparing the results of a standard curve using serial dilution of RNA samples. 
Stratagene MXPro software was then used to analyse the data. Threshold of detection 
and ratio determinations were automatically performed by the software and the 











2.5.4 Primer list 
The following lipid genes were used to examine the effect of mCMV infection as summarised in Table 2-2. 
Table 2-2: TaqMan primers/probes 







Coenzyme A reductase 
Mm.475623 Mm01282500_g1 19 - 20 82 82% 
Hmgcs1 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1 
Mm.61526 Mm00524111_m1 2 - 3 62 98% 
Sqle squalene epoxidase Mm.218665 Mm00436772_m1 2 - 3 72 105% 
Ldlr low density lipoprotein receptor Mm.3213 Mm00440169_m1 14 - 15 63 95% 
Ch25h cholesterol 25-hydroxylase Mm.30824 Mm00515486_s1 1 - 1 126 69% 
Idi1 isopentenyl-diphosphate delta 
isomerase 
Mm.29847 Mm00836417_g1 2 - 3 82 101% 
Abca1 ATP-binding cassette, sub-
family A (ABC1), member 1 
Mm.277376 Mm01350760_m1 2 - 3 65 74% 
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2.6 Measurement of free cholesterol concentration by enzymatic method 
Intracellular cholesterol concentration was determined enzymatically using the 
Amplex-Red cholesterol Assay Kit (Molecular Probes, the Netherlands) according to 
manufacturer protocol (Cullen, Tegelkamp et al. 1997; Amundson and Zhou 1999).  
Briefly, cells were washed with 1 ml cold PBS and then lysed in 200 μl cold “Lipid 
buffer” containing 0.5M of potassium phosphate, pH 7.4, 0.25 mM cholic acid, and 
0.5% Triton X-100. Cell lysates were sonicated on ice with three 10-second pulses at 
high intensity (800 W).  
To determine free cholesterol concentration, 20 μl of the samples were then mixed in 
a 96 well plate with 80 μl assay solution containing 300 μM Amplex Red reagent, 2 
U per ml of horse radish peroxidise (HRP) and 2 U per ml cholesterol oxidase, 0.1M 
of potassium phosphate, pH 7.4, 0.05 mM cholic acid, and 0.1% Triton X-100. 
After preincubation for 30 min at 37 °C in the dark, fluorescence was measured for 
30 min (excitation signal of 530 ± 2.5 nm and fluorescence detection at 590 ± 2.5 
nm) using a Polarstar Optima Multifunciton Microplate Reader (BMG Labtech, UK). 
The values were corrected for the background signal determined by blank samples 
value.  
A standard curve was constructed using the manufacturer’s supplied free cholesterol 
and was used to calculate the amount of free intra cellular cholesterol. 
 
2.7 Analysis of lipids using high performance liquid chromatography/mass 
spectrometry and Electrospray ionization.  
Lipid extraction of samples was performed using Bligh and Dyer method (Bligh and 
Dyer 1959) with chloroform methanol 2:1 ration. Samples were dried under Argon 
and re-suspended in chloroform 1:1. An Agilent high performance liquid 
chromatography (HPLC) system coupled with an Applied Biosystem Triple 
Quadrupole/Ion Trap mass spectrometer (4000Qtrap) was used for quantification of 
individual polar lipids (Phospholipids and sphingolipids). Electrospray ionization-
based multiple reaction monitoring (MRM) transitions were set up for the 
quantitative analysis of various polar lipids (Fei, Shui et al. 2008). HPLC atmosphere 
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chemical ionization (APCI)/MS were carried out for analysis of sterols (Huang, Shen 
et al. 2006). Samples preparation and lipid extraction was performed by M BLANC, 
University of Edinburgh, UK, lipidomic analysis was performed by Dr G SHUI, 
National University of Singapore, Singapore.  
 
2.8 Transfection and SiRNA knock down assay   
To transfect NIH/3T3 cell in 96 well plate’s format at a SiRNA concentration of 25 
nM, the following protocol was applied. 
NIH/3T3 cells were grown to 70-80 % confluency, washed with PBS, trypsynised 
and resuspended in antibiotic free media on ice until transfection. 
SiRNAs (SMARTpools -ON-TARGETplus modification) were from Thermo Fisher 
Inc, USA.  Various SiRNA samples (5 nM) were supplied in powder form, dissolved 
and aliquoted (2 µM) in SiRNA buffer 1X (Thermo Fisher). 
For each transfected well, 1 µl of siRNA SMARTpool was used with 9 µl of 
Optimem solution (Invitrogen, CA, USA) while 0.4 µl of Dharmafect1 (Dharmacon, 
Perbio Science, Bonn, Germany) was mixed with 9.6 µl Optimem. Following 
incubation for 5 minutes, the SiRNA mix was added to the Dharmafect1 mix (0.4%) 
and incubated for a further 30 minutes. 
NIH/3T3 cells (1.5x104 in 80 µl of DMEM 10% CS medium lacking antibiotics) 
were added to the SiRNA-Dharmafect1 complexes and mixed gently for few min. 
Growth medium was then removed  from the wells and cells were washed once with 
PBS before 100 µl of the siRNA:. Dharmafect1-liposomes mixture was added 
carefully to the well. 
Transfection conditions were optimized by using SiGLO red (Dharmacon) as an 
indicator of transfection efficiency and cell viability was assessed using Cell titer 
blue assay (Promega) according to manufacturer instruction. SiGLO red contains 
fluorescent oligonucleotides that localise to the nucleus thus permitting the visual 
assessment of SiRNA uptake into mammalian cells.  
For negative control, SiGLO Risk free, non-targeting (SiRNA having no target 




Transfection efficiency during each experiment was monitored by using eGFP 
SiRNA to knock-down the GFP expression induced by the viral gene expression. 
2.9 Live cell replication assay 
To measure the effect of multiple drugs and SiRNA transfection on viral growth, a 
sensitive live cell infection assay was developed using the properties of the mCM 
GFP tagged virus.  1.5 x 104 NIH/3T3 cells were infected for 1 hr in black 96 well 
plates (Costar, UK) at a MOI of 0.2 in 25 µl of fresh DMEM phenol red-free media, 
3% FCS, and 100 U of penicillin/streptomycin per ml. After infection, the inoculums 
was carefully removed by pipetting and replaced by 150 µl of DMEM phenol red-
free media with 10% FCS.  
Viral growth was measured by recording the GFP signal over time using an 
OPTIMA Polarstar plate reader (excitation wave length of 485 nm and emission of 
520 nm). As an optimisation step we checked the correlation between GFP levels and 
MOIs. Results showed a correlation between multiplicity of infection and growth 
kinetics (Figure 2-6). Levels of GFP signal corresponding to different levels of virus 
was checked by comparing the GFP value and number of viral particles per ml using 
plaque assay. A strong correlation between differences in levels of GFP expression 
and differences in number of viral particles assessed by plaque assay: a drop of 20% 
of GFP signals corresponding to log difference in the number of viral particles 































1.5 x 104 NIH/3T3 cells were infected for 1 hr in black 96 well plates (Costar, UK) 
at a MOI of 0.0.1, 0.1 or 1 in 25 µl of fresh DMEM phenol red-free media, 3% FCS, 
and 100 U of penicillin/streptomycin per ml. After infection, the inoculums were 
carefully removed by pipetting and replaced by 150 µl of DMEM phenol red-free 
media with 10% FCS.  
Viral growth was measured by recording the GFP signal over time using an 
OPTIMA Polarstar plate reader (excitation wave length of 485 nm and emission of 
520 nm). One experiment with six biological replicates for each conditions was 
performed (n=6).Each data point represents the average and standard deviation from 
six independent wells. 
Figure 2-6: Correlation between multiplicity of infection and GFP signal 
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2.10 Bioinformatics analysis 
2.10.1 Micro-array experiment and data analysis 
For the research reported in this thesis, three micro-array data sets were used to 
examine the effect of interferon treatment or viral infection on BMDMs. 
Experiments were performed by Dr Garwin Sing and Andrew Livingstone, array data 
processing was performed by Marie Craigon and Alan Ross. Data analysis was 
performed by Thorsten Forster and Dr Paul Dickinson. All are from the Division of 
Pathway Medicine (University of Edinburgh). Details of the experiments and data 
processing and analysis are in appendix 3. 
2.10.2 Pathway analysis 
Generation of lipid associated genes list 
In order to create a database of lipid associated genes (LAGs) list, we used a 
published database of 1224 proteins associated to lipid or lipid metabolism 
(http://www.lipidmaps.org). Lipid maps proteome database (LMPD) is an object-
relational publicly available database of lipid-associated protein sequences and 
annotations using UniProt, EntrezGene, ENZYME, GO, KEGG and other public 
resources. Using web resources:  Netaffx (http://www.affymetrix.com), DAVID 
(http://david.abcc.ncifcrf.gov) and NCBI website, a list of 1080 LAGs was created. 
Each LAGs is associated with LMPD identification number, gene symbol, uniprot Id, 
unigen ID, David ID, Affy ID, Agilent ID, lipids categories (appendix 4). 
 
KEGG analysis 
KEGG metabolic pathway analysis of the LAGs was performed with DAVID, online 
pathway annotation software based on scoring and visualization of the metabolic 
pathways collected in the KEGG database (http://david.abcc.ncifcrf.gov/home.jsp). 
Fisher’s exact test was applied to determine whether or not the proportion of those 
genes is overrepresented in the KEGG pathway. P-value < 0.05 cut off was chosen to 





Ingenuity Pathway network analysis (IPA) 
To extend the pathway analysis of significantly altered lipid associated genes we also 
use the IPA tool (www.ingenuity.com). IPA analysis generates networks connecting 
the differentially regulated genes from published interactions. This approach has the 
advantage of building pathways independently of the traditional canonical pathways 
database. Therefore, this approach potentially highlights unknown relationships and 
connections between genes and proteins. The relationship between the genes (nodes 
in the pathway) is indicated by a line, which corresponds to at least one reference 
from literature. The significance of a canonical pathway is controlled by p-value 
(right-tailed Fisher’s exact test). The significance threshold of a canonical pathway is 
set to two which is derived by -log10 [p value], with p ≥ 2. 
 
Lipid class analysis 
Traditionally lipids are grouped in structurally related classes. In order to study the 
representation of lipids class associated with the regulated LAGs by mCMV 
infection or IFNγ treatment or both, genes were grouped by lipid classes according to 
LMPD classification (http://www.lipidmaps.org). 
 
Clustering analysis of selected metabolic pathways 
Altered metabolic pathways were clustered by the number of common genes 
significantly regulated in each pathway. For this purpose, a matrix of distance of the 
genes shared between each of the significantly altered pathways was created by 
attributing a score of 1 if a gene belongs to both pathways or 0 if not. From the 
matrix a dendogramm representing the distance between each pathway was created. 
The distance between branches represents, how related the metabolic pathways are 









2.11 Statistical analysis 
 
For QPCR and cholesterol metabolism assay, the normal distribution of the data was 
tested by performing a Kolmogorov-Smirnov (KS) test using the online resource: 
(http://www.physics.csbsju.edu/stats/KS-test.n.plot_form.html). 
The data set of the measurement of the gene expression of Hmgcs1: mock vs. mCMV 
which represented 15 data points in each group was used to control the normal 
distribution of the QPCR. 
For the group1: mock treated samples: 0.680 0.700 0.750 0.780 0.950 0.950 0.960 
1.02 1.03 1.20 1.23 1.30 1.35 1.36 1.45. 
KS test showed that the data were consistent with a normal distribution: P= 0.95 
where the normal distribution has a mean= 1.051 and an sdev= 0.2794. 
For the group2: mCMV infected samples: 6.000E-02 0.150 0.210 0.250 0.260 0.290 
0.300 0.340 0.350 0.380 0.400 0.410 0.430 0.520 0.600. 
KS test that the data were consistent with a normal distribution: P= 0.89 where the 
normal distribution has a mean= 0.3314 and an sdev= 0.1675. 
We also evaluated the distribution of the free cholesterol measurement and showed 
with a KS test that there were also following a normal distribution (data not shown)  
As a result for evaluation of statistical significance of QPCR and free cholesterol 
measurement, we used a Welch's t test assuming that the two groups of samples had 
possibly an unequal variance. 
For in vivo experiment, a Mann-Whitney non-parametric test was performed for 
evaluation of statistical significance. 









3 Chapter 3: System level analysis of perturbation of host lipid 
pathways associated with mCMV 
3.1 Introduction 
Perturbation of lipid metabolism in cells is a hallmark of infection. However there is 
little published evidence of the lipidomic changes induced by mCMV infection in 
BMDMs (1.4.2). 
The concentrations of lipids are stringently regulated by the cell using a range of 
proteins acting as enzymes or transport proteins. These proteins control the uptake, 
efflux, synthesis and degradation of lipid species. Consequently, the study of the 
expression of the genes coding for these proteins defined as lipid associated genes 
(LAGs) constitutes a valuable tool to understand the role played by lipid pathways in 
biological processes.  
In this chapter, we have sought to undertake a system level analysis approach using 
bioinformatics and pathway analysis tools to perform a transcriptional analysis of 
infected BMDMs in response to mCMV infection. The aim is to characterise the 



















3.2.1  Identification of altered genes by mCMV infection 
The first objective of the study was to identify the genes regulated by mCMV 
infection in BMDMs. For this purpose a micro array data set of BMDMs infected for 
24 hrs with mCMV at an MOI of 1 was analysed (n= 3 biological replicates) 
(2.10.1).  
Using this resource a stringent p-value cut off of p <0.05 and a fold change ≥ 1.25 
were chosen to select the significantly regulated genes and to avoid a maximum of 
false positive. As a result 1076 genes were considered significantly up or down 
regulated by the viral infection. Four hundred and forty six genes (41.5%) were down 
regulated and 630 genes (58.5%) were up regulated (Appendix 1 and 2). 
3.2.2 Identification of metabolic pathways altered by mCMV infection  
We next looked at the overrepresentation of metabolic pathways of these altered 
genes to identify if any were regulated by mCMV infection. KEGG, a database of 
genes, metabolic interactions and enzymatic pathways was queried using the web 
resource DAVID to identify any overrepresented pathways (Kanehisa and Goto 
2000; Sherman, Huang da et al. 2007) (See section 2.10). 
Of the 1028 genes altered by mCMV infection, 24 % (247) were identified as being 
part of the KEGG metabolic pathways. For the pathway enrichment analysis a p-
value < 0.05 was chosen as significant threshold. As a result, 8 metabolic pathways 
were identified from the 101 up regulated genes and 17 metabolic pathways were 





Table 3-1: Significant metabolic pathways up regulated by mCMV infection in 
BMDMs 
Metabolic pathway KEGG ID Genes present in the pathway P-value < 
Antigen processing and presentation nmu04612 25 2.58E-12 
Type I diabetes nmu04940 17 1.18E-08 
Proteasome nmu03050 11 1.05E-06 
Cell adhesion molecules (CAMs) nmu04514 21 2.06E-05 
Haematopoeitic cell lineage nmu04640 11 5.81E-03 
Parkinson disease nmu05020 5 1.41E-02 
P53 signalling pathway nmu04115 8 3.66E-02 
Fatty acid elongation in mitochondria nmu00062 3 4.16E-02 
 
Table 3-2: Significant metabolic pathways down regulated by mCMV infection 
in BMDMs 
Metabolic pathway KEGG ID Genes present in the pathway P-value < 
Biosynthesis of steroids nmu00100 15 3.72E-15 
Pentose and glucuronate metabolism nmu00040 8 4.68E-06 
Porphyrin and chlorophyll 
metabolism 
nmu00860 8 2.09E-04 
Terpenoids biosynthesis nmu00900 4 4.90E-04 
Cell cycle nmu04110 13 6.77E-04 
Focal adhesion nmu4510 18 7.20E-04 
Androgen and estrogen metabolism nmu00150 8 1.24E-03 
Cytochrome P450 nmu00980 9 3.90E-03 
Starch and sucrose metabolism nmu00500 8 6.62E-03 
B cell receptor signalling pathway nmu04662 8 8.64E-03 
P53 signalling pathway nmu04115 8 1.02E-02 
ECM-receptor interaction nmu04512 9 1.27E-02 
Pancreatic cancer nmu05212 7 2.46E-02 
Adherents junction nmu04520 7 2.57E-02 
Pentose phosphate pathway nmu00030 4 2.61E-02 
Bladder cancer nmu5219 5 3.59E-02 
Colorectal cancer nmu5210 7 3.98E-02 
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3.2.3 Analysis of KEGG pathways altered by mCMV infection 
Two pathways identified by our analysis related to lipids metabolism were 
significantly regulated. The fatty acid elongation in mitochondria (p-value =0.0416, 3 
genes) was found to be up regulated and the sterol biosynthesis pathway (p-value 
=3.72E-15, 15 genes) was the most significantly down-regulated pathway. 
The fatty acid elongation pathway allows the synthesis of very long chain fatty acids 
(VLCFA) from C16 and C18 fatty acids (Cinti, Cook et al. 1992). C16 and C18 
species represent more than 90% of total fatty acids present in most mammalian 
tissues. However, many biological processes depend on VLCFA (Poulos 1995). 
VLCFA are essential for the synthesis of sphingolipids and phospholipids (Lester, 
Wells et al. 1993). Three genes associated with fatty acid elongation were found to 
be up-regulated: Acca2, +1.52, Hadhb, +1.33 and Hadha2, +1.45). 
Strikingly, 10 genes of the sterol pathway were down regulated by mCMV infection. 
These are Hmgcs1: -3.25, Idi1: -3.22, Fdps: -3.06, Sqle: -3.05, Scd2: -2.79, Sc4mol: -
2.5, Fdft1: -2.17, Mvd: -1.85, Hmgcr: -1.81, Hsd17b7: -1.52, Lss: -1.45, Dhcr24: -
1.41. More than 60% of the main genes regulating the sterol pathway are down 
regulated, which indicate that there might be coordinate down regulation in response 
to mCMV infection (Figure 3-1). 
 
Furthermore, several of the other identified metabolic pathways have previously been 
shown to be modulated in response to infection. Indeed, among the eight 
significantly up regulated pathways, five were linked with the activation of the 
immune and inflammatory response. These include antigen processing and 
presentation type I diabetes, P53 signalling, haematopoietic cell lineage. These 
pathways also have been previously shown to be modulated in response to mCMV 
infection (Hanson, Slater et al. 1999; Chan, Stinski et al. 2004; Crane, Hokeness-
Antonelli et al. 2009). In addition, among the 17 down regulated pathways, six were 
related to the cell cycle and DNA production. These are cell cycle, P53 signalling 
pathway, pancreatic bladder and colorectal cancer pathways as well as pentose and 
glucuronate interconversions and pentose phosphate pathway. This is in agreement 




prevent cellular DNA replication (Castillo and Kowalik 2004; Cinatl, Vogel et al. 
2004; Sanchez and Spector 2008) and confirmed the validity of the dataset. 
The pathway is shown in KEGG notation (above and to the right hand side of the 
table), with abbreviated metabolites. Genes highlighted in green are down regulated 
and in red are up regulated. The last column of the table shows the fold changes from 
the microarray experiment of the corresponding genes.  
Metabolic abbreviation: ACoA: acetyl – CoA, AaCoA: Acetoacetyl-CoA, HCoA: 
HMG-CoA, M:mevalonate, M5P: mevalonate-5P, M5PP: mevalonate-5PP, IsPP: 
isopentyl-PP, FPP: farnesyl-PP, Squa: squalene, 23Ox: 2,3 oxydosqualene, Lan: 
lanesterol, 44Di: 4,4 dimethyl-cholesta, 8,14,24-trienol, 14De: 14-demethyl-
lanosterol, 4MZC: 4-methylzymosterol-carboxylate, 3K4M: 3-keto-4-methyl-
zymosterol, Zym: zymosterol, Cho8: cholesta-8,en-3beta-ol, Lath: lathosterol, 7DeC: 
7-dehydro-cholesterol, Cho7: cholesta-7,24-dien-3beta-ol, 7DeD: 7-dehydro-
desmosterol, Des: desmosterol, Chol: cholesterol. 
Figure 3-1: Collective down regulation of the sterol biosynthesis pathway in 
response to mCMV in BMDMs 
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3.2.4 Identification and expression of altered Lipid Associated Genes in mCMV 
infected macrophages 
KEGG analysis of the genes altered in response to mCMV infection highlighted the 
importance of sterol and fatty acid pathways in response to mCMV infection. 
However, the number of significant lipid pathways differentially regulated by the 
infection was relatively small.  
Since regulation of metabolic pathways often involves small coordinate changes, we 
suspected that many of the changes in the metabolic pathways were below our 
previous detection limit. As a consequence, we decided to use another strategy and to 
restrict our analysis of expression data exclusively to lipid-associated genes. A 
combination of literature and data-mining identified 1089 genes that had published 
direct and indirect functions relating to cellular lipid metabolism, regulation and 
synthesis (742.10 and Appendix 3). 
Of the 1089 LAGs identified, 789 (72%) were present in the micro array dataset and 
643 (59%) were found expressed in BMDMs. Using our previous selection criteria 
(P-value ≤ 0.05 and cut off threshold of 1.25), 74 LAGs were found significantly up 
or down regulated (33 down and 41 up) upon infection. These represent 18% of the 
total LAGs expressed in the array and 8% of all altered genes (Table 3-3and Table 
3-4). 
These results indicate that there are not general changes in the regulation of lipid 
associated genes in response to infection after 24 hrs, rather the infection causes 
specific regulation of them. It is also worth noting that, as mentioned earlier, the 
observed quantifiable level of reduction in expression of the lipid associated genes at 




























GENE SYMBOL AFFY ID FC P-VALUE 
Ptafr 94158_f_at 2.14 2.52E-07 
St3gal6 102208_at 1.86 5.02E-08 
Pld4 103299_at 1.64 6.56E-08 
Crabp2 100127_at 1.62 3.09E-06 
Acaa2 95064_at 1.52 2.65E-07 
Abhd5 102052_at 1.52 5.25E-06 
Crabp1 98108_at 1.51 2.12E-05 
Stard3 95607_at 1.47 6.55E-07 
Gpd2 98984_f_at 1.46 8.01E-07 
Nmt1 102047_at 1.39 7.57E-06 
Pla2gl2a 104343_f_at 1.38 3.92E-06 
Slcl0a3 103218_at 1.35 1.46E-04 
Ugcg 96623_at 1.35 2.03E-05 
Pgrmc1 101585_at 1.34 2.19E-05 
Pparg 97926_s_at 1.34 1.53E-03 
Ch25h 104509_at 1.34 2.67E-05 
Decrl 160711_at 1.34 5.03E-04 
Mcee 102022_at 1.33 6.14E-05 
Hadhb 96913_at 1.33 4.79E-06 
Phyh 96608_at 1.33 9.03E-06 
Bckdha 96035_at 1.32 3.50E-05 
Pik3ca 92452_at 1.31 6.96E-05 
Dgka 103596_at 1.30 8.33E-03 
Arsa 100931_at 1.28 1.83E-04 
Pigx 160444_at 1.28 2.63E-04 
Dhrs7 95620_at 1.28 3.90E-05 
Lrrc8a 104250_at 1.27 1.23E-04 
Sptlc1 100608_at 1.27 1.07E-04 
Chpt1 93994_at 1.26 9.40E-04 
Cds2 104627_at 1.26 2.68E-05 
Vkorc1 95709_at 1.26 5.02E-05 
Apobec1 98398_s_at 1.25 5.35E-05 
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GENE SYMBOL AFFY ID FC P-VALUE 
Ldlr 160832_at -3.63 7.51E-10 
Hmgcs1 94325_at -3.25 2.14E-10 
Idi1 96269_at -3.22 1.12E-10 
Fdps 160424_f-at -3.06 4.73E-09 
Sqle 94322_at -3.05 4.57E-10 
Scd2 162077_f_at -2.79 1.18E-09 
Fpr1 99387_at -2.60 3.40E-08 
Cyp51 94916_at -2.54 7.77E-08 
Sc4mol 160388_at -2.50 2.14E-09 
Fdft1 97518_at -2.17 6.34E-08 
Fabp5 160544_at -1.98 3.02E-08 
Cav1 160280_at -1.92 4.44E-07 
Mvd 160770_at -1.85 2.09E-08 
Hmgcr 104285_at -1.81 3.41E-06 
Fasn 98575_at -1.64 3.20E-07 
Anxa3 101393_at -1.64 3.55E-07 
Gpx3 101676_at -1.56 7.91E-07 
Akrlb8 100884_at -1.53 6.23E-06 
Hsdl7b7 94177_at -1.52 4.22E-07 
Pcyt2 103914_at -1.50 9.25E-06 
Lss 160737_at -1.45 8.08E-05 
Srebf1 93264_at -1.43 1.40E-06 
Dhcr24 160369_at -1.41 7.27E-06 
Dbi 97248_at -1.40 1.56E-06 
Ptgs1 95597_at -1.39 5.08E-06 
Galc 93131_at -1.37 9.65E-05 
Dhcr7 98989_at -1.36 1.14E-05 
Npc1 98114_at -1.34 1.04E-05 
Rdh11 99114_at -1.34 1.04E-05 
Oxct1 92845_at -1.33 1.02E-05 
Prkcd 104531_at -1.32 3.00E-05 
Abcc1 99329_at -1.31 1.09E-05 
Pitpna 160409_at -1.31 8.44E-05 
Aoah 99838_at -1.30 9.50E-05 
Ugtlal 99580_s_at -1.30 2.15E-05 
Atp6v0al 103275_at -1.27 3.08E-05 
Neu1 101546_at -1.27 1.67E-04 
Nqol 94351_r_at -1.26 3.50E-03 
Impad1 95457_at -1.26 3.52E-04 
B4galt6 102936_at -1.25 1.70E-03 
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3.2.5 Lipid class analysis 
We then asked if a specific class of lipids was affected by the viral infection. Thus, 
we used the constructed lipidomic gene list and associated LMPD classification to 
look at overrepresentation of regulated lipid class by mCMV infection. At the time of 
the analysis lipids were classified in six major classes: fatty acids, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids (Fahy, Subramaniam 
et al. 2009).  
The specific distribution of lipids classes of the altered LAG list in comparison to the 
normal distribution of lipid class in the 1079 LAGs was analysed. Results show that 
among the altered LAGs, genes associated with sterol lipid class were largely 
overrepresented in the group of down regulated genes, 34 % of the altered LAGs 
against 13% of the total (Table 3-5 and Table 3-6). These results indicated that 
mCMV infection induced the selective down regulation of the genes associated with 
sterol and prenol metabolism. Results show also a trend for the overrepresentation of 
genes that control fatty acid and glycerophospholipids levels in the up-regulated list. 









Table 3-5: Lipid class analysis of 33 significantly up regulated LAGs by mCMV 
infection 
LIPID CLASS NUMBER 
OF LAGS 
% OF TOTAL 
REGULATED LAGS 
% OF THE GENES OF 
THE LIPID CLASS 
Not classified 13 39 45 
Fatty acids/Eicosanois 
(FA) 
6 18 15 
Glycerophospholipids 
(GP) 
6 18 12 
Sterol lipids (ST) 4 12 13 
Prenol lipids (PR) 2 6 3 
Glycerolipids (GP) 1 3 5 
Sphingolipids (SP) 1 3 6 
 
Table 3-6: Lipid class analysis of 41significantly down regulated LAGs by 
mCMV infection 
LIPID CLASS NUMBER 
OF LAGS 
% OF TOTAL 
REGULATED LAGS 
% OF THE GENES OF 
THE LIPID CLASS 
Sterol lipids (ST) 14 34 13 
Not classified 7 17 45 
Fatty acids/Eicosanois 
(FA) 
7 17 15 
Glycerophospholipids 
(GP) 
4 10 12 
Prenol lipids (PR) 3 7 5 
Glycerolipids (GP) 3 7 5 
Sphingolipids (SP) 3 7 6 
NB: The genes involved in lipid metabolism with missing or incomplete information 









3.2.6 Lipidomic profiling of mCMV infected BMDMs 
We next studied the changes induced by mCMV infection in the content of the major 
lipid class. 
Lipid extraction of mock treated and mCMV infected macrophages at 24 and 48 hrs 
was carried out using chloroform methanol at Edinburgh University and the 
APCI/MS analysis were performed in a collaborative project by Dr Markus Wenk 
and Dr Shui Guanghou at the University of Singapore (Methods). Electrospray 
ionization mass spectrometry was used to quantify the major membrane lipid: 
phosphatidyl choline (PC); phosphatidyl ethanolamine (PE); phosphatidylserine 
(PS); phosphatidylglycerol (PG); phosphatidylinositol (PI);sphingomyelin (SM), 
ceramide (Cer), ganglisoside 3 (GM3), and triacylglycerol (TAG). We found no 
substantial differences in the overall levels of major glycerophospholipids 
(phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine) at 24 and 
48 hrs post mCMV infection (Figure 3-2). However, significant increases due to the 
infection includes GM3 and Cer at 24 and 48 hrs post infection, while decreases due 
to infection includes PG and SM at 24 and 48 hrs post infection. PG levels were 
found only significantly decreased at 48 hrs post infection. 
Using the same technique, we then characterized the individual lipid species level. 
All SM and PG species and some PC were significantly decreased in response to 
infection. All PI and Cer species were increased in infected BMDMs.  
Interestingly, polyunsaturated fatty acid (PUFA) containing phospholipids were 
significantly increased in most phospholipids while more saturated FA containing 
phospholipids were significantly decreased. 
These results indicate that there are not global changes of membrane lipid content in 
response to infection but rather a selective alteration of lipids species by mCMV 










Y-axis: normalized intensity (NI). One independent experiment with triplicate assays 
was performed for this analysis (n=3) and ESI-based MRM analysis was used of the 
analysis of the samples. 
 
Figure 3-2: Lipidomic analysis of the changes in the major membrane lipid class 






























Figure 3-3: Lipidomic analysis at high sensitivity of the changes in the major membrane individual molecular lipid 
species induced by mCMV infection. 
Y-axis: Arbitrary Unit. One independent experiment with triplicate assays was performed for this analysis (n=3) and ESI-
based MRM analysis was used of the analysis of the samples. Significance was calculated using a Student T-test: *, P<0.05; 
**, p<0.01; ***, p<0.005); red and black indicated significant increases and decreases, respectively. Panel A, PC:
Phosphatidylcholine, PE: phosphatidylethanolamine, PS: phosphatidylserine, PI: phosphatidylinositol, PG: 
phosphatidylglycerol, SM: sphingomyelin, Cer: ceramide. Panel B: tryglycerides. The signal intensity of each MRM value 




3.2.7 IPA canonical pathway analysis 
The list of significantly altered LAGs was used to perform a canonical pathways 
analysis using IPA software (2.10.2). IPA canonical pathways analysis identified the 
most significant known biological pathways for a given set of genes. We used also 
IPA to independently verify the previous KEGG analysis. The list of significantly 
altered LAGs was uploaded and over expression of pathways calculated. A stringent 
p-value ≤ 0.01was chosen (right-tailed Fisher’s exact test). Results show that 22 lipid 
pathways were significantly altered by mCMV infection. As expected the most 
significant down regulated pathway was the biosynthesis of steroids (-Log (p-value) 
=14.7, 9 genes). Moreover fatty acid elongation in mitochondria was also present (-
Log (p-value) =2.60, 2 genes). Furthermore, we could identify 20 significantly lipids 
related pathways that were altered by mCMV infection and that had not been 
identified by our previous analysis (Table 3-7). 
 
NB: Ratios represent the number of LAGs represented in the total number of genes present in the 
given canonical pathway (Parameter of the analysis: -Log (P-value ≥ 2). 




3.2.8 Clustering of metabolic pathways 
To make biological sense of the previous results and since lipid pathways are 
strongly interconnected, we thought of clustering the altered lipid pathways to 
identify the biological “nodes” which could be at the origin of these regulation. For 
that purpose, we thought to build a matrix of distance representing the number of 
shared genes among two canonical pathways. Agglomerative hierarchical clustering, 
using function hclust() in R statistical programming language was performed by 
Thorsten Forster from the DPM (University of Edinburgh).The results are presented 
as a dendogram (Figure 3.4) . 
Using this approach we could identify 4 major clusters of pathways altered by the 
viral infection, which were clearly separated. We used literature-based analysis to 
understand which biological “node” could be at the origin of the alteration of these 
pathways (Table 3.8).  
 
Many of the pathways belonging to the cluster one and four were related to G 
proteins-dependent signalling. Indeed, G-protein phosphorylation has been shown to 
activate ERK MAPK kinase pathways (Goldsmith and Dhanasekaran 2007), retinoic 
acid receptor (Kiefer, Lai et al. 2005), nitric oxide signalling (Ushio-Fukai 2009), 
viral entry (Unutmaz, KewalRamani et al. 1998) as well as in arachidonic acid, 
sphingolipids, aminophosphate and inositol mechanism (Naor 2009). G proteins also 
called “molecular switches” are guanine nucleotide binding proteins involved in the 
activation of second messengers. These second messengers are mainly lipid 
compounds. G-protein alternate from a dephosphorylated form (GDP) to an active 
phosphorylated form (GTP) and are usually associated with G-protein coupled 
receptors (GPCR) (although soluble G-proteins are also present in the cells). GPCRs 
represent a large family of extracellular transmembrane receptors. A large number of 
ligands bind GPCRs and activate the phosphorylation of G-proteins which trigger 
downstream signal transduction (Gilman 1987; Neves, Ram et al. 2002; Vassilatis, 
Hohmann et al. 2003).  
We could identify several key genes involved in the activation of these pathways, 
which were modulated by the viral infection. For example, phosphatidylinositol 3-
kinase (PI3K), key in the inositol metabolism is slightly but significantly up 
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regulated by the virus (+1.32 fold change), while the expression of protein Kinase C 
(PKC) is down regulated (-1.32). 
 
Furthermore, the expression of phospholipase A2 (PlA2), a key enzyme responsible 
of the control of cellular arachidonic acids (AA), is up regulated (+1.38). AA is the 
principle substrate for the prostaglandin pathway. This pathway is key in the control 
of the inflammatory response. Indeed, AA is converted into prostaglandin by PGH2 
synthase in a reaction creating reactive oxygen intermediates (ROI), which will then 
activate NFκB. Prostaglandin pathway activates the leukotriene pathway that is 
involved in the control of inflammatory mechanisms. Interestingly in our dataset, 
prostaglandin-endoperoxide synthase 1 (Ptgs1) expression is down regulated (-1.39). 
Furthermore, two genes involved in the regulation of retinoic acid pathway were 
found to be up regulated. These two are related, cellular retinoic acid-binding protein 
1 and 2 (Crabp1 and 2) (+1.51, +1.62). However, it is difficult to predict if these 
pathways are being activated or blocked, since the change in the level of expression 
of these genes is small. Furthermore the regulation of these kinases or enzymes does 
not only depend of their gene expressions levels and other mechanisms of 
modulation could occur. However, the number of genes significantly regulated 
belonging to the G-protein downstream signalling pathways are sufficient to indicate 
that G-proteins are activated at 24 hours in response to mCMV infection. 
 
Almost all the pathways of the second cluster are related to acetyl-CoA. Indeed 
carbohydrate, butanoate, valine, leucine and isoleucine and ketone bodies  can all be 
converted into acetyl-CoA and induce the production of ATP to provide energy for 
the cell (Hers and Hue 1983). Acetyl-CoA is a coenzyme which is at the cross road 
of many metabolic pathways regulating the production of energy, lipogenesis or the 
synthesis of fatty acids and de novo sterol production. Acetyl CoA is also involved in 
the degradation and synthesis of amino acids. (Barnes and Weitzman 1986). 
Interestingly, several important genes in the production of acetyl-CoA were up 
regulated. These are methylmalonyl CoA epimerase (Mcee, +1.33), Acetyl-COA 
carboxylase (Acca2, +1.52), which may indicate that this pathway is activated in 
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response to infection. Fatty acid synthesis and elongation is also directly dependent 
on the production of acetyl-CoA. 
 
Finally in the third cluster as expected by our previous analysis, the pathways leading 
to the biosynthesis of steroids are statistically altered by mCMV infection in 
macrophages. This cluster also linked the biosynthesis of sterols with the expression 
of proliferator-activated receptors γ (Pparγ, +1.34), a nuclear receptor which has 
been linked with immune and inflammatory response (1.5.1). In addition, cholesterol 
25-hydroxylase (Ch25h), which transforms cholesterol in 25-hydroxycholesterol, is 
up regulated (+1.34) in cluster 3. Notably, 25-hydroxycholesterol control cholesterol 
































IN THE CLUSTERS 
1 G-protein signalling 
RAR activation, NRF2 
mediated oxidative stress 
response Nitric oxide 
signalling in the 
cardiovascular system, virus 
entry via endocytic 
pathways, endotothelin 1 
signalling, ERK/MAPK 
signalling 
CRABP1, CRABP2, PRKCD, 
RDH11, PIK3CA, PIK3CA, 
ABCC1, NQO, CAV1, 




Valine leucine and 
isoleucine degradation, 
Synthesis and degradation of 
ketone bodies, fatty acid 
elongation in mithochondria, 
propanoate metabolism, 
tryptophan metabolism 
OXCT1, HADHB, HMGCS1, 
MCEE, ACAA2, BCKDHA, 
DHCR24, CYP51A1 
3 







FDPS, GGPS1, FDFT1, SQLE, 
CYP24A1, IDI1, DHCR7, 
HMGCR, VKORC1, LSS, NQO1, 
MVD SREBF1, APOE, ABCA1, 
NR1H2, LDLR, FASN,CH25H 








CYP51A1, PLA2G12A, PTGS1, 
GPX3, GPD2, PLA2G12A, CDS2, 
DGKA, PCYT2, CHPT1, PLD4, 
PCYT2, BCKDHA, CHPT1, 
HSD17B7, ARSA, UGT1A1, 
SPTLC1, ARSA, UGCG, GALC, 






Increasing evidence suggest that the regulation of lipid metabolism is critical to the 
outcome of viral infection. However the modulation of lipids by viral infections are 
still not well characterised. In this chapter we used gene expression and pathway 
analysis of mCMV infected BMDMs to characterise the lipid pathways altered by 
mCMV infection. 
Genome wide analysis of mCMV infected BMDMs at 24 hrs post infection identified 
1028 up or down regulated genes. Pathway analysis using public domain resources 
(DAVID and KEGG) to study the overrepresentation of these genes revealed that 
fatty acid elongation is up-regulated and sterol biosynthesis is down regulated in 
response to mCMV infection. Several studies have shown the modulation of gene 
regulation and metabolism of fatty acid in HCV infection (Diamond, Syder et al. ; 
Kapadia and Chisari 2005)  and HIV (Chan, Qian et al. 2007; Ringrose, Jeeninga et 
al. 2008; Chan, Sutton et al. 2009). Recently, Munger and colleagues have shown 
that fatty acid synthesis up regulated upon hCMV infection (Munger, Bennett et al. 
2008). Moreover, inhibition of the fatty acid pathway by drugs decreases the 
infectivity of viruses (Kapadia and Chisari 2005; Munger, Bennett et al. 2008). Here 
we provide evidence that among fatty acid synthesis, fatty acid elongation is 
increased by mCMV infection at the gene expression level after 24 hrs post infection. 
Further studies are necessary to understand if fatty acid elongation plays a crucial 
role for CMV infection. 
The most pronounced pathway-related changes occurred in sterol biosynthesis. 
Significantly, it appears that gene expression associated with sterol biosynthesis is 
co-ordinately down regulated during the infection. To our knowledge, this was the 
first time that the coordinate down regulation of the entire sterol synthesis pathway 
has been described in response to a Herpes virus infection. In addition, these results 
support the observation of Robinson and colleagues who have recently shown that 
Measles virus induce the down regulation of sterol biosynthesis pathway (Robinzon, 
Dafa-Berger et al. 2009). Furthermore, several viruses such as HIV, HCV, West Nile 
virus have developed multiple strategies to up regulate the sterol biosynthesis for 
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their benefit (Zheng, Plemenitas et al. 2003; Mackenzie, Khromykh et al. 2007; Park, 
Jun et al. 2009). This raises the question whether the down regulation of the sterol 
pathway induced by mCMV infection was directly triggered by the viral gene 
expression and if the alteration of the pathway is beneficial or not for viral 
replication. 
Inhibition of the cholesterol synthesis pathway by drug has an antiviral effect for 
many viruses (See 1.4.2.2). Therefore it is possible that the down regulation of the 
sterol pathway in response to mCMV infection may be antiviral. This may indicate 
an activation of an immune mechanism directed against the virus. Recently, several 
studies have shown that the nuclear receptor LXRα was activated by an innate 
immune response following an exposure to pathogens. This response regulates 
cholesterol efflux (Castrillo, Joseph et al. 2003). Here we show the potential 
involvement of another nuclear receptor, PPARγ in the regulation of sterol 
biosynthesis. Further studies need to be conducted to evaluate the role of PPARγ in 
mCMV infection and its relation to the regulation of sterol biosynthesis. 
SREBP2 proteins have been shown to modulate the expression of most of the genes 
of the sterol synthesis pathway (See 1.4.1.3). This sterol regulatory element binding 
protein constitutes therefore a strong candidate to explain the collective down 
regulation of the entire pathway in mCMV infection. Unfortunately, SREBP2 was 
not present in the microarray chip and therefore we could not evaluate its regulation 
by mCMV infection in this analysis. 
It is worth noticing that the down regulation of the sterol genes is relatively small and 
did not exceed 4 fold. Furthermore, Hmgcr, the rate-limiting enzyme of the pathway, 
is very weakly down regulated. We can speculate that the modulation of cholesterol 
biosynthesis via coordinated small transcriptional changes offers advantages over 
control by a single enzyme.  Biologically, coordinate control can potentially increase 
the robustness of modulation; the redundant rate limiting interactions downstream of 
the true rate limiting interaction can protect the pathway from surges in the levels of 
downstream metabolites. Coordinate control also increases the specificity of the 
pathway modulation as a small reduction of the enzyme level in an interaction 
ensures that the level of the interacting metabolite need not drop as far to affect a 
reduction in flux. This has the advantage of potentially lessening the impact on other 
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branched pathways that use the same metabolites and thus provides a high degree of 
pathway specificity. 
In regards to the small number of the altered lipid pathways, we decided to restrict 
our analysis of gene expression data to that of the lipid-associated genes. Using this 
new approach, we could identify 74 LAGs specifically regulated by mCMV 
infection.  
Lipid class analysis of the 74 altered LAGs has showed that sterol associated genes 
were specifically down regulated by the virus. Furthermore, lipidomic analysis using 
electrospray ionization mass spectrometry showed that mCMV infection altered 
specific membrane lipids in response to infection such as ganglioside-3 and 
ceramides. 
To understand which lipid pathways were affected by mCMV infection, a new 
pathway analysis of the restricted altered lipid genes using proprietary pathway tools 
(Ingenuity software IPA) was performed. Results showed that 22 lipid-associated 
pathways were significantly altered during infection.  
Taken together, these results suggest that mCMV infection alter selectively and 
specifically lipids and lipid regulatory pathways in BMDMs.  
Since lipid pathways are strongly interconnected, activation of a specific pathway or 
metabolite will have an effect on many neighbouring lipid pathways. We thought to 
use these properties to identify the common biological events or “nodes” leading to 
the alteration of the downstream pathways. For that reason, we clustered the 22 lipids 
pathways altered in response to infection by the number of their shared regulatory 
elements. This analysis revealed 4 major clusters of pathways altered by mCMV 
infection. 
Applying literature searching, two of the clusters were clearly linked by the 
activation of G-protein signalling. UV inactivated hCMV triggers within the first hr 
post infection the activation of the G-protein-coupled receptor dependent pathways 
leading to important cellular metabolic changes (AbuBakar, Boldogh et al. 1990; 
Albrecht, Fons et al. 1991; Fortunato, McElroy et al. 2000).  
The presence of numerous G protein-coupled receptor (GPCR) homologues has been 
found in several Herpes viral genomes. In addition, hCMV carry a cell-derived 
phospholipase A2 required for its infectivity (Welch, McGregor et al. 1991; Allal, 
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Buisson-Brenac et al. 2004). This suggests an essential role for G-protein in CMV 
replication.  
Furthermore, inhibition of many members of these pathways limit CMV replication 
(Speir, Shibutani et al. 1996; Shibutani, Johnson et al. 1997; Speir, Yu et al. 1998; 
Kucic, Mahmutefendic et al. 2005). Moreover, G protein activation in response to 
infection activates phospholipase C (PLC). This resulted in the production of a 
second messenger inositol (1,4,5)-trisphosphate (PIP3) and diacylglycerol (DG) 
which will activate the release of Ca2+, many kinases: PKC, PKA, PI3K, MAPK 
(Kristoffersen, Tasken et al. 1994; Keay and Baldwin 1996; Sherrill, Stropes et al. 
2009). We identified several of the key genes of these pathways such as Pkc, Pi3k 
and Pla2 as being regulated by the virus. 
In addition, lipidomic analysis at high sensitivity of the changes in the major 
membrane individual molecular lipid species induced by mCMV infection showed 
that lipid second messenger induced by G-coupled receptor activation such as 
phosphoinositols, ceramides and gangliosides were increased in response to 
infection. 
To date, the direct mechanisms to explain G-protein-dependent crucial activation for 
the efficient replication of the CMV virus are still not completely elucidated. One 
possible explanation is that the secondary messengers induced by the activation of G-
protein directly enhance viral gene expression. Indeed, the immediate early promoter 
of CMV contains binding sites for ligands such as retinoic acid and NFκB (Kowalik, 
Wing et al. 1993; Angulo, Suto et al. 1996). On the other hand, the activation of the 
G-protein pathway activates many other pathways which could play an indirect role 
in the regulation of the virus. Exemple might be the leukotriene pathway or the 
MAPK kinases pathway involved in the modulation of inflammatory response. 
In addition, activation of the G-protein signalling pathways has been shown to 
modulate cytokine and chemokines expression. Shingai and colleagues have shown 
that soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-
mediated IFNβ induction (Shingai, Azuma et al. 2008). In view of this evidence, we 
can speculate that by interacting with the G-proteins derived pathways, the virus 
limits, the innate immune response. So far the activation of these pathways in 
response to CMV infection has been an early event post infection. Our results 
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provide evidence that these pathways are still modulated 24 hrs after infection and 
may still play a role in viral infection. Further studies will be necessary to validate 
and understand the role of the G-proteins in mCMV infection at later times post 
infection. 
Another interesting result from our analysis reveals the importance of acetyl-CoA in 
many lipid pathways that are regulated by mCMV infection. Since acetyl-CoA is at 
the cross road of various biological processes, such as energy supply, protein 
synthesis, fatty acid and sterol synthesis, it is not surprising that it is modulated by 
viral infection. 
Diamond and colleagues have shown that HCV infection shifts the production of 
energy towards the synthesis of cellular metabolites supporting viral life cycle 
through the modulation of glycolysis and TCA cycle (Diamond, Syder et al.) 
Munger and colleagues have shown that hCMV induced an increase in the level of 
acetyl-CoA at early and late stage of infection (Munger, Bajad et al. 2006). They 
speculate that the virus modulates the cellular metabolic pathways to its advantage. 
Our results complement Munger’s study and highlight the important role of 
glycolysis and the TCA cycle in the viral cycle. Further analyses are required to 
understand whether mCMV modulates a specific pathway, which requires acetyl-
CoA. However, since we have shown an up regulation of fatty acid elongation and a 
down regulation of sterol synthesis it is possible that the virus targets specifically 
theses two pathways by regulating the level of Acetyl-CoA. Alternatively, the 
changes observed reflect a compensatory mechanism. The understanding of the 
mechanisms involved could help to identity new antiviral targets.  
To conclude, in this chapter we have characterised the lipid metabolic pathways 
regulated in response to mCMV infection in macrophages. Our analysis showed that 
there is a specific and selective regulation of lipid metabolism upon infection. Some 
of these pathways such as fatty acid, G-protein activated second messenger or acetyl-
CoA associated pathways have previously been linked with physiological processes 
occurring at early time post mCMV infection. Here we provide evidence that these 
pathways are still modulated by the virus at 24 hrs post infection. In addition, we 
identified for the first time that the sterol biosynthesis pathway is co-ordinately down 
regulated in response to mCMV infection 
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4 Chapter 4: mCMV infection impaired cholesterol homeostasis at 
metabolic and transcriptional levels 
4.1 Introduction 
Several viruses such as HCV, HIV, Western Nile virus, have been shown to alter the 
intra cellular cholesterol synthesis of their host (Zheng, Plemenitas et al. 2003; 
Mackenzie, Khromykh et al. 2007; Waris, Felmlee et al. 2007). Furthermore, 
cholesterol homeostasis and pharmacological inhibition of the sterol biosynthesis 
pathway have been shown to modulate the infection of many viruses, suggesting an 
important role for cholesterol homeostasis in viral infection (1.4). However, to date, 
very little is known about the regulation of intra cellular cholesterol synthesis by 
mCMV infection. Nevertheless, there is evidence that cholesterol is important for 
Herpes virus life cycle. For example, Herpes Zoster infection has been shown to 
induce the level of serum cholesterol in infected patients and cholesterol has been 
shown to be important for Herpes viruses entry and replication (Bender, Whitbeck et 
al. 2003; Potena, Frascaroli et al. 2004; Cohen 2005; Hill, Steiner et al. 2005; 
Hambleton, Steinberg et al. 2007; Del Pozo, van de Beek et al. 2010). Furthermore, 
Hajjar and colleagues have shown that Herpes virus altered the transcriptional and 
lipidomic cholesterol homeostasis in smooth muscle cells (Hajjar, Falcone et al. 
1985; Hsu, Nicholson et al. 1995).  
Since we identified the sterol biosynthesis pathway to be co-ordinately down 
regulated in response to mCMV infection, the aim of this chapter was to validate our 
previous observations and to characterise the changes in cholesterol synthesis 
induced by mCMV infection. 
In addition, given that the cellular cholesterol homeostasis is also regulated by the 
cholesterol entry, storage and efflux, we studied the regulation of these other 
pathways by mCMV infection. Finally we examined the consequences of mCMV 








4.2.1 Characterization of the cholesterol regulating genes expression upon mCMV 
infection 
The expression of cholesterol synthesis, uptake, storage, efflux and regulators marker 
genes in mCMV infected or mock treated cells were measured by quantitative PCR. 
For this experiment BMDMs and 3T3-NIH fibroblasts were mock treated or infected 
at a MOI of 1 and RNA was extracted and purified at 24 hrs post infection (2.5.3). 
 
Hmgcs1, Hmgcr, Idi1 and Sqle were chosen as marker genes of the sterol 
biosynthesis pathway because they were the most down regulated genes in our 
previous micro-array experiment (See Chapter 3). QPCR analysis with Taqman 
primer-probes sets confirmed that Hmgcs1, Hmgcr, Idi1 and Sqle gene expression 
were down regulated at 24 hrs post infection in both BMDMs (Figure 4-1A) and 
3T3-NIH fibroblasts (Figure 4-1B). The fold changes in gene expression for infected 
compared to mock treated cells were for BMDMs: Hmgcs1:-4.28, Hmgcr: -2.64, 
Idi1: -7.14, Sqle: -6.83 and for 3T3 NIH fibroblasts: Hmgcs1:-7.95, Hmgcr: -4.04, 
Idi1: -7.2, Sqle: -18.8 
The scale of the regulation in BMDMs and NIH/3T3 was comparable although the 
alteration is more pronounced in the fibroblast cells. Furthermore, these changes are 
very similar to the ones observed in the previous micro-array analysis and confirm 
with an independent technique that mCMV infection down regulates the sterol 
biosynthesis pathway. In addition these results showed that the response is not 
specific to BMDMs. 
 
We then measured the expression of the genes involved in the regulation of 
cholesterol uptake (Ldlr), storage (Soat1) and efflux (Abcg1 and Apoe) in mCMV 
infected compared to mock treated cells. Results show that Soat1, Abcg1 and Apoe 
are significantly up regulated after 24 hrs infection in BMDMs and NIH/3T3 
fibroblasts (fold changes for BMDMs: Soat1:+4.39, Abcg1: +3.25, Apoe: +4.29 and 
for NIH/3T3 Soat1:+7.62, Abcg1: +4.70, Apoe: +4.29) (Figure 4-1C and Figure 
4-1D). However, Ldlr expression is significantly down regulated by mCMV 
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infection at 24hrs post infection in BMDMs and NIH/3T3 fibroblasts (fold changes -
7 and -6.37 respectively) (Figure 4-1C and Figure 4-1D). These results validate our 
previous observations and indicate that storage and efflux of cholesterol are up 
regulated while uptake of cholesterol into the cell is down regulated at the 
transcriptional level. 
 
Since we observed a coordinate down regulation of the sterol pathways genes in 
response to infection, we next wondered if the expression of Srebfs genes, master 
regulators of the sterol and fatty acid metabolism, was also regulated by the mCMV 
infection. We were especially interested in the regulation of Srebf2 since it has been 
shown to specifically regulate the sterol pathway (1.4.1.103).  
Previous micro array analysis showed that Srebf1 was weakly down regulated; 
however a Srebf2 probe was not present in the micro array chip. To investigate 
whether Srebfs genes were modulated by mCMV infection, gene expression levels of 
Srebf1 and Srebf2 in infected and mock treated BMDMs and NIH/3T3 for 24 hrs 
were compared. 
 
Results in Figure 4-1E and Figure 4-1F show that Srebf1 was not significantly down 
regulated by mCMV infection in BMDMs and NIH/3T3 although there is a trend for 
the down regulation of the gene. However Srebf2 was found significantly down 
regulated at 24 hrs post infection (p-value<0.05) in both cell types. Significant fold 
changes of Srebf2 were: -3.27 in BMDMs and-3.70 in NIH/3T3s. 
These results indicate the Srebf2 is down regulated in response to infection, which 
could explain the co-ordinate down regulation of the sterol biosynthesis pathway in 








A –B: Changes in gene expression of Acat1, Hmgcs1, Hmgcr, Idi1 and Sqle 
expression in BMDMs (A) and NIH/3T3 (B) at 24 hrs post infection compared to 
mock treated cell. 
Bars represent means ± S.D. of 5 independent experiments with triplicate 
measurements for each experiments for BMDMs (n=15) and 2 independent 
experiments with quadruplicate measurements for NIH/3T3 (n=8).  
C-D: Changes in gene expression of Soat1, Abcg1, Apoe and Ldlr expression in 
BMDMs (C) and NIH/3T3 (D) at 24 hrs post infection compared to mock treated 
cell. 
Bars represent means ± S.D. of 3 independent experiments with triplicate 
measurements for each experiments for BMDMs (n=9) and 2 independent 
experiments with quadruplicate measurements for NIH/3T3 (n=8).  
E-F: Changes in gene expression of Srebf1 and Srebf2 expression in BMDMs (E) and 
NIH/3T3 (F) at 24 hrs post infection compared to mock treated cell. 
Bars represent means ± S.D. of 2 independent experiments with triplicate 
measurements for each experiment for BMDMs (n=6) and 2 independent 
experiments with quadruplicate measurements for NIH/3T3 (n=8).  
A Welsh t-test was used for evaluation of statistical significance: *P < 0.05, **P < 










Figure 4-1: Changes in the genes expression of the cholesterol metabolism upon 
mCMV infection in BMDMs and NIH/3T3 compare to mock treated cells 
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4.2.2 Kinetics of free cholesterol concentration in mCMV infected BMDMs and 
NIH/3T3 fibroblasts 
mCMV infection induces the transcriptional regulation of the uptake synthesis, 
storage and efflux genes. However, given that the changes are quantitatively modest 
it was not clear whether such small, coordinate temporal reductions in the level of 
individual components of cholesterol homeostasis will have any functional 
consequence on the overall pool of intra cellular cholesterol. Especially since Hmgcr 
the rate-limiting enzyme of the cholesterol synthesis pathway is very weakly 
regulated by mCMV infection at the transcriptional level.  
 
To measure the dynamic changes of the free cellular cholesterol concentration in 
BMDMs and NIH/3T3s, we developed a biochemical assay based on an enzymatic 
assay method (2.6). Changes were measured over a period of 72 hrs after mCMV 
infection at a MOI of 1 to take into account the delay of the proteins translation and 
consequent metabolic adjustments.  
 
Results (Figure 4-2) show that mCMV infection induced a significant decrease of 
free intra-cellular cholesterol concentration after 48 hrs of infection up to 72 hrs in 
both BMDMs and NIH/3T3s. Furthermore, the reduction in both cell types is 
comparable (approximately 50 to 60% of the initial amount of free cholesterol).  
These results demonstrate that mCMV infection induces a drop of free intra cellular 
cholesterol after 48 hrs infection. However, these results are not sufficient to attribute 
the drop of free intra cellular cholesterol to the down regulation of the sterol 
biosynthesis pathway since the cholesterol efflux storage and uptake could also 
modulate the intra cellular cholesterol concentration. 
 
To further validate these results and investigate the role of each component of the 
cholesterol homeostasis, an independent analytical technique based on APCI/MS was 
used to examine the level of free cholesterol, of an immediate precursor of 
cholesterol: 7-dehydrocholesterol and of cholesterol ester, as well as the storage form 
of cholesterol. Lipid extraction of mock treated and mCMV infected macrophages at 
24 and 48 hrs was carried out using chloroform methanol at Edinburgh University 
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and the APCI/MS analysis were performed in a collaborative project by Dr Markus 
Wenk and Dr Shui Guanghou at the University of Singapore (See section 2.6). 
As expected, the analysis shows a decrease of 50 to 65% of free intra cellular 
cholesterol level in response to infection at both 24 and 48 hrs post infection 
confirming our previous analysis (Figure 4-2C). The level of 7-dehydrocholesterol 
was also dramatically reduced after 24 hrs and 48 hrs post infection (80 and 90%) 
(Figure 4-2D). Furthermore, the level of cholesterol ester was increased at 24 and 48 
hrs post infection (8 and 5 fold respectively) (Figure 4-2E). 
These results confirmed with an independent assay that mCMV infection induces a 
significant decrease of free intra cellular cholesterol in response to infection after 24 
and 48 hrs post infections. Furthermore, the synthesis of free cholesterol is also 
reduced by 80 to 90% as a consequence of the infection. In addition, the storage of 














A-B: Free cholesterol concentration was determined at 0, 6, 24, 48 and 72 hrs post 
infection in BMDMs (A) and NIH/3T3 cells (B) infected with mCMV. Three 
independent experiments with quadruplicate assays for each experiment were 
performed (n=12). Cholesterol content is presented as the percentage of free 
intracellular cholesterol concentration from infected cells compared to mock 
treatment. Graphs show means ± S.D 
C-E: Free cholesterol and 7-dehydrocholesterol analysis was performed using 
APCI/MS from mCMV infected BMDMs at 24 and 48 hrs post infection. Dramatic 
decreases in free cholesterol (p-value = 0.009 at 24 hrs and 0.003 at 48 hrs) and 7-
dehydrocholesterol (p-value = 0.00002 at 24 hrs and 0.0074 at 48 hrs) were observed 
in infected mice. Y-axis, arbitrary unit (AU), relative ratio to deuterated sterol 
standards. One independent experiment with triplicate assays for each experiment 
was performed for this analysis (n=3). 





















4.2.3 Temporal regulation of cholesterol biosynthesis pathway 
We next were interested in understanding the dynamic of the regulation of the sterol 
genes in the first hrs post infection. Indeed, early changes in cellular gene expression 
are indicators of the event following viral gene entry into the cell (Fortunato, 
McElroy et al. 2000; Kropp, Simon et al. 2009). 
 
To analyse the changes in temporal gene expression of the sterol regulating genes, 
two micro-array time-courses dataset of mCMV infected (MOI of 1) BMDMs and 
NIH/3T3 respectively were analysed (2.10.1). 
For the first experiment, BMDMs were infected for 12 hours; RNA samples were 
extracted every 30 minutes for the first 12 hrs following the infection and RNA was 
analysed using a Mouse Agilent V2 chip array. In a separate experiment NIH/3T3 
infected RNA samples were taken at 3, 16 and 24 hrs post infection and processed in 
an Affymetrix U74 chip. Results are presented figure 4.2 as a heat map representing 
the log fold changes of expression of infected compared to the mock treated samples. 
(Experiment, processing and statistical analysis were performed by Dr Garwin Sing 
and Dr Paul Dickinson in the Division of Pathway and Medicine – See section 
2.10.1). 
Temporal analysis of the changes in expression of the sterol associated genes in 
response to mCMV infection confirmed our previous observation, indeed, for both 
BMDMs and NIH/3T3 the expression of the sterol genes was down regulated at 12 
and 24 hrs post infection. Furthermore, the down regulation of the biosynthesis 
pathway occurs in a gradual and temporal manner from an early time (3 hrs) up to at 
least 12 hrs post infection for BMDMs and 24 hrs for NIH/3T3. 
In the BMDMs infected experiment, the sterol-associated genes are at first briefly up 
regulated in response to infection (up to 300 min) before being down regulated. In 
addition, there are differences in the timing of the down regulation of some sterol 
associated genes in BMDMs: While Hmgcs1, Hmgcr, Fdft1, Sqle, Lss, Sc4mol, 
Nsdhl, Hsd17b7, Dhcr24 and Dhcr7 are down regulated at 300 minutes, Mvk, Pmvk, 
Mvd, and Cyp51and Ebp begins to be down regulated at a later stage of the infection 
(around 600 minutes). Moreover, in BMDMs but not NIH/3T3s, the expression of 
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Cyp51 is increased until 600 minutes post infection before being down regulated in 
comparison to mock treated cells.  
Taken together these results indicate that the co-ordinate down regulation of the 
sterol genes consecutively to mCMV infection occurs both in BMDMs and NIH/3T3 





























A. The Sterol biosynthesis pathway, shown in KEGG notation,  
B. Heat map of the temporal expression levels of 15 genes of the cholesterol 
biosynthesis pathway during the first 12 hrs of mCMV infection in BMDMs. 
Columns indicate time in minutes. Scale: (from, in Log scale, -0.83 to +1.13)  
C. Heat map representing the temporal expression levels of 15 genes of the 
cholesterol biosynthesis pathway at 3, 16 and 24 hrs of mCMV infection in NIH/3T3. 
Scale: (from, in Log scale, -0.85 to +1.14)  




Figure 4-3: Down regulation of the cholesterol biosynthesis pathway upon mCMV 
infection in BMDMs and NIH/3T3 
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4.2.4 Regulation of the sterol genes expression by mCMV IE3Ko infection 
The early regulation of the sterol associated genes in response to mCMV infection 
led us to wonder if this alteration of the pathway was due to the binding and entry of 
the virion into the cell or was driven by viral gene expression. Indeed virion binding 
and tegument proteins trigger a large transcriptional host response (Fortunato, 
McElroy et al. 2000), which could be at the origin of the down regulation of the 
sterol biosynthesis pathway. In the other hand, immediate early gene expression 
during mCMV infection occurs as early as 30 minutes post infection (Kropp, Simon 
et al. 2009). Since our results show that sterol genes are initially up regulated in 
response to infection before being gradually down regulated, it was possible that the 
down regulation of the cholesterol associated genes is driven by viral gene 
expression or by the cellular host response. 
To understand whether the down regulation of the sterol pathway was related to an 
early host response to infection or induced by viral gene expression, we used a 
replication and early/late gene defective mCMV virus (mCMV-IE3KO) (See section 
2.2.1). mCMV-IE3KO is capable of infecting cells at levels equivalent to wild-type 
virus but is incapable of expressing its genome downstream of a rather restricted 
immediate-early set of genes (Angulo, Ghazal et al. 2000; Lacaze 2010).  
For these experiments, BMDMs were infected with mCMV wild type or mCMV-
IE3KO viruses or mock treated for 24 hrs in BMDMs and RNA extracted to perform 
QPCR analysis of Hmgcs1, Hmgcr, Idi1 and Sqle gene expression. 
Results in Figure 4-3show that the mCMV and mCMV-IE3Ko induce the down 
regulation of the sterol genes. Additionally, the scale of the down regulation induced 
by mCMV-IE3 infection is even greater than the wild type. Fold changes for Hmgcs1 
(mCMV: -2.5 and mCMV-IE3Ko: -5.2), for Hmgcr (mCMV: Not significant and 
mCMV-IE3Ko: -1.72), for Idi1 (mCMV: -2.9 and mCMV-IE3Ko: -18.65) and for 
Sqle (mCMV: -3.3 and mCMV-IE3Ko: -11.6). 
These results clearly indicate that the alteration of the sterol biosynthesis pathway in 
response to mCMV infection is not driven by late gene expression and suggest that 



















Changes in gene expression of Acat1, Hmgcs1, Hmgcr, Idi1 and Sqle expression in 
mock treated, mCMV or mCMV-IE3KO infected BMDMs at 24 hrs post infection.  
Bars represent means ± S.D. of 2 independent experiments with triplicate 
measurements for each experiment (n=6). A Welsh t-test was used for evaluation of 









Figure 4-4: Regulation of sterol gene expression by non-replicative mCMV-IE3 
KO virus in BMDMs  
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4.2.5 The specificity of the viral infective agent 
Previous results showed that the down regulation of the sterol biosynthesis associated 
genes by mCMV infection were not dependent on late viral gene expression. We 
next asked if the alteration of the sterol pathway was specific to mCMV infection or 
rather a general cellular response to viral infection.  
For that purpose we exploited an Affymterix MOE430v2 chip micro array dataset of 
BMDMs mock treated or infected with Herpes Simplex virus 1 (HSV1), Semliki 
Forest Virus (SFV), Vaccinia virus (VV) or adenovirus (AD) for 24 hrs post 
infection (See section 2.2.1). 
This experiment presented four families of viruses having very different 
characteristics and therefore, it is a good representation of a broad viral infection. 
HSV1 is an enveloped DNA alpha Herpes virus replicating in the nucleus of the cell, 
VV is an enveloped DNA virus that replicates only in the cytoplasm of the infected 
cells, AD is a non-enveloped DNA virus and finally SFV is a positive-stranded RNA 
virus which replicates from its negative strands in the cytoplasm of the cell.  
Mock treatment, HSV1 (MOI=1), SFV (MOI=10), VV (MOI=1) infection of 
BMDMs for 24 hrs were performed in 3 independent replicates while only 2 
independent replicates where used for Ad (MOI=100) infection of BMDMs.  RNA 
was hybridised and processed in an Affymetrix MOE 430-2 chip array (Experiment, 
processing and statistical analysis were performed by Dr Garwin Sing and Dr Paul 
Dickinson in the Division of Pathway and Medicine –See section 2.10.1) 
To verify that the infection was successful for every viral species, activation of IFN 
response and of the MHC class II presentation genes was checked and the results 
showed that while there is almost no activation of the IFN signalling or MHC class II 
in the mock treated macrophages, the infection of the 4 viruses induced a strong 
immune response (Figure 4-5). 
We then looked at the regulation of the sterol biosynthesis genes and of the genes 
responsible for uptake, storage, efflux and regulation of intra cellular cholesterol 
concentration (Ldlr, Soat1, Apoe, Abca1 and Abcg1). 
Results in Figure 4-5, showed that after 24 hrs infection in BMDMs the sterol 
biosynthesis regulating genes were globally down regulated by HSV1, SFV, VV and 
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Ad compared to the mock treated samples. These results are similar to the one 
observed in response to mCMV infection. Moreover, Ldlr implicated in the cellular 
entry of cholesterol was down regulated, and the genes implicated in storage and 
effluxes of cellular cholesterol (respectively Soat1, Apoe, Abca1 and Abcg1) were 
globally up regulated in response to infection. 
Srebf2 was significantly down regulated by all four viruses while Srebf1 is not 
altered by the infection of the four viruses. 
These results are similar to the effect of mCMV infection in BMDMs and NIH/3T3s 
sterols associated genes previously observed and strongly argue that the down 
regulation of sterol pathway synthesis is a general host response towards viral 
infection. 
To further validate these results the gene expression of Hmgcs1. Hmgcr, Idi1 and 
Sqle of HSV1 or mCMV infected BMDMs for 24 hrs was measured by QPCR.  
Even if a formal statistical analysis was not performed on these samples, as only a 
few replicates could be analysed, nevertheless these results confirmed that HSV1 and 
mCMV infection down regulate Hmgcs1, Hmgcr, Idi1 and Sqle gene expression after 




Hit map representing the fold changes of gene expression of the cholesterol regulating genes HSV1, SFV and VV infected BMDMs 
compared to mock treated samples. 




Bars represent means ± S.D. of one independent experiment with quadruplicates 
measurements (n=4).
Figure 4-6: Quantitative PCR of Hmgcs1, Hmgcr, and Idi1 and Sqle gene 





The aim of this chapter was to characterise the genetic and metabolic regulation of 
the cholesterol homeostasis in response to mCMV infection. 
We first look at the transcriptional regulation of the genes responsible for the control 
of uptake, synthesis, efflux and storage representing the main pathways regulating 
cholesterol homeostasis: First of all, measurement of gene expression of infected 
macrophages by RT-QPCR confirmed the down regulation of the sterol biosynthesis 
in BMDMs at 24 hrs post mCMV infection. We have also shown that this response 
was similar in NIH/3T3 fibroblasts cells. In addition, this study provides evidence 
that mCMV infection induced the transcriptional down regulation of cholesterol 
uptake (Ldlr) and the up regulation of the storage (Soat1) and of the efflux of 
cholesterol (Abaca1, Abcg1, Apoe) in BMDMs and NIH/3T3s. 
In addition, we have shown that Srebf2, a key gene involved in the coordinate 
regulation of the entire sterol synthesis pathway is down regulated upon infection. 
Further studies need to be done to assess whether Srebf2 is directly responsible for 
the down regulation of the cholesterol pathway in response to infection. 
Since the regulation of genes associated with cholesterol homeostasis is complex and 
is normally driven by feedback mechanisms (Simons and Ikonen 2000), we then 
wonder if the changes induced by mCMV infection in the regulation of cholesterol 
homeostasis at the transcriptional level resulted in an alteration of the concentration 
of intra cellular cholesterol. Free intracellular measurement using two independent 
analytical methods shows that mCMV infection results in a drop of free intra cellular 
cholesterol of 50% after 48 and 72 hrs experiments. Additionally, we have shown 
that the biosynthesis of de novo cholesterol was directly reduced since the 
concentration of a sterol intermediary of the sterol synthesis pathway 7-
hydroxycholesterol was decreased by 70 to 80% in response to infection. In addition 
cholesterol ester concentration was increased by 5 to 8 fold as a result of infection. 
Taken together these results indicate that, mCMV infection induces a complete 
reprogramming of the regulation of cholesterol homeostasis at the transcriptional and 
metabolic level. Indeed mCMV infection decreases the gene expression of the 
synthesis and uptake of cholesterol, and increases the one of the storage and efflux. 
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Conversely, mCMV infections decrease the level of production of de novo 
cholesterol as well as the overall pool of free intra-cellular cholesterol and increase 
the cholesterol ester concentration. However, these results are not sufficient to 
conclude that transcriptional changes in the regulation of the cholesterol associated 
genes directly induce changes at the metabolic levels since other regulatory 
mechanisms could also playing a role. Measurements of the protein levels by 
Western Blot technique and use of radioactive probe such as [3H] mevalonate, [3H] 
LDL and [3H] HDL to measure qualitative synthesis, uptake and efflux of cholesterol 
(Xu, Zhou et al. 2009) are required to understand completely the dynamic of the 
changes in intra cellular cholesterol in response to mCMV infection. Never the less 
these study characterise for the first time the modulation of cholesterol homeostasis 
in response to mCMV infection in BMDMs and NIH/3T3. 
In addition, these results designate that drop in cholesterol concentration is an early 
marker of mCMV infection in vitro. Further work will be required to evaluate if the 
level of cholesterol could constitute a marker of acute infection in vivo. 
Previously, Herpes viruses and especially MDV has been shown to increase free 
cholesterol and cholesterol ester level in vitro in smooth cell muscles and in the 
arterial wall(Hajjar, Falcone et al. 1985). Furthermore, Ldlr and Hmgcr expression 
has been shown to be increased in response to hCMV and MDV infection (Hsu, 
Nicholson et al. 1995; Zhou, Guetta et al. 1996). 
Our results differ from previous published studies since both Ldlr and Hmgcr gene 
expression is decreased by mCMV infection and HSV1 in BMDMs. Furthermore we 
have shown that total cholesterol level was decreased in response to mCMV 
infection in BMDMs and NIH/3T3s while Hajjar and colleagues have shown that 
there is an increase of total cholesterol. Here, we can speculate that smooth cell 
muscle may have a different cellular response in the regulation of sterol associated 
genes in response to infection or that experimental conditions were different. In any 
case further study will be required to understand the differences in these results. 
Nevertheless, our results show that cholesterol ester is increased in response to 
mCMV infection and are in agreement with Hajjar and colleagues and others. This 
points at a possible mechanism for macrophage foam cell formation in response to 
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mCMV infection and could provide new mechanism in the understanding of the 
initiation of the atherosclerosis disease. 
To understand the mechanisms at the origin of the transcriptional modulation of the 
cholesterol homeostasis, we next considered the temporal regulation of the sterol 
associated genes in response to infection. Temporal gene expression analysis of two 
independent micro array data sets showed that the modulation of the genes associated 
with cholesterol concentration was occurring at a very early time post infection 
(around 3hrs pi). Since both, viral binding and expression of early viral gene could 
have been at the origin of the regulation, we wondered if the regulation of these 
genes was the consequence of viral gene expression or a cellular response to viral 
entry. Infection of BMDMs with a mutant virus mCMV-IE3KO unable to express 
any viral transcript showed that the modulation of the cholesterol associated genes 
was maintained and even greater than the one observed with the wild type virus 
infection. These results strongly support the view that the modulation of the 
cholesterol regulating genes in response to viral infection is triggered by viral 
binding or entry into the cell and not by viral gene expression. However, mCMV-
Ie3-KO have been shown to have very low expression of immediate early and early 
genes compare to the wild type virus (Lacaze 2010), therefore we cannot exclude 
that this very weak expression regulates sterol associated genes. 
We then looked if the regulation of the expression the sterol biosynthesis pathway 
was specific to mCMV infection or was a general response to infection. Analysis of 
micro array data set from BMDMs infected with 4 structurally very different viruses 
(HSV1, SFV, VV and Ad) showed that all four infections induced the down 
regulation of the sterol associated genes. 
Taking together, these results indicate that the regulation of cholesterol synthesis in 
response viral infection is a general cellular response. 
To date, several viruses such as HIV, HCV have been shown to manipulate intra 
cellular cholesterol location for their own benefit, for example HCV hijacks the lipid 
droplets pathway for efficient replication and budding (Boulant, Douglas et al. 
2008), HIV redistributes cellular cholesterol to specific membrane compartment to 
increase its replication. HCV viruses have been shown to hijack and redistribute the 
intra-cellular cholesterol pool (Mackenzie, Khromykh et al. 2007). 
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Furthermore, HIV, HCV and measles viruses have been shown to code for viral 
proteins which increase the sterol biosynthesis gene expression. NEF for HIV and 
NS4B for HCV, have been shown to directly up regulate the expression of SREBPs 
(Zheng, Plemenitas et al. 2003; Mackenzie, Khromykh et al. 2007; Waris, Felmlee et 
al. 2007).  
Recently, measles viruses have been shown to induce the down regulation of the 
sterol biosynthesis pathway in persistent infection but not in acute infection. The 
authors of this study conclude that alteration of cholesterol synthesis may limit the 
budding of the virus, which is a characteristic of measles persistent infection 
(Robinzon, Dafa-Berger et al. 2009). 
In this study we are showing that down regulation of the sterol biosynthesis is a 
general cellular response to viral infection occurring independently of viral gene 
expression. Since viruses have evolved to take advantage of the host cholesterol 
homeostasis, it is possible that cells have developed innate immune mechanisms to 
counteract viral infection by influencing the cholesterol homeostasis. Our results 
raise also the question whether the down regulation of the sterol biosynthesis 
pathways and the decrease in intracellular cholesterol concentration in response to 
viral infection have an effect on the output of the infection. 
Since pharmacological inhibition of Hmgcr the first step of the sterol synthesis 
pathway has been shown to be antiviral for many viruses in vitro and in vivo (See 
1.4.2.2), it is possible that the down regulation of the cholesterol synthesis pathway 
by the cell in response to viral infection is antiviral. Antiviral effects of statins have 
been attributed to the drop of cholesterol but most often of the prenylation of 
proteins. Drop in free cholesterol concentration might results in alteration of viral 
virion structure, intra cellular movement and budding and therefore be beneficial for 
the infected organism. Alternatively, reduction of sterol biosynthesis flux may alter 
the prenylation of proteins require for efficient viral growth such as FBL2 for 
HCV(Wang, Gale et al. 2005).  
In addition, alteration of intra cellular cholesterol may alter the stability and number 
of the lipid rafts. However, it is difficult to predict what effects the alteration of lipid 
rafts will have on viral infection. Indeed, alteration of rafts may perturb the viral 
replication cycle but may also decrease antiviral pathways such as MHC class I 
123 
 
presentation (Mackenzie, Khromykh et al. 2007). Interestingly since lipid raft have 
been shown to be essential for the cellular entry of many viruses (See section 
1.4.2.2), we can speculate that drop of cholesterol in response to infection may also 
affect further viruses entry. Further experiments will be required to assess the effect 
of the drop of cholesterol synthesis on mCMV replication. 
 
To conclude, in this chapter we have shown for the first time that mCMV infection 
induces the impairment of cholesterol homeostasis as both transcriptional and 
metabolic level in BMDMs and NIH/3T3. In addition, we have shown that the down 
regulation of the sterol associated genes is occurring at a very early time post 
infection (three hrs) and is not dependent of the viral genes. Finally, we provide 
evidence that the down regulation of sterol associated genes is a general cellular 




















5 Chapter 5: Alteration of the sterol biosynthesis pathway is 
antiviral for mCMV infection 
5.1 Introduction 
Previously, we have shown that the coordinate down regulation of the sterol 
biosynthesis pathway at the transcriptional and metabolic level is induced by mCMV 
infection in BMDMs and NIH/3T3s (See chapter 3 and 4). 
Recently, sterol biosynthesis has been identified as an important modulator of viral 
infection (See section 1.4.2.2). This raises the question whether cellular down 
regulation of the sterol synthesis pathway in response to mCMV infection affects the 
outcome of mCMV infection. 
Inhibition of sterol synthesis by statins has been shown to limit hCMV infection in 
vitro (Potena, Frascaroli et al. 2004). However to date, the contribution of sterol 
synthesis to mCMV infection has not been studied in vitro or in vivo. 
To address this question, we used a combined approach using pharmacological 
inhibition and selective gene expression knock downs to perturb the sterol 
biosynthesis pathway and monitor the effects on mCMV infection (Figure 5-1).  
Furthermore, several studies have shown that the alteration of protein prenylation, a 
branch of the mevalonate pathway, was implicated in the modulation of viral 
replication (Bordier, Ohkanda et al. 2003; Einav and Glenn 2003; Glenn 2006). For 
that reason, we performed a supplementation assay with a mevalonate intermediate 















Figure 5-1: Pharmacological inhibition and supplementation with an 
intermediary of the mevalonate pathway helps to decipher the involvement of 
different branches of the pathway in mCMV replication 
Statins inhibit Hmgcr, the rate-limiting enzyme of the sterol pathway. Activated 
statins bind approximately 1,000 times more effectively to HMGCR than its natural 
substrate HMG-CoA. Statin treatment inhibits the formation of both mevalonate and 
its downstream product, isopentyl pyrophosphate (IPP). This inhibition can be 
reversed completely by replenishment with mevalonate. Additions of farnesol restore 
farnesylation but not geranylgeranylation, as IPP is not available to convert farnesyl 
pyrophosphate (FPP) into geranylgeranyl pyrophosphate (GGPP). Addition of 
geranylgeranyol will only restore geranylgeranylation while addition of squalene and 
cholesterol will restore sterol biosynthesis (Liao 2002; Mo and Elson 2004). 
Proteins containing a carboxy terminal CaaX motif (C is a cysteine, a is an aliphatic 
amino acid and X is an amino acid) such as Ras, Rheb and PTP4A3 families are 
farnesylated by farnesyl transferase while proteins containing a CC or C(X)C 
sequence such as Rho, Rac and Cdc42 families are geranylgeranylated by 
geranylgeranyl transferase. A few G-proteins such as RHOB and NRAS can either be 
farnesylated or geranylgeranylated (Takai, Sasaki et al. 2001). In addition, other 
isoprenoid side-branches are also altered by Statin inhibition: Dolichol 
pyrophosphate which plays a role in the synthesis of oligosaccharide chains of 
glycoproteins and is found in many membranes of cells, Ubiquinone, (Coenzyme Q), 
is involved in the electron transfer chain and finally Heme A, a constituent of 
respiratory chain complexes, which contain a farnesyl side-chain. 
Stars represent the genes targeted by SiRNA knock down during this study: Hmgcs1, 










5.2.1  Effect of simvastatin treatment on NIH/3T3 fibroblast cell viability 
Pharmacological inhibition of the sterol pathway using statins, inhibitors of the rate 
limiting enzyme of the cholesterol synthesis pathway have been used extensively to 
study the involvement of cholesterol synthesis for the viral replication of many 
viruses (See section 1.4.2.2). Since simvastatin treatment has been shown to induce 
cellular toxicity and to trigger apoptosis (Demierre, Higgins et al. 2005), we first 
determined the range of simvastatin concentration which was non-toxic for the cells. 
NIH/3T3 fibroblast cells (2.5 × 104) were seeded in 96-well plates and treated with 
increasing concentrations (0.25 – 25 µM) of simvastatin for 120 hrs. Cell viability 
was measured using the cell titre blue assay (Promega). As seen in Figure 5-2A, 
increasing concentrations of simvastatin resulted in no significant difference in the 
cell viability of the NIH/3T3 fibroblasts after 72 hrs of treatment with 0.25 to 10 µM. 
However, a significant decrease in cell viability is observed when the cells are 
treated with more than 15 µM of simvastatin, and when treated with 25 µM, cells 
were no longer viable. BMDMs however were more susceptible to simvastatin 
toxicity than NIH/3T3. Indeed, macrophage viability was affected with 
concentrations as low as 1 µM after 72 hrs (Figure 5-2B). 
To avoid any results which could have been biased by the toxicity of the simvastatin 
per se, we decided to restrict our analysis to the NIH/3T3 cells as the down 
regulation of the sterol pathway regulation in response to infection was observed in 
both cell types. 
5.2.2 Consequences of simvastatin treatment on mCMV infection in vitro 
We next evaluated whether inhibition of the biosynthesis pathway by simvastatin 
will affect mCMV infection. For this purpose, we performed a one-step growth 
analysis of NIH/3T3 fibroblasts infected with mCMV at a MOI of one in the presence 
and absence of a non-toxic dose of 10 µM of simvastatin for 5 days (Figure 5-2C). 
At different times after infection, the presence of extracellular virus in the cultures 
was determined by standard plaque assay (See section 2.2.5). As shown in Figure 
5-3, the rates of growth of mCMV decreased markedly in the presence of 
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Simvatstatin, where there is at least one log difference in the amount of virus 
measured between the treated and untreated cells after three days and up to five days 
post-infection. 
These results indicate that simvastatin has an antiviral effect on the viral replication 
of mCMV in NIH/3T3 cells.   
5.2.3 Dose effect of simvastatin treatment on mCMV infection 
We next looked at the dose dependency of the inhibition of mCMV growth by 
simvastatin treatment. For that purpose, we used a live cell assay using mCMV-GFP 
tagged virus to monitor the effect of increasing doses of simvastatin on mCMV 
replication. In this assay, the amount of GFP signal emitted in an infected cell is 
directly proportional to the amount of viral replication (See section 2.9). 
For this experiment, NIH/3T3 were infected with mCMV-GFP at a MOI of 0.2 and 
then treated immediately after with an increasing amount of simvastatin (0.001 to 10 
µM). As a positive control, NIH/3T3 cells were also treated in a similar manner with 
an increasing amount of gancyclovir (0.001 to 10 µM), a drug known to alter mCMV 
infection (Matthews and Boehme 1988). The GFP-fluorescence was recorded over 
96 hrs to monitor the growth of the virus. 
Results (Figure 5-4D) demonstrate that simvastatin inhibits mCMV-GFP viral 
growth in a dose dependent manner with a half maximal inhibitory concentration 
(IC50) equal to 2µM. Gancyclovir, as expected, also inhibited mCMV-GFP viral 
growth with an IC50 of 1 µM (Gschwentner, Susanna et al. 1995).  
5.2.4 Specificity of the simvastatin antiviral effect 
Statins have been shown to have other effects than inhibiting the mevalonate 
pathway (Demierre, Higgins et al. 2005; Shaw, Fildes et al. 2009). For that reason, 
we investigated if the antiviral effect of simvastatin in mCMV viral growth was 
specific to the mevalonate pathways. 
Since mevalonate concentrations are decreased by simvastatin treatment (Goldstein 
and Brown 1990), NIH/3T3 fibroblasts were infected with mCMV-GFP and treated 
with 2.5µM of simvastatin supplemented with or without 300µM of mevalonate. 
Results (Figure 5-2E) show that while simvastatin treatment altered mCMV growth, 
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this effect is abolished by the addition of mevalonate. Moreover, the level of 
infection was restored to a level comparable to the untreated cells. Altogether, these 
results indicate that inhibition of viral growth by simvastatin is specific to the 
inhibition of the mevalonate pathway. 
5.2.5 Effect of simvastatin treatment on mCMV infection in vivo 
We next evaluated the antiviral effect of simvastatin towards mCMV infection in 
vivo. In two separate experiments representing a total of 2 groups (control and 
treated) of 12 animals each, Balb/C mice received simvastatin (50mg/kg/mice) daily 
for five days by gavage. The non-toxic dose of the drug administered was chosen 
according to previous studies (Gower and Graham 2001).  
At day 1 post-treatment, mice were then challenged with 2 x 106 PFU of mCMV by 
intraperitoneal injection, and sacrificed at 4 days post-infection (See section 2.4).  
Spleen, liver, kidney, heart and lung were harvested and the viral titre of each organ 
was measured by plaque assay (See section 2.2.5). Each of the organs treated with 
simvastatin over 5 days had a significant lower amount of virus (approximately a log 
less) that those treated with vehicle (Figure 5-2F). These results indicate that 








A-B: Dose effect of simvastatin on NIH/3T3and BMDM cell viability.  
NIH/3T3 fibroblasts (A) or BMDMs (B) were treated with an increasing range of 
simvastatin concentration (0 to 25µM) or with vehicle for 72 hrs. Cell viability was 
determined using the Cell titre blue assay and is expressed as the percent of 
fluorescence signal from treated cells in comparison to untreated cells. Graphs 
represent the average values (± S.D.) of two independent experiments in triplicate 
(n=6). A Welsh t-test was used for the evaluation of statistical significance. 
C: Effect of simvastatin on mCMV replication measured by plaque assay. 
NIH/3T3 cells were infected with mCMV at a MOI of 1 PFU/cell. After one hr 
incubation, fresh media containing 10 µM simvastatin or vehicle was added to the 
culture for 5 days. At the different times indicated in the graph, aliquots of the 
culture were taken and the amount of viable viral particles present in the media was 
determined by standard plaque assay (see methods). Each data point represents the 
average values (± S.D.) of two independent experiments in triplicate (n=6). 
D: Dose dependent inhibition of mCMV replication by simvastatin.  
NIH/3T3 cells were infected with mCMV-GFP at a MOI of 0.2 for one hr and then 
treated with increasing concentrations of simvastatin or gancyclovir immediately 
after infection (0 to 10 µM). GFP expression was measured to establish the level of 
infection (Materials and methods).  The graph represents the percentage of viral 
inhibition as a function of drug treatment where 100% inhibition represents the 
maximum level of inhibition of the simvastatin or gancyclovir treatment. Data points 
represent average values (± S.D.) of two independent experiments with six replicates 
for each experiment (n=12).  
E: Mevalonate rescues infectivity of NIH/3T3 infected mCMV-GFP. 
NIH/3T3 cells were infected for one hr at a MOI of 0.2 and then immediately treated 
with vehicle or 2.5 μM of simvastatin with or without 300 μM of mevalonate. The 
level of infection was determined by measuring the level of GFP fluorescence at 72 
hrs (Materials and methods). The bars represent average values (± S.D.) of 3 
independent experiments with 5 replicates for each experiment (n=15). A Welsh t-
test was used for the evaluation of statistical significance. 
 
Figure 5-2: Pharmacological inhibition of mCMV viral infection with simvastatin 
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F: Effect of simvastatin treatment on mCMV replication in vivo.  
Two groups (control and treated) of 12 animals were given either simvastatin 
(50mg/kg/mice) or PBS daily for five days by gavage. After one day of drug 
treatment, the mice were then challenged with 2 x 106 PFU of mCMV by 
intraperitoneal injection, and sacrificed at 4 days post-infection. Spleen, liver, 
kidney, heart and lung were harvested and the viral titres were measured by plaque 
assay. Individual viral titres for each mouse (white circle or dark circle) are 
expressed per gram of tissue. The mean value of 4 to 6 mice is represented by a red 
horizontal bar, the blue bar represents the limit of detection of the assay, and the 
values were subjected to a Mann-Whitney U test for determination of statistical 
significance. 























5.2.6 Gene-by-gene knock down of the sterol pathway 
To corroborate our previous results and study in more detail the role of sterol 
biosynthesis in mCMV infection, we used a mCMV-GFP-based replication assay 
(See section 2.8) to study the effect of knocking-down the expression of Hmgcs1, 
Hmgcr, Sqle, Fdft1 and Dhcr7 on mCMV viral growth. 
 
Once SiRNA are transfected into the cell, the amount of the related mRNA decreases 
within 24–48 hrs and the targeted protein is knocked down 48 to72 hrs later for 
approximately 5 days (Elbashir, Harborth et al. 2001). Consequently, NIH/3T3 cells 
were transfected for 48 hrs to allow gene and protein knock down before being 
infected. The fluorescence signal was monitored at 76 hrs post infection to compare 
the level of viral replication.  
Transfection conditions and SiRNA concentration were optimised to obtain the best 
knock down, using the lowest amount of SiRNA and transfection reagent possible. 
Indeed high concentrations of SiRNA or transfection reagent have been reported to 
trigger off-target effects such as unspecific knock down and activation of the 
immune response (Lacaze, Raza et al. 2009). Non-target SiRNA was used as a 
negative control to test whether the transfection conditions alone may affect viral 
replication because it contains unspecific sequence to the mouse genome. We also 
included as a control the treatment of the cells with the transfection reagent only: 
Dharmafect-1 called “lipid only” in our figures. 
The efficiency of the transfection for each assay was monitored by transfecting the 
cells with EGFP SiRNA which knocked down the viral GFP gene expression. 
However, since mCMV-GFP virus express the WtGFP and the SiRNA targets the 
mutated version of the gene: EGFP, the knock down of the signal was incomplete. 
Nevertheless previous experiments have demonstrated that a reduction of 30 to 40% 
of the GFP signal using EGFP SiRNA corresponded to efficient transfection 
conditions (data not shown). 
A combination of  a concentration of 25 nM of SiRNA and 0.4% of Dharmafect-1 
was found to be the optimal conditions to ensure the best knock down efficiency for 
the minimal amount of SiRNA and transfection reagent possible (data not shown). 
With these conditions, Hmgcs1, Hmgcr, and Sqle expressions were decreased 
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dramatically by SiRNA transfection (81%, 70% and 82% respectively) (Figure 
5-3A). 
Because of time constraint and costs, the efficiency of Fdft1 and Dhcr7 transfection 
could not be tested. We therefore assumed in view of the previous results that the 
knock down of these genes would be comparable. Given that differences in cell 
number affects the level of GFP signal regardless of the treatment, which could lead 
to the mis-interpretation of the results, we checked the effect of knocking down the 
five genes on the cell viability of NIH/3T3 cells after 48 hrs post-transfection. 
Results (Figure 5-3B) showed that transfection with each of the five SiRNAs used to 
target the sterol synthesis pathway did not affect the viability of the NIH/3T3 
fibroblasts after 48 hrs. This assay was also repeated after 100 hrs post-transfection 
and none of the SiRNAs used affected the long term viability of the cells (data not 
shown). 
 
Once confident in our experimental setup, the effect of knocking down Hmgcs1, 
Hmgcr, Sqle, Fdft1 and Dhcr7 on mCMV replication was measured with the live cell 
replication assay. 
Figure 5F shows that knocking down Hmgcs1 and Hmgcr significantly decreases 
(25% and 27%) the level of infection of mCMV compared to the control non-
targeted SiRNA. In contrast, knocking down Sqle, Fdft1and Dhcr7 significantly 
increased the level of infection by 32, 41 and 20 % respectively.  
 
These results indicate that decreases in gene expression of the first step of sterol 
biosynthesis results in an inhibition of viral replication. Moreover, since decreasing 
expression of the genes that specifically regulate the last steps of sterol synthesis 
results in an increase of viral replication, this strongly suggest that one or several side 
isoprenoid pathways are responsible for the modulation of the viral replication rather 











A: Knock down efficiency of Hmgcs1, Hmgcr and Sqle SiRNA: 
NIH/3T3 cells were transfected with Hmgcs1, Hmgcr or Idi1 On target plus SiRNA 
smart pool (Dharmacon). After 48 hrs, RNA was collected and QPCR was performed 
to measure the gene expression of Hmgcs1, Hmgcr and Idi1. Results represent the % 
of gene expression in the transfected cells (Hmgcs1, Hmgcr or Sqle SiRNA) 
compared to the level of expression in the control cells (non-targeting SiRNA). Bars 
represent average values ± S.D of one experiment with 3 biological replicates (n=3). 
B: Effect of SiRNA transfection on the cell viability of NIH/3T3 fibroblasts: 
NIH/3T3 cells were transfected with lipid only, None-targeted, eGFP, Hmgcs1, 
Hmgcr, Sqle, Fdft1 and Dhcr7 On-target plus SiRNA smart pool (Dharmacon). After 
48 hrs, cell viability was determined using the Cell titre blue assay. Cell viability is 
expressed as the percent of fluorescence signal from treated cells compared to 
controls, Bars represent the average values ± S.D. of 3 independent experiments with 
5 biological replicates for each experiment (n=15). 
C: Effect of inhibition of Hmgcs1, Hmgcr, Sqle, Fdft1 and Dhcr7 mCMV replication. 
After 48 hrs, media was removed and cells infected for 1 hr with mCMV-GFP virus 
at a MOI of 0.2 and the GFP signal was recorded for 100 hrs. At 76 hrs, the level of 
non-targeting siRNA treated cells was used as a baseline estimate for the cut off 
point (using two standard deviations and a p-value < 0.001). Bars represent average 
values ± S.D. of 3 independent experiments with 5 biological replicates for each 
experiment (n=15). 
A Welsh t-test was used for the evaluation of statistical significance: *P < 0.05, **P 











5.2.7 Contribution of prenylation in the Simvastatin antiviral effect  
Isoprenoids are at the branch point of the synthesis of several downstream 
metabolites, such as cholesterol and prenylpyrophosphate (farnsesyl pyorphospahte 
and geranygeranylpyrophosphate), as well as dolichol, a precursor of Heme A and 
ubiquinone (Figure 5-1). 
In order to identify which one of the branches of the mevalonate pathway was 
responsible for the antiviral effect induced by simvastatin on mCMV growth, 
supplementation experiments were performed with mevalonate pathway 
intermediates. 300 µM mevalonate, 15µM of geranylgeraniol, 15 µM of farnesol, 15 
µM of squalene or 5 µg/ml of water soluble cholesterol were added to the culture 
media of mCMV-GFP-infected and simvastatin treated cells for 72 hrs (Figure 
5-3C). The metabolite doses were chosen by taking the highest concentration of each 
metabolite which had no significant effect on the cell viability of the NIH/3T3 
fibroblasts over a period of 72 hrs (data not shown). 
Furthermore, addition of mevalonate and geranylgeraniol completely rescued the 
decrease of infectivity induced by simvastatin treatment, while addition of farnesol, 
squalene and water-soluble cholesterol did not rescue the mCMV infectivity (Figure 
5-4).  
Taken together these results indicate that the alteration of geranylgeranilation is 





Figure 5-4: Effects of mevalonate pathway intermediates on the level of 
infection of mCMV in 
Simvastatin treated NIH/3T3 fibroblast cells. 
300 µM mevalonate, 15µM of geranylgeraniol, 15 µM of farnesol, 15 µM of 
squalene or 5 µg/ml of water soluble cholesterol (See section 2.3) were added to the 
culture media of mCMV-GFP infected and simvastatin treated NIH/3T3 fibroblast 
cells for 72 hrs and GFP fluorescence was recorded with a spectrophotometer. 
Results represent the relative level of infection compared to the untreated cells. The 
level of infection was determined by measuring GFP fluorescence at 72 hrs (See 
section 2.8). Graphs represent average values ± S.D. of 3 independent experiments 
with 5 replicates for each experiment (n=15). Statistical significance was used for the 








The aim of this chapter was to investigate whether the cellular modulation of the 
sterol synthesis pathway altered mCMV infection. To answer that question, we 
applied a combined approach using pharmacological inhibition and gene expression 
knock-down to modulate the sterol pathway and monitor effects on mCMV infection. 
 
Pharmacological inhibition of the sterol biosynthesis pathway with simvastatin 
decreased the amount of mCMV replication in a dose dependent manner (IC50 = 
2µM). This effect was not due to an alteration of cell growth due to simvastatin 
treatment, since cell viability was not affected at the dose having an antiviral effect. 
Furthermore, we have shown that inhibition of mCMV replication by simvastatin 
was specifically due to the alteration of the mevalonate pathway since addition of 
mevalonate in simvastatin treated cells restored the infection to a level comparable to 
the non-treated cells. This is the first time that the involvement of sterol biosynthesis 
in the regulation of mCMV infection has been demonstrated. These results are 
comparable to the inhibition of hCMV replication by fluvastatin in human 
endothelial cells, as demonstrated by Potena and colleagues (Potena, Frascaroli et al. 
2004). In this study, the expression of immediate early genes is reduced by 
fluvastatin treatment, suggesting that modulation of sterol synthesis alters viral gene 
expression. We can speculate that the mechanisms of inhibition of mCMV 
replication by simvastatin are similar. Nevertheless, further studies will be require to 
understand the mechanisms driving the antiviral effect of simvastatin on mCMV 
replication and especially whether simvastatin alters the gene expression of mCMV 
or perturbs the assembly and budding of the viral particle. Since simvastatin 
treatment induced cell death of BMDMs even at a very low concentration, combined 
with the difficulty of transfecting primary macrophages, we could not study the 
effect of the inhibition of the sterol pathway on mCMV infection in the macrophage 
model. 
As a result we cannot exclude that the inhibition of sterol synthesis in BMDMs will 




In this chapter we have also demonstrated that simvastatin treatment of Balb/C mice 
in vivo significantly reduced (one log scale) the level of mCMV infection in the liver, 
spleen, lung, kidney and heart after 4 days of infection compared to untreated mice. 
To our knowledge, this is the first time that the antiviral effect of statins on herpes 
virus replication has been demonstrated in vivo. However, these results do not prove 
a direct correlation between down regulation of the sterol biosynthesis pathway and 
the reduction of mCMV infection. Indeed, simvastatin has been shown to have 
various effects not linked to the inhibition of cholesterol synthesis. In particular, 
statins have been shown to modulate the adaptive immune response which is crucial 
in the control of mCMV infection. In order to directly correlate the antiviral effect of 
statins in vivo to the inhibition of the sterol biosynthesis pathway, the antiviral effects 
of statin treatment supplemented with mevalonate or the use of drugs targeting 
downstream proteins of the mevalonate pathway will be required in vivo. Although it 
is still controversial, several studies have shown that statin treatment could be used 
efficiently as an antiviral agent against HCV and HIV in patients. Our results suggest 
that statins could also be potentially used as a therapeutic treatment against acute 
cytomegalovirus or herpes virus infection in patients. However, the dose of 
simvastatin used in the in vivo experiment (50 mg per day per kilo) is 50 to 100 fold 
higher than the doses prescribed to patients. Since there are more than nine different 
statins available, each with different properties and inhibitory effects, it will be of 
interest to study the antiviral effect of each statin (IC50 and specificity) on mCMV 
replication to reduce the dose required for an antiviral effect.  
 
We also confirmed with SiRNA gene knock down that reduction of the gene 
expression of Hmgcr and Hmgcs1 reduced viral replication. To our knowledge this is 
the first time that transcriptional down regulation of sterol synthesis genes have been 
shown to have an antiviral effect. 
In order to understand if sterol biosynthesis or the isoprenoid alternative pathway 
(prenylation, dolichol, heme A) were responsible for the antiviral effect we also 
knocked down the expression of Fdft1, Sqle and Dhcr7, three genes positioned 
downstream of the isporenoid branch points of the pathway and specifically involved 
in cholesterol synthesis. Surprisingly, the knock down of these three genes 
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significantly increased viral replication. Pharmacological inhibition of squalene 
synthase (Fdft1) with zaragocid acid has been shown to induce the accumulation of 
upstream intermediates and enzyme gene expression (Bergstrom, Kurtz et al. 1993; 
Vaidya, Bostedor et al. 1998), therefore we can speculate that the knock down of 
Fdft1 may be beneficial for the virus by increasing upstream metabolites or gene 
expression involved in mCMV replication. In addition, we have demonstrated that 
addition of geranylgeranyol, but not farnesol or squalene and cholesterol, could 
restore the infectivity of mCMV infection in simvastatin treated cells. Further 
experiments are required to confirm the direct involvement of geranylgeranylation in 
mCMV replication. For example, knock down of the gene expression of the enzymes 
responsible for prenylation or the use of chemical inhibitors of prenylation (FTIs and 
GGTIs) will confirm that the inhibition of geranylgeranylation is responsible for the 
inhibition of mCMV replication. Nevertheless, taken together, these results provide 
evidence for the first time that inhibition of geranylgeranylation, rather than the 
synthesis of cholesterol itself, is responsible for the inhibition of mCMV replication 
in NIH/3T3 cells. Since the use of statins as an antiviral agent may be problematic 
because of their pleitotropic effects and the high dose required, our results suggest 
that the use of chemical inhibitors of geranylgeranylation may be more appropriate 
as an antiviral agent. Further investigation should look at the antiviral effect of 
geranylgeranyl transferase inhibitors (GGTIs) in herpes virus infection, in vitro and 
in vivo. 
The mechanisms involved in the modulation of viral infection by the prenylation of 
proteins remains unclear. Geranylgeranylation has been previously shown to regulate 
the replication of other viruses such as HCV, HDV, EBV (Bordier, Ohkanda et al. 
2003; Einav and Glenn 2003; Glenn 2006). Some viruses have been shown to require 
viral protein prenylation (HDV) (Glenn 2006), while other viruses require a host 
protein geranylgeranylation (HCV) (Wang, Gale et al. 2005). Further work is 
required to understand the mechanisms involved in the modulation of mCMV 
infection by geranylgeranylation and especially if a specific host protein from the 
Rho, Rac or CD32 small G-protein family requires geranylgeranylation for efficient 
replication of the virus. We can also not exclude that a viral protein requires direct 
geranylgeranylation for efficient replication of the virus. 
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In conclusion, we have shown that inhibition of the sterol pathway at the 
transcriptional and protein level reduces viral replication. These results suggest that 
regulation of sterol biosynthesis upon mCMV infection contribute to the 



























6 Chapter 6: Type I interferon receptor regulates the sterol 
biosynthesis pathway 
6.1 Introduction 
In the previous chapters, we provided evidence that the down regulation of the sterol 
biosynthesis pathway is a general cellular response to viral infection, and is 
independent of viral gene expression (see chapters 3 and 4). We then demonstrated 
that transcriptional and protein inhibition of the sterol biosynthesis pathway inhibits 
viral replication (see chapter 5).  
Altogether, these observations led us to hypothesise that the modulation of the sterol 
synthesis pathway in response to infection is part of a host innate immune response. 
Upon infection, the innate immune response takes place in two distinct phases. The 
first is initiated by the detection of viral pathogen associated molecular patterns 
(PAMPs) by host pattern recognition receptors (PRRs), such as TLRs. Activation of 
these receptors lead to activation of transcription factors that activate the primary 
antiviral response. Some of the transcription factors activated, such as IRF3 or IRF7, 
will then rapidly induce the secretion of inflammatory cytokines and chemokines. 
When secreted, these molecules bind to specific cellular receptors, and via an 
autocrine loop, induce a cascade of signalling events leading to the secondary 
immune response (see the introduction chapter). In macrophages and NIH/3T3 cells, 
Interleukins (IL-1β, Il6), IFNα and β, as well as Tumour necrosis factor alpha 
(TNFα), are secreted rapidly in response to infection (see the introduction chapter).  
The aim of this chapter is to understand whether the down regulation of sterol 
biosynthesis is part of the innate immune response triggered by infection, and to 











6.2.1 Effect of conditioned media on the regulation of the sterol biosynthesis 
pathway 
To test whether immune factors secreted in response to infection were capable of 
regulating the sterol biosynthesis pathway, we thought of using the media of infected 
cells that contain inflammatory cytokines, but no viral particles, to treat uninfected 
BMDMs. 
Conditioned media from 8 hrs infected BMDMs at a MOI of 1, or fresh media, were 
immediately added to uninfected BMDMs. The absence of any viral particle in the 
conditioned media was tested by plaque assay (Figure 6-1A). After 24 hrs 
incubation, macrophage RNA was extracted and the expression of Hmgcs1, Hmgcr 
and Sqle was measured by QPCR. Results (Figure 6-1B) show that each of the three 
genes are down regulated significantly by treatment with conditioned media 
compared to the mock treated macrophages. Fold change for Hmgcs1: -2.56, Hmgcr: 
-1.72 and Sqle : -2.32. 
These results indicate that after viral infection, one or several factors secreted in 
response to infection are responsible for the down regulation of genes associated 




















BMDMs were infected with mCMV at a MOI of 1, or mock treated. Supernatant was 
collected after 8 hrs and added to fresh BMDMs.  
A: NIH/3T3 cells were treated with conditioned media, or as a control, infected at a 
MOI of 0.1 with mCMV-C3X. At the indicated time points after infection (dpi) 
supernatants from the infected cultures were harvested, and titres were determined by 
standard plaque assays on MEF p53 -/- cells. Each data point represents the average 
and standard deviation from three independent wells (n=3). 
B: After 24 hrs, RNA was collected and Hmgcs1, Hmgcr and Sqle expression was 
measured by QPCR. The bars represent the relative amount of RNA compared to the 
untreated samples. Results represent average ± S.D. of two experiments with 
triplicate assays (n=6). 






















6.2.2 Effect of IFNγ, IFNβ, IL1β, IL6 and TNFα treatment on the regulation of the 
sterol biosynthesis pathway and on free cellular cholesterol levels 
Next, we thought of testing if antiviral cytokines could modulate sterol biosynthesis. 
For that reason BMDMs were treated with fresh media or fresh media containing 10 
and 100 units of TNFα and IFNγ, or 10 and 25 units of IFNβ, IL1β, and IL6. 
BMDMs were also infected with mCMV at a MOI of 1 as a positive control. After 24 
hrs incubation, macrophage RNA was extracted and the level of Hmgcs1, Hmgcr, 
Idi1 and Sqle expression was measured by QPCR. Results (Figure 6-2A-E) 
demonstrate that during mCMV infection, IFNγ and IFNβ treatments significantly 
down regulated Hmgcs1, Hmgcr, Idi1 and Sqle gene expression, and treatment with 
IL1β, IL6 or TNFα did not affect the expression of these genes. Furthermore, the 
amplitudes of the decrease in gene expression induced by IFNβ and IFNγ are 
comparable to those induced by mCMV infection. In addition, the down regulation 
of the markers of sterol biosynthesis is more pronounced with increasing doses of 
IFNβ and IFNγ, which might suggest that there is a dose effect in its regulation. 
We then measured the effect of cytokine treatment on the levels of free intracellular 
cholesterol concentration. BMDMs were treated with the same concentration of 
IFNγ, IFNβ, IL1β, IL6 or TNFα as in the previous experiment for 48 hrs, and the free 
cholesterol concentration was measured as previously described (see section 2.6). 
Results (Figure 6-3) show that treatment with IFNβ decreases the amount of free 
intracellular cholesterol by 40 to 50% after 48 hrs. Inversely, IL1β, IL6 or TNFα 
treatment did not induce any changes in the free cholesterol concentration of 
BMDMs. Taken together, these results indicate that among the inflammatory 
cytokines inhibiting mCMV infection, IFNβ and IFNγ are key players in the 
regulation of sterol gene expression. 
Since IFNβ is secreted in response to infection, these results, and the fact that IFN 
treatment and the cell response to infection are equally capable of causing a down-
regulation of the sterol metabolic pathway, raises the question of whether infection 








A- D: BMDMs were treated with fresh media or fresh media containing 10 and 100 
units of TNFα and IFNγ, or 10 and 25 units of IFNβ, IL1β, and IL6. BMDMs were 
also infected with mCMV at a MOI of 1 as a positive control. After 24 hrs 
incubation, macrophage RNA was extracted and the level of Hmgcs1, Hmgcr, Idi1 
and Sqle gene expression was measured by QPCR. Bars represent average 
values ± S.D. of five independent experiments with triplicate measurements for each 
experiment (n=15).  
E: BMDMs were treated with the same concentration of IFNγ, IFNβ, IL1β, IL6 or 
TNFα as in the previous experiment for 48 hrs, and the free cholesterol concentration 
was measured as previously described (see section 2.6). Results represent 
average ± S.D. of two independent experiments with quadruplicate assays for each 
experiment (n=8).  

















Figure 6-2: Effect of inflammatory cytokines on BMDM sterol biosynthesis gene expression 
and cellular free cholesterol levels 
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6.2.3 Type I receptor knockout mice abolish transcriptional and metabolic 
regulation of cellular free cholesterol by mCMV infection and IFNβ. 
To directly test the hypothesis that down regulation of the sterol synthesis pathway is 
occurring through a type I interferon autocrine loop, BMDMs cultures from 
IFNAR1-/- mice lacking sub-unit 1 of the type I receptor were infected with mCMV, 
or treated with 10 Units per ml of IFN. After 24 hrs, the gene expression of 
Hmgcs1, Hmgcr, Idi1 and Sqle, as well as the level of free cellular cholesterol, were 
measured. As shown in Figure 6-3A-B, in the WT backgrounds, mCMV infection 
and IFN treatment down regulates Hmgcs1, Hmgcr, Idi1 and Sqle expression after 
24 hrs, as observed previously. Fold changes for mCMV infection: Hmgcs1: -5.2, 
Hmgcr: -1.64, Idi1: - 4.2 and Sqle: -4.54, and for IFN treatment: Hmgcs1: -2.28, 
Hmgcr: not significant, Idi1: - 2.39 and Sqle: -2.63. However, the lack of an IFN type 
I receptor abolished the ability of BMDMs to reduce sterol biosynthesis gene 
expression upon either infection with mCMV or treatment with IFN. Additionally, 
we measured the level of free cellular cholesterol in WT and IFNAR1 -/- cells treated 
with the same conditions as the previous experiment. As a result, mCMV infection 
and IFN treatment significantly decreased the level of free cellular cholesterol in 
WT BMDMs (35 % and 22 % respectively), but not in IFNAR1-/- BMDMs (Figure 
6-3C-D).  
We concluded from these experiments that a type I IFN-dependent innate immune 
response stringently regulates the transcriptional and metabolic alterations of the 
sterol biosynthesis pathway and overall free cellular cholesterol levels. 
We then wondered if the abolition of the reduction in gene expression of the sterol 
biosynthesis pathway was specific to IFNβ secretion, since IFNα has also been 
shown to be produced upon infection (Dalod, Hamilton et al. 2003). BMDMs 
derived from IFN gene knockout mice were challenged with mCMV infection for 
24 hrs and the sterol biosynthesis gene expression analyzed. As shown in Figure 6-
3E, the deletion of IFN genes only partially, but significantly, abolished the down 
regulation of the sterol pathway induced by mCMV infection. However, due to time 
constraints, this experiment could only been done once, limiting our confidence in 
the validity of these results. Nevertheless, if these results are confirmed, it will 
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indicate that IFN is not the only factor responsible for the down regulation of the 

































Figure 6-3: Type I receptor knockout mice abolish transcriptional and 
metabolic regulation of cellular free cholesterol by mCMV infection and IFNβ 
A-B: Wild type BMDMs or BMDMs from IFNAR1-/- mice were mock treated, or 
infected with mCMV at a MOI of 1 or treated with 10 units of IFNβ. After 24 hrs, 
RNA was collected and the gene expression of Hmgcs1, Hmgcr, Idi1 and Sqle 
measured by QPCR. Results represent the average values ± S.D. of 2 independent 
experiments with three biological replicates for each experiment (n=6). 
C-D: Wild type or IFNAR1-/- BMDMs were infected with mCMV at a MOI of 1 
(left panel) or treated with 10U/ml of IFNβ (right panel). After 48 hrs, free 
cholesterol concentration was measured (see section 2.6). Results represent the 
average values ± S.D of 2 independent experiments with three biological replicates 
for each one (n=6).  
E: Wild type or IFNβ -/- BMDMs were mock treated or infected with mCMV at a 
MOI of 1.  
After 24 hrs, RNA was collected and the gene expression of Hmgcs1, Hmgcr, Idi1 
and Sqle was measured by QPCR. Results represent the average values ± S.D. of one 
experiment with a total n of four. 

















6.2.4 IFNγ regulation of the sterol biosynthesis pathway 
As demonstrated in section 6.1.1, IFNγ treatment also induces the down regulation of 
sterol pathway-related gene expression. This raised the question of the involvement 
of type II interferon in the regulation of sterol biosynthesis. Mechanistically, one 
possibility is that IFNγ binds to a type II receptor and consequently triggers the 
initiation of a signalling cascade leading to the down regulation of the sterol 
pathway. Alternatively, IFNγ could lead to the secretion of IFNβ, which will then 
bind to its receptor and induce the down regulation of sterol biosynthesis. 
To test whether IFNγ treatment of BMDMs induces a type–I independent regulation 
of the sterol pathway, IFNAR1 knock out or wild type macrophages were treated 
with 10 U per ml of IFNγ for 24 hrs, and the gene expression of Hmgcs1, Hmgcr, 
Idi1 and Sqle were compared. Results (Figure 6-4) demonstrate that IFNγ treatment 
of BMDMs results in the down regulation of four gene markers of sterol biosynthesis 
in WT and IFNAR1 -/- KO BMDMs. Fold changes in WT BMDMs: Hmgcs1: -4.4, 
Hmgcr: - 1.7, Idi1: -5.2 and Sqle:-7.7. Fold changes in IFNAR1 -/- BMDMs: 
Hmgcs1: -5.3, Hmgcr:-1.9, Idi1: -5.7 and Sqle: -4.8. These results clearly show that 











Wild type BMDMs or BMDMs from IFNAR1-/- mice were mock treated, or infected 
with mCMV at a MOI of 1 or treated with 10 units of IFNγ. After 24 hrs, RNA was 
collected and the gene expression of Hmgcs1, Hmgcr, Idi1 and Sqle measured by 
QPCR. Results represent the average values ± S.D. of 2 independent experiments 
with three biological replicates for each experiments (n=6). Statistical significance in 












In the previous chapters, we have shown that down regulation of sterol biosynthesis 
is a general response to infection. We also provided evidence that this regulation 
occurs rapidly after the first contact with the virus, and does not require viral gene 
expression. In addition, we have demonstrated that transcriptional or protein 
inhibition of sterol biosynthesis reduces mCMV replication. 
This led us to hypothesise that the regulation of the sterol pathway in response to 
infection is triggered by an innate immune mechanism. 
In this study we have shown that the regulation of the sterol cholesterol pathway was 
dependent on factors secreted in response to infection. This evidence strongly 
suggests that the regulation of the sterol pathway in response to infection is part of a 
second autocrine signalling cascade. However, we could not exclude that the primary 
activation had a direct effect on the regulation of sterol synthesis. Consequently, we 
aimed to identify the effectors secreted in response to infection which were 
responsible for the regulation of the sterol pathway. Transcriptional and metabolic 
screening of the effect of five inflammatory cytokines and chemokines known to 
induce an antiviral state showed that IFNβ and IFNγ treatment, but not IL6, IL1β or 
TNFα, down regulated sterol biosynthesis gene expression, and decreased levels of 
free cellular cholesterol. These results raised the hypothesis for an IFN regulatory 
loop mechanism that is responsible for modulating sterol biosynthesis. However, we 
cannot exclude that other secreted factors in response to infection may also modulate 
the sterol biosynthesis pathway, or that the doses of cytokines and chemokines used 
for this experiment were not sufficient. Future experiments should characterise and 
test the effect of other inflammatory cytokines and chemokines. In addition, the use 
of neutralising antibodies against IFNs in the media of the treated cells should 
indicate if IFNs are the only effectors of the down regulation of the sterol pathway. 
We next investigated whether the sterol response to infection is dependent on the 
type I IFN receptor and the expression of IFNβ using genetic deficient mice. The 
lack of IFN type I receptor completely abolished the ability of BMDMs to reduce 
both sterol biosynthesis gene expression and cholesterol yield upon either infection 
with mCMV or treatment with IFN. However, the reduction of sterol gene 
expression was only partial in mice lacking the IFNβ gene. 
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We conclude from these experiments that a type I IFN-dependent innate immune 
response stringently regulates the metabolic alteration of the sterol biosynthesis 
network observed upon infection. However, since IFN is not the only secreted 
factor responsible for this regulation, these results suggest that other type I IFN 
members may compensate for the lack of IFN. Further studies will be required to 
understand the role of type I IFN in the regulation of sterol biosynthesis. 
Nevertheless, to our knowledge, this is the first time that the regulation of sterol 
biosynthesis in response to infection, or direct IFN treatment, has been shown to be 
type I signalling dependent. 
In this chapter, we also demonstrated that type II interferon treatment of BMDMs 
induced the down regulation of sterol synthesis independently of the type I 
regulatory response. Since we could not obtain type II receptor knockout mice we 
could not formally prove that IFNγ regulation of sterol synthesis is the consequence 
of a direct type II signalling cascade. 
To date, cellular metabolic, signalling and regulatory pathways causally linked with 
immunity have been argued to play a critical role in modulating infection (Diamond, 
Syder et al.). In this regard, toll-like receptors, the central pathogen recognition 
receptor systems of innate immune signalling, have recently been shown upon 
bacterial infection to regulate the expression of key lipid-associated genes through 
IRF3 and the nuclear receptor LXR. In this study, microbial ligand activation of the 
IRF3 pathway blocked the induction of LXR target genes, such as ABCA1, and 
inhibited cholesterol efflux from macrophages (Castrillo, Joseph et al. 2003). 
Additionally, knockout mice deficient for LXR are more susceptible to bacterial 
infection (Joseph, Bradley et al. 2004), suggesting the importance of this pathway in 
the innate immune response. However, Castrillo and colleagues demonstrated that 
the regulation of the ABCA1 gene by the innate immune response through the IRF3-
LXRα pathway is independent of the type I signalling response.  
Our results complement these studies by revealing an unknown mechanism of cross 
talk between innate immunity and lipid regulation through a type I response. The 
involvement of TLR and IRF signalling in the regulation of sterol biosynthesis is still 
undefined. Since IRF3 has been involved in the transcription of type I interferon 
genes, we can speculate that it is its activation which leads to sterol synthesis through 
158 
 
a type I signalling cascade. Use of IRF3 deficient macrophages will be required to 
test this hypothesis. 
In addition, the mechanisms of regulation of sterol biosynthesis by the activation of 
interferon signalling are not yet fully understood. In particular, the involvement of 
JAK1, TYK2, STAT1 and STAT2 in the regulation of sterol synthesis is still to be 
addressed. Since both IFNβ and IFNγ induce the down regulation of sterol 
biosynthesis, we can speculate that STAT1 is involved in the regulation, as activation 
of both signalling cascades induces the activation of STAT1. However, this 
hypothesis raises the question of the direct or indirect action of STATs on the 
regulation of sterol biosynthesis gene expression. Indeed, when activated the STAT 
proteins migrate to the nucleus, where they bind to promoter elements on the DNA 
molecule, leading to the expression of target genes. This indicates that IFNAR/STAT 
regulation of sterol gene synthesis occurs through the active expression of a repressor 
of sterol biosynthesis. Since we have shown that the free cellular cholesterol levels 
are decreased in response to infection, the involvement of a negative feedback 
mechanism in consequence of high cholesterol concentration have to be excluded. 
Several hypotheses can be proposed to explain the mechanism of this regulation. 
Firstly, IFNAR activation may induce the regulation of nuclear factors such as 
PPARs, LXRs FXR. These nuclear factors may in turn down regulate sterol 
biosynthesis. However, the direct down regulation of Srebf2 and the sterol 
biosynthesis genes by activation of nuclear factors has been shown, yet also there is 
some evidence linking the regulation of Srebf1 by PPARγ and LXRα in the literature 
(Schultz, Tu et al. 2000; Davidson 2006; Kadegowda, Bionaz et al. 2009; Kim, Kim 
et al. 2009).  
Another possible mechanism of the regulation of sterol biosynthesis by a 
IFN/IFNAR dependent pathway, is the involvement of oxysterols as a repressor of 
the sterol biosynthesis genes. In particular, 25-hydroxycholesterol has been shown to 
directly interact with SCAP and INSIG proteins to block the cleavage of SREBP2, 
leading to the down regulation of the sterol biosynthesis genes (Adams, Reitz et al. 
2004). Given that mCMV infection and IFNβ and IFNγ treatment results in the 
coordinate transcriptional regulation of sterol biosynthesis, we can speculate that 
Srebf2 is involved in this process, as well as being IFNAR dependent, although 
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further experiments are required to test this hypothesis. Recently, 25-
hydroxycholesterol secretion by macrophages has been shown to be dependent on 
TLR activation (Bauman, Bitmansour et al. 2009; Diczfalusy, Olofsson et al. 2009). 
The expression of cholesterol 25-hydroxylase (CH25H) catalyses the production of 
25-hydroxycholesterol from cholesterol, and we have seen that mCMV infection and 
IFNγ treatment increases the expression of CH25H at a very early time post-
treatment and infection. Furthermore, this up regulation is abolished in IFNAR -/- 
macrophage cells infected with mCMV or treated with IFNβ and IFNγ (data not 
shown- unpublished data). We can speculate that the activation of a type I IFN 
signalling cascade results in the activation of the expression of CH25H and 
consequently regulates sterol biosynthesis gene expression through the inhibition of 
SREBP2 cleavage. On the other hand, a few studies have shown that STAT proteins 
are capable of directly inhibiting gene transcription (Foley, Ofori-Acquah et al. 2002; 
Ma, Chang et al. 2005), and we cannot exclude a direct negative regulation by 
STATs on sterol-associated genes and Srebf2 gene expression. 
Moreover, type I interferon activation also interacts with other signalling pathways 
which may also be involved in the regulation of sterol synthesis. JAK/STAT 
phosphorylation leads to the activation of the Ras receptor tyrosine kinase (RTK) and 
mitogen-activated protein kinase (MAPK) pathways, which result in the activation of 
the phosphoinositide 3-kinase (PI3K) pathway. Recently, activation of 
PI3K/AKT/mTORc1/AMPK pathway has been shown to regulate the expression of 
Srebf1 (Porstmann, Santos et al. 2008). This mechanism could also explain the 
regulation of sterol synthesis by IFN signalling activation. 
Finally, a plethora of studies has reported an interplay between the inflammatory 
response and cholesterol metabolism. For example, it is well documented that the 
acute phase response induces a rapid decrease of total cholesterol serum levels 
(Khovidhunkit, Kim et al. 2004), and IFNβ treatment has also been shown to 
decrease cholesterol plasma levels in multiple sclerosis patients (Morra, Coppola et 
al. 2004). However, the mechanisms involved in this process are not fully 
understood. The results of our study may provide mechanisms to explain this clinical 
observation. It will be of interest to study the correlation between the type I 




However, this study did not address certain important questions; firstly, we did not 
define whether the same regulatory mechanisms occur in other cell types and species. 
Nevertheless, in view of the fact that the IFN signalling pathway is ubiquitously 
conserved among vertebrates (Rawlings, Rosler et al. 2004), we can speculate that it 
is the case, but further experiments need to be conducted to test this hypothesis. 
Secondly, we did not study the dependency to type I signalling of the regulation of 
the mechanisms regulating cholesterol homeostasis, such as efflux, uptake and 
storage. Castrillo and colleagues have demonstrated that cholesterol efflux is 
dependent on IRF3/LXRα activation in an IFNAR independent manner. These 
results need to be validated in our model and the role of IFN signalling in the 
regulation of cholesterol efflux, uptake and storage needs to be addressed (Castrillo, 


















7 Chapter 7: Discussion 
7.1 Rational of the study 
Cholesterol metabolism has been shown to be involved in every step of the virus life 
cycle (see section 1.4.2.2). Indeed, cholesterol has been shown to be structurally 
important for viral entry, assembly and budding. Additionally, pharmacological 
inhibition of the de novo cholesterol synthesis pathway using statins has also been 
shown to result in a reduction of viral infection in vitro and in vivo, highlighting the 
importance of this process for viral replication. Although the mechanisms are still 
unclear, it appears that the synthesis of specific isoprenyl lipids, but not of de novo 
cholesterol, is involved in this process. For example, HCV infection requires the 
geranylgeranylation of a cellular protein FBL2 for efficient replication (Wang, Gale 
et al. 2005). 
Since the sterol synthesis pathway is important for viral replication, it is not 
surprising that some viruses have developed mechanisms to exploit the pathway 
regulating cholesterol metabolism to increase their replication efficiency. For 
example, the HIV protein NEF and the HCV protein NS4B have been shown to 
directly increase the expression of the genes regulating the sterol synthesis pathway 
(Zheng, Plemenitas et al. 2003). 
However, the involvement of the sterol biosynthesis pathway in the herpes virus life 
cycle has not yet been fully characterised. Nonetheless, Potena and colleagues have 
shown that treatment with statins inhibited hCMV early gene expression, suggesting 
that sterol biosynthesis is also important for herpes viral replication (Potena, 
Frascaroli et al. 2004). However, the mechanisms of this inhibition are still 
unknown. 
On the other hand, recent studies suggest that the innate immune response modulates 
several aspects of cholesterol metabolism. Indeed, TLR activation through IRF3 and 
the nuclear receptor LXRα have been shown to reduce the efflux of cellular 
cholesterol (Castrillo, Joseph et al. 2003). Furthermore, LXRα KO mice have been 
demonstrated to be more susceptible to viral infection. In addition, TLR activation 
has been demonstrated to increase oxysterol levels and consequently negatively 
regulate the activation of B cells (Bauman, Bitmansour et al. 2009). However, the 
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question remains open as to whether innate immunity modulates the sterol 
biosynthesis pathway and if cholesterol modulation is part of a protective immune 
response against viral infection. 
Moreover, it is well documented that cytokines and chemokines treatment modulates 
cholesterol metabolism in patients. For example, an acute phase response induces a 
decrease of total serum cholesterol levels (Khovidhunkit, Kim et al. 2004). IFNβ 
treatment has also been shown to decrease cholesterol plasma levels in multiple 
sclerosis patients (Morra, Coppola et al. 2004). However, the mechanisms involved 
in this regulation are still unknown. 
Taken together, these observations led us to hypothesise that the innate immune 
response interacts with the regulation of cholesterol to modulate viral infection. 
To understand the host-pathogen interaction with cholesterol metabolism, we used 
mCMV, a large double strand DNA virus which represents one of the few models of 
a natural infection of its host, and which has both biological and clinical relevance to 
human CMV diseases. Since the macrophage is one of the central players of the 
regulation of the innate immune response and of the CMV infection, as well as being 
implicated in the development of diseases such as atherosclerosis, which results in 
abnormal cellular cholesterol regulation, we used BMDMs as a model in our study. 
 
At the start of this project, three major questions were defined to validate our 
hypothesis: 
1. Does mCMV infection regulate cholesterol homeostasis? 
2. How do those changes modulate viral replication? 
3. Does the innate immune response play a role in the modulation of cholesterol 








7.2 Summary of the results 
The sterol biosynthesis pathway is down regulated at the transcriptional and 
metabolite level by mCMV infection in BMDMs and NIH/3T3 fibroblasts. 
As a first step, we transcriptionally and metabolically characterised the regulation of 
cholesterol metabolism upon mCMV infection. We first applied a global non-biased 
transcriptional analysis coupled to the analysis of expression data exclusively 
restricted to lipogenic associated genes of mCMV-infected BMDMs to characterise 
the regulation of lipid pathways by mCMV infection. In addition, we performed a 
lipidomic quantification of the major membrane lipid classes as well as individual 
molecular lipid species at high sensitivity. 
This approach revealed a selective and specific regulation of the lipid pathway by 
viral infection. Moreover, we provided evidence that fatty acid elongation, acetyl-
COA-associated pathways and G-protein signalling are modulated by mCMV 
infection. Furthermore, this analysis demonstrated that sterol synthesis-regulating 
genes were co-ordinately down regulated by the mCMV infection. 
However, the observed quantifiable level of reduction in expression of the sterol-
associated genes was relatively modest (ranging from 1.3 to 3-fold). Hence, to 
independently validate the microarray data and extend our analysis, we then 
performed a more focused analysis of the gene expression of the cholesterol 
homeostasis-associated genes using QPCR and of the free cellular cholesterol 
changes induced by the mCMV infection in BMDMs. Our results showed that there 
is a complete reprogramming of the pathways regulating cholesterol homeostasis in 
response to infection. Indeed, sterol synthesis and uptake were down-regulated and 
cholesterol storage and efflux was up-regulated at the transcriptional level. 
Consistent with the transcriptional changes, the free cellular cholesterol levels, as 
well as its immediate precursor, 7-dehydrocholesterol, were strongly reduced 
(approximately 50%) by mCMV infection in BMDMs and NIH/3T3 fibroblasts, 
while the cholesteryl ester levels was increased in BMDMs. Moreover, we have 
shown that the down regulation of the sterol biosynthesis pathway does not require 
viral gene expression and is generalised to other viral infections since HSV1, SFV, 
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VV and Ad infections also down-regulate the expression of the sterol biosynthesis 
pathway. 
Pharmacologic inhibition and siRNA knock-down of the sterol biosynthesis 
pathway has an antiviral effect. 
Since we identified the sterol synthesis pathway as being regulated by mCMV 
infection, we then wondered if the alteration of the sterol pathway had any 
consequences on the mCMV replication. We used pharmacological inhibition with 
simvastatin and gene expressions knock-down to modulate the sterol pathway and 
monitor its effect on mCMV infection. This combined approach showed that 
inhibition at the protein and transcriptional level of the sterol biosynthesis pathway 
induced a decrease in mCMV replication. We also showed that simvastatin treatment 
has an antiviral effect against acute mCMV infection in vivo. These results are in 
agreement with a previous study (Potena, Frascaroli et al. 2004) and indicate that the 
sterol synthesis pathway is important for cytomegalovirus replication. Furthermore, 
by performing a selective knock-down assay and sterol intermediary supplementation 
of simvastatin treated cells, we could identify the prenylation branch and not the 
synthesis of cholesterol itself as being responsible for the modulation of the mCMV 
infection. This is the first time that the prenylation pathway has been shown to play a 
role in herpes virus replication. However, we did not identify the molecular 
mechanisms of the modulation of mCMV replication by the prenylation pathway. 
Taken together, these results support a role for the mevalonate-prenylation arm of the 
sterol pathway for optimal mCMV replication, and highlight its potential in 
protecting the host from viral infection. 
An interferon regulatory loop mechanism induces the transcriptional down-
regulation of the sterol biosynthesis pathway in response to infection. 
The demonstration that down-regulation of the sterol pathway is a general early 
response to infection and does not require viral gene expression added to the 
observation that the alteration of the sterol synthesis inhibits viral replication. This 
led us to hypothesise that the regulation of sterol biosynthesis is part of an innate 
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immune response. On the basis that secreted factors in response to infection also 
down-regulate the sterol synthesis pathway, a screen for a cytokine effect on sterol 
synthesis gene expression demonstrated that IFN and IFNγ, but not IL1, IL6 or 
TNFα treatment, were able to alter sterol synthesis pathway. These results raised the 
hypothesis for a potential IFN regulatory loop mechanism that is responsible for 
modulating sterol biosynthesis. Consequently, we investigated whether type I IFN 
receptor was required for the regulation of sterol biosynthesis in response to 
infection. Our results demonstrated that the lack of IFN type I receptor abolished the 
ability of BMDMs to reduce both sterol biosynthesis gene expression and cholesterol 
yield upon either infection with mCMV or treatment with IFN, but not IFNγ. We 
conclude from these experiments that a type I IFN-dependent innate immune 
response stringently regulates the metabolic alteration of the sterol biosynthesis 
network observed upon infection. Moreover, we demonstrated that genetic ablation 
of IFN results in a partial loss but still statistically reduced sterol gene expression 
indicating that it is not absolutely necessary and strongly suggesting that other type I 
interferons may also play a role in the regulation of the sterol pathway in response to 
infection. 
Additionally we also demonstrated that type II interferon treatment of BMDMs 
induced the down regulation of sterol synthesis independently of the type I 
regulatory response suggesting that an alternative type II interferon signalling 












In this study, we confirmed the central hypothesis of this thesis, that the innate 
immune response interacts with the regulation of cholesterol to modulate viral 
infection. Indeed, by using a strategy integrating genomic, lipidomic and biochemical 
approaches, we identified that the prenylation arm of the sterol pathway as playing a 
pivotal role in antiviral functions coupled to the type I IFN response. A definitive 
link to sterol metabolism that is independent of cholesterol was established by the 
observation that the anti-viral effect of down-regulating the sterol pathway upon 
infection is completely blocked if cells are provided with an excess of mevalonate 
but not cholesterol. Furthermore, on the basis of genetic elimination studies, we 
document for the first time a molecular dependency between sterol biosynthesis and 
IFN signalling upon infection, leading to small coordinate changes in gene 
expression.  
Our results are consistent with a model involving a canonical two-step IFN response 
for modulating endogenous sterol pathway activity upon infection.  
Figure 7-1 illustrates the two signalling cascades; a virus-induced IFN-producing 
signal and an IFN receptor-mediated secondary signal. The first is initiated by the 
detection of viral structural proteins and nucleic acids by host recognition receptors, 
in the case of mCMV this has been extensively investigated and shown to involve 
TLR2 and -9 recognition receptors (Compton, Kurt-Jones et al. 2003; Tabeta, 
Georgel et al. 2004), and this has been seen to lead to the activation of the 
transcription factors, NFkB, ATF2/c-Jun, and IRF3 that directly activate IFNA and 
 genes. Interestingly, previous studies have shown that microbial activation of 
TLR3 or TLR4 inhibits LXR target genes such as ABCA1 by an unknown 
mechanism, resulting in the inhibition of cholesterol efflux from macrophages, which 
is reported to occur in a type I interferon-independent manner (Castrillo, Joseph et al. 
2003). Similar to the microbial-mediated TLR activation of IRF3, many viruses 
including mCMV potently induce IRF3 and may also have the potential to inhibit 
LXR functions. Despite the recent progress in finding a link between intracellular 
cholesterol homeostasis and innate immunity, little is known regarding the impact of 
an IFN-regulated loop signalling, as the second step, through interactions with IFN 
receptors that activate the JAK-STAT pathway. We demonstrate here that 
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transcriptional regulation of the cellular sterol biosynthesis pathway upon infection 
impacts viral replication and mechanistically requires an IFN-regulated loop 
dependent on type I interferon signalling. We also showed that viral infection or 
direct IFN stimulation is accompanied by the down-regulation of sterol biosynthesis 
genes, and in the context of ligand activation, of IFNAR1. The IFN-dependent 
coupling of the mevalonate-sterol metabolic network and anti-viral activity 
represents a previously unrecognised mechanism for the regulation of protective 
immunity. 
Several viruses including human CMV have been reported to be sensitive to statin 
administration (Gower and Graham 2001; del Real, Jimenez-Baranda et al. 2004; 
Potena, Frascaroli et al. 2004; Cohen 2005; Bader, Fazili et al. 2008; Mohan, Muller 
et al. 2008), and although the mechanism of action of most is not known, it has been 
correlated with a lower abundance of cholesterol in lipid rafts of cell membranes. A 
potential complicating factor of using statins is that suppression of the mevalonate 
pathway also perturbs synthesis of non-sterol mevalonate derivatives such as 
geranylgeraniol and farnesol involved in protein farnesylation and prenylation 
pathways, although in the case of HCV, the mechanisms of the inhibitory effects of 
the statins have been examined and are related to the prenylation of essential 
proteins. In our current study we uncoupled the cholesterol synthetic pathway from 
the non-steroidal modifications through targeted metabolic rescue and siRNA knock-
down studies of mCMV and revealed an absolute requirement for the prenylation 
branch of the sterol pathway for mediating anti-viral effects.  
HMGCR is likely to have broad range of non-specific effects on various efferent 
branch points of the pathway and thus may well not be ideal for an anti-infective 
therapy. In addition, statins are also known to have a range of immune modulatory 
activities by mechanisms yet to be fully characterised. In this connection, it is worth 
noting that type I IFN, especially IFN, have considerable overlap with many of the 
immune related activities of statins (Neuhaus, Stuve et al. 2005). Moreover, it is 
especially noteworthy that IFN treatment in patients has also been reported to 
decrease cholesterol plasma levels. Since our studies uncover a molecular 
dependency of type 1 signalling this may provide an entirely new therapeutic 
pathway for lowering cholesterol. Moreover, our findings may have important 
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implications for the development of new adjuvant strategies to existing anti-infective 
therapies based on the principal of using metabolic modifiers (drugs that target 





















7.4 Future work 
The different findings of this investigation also have raised new questions which 
should be addressed in future studies to fully understand the mechanisms involved in 
the regulation of sterol synthesis as an antiviral response by innate immunity. 
1. What are the mechanisms and signalling cascade involved in the down-
regulation of the sterol biosynthesis pathway by the activation of the type 
I interferon receptor? 
 Are nuclear receptors such as LXRs or PPAR involved in the regulation 
of the sterol synthesis by interferon signalling? 
 Is TYK2 and STAT1 activation involved in the regulation of sterol 
biosynthesis, and if so, is it by a direct or indirect mechanism? 
 Is SREBP2 regulated at the protein and/or the expression level by type I 
interferon signalling? 
 Are oxysterols, especially 25-hydroxycholesterol, involved in this 
regulation? 
2. What are the mechanisms involving the prenylation branch of the sterol 
biosynthesis pathway which regulates mCMV replication? 
 Does a viral protein require prenylation for efficient mCMV replication? 
 Is it due to an alteration of the cell cycle? 
 Is it due to an induction of apoptosis/necrosis? 
 Does it involve the prenylation of a G-protein? 
3. Are other components involved in cholesterol homeostasis (cholesterol 
efflux, uptake and storage) also regulated by the interferon response to 
infection? 
4. What is the signalling cascade involved in the regulation of the sterol 
biosynthesis pathway by type II interferon? 
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Figure 7-1: Proposed model for the regulation of sterol biosynthesis by IFN in 





Abrahamsen, L. H., M. J. Clay, et al. (1996). "The effects of cytomegalovirus 
infection on polar lipids and neutral lipids in cultured human cells." 
Intervirology 39(4): 223-9. 
AbuBakar, S., I. Boldogh, et al. (1990). "Human cytomegalovirus stimulates 
arachidonic acid metabolism through pathways that are affected by inhibitors 
of phospholipase A2 and protein kinase C." Biochem Biophys Res Commun 
166(2): 953-9. 
Adam, E., J. L. Melnick, et al. (1987). "High levels of cytomegalovirus antibody in 
patients requiring vascular surgery for atherosclerosis." Lancet 2(8554): 291-
3. 
Adams, C. M., J. Reitz, et al. (2004). "Cholesterol and 25-hydroxycholesterol inhibit 
activation of SREBPs by different mechanisms, both involving SCAP and 
Insigs." J Biol Chem 279(50): 52772-80. 
Ahn, A., D. L. Gibbons, et al. (2002). "The fusion peptide of Semliki Forest virus 
associates with sterol-rich membrane domains." J Virol 76(7): 3267-75. 
Akira, S. (2009). "Pathogen recognition by innate immunity and its signaling." Proc 
Jpn Acad Ser B Phys Biol Sci 85(4): 143-56. 
Akira, S. and K. Takeda (2004). "Toll-like receptor signalling." Nat Rev Immunol 
4(7): 499-511. 
Alber, D. G., K. L. Powell, et al. (2000). "Herpesvirus infection accelerates 
atherosclerosis in the apolipoprotein E-deficient mouse." Circulation 102(7): 
779-85. 
Albrecht, T., M. P. Fons, et al. (1991). "Metabolic and cellular effects of human 
cytomegalovirus infection." Transplant Proc 23(3 Suppl 3): 48-54, discussion 
54-5. 
Alcami, A. and U. H. Koszinowski (2000). "Viral mechanisms of immune evasion." 
Immunol Today 21(9): 447-55. 
Allal, C., C. Buisson-Brenac, et al. (2004). "Human cytomegalovirus carries a cell-
derived phospholipase A2 required for infectivity." J Virol 78(14): 7717-26. 
Amundson, D. M. and M. Zhou (1999). "Fluorometric method for the enzymatic 
determination of cholesterol." J Biochem Biophys Methods 38(1): 43-52. 
Andrews, D. M., C. E. Andoniou, et al. (2001). "Infection of dendritic cells by 
murine cytomegalovirus induces functional paralysis." Nat Immunol 2(11): 
1077-84. 
Andrews, D. M., A. A. Scalzo, et al. (2003). "Functional interactions between 
dendritic cells and NK cells during viral infection." Nat Immunol 4(2): 175-
81. 
Angulo, A., P. Ghazal, et al. (2000). "The major immediate-early gene ie3 of mouse 
cytomegalovirus is essential for viral growth." J Virol 74(23): 11129-36. 
Angulo, A., M. Messerle, et al. (1998). "Enhancer requirement for murine 
cytomegalovirus growth and genetic complementation by the human 
cytomegalovirus enhancer." J Virol 72(11): 8502-9. 
Angulo, A., C. Suto, et al. (1996). "Characterization of the sequences of the human 
cytomegalovirus enhancer that mediate differential regulation by natural and 
synthetic retinoids." Mol Endocrinol 10(7): 781-93. 
172 
 
Arase, H., E. S. Mocarski, et al. (2002). "Direct recognition of cytomegalovirus by 
activating and inhibitory NK cell receptors." Science 296(5571): 1323-6. 
Atalay, R., A. Zimmermann, et al. (2002). "Identification and expression of human 
cytomegalovirus transcription units coding for two distinct Fcgamma receptor 
homologs." J Virol 76(17): 8596-608. 
Babic, M., M. Pyzik, et al. (2010). "Cytomegalovirus immunoevasin reveals the 
physiological role of "missing self" recognition in natural killer cell 
dependent virus control in vivo." J Exp Med 207(12): 2663-73. 
Bader, T., J. Fazili, et al. (2008). "Fluvastatin inhibits hepatitis C replication in 
humans." Am J Gastroenterol 103(6): 1383-9. 
Bale, J. F., Jr., J. A. Blackman, et al. (1990). "Outcome in children with symptomatic 
congenital cytomegalovirus infection." J Child Neurol 5(2): 131-6. 
Banks, T. A., S. Rickert, et al. (2005). "A lymphotoxin-IFN-beta axis essential for 
lymphocyte survival revealed during cytomegalovirus infection." J Immunol 
174(11): 7217-25. 
Barnes, S. J. and P. D. Weitzman (1986). "Organization of citric acid cycle enzymes 
into a multienzyme cluster." FEBS Lett 201(2): 267-70. 
Basak, S., H. Kim, et al. (2007). "A fourth IkappaB protein within the NF-kappaB 
signaling module." Cell 128(2): 369-81. 
Bauman, D. R., A. D. Bitmansour, et al. (2009). "25-Hydroxycholesterol secreted by 
macrophages in response to Toll-like receptor activation suppresses 
immunoglobulin A production." Proc Natl Acad Sci U S A 106(39): 16764-9. 
Bavari, S., C. M. Bosio, et al. (2002). "Lipid raft microdomains: a gateway for 
compartmentalized trafficking of Ebola and Marburg viruses." J Exp Med 
195(5): 593-602. 
Bender, F. C., J. C. Whitbeck, et al. (2003). "Specific association of glycoprotein B 
with lipid rafts during herpes simplex virus entry." J Virol 77(17): 9542-52. 
Benedict, C. A., T. A. Banks, et al. (2001). "Lymphotoxins and cytomegalovirus 
cooperatively induce interferon-beta, establishing host-virus detente." 
Immunity 15(4): 617-26. 
Bentz, M. H. and J. Magnette (1998). "[Hypocholesterolemia during the acute phase 
of an inflammatory reaction of infectious origin. 120 cases]." Rev Med 
Interne 19(3): 168-72. 
Bergstrom, J. D., M. M. Kurtz, et al. (1993). "Zaragozic acids: a family of fungal 
metabolites that are picomolar competitive inhibitors of squalene synthase." 
Proc Natl Acad Sci U S A 90(1): 80-4. 
Beutler, B. A. (2009). "TLRs and innate immunity." Blood 113(7): 1399-407. 
Biron, C. A. (2001). "Interferons alpha and beta as immune regulators--a new look." 
Immunity 14(6): 661-4. 
Biron, C. A., K. S. Byron, et al. (1989). "Severe herpesvirus infections in an 
adolescent without natural killer cells." N Engl J Med 320(26): 1731-5. 
Bligh, E. G. and W. J. Dyer (1959). "A rapid method of total lipid extraction and 
purification." Can J Biochem Physiol 37(8): 911-7. 
Boeckh, M. and R. Bowden (1995). "Cytomegalovirus infection in marrow 
transplantation." Cancer Treat Res 76: 97-136. 
Bordier, B. B., J. Ohkanda, et al. (2003). "In vivo antiviral efficacy of prenylation 
inhibitors against hepatitis delta virus." J Clin Invest 112(3): 407-14. 
173 
 
Boulant, S., M. W. Douglas, et al. (2008). "Hepatitis C virus core protein induces 
lipid droplet redistribution in a microtubule- and dynein-dependent manner." 
Traffic 9(8): 1268-82. 
Brown, M. S. and J. L. Goldstein (1997). "The SREBP pathway: regulation of 
cholesterol metabolism by proteolysis of a membrane-bound transcription 
factor." Cell 89(3): 331-40. 
Browne, E. P., B. Wing, et al. (2001). "Altered cellular mRNA levels in human 
cytomegalovirus-infected fibroblasts: viral block to the accumulation of 
antiviral mRNAs." J Virol 75(24): 12319-30. 
Campbell, A. E., V. J. Cavanaugh, et al. (2008). "The salivary glands as a privileged 
site of cytomegalovirus immune evasion and persistence." Med Microbiol 
Immunol 197(2): 205-13. 
Caraglia, M., A. Budillon, et al. (2005). "Isoprenylation of intracellular proteins as a 
new target for the therapy of human neoplasms: preclinical and clinical 
implications." Curr Drug Targets 6(3): 301-23. 
Carter, C. J. (2008). "Interactions between the products of the Herpes simplex 
genome and Alzheimer's disease susceptibility genes: relevance to 
pathological-signalling cascades." Neurochem Int 52(6): 920-34. 
Castillo, J. P. and T. F. Kowalik (2004). "HCMV infection: modulating the cell cycle 
and cell death." Int Rev Immunol 23(1-2): 113-39. 
Castrillo, A., S. B. Joseph, et al. (2003). "Crosstalk between LXR and toll-like 
receptor signaling mediates bacterial and viral antagonism of cholesterol 
metabolism." Mol Cell 12(4): 805-16. 
Chakravarty, E. F. (2008). "Viral infection and reactivation in autoimmune disease." 
Arthritis Rheum 58(10): 2949-57. 
Chan, E. Y., W. J. Qian, et al. (2007). "Quantitative analysis of human 
immunodeficiency virus type 1-infected CD4+ cell proteome: dysregulated 
cell cycle progression and nuclear transport coincide with robust virus 
production." J Virol 81(14): 7571-83. 
Chan, E. Y., J. N. Sutton, et al. (2009). "Dynamic host energetics and cytoskeletal 
proteomes in human immunodeficiency virus type 1-infected human primary 
CD4 cells: analysis by multiplexed label-free mass spectrometry." J Virol 
83(18): 9283-95. 
Chan, G., M. F. Stinski, et al. (2004). "Human cytomegalovirus-induced upregulation 
of intercellular cell adhesion molecule-1 on villous syncytiotrophoblasts." 
Biol Reprod 71(3): 797-803. 
Chang, K. O. (2009). "Role of cholesterol pathways in norovirus replication." J Virol 
83(17): 8587-95. 
Chang, W. L., N. Baumgarth, et al. (2004). "Human cytomegalovirus-encoded 
interleukin-10 homolog inhibits maturation of dendritic cells and alters their 
functionality." J Virol 78(16): 8720-31. 
Chawla, A., W. A. Boisvert, et al. (2001). "A PPAR gamma-LXR-ABCA1 pathway 
in macrophages is involved in cholesterol efflux and atherogenesis." Mol Cell 
7(1): 161-71. 
Chazal, N. and D. Gerlier (2003). "Virus entry, assembly, budding, and membrane 
rafts." Microbiol Mol Biol Rev 67(2): 226-37. 
174 
 
Chee, M. S., A. T. Bankier, et al. (1990). "Analysis of the protein-coding content of 
the sequence of human cytomegalovirus strain AD169." Curr Top Microbiol 
Immunol 154: 125-69. 
Chiarla, C., I. Giovannini, et al. (2004). "The relationship between plasma 
cholesterol, amino acids and acute phase proteins in sepsis." Amino Acids 
27(1): 97-100. 
Chiu, Y. H., J. B. Macmillan, et al. (2009). "RNA polymerase III detects cytosolic 
DNA and induces type I interferons through the RIG-I pathway." Cell 138(3): 
576-91. 
Cinatl, J., Jr., J. U. Vogel, et al. (2004). "Oncomodulatory signals by regulatory 
proteins encoded by human cytomegalovirus: a novel role for viral infection 
in tumor progression." FEMS Microbiol Rev 28(1): 59-77. 
Cinti, D. L., L. Cook, et al. (1992). "The fatty acid chain elongation system of 
mammalian endoplasmic reticulum." Prog Lipid Res 31(1): 1-51. 
Cohen, J. I. (2005). "HMG CoA reductase inhibitors (statins) to treat Epstein-Barr 
virus-driven lymphoma." Br J Cancer 92(9): 1593-8. 
Colonna, M., A. Krug, et al. (2002). "Interferon-producing cells: on the front line in 
immune responses against pathogens." Curr Opin Immunol 14(3): 373-9. 
Compton, T., E. A. Kurt-Jones, et al. (2003). "Human cytomegalovirus activates 
inflammatory cytokine responses via CD14 and Toll-like receptor 2." J Virol 
77(8): 4588-96. 
Cosman, D., J. Mullberg, et al. (2001). "ULBPs, novel MHC class I-related 
molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity 
through the NKG2D receptor." Immunity 14(2): 123-33. 
Cousens, L. P., J. S. Orange, et al. (1997). "Interferon-alpha/beta inhibition of 
interleukin 12 and interferon-gamma production in vitro and endogenously 
during viral infection." Proc Natl Acad Sci U S A 94(2): 634-9. 
Crane, M. J., K. L. Hokeness-Antonelli, et al. (2009). "Regulation of inflammatory 
monocyte/macrophage recruitment from the bone marrow during murine 
cytomegalovirus infection: role for type I interferons in localized induction of 
CCR2 ligands." J Immunol 183(4): 2810-7. 
Cull, V. S., E. J. Bartlett, et al. (2002). "Type I interferon gene therapy protects 
against cytomegalovirus-induced myocarditis." Immunology 106(3): 428-37. 
Cullen, P., K. Tegelkamp, et al. (1997). "Measuring cholesterol in macrophages: 
comparison of high-performance liquid chromatography and gas-liquid 
chromatography with enzymatic fluorometry." Anal Biochem 251(1): 39-44. 
Curtiss, L. K. and P. S. Tobias (2009). "Emerging role of Toll-like receptors in 
atherosclerosis." J Lipid Res 50 Suppl: S340-5. 
Dalod, M., T. Hamilton, et al. (2003). "Dendritic cell responses to early murine 
cytomegalovirus infection: subset functional specialization and differential 
regulation by interferon alpha/beta." J Exp Med 197(7): 885-98. 
Dalod, M., T. P. Salazar-Mather, et al. (2002). "Interferon alpha/beta and interleukin 
12 responses to viral infections: pathways regulating dendritic cell cytokine 
expression in vivo." J Exp Med 195(4): 517-28. 
Danesh, J. and P. Appleby (1998). "Persistent infection and vascular disease: a 
systematic review." Expert Opin Investig Drugs 7(5): 691-713. 
Danesh, J., R. Collins, et al. (1997). "Chronic infections and coronary heart disease: 
is there a link?" Lancet 350(9075): 430-6. 
175 
 
Dankner, W. M., J. A. McCutchan, et al. (1990). "Localization of human 
cytomegalovirus in peripheral blood leukocytes by in situ hybridization." J 
Infect Dis 161(1): 31-6. 
Davidson, M. H. (2006). "Mechanisms for the hypotriglyceridemic effect of marine 
omega-3 fatty acids." Am J Cardiol 98(4A): 27i-33i. 
Davignon, J. L., P. Castanie, et al. (1996). "Anti-human cytomegalovirus activity of 
cytokines produced by CD4+ T-cell clones specifically activated by IE1 
peptides in vitro." J Virol 70(4): 2162-9. 
Davison, A. J., R. Eberle, et al. (2009). "The order Herpesvirales." Arch Virol 
154(1): 171-7. 
De Fabiani, E., N. Mitro, et al. (2001). "The negative effects of bile acids and tumor 
necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase 
gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of 
feedback regulation of bile acid synthesis mediated by nuclear receptors." J 
Biol Chem 276(33): 30708-16. 
DeFilippis, V. R., D. Alvarado, et al. "Human cytomegalovirus induces the interferon 
response via the DNA sensor ZBP1." J Virol 84(1): 585-98. 
Deigendesch, N., F. Koch-Nolte, et al. (2006). "ZBP1 subcellular localization and 
association with stress granules is controlled by its Z-DNA binding domains." 
Nucleic Acids Res 34(18): 5007-20. 
Del Pozo, J. L., D. van de Beek, et al. (2010). "High serum cholesterol levels are 
associated with herpes zoster infection after heart transplantation." Clin Infect 
Dis 50(1): 121-2. 
del Real, G., S. Jimenez-Baranda, et al. (2004). "Statins inhibit HIV-1 infection by 
down-regulating Rho activity." J Exp Med 200(4): 541-7. 
Delale, T., A. Paquin, et al. (2005). "MyD88-dependent and -independent murine 
cytomegalovirus sensing for IFN-alpha release and initiation of immune 
responses in vivo." J Immunol 175(10): 6723-32. 
Demierre, M. F., P. D. Higgins, et al. (2005). "Statins and cancer prevention." Nat 
Rev Cancer 5(12): 930-42. 
Demmler, G. J. (1991). "Infectious Diseases Society of America and Centers for 
Disease Control. Summary of a workshop on surveillance for congenital 
cytomegalovirus disease." Rev Infect Dis 13(2): 315-29. 
Desplanques, A. S., H. J. Nauwynck, et al. (2008). "Plasma membrane cholesterol is 
required for efficient pseudorabies virus entry." Virology 376(2): 339-45. 
Diamond, D. L., A. J. Syder, et al. "Temporal proteome and lipidome profiles reveal 
hepatitis C virus-associated reprogramming of hepatocellular metabolism and 
bioenergetics." PLoS Pathog 6(1): e1000719. 
Diczfalusy, U., K. E. Olofsson, et al. (2009). "Marked upregulation of cholesterol 25-
hydroxylase expression by lipopolysaccharide." J Lipid Res 50(11): 2258-64. 
Diebold, S. S., M. Montoya, et al. (2003). "Viral infection switches non-
plasmacytoid dendritic cells into high interferon producers." Nature 
424(6946): 324-8. 
Einav, S. and J. S. Glenn (2003). "Prenylation inhibitors: a novel class of antiviral 
agents." J Antimicrob Chemother 52(6): 883-6. 
Elbashir, S. M., J. Harborth, et al. (2001). "Duplexes of 21-nucleotide RNAs mediate 
RNA interference in cultured mammalian cells." Nature 411(6836): 494-8. 
176 
 
Ettinger, W. H., V. K. Varma, et al. (1994). "Cytokines decrease apolipoprotein 
accumulation in medium from Hep G2 cells." Arterioscler Thromb 14(1): 8-
13. 
Fabricant, C. G. and J. Fabricant (1999). "Atherosclerosis induced by infection with 
Marek's disease herpesvirus in chickens." Am Heart J 138(5 Pt 2): S465-8. 
Fahy, E., S. Subramaniam, et al. (2009). "Update of the LIPID MAPS 
comprehensive classification system for lipids." J Lipid Res 50 Suppl: S9-14. 
Farrell, H. E., H. Vally, et al. (1997). "Inhibition of natural killer cells by a 
cytomegalovirus MHC class I homologue in vivo." Nature 386(6624): 510-4. 
Fei, W., G. Shui, et al. (2008). "Fld1p, a functional homologue of human seipin, 
regulates the size of lipid droplets in yeast." J Cell Biol 180(3): 473-82. 
Fennie, E. H., Y. S. Lie, et al. (1988). "Reduced mortality in murine cytomegalovirus 
infected mice following prophylactic murine interferon-gamma treatment." 
Antiviral Res 10(1-3): 27-39. 
Feramisco, J. D., J. L. Goldstein, et al. (2004). "Membrane topology of human insig-
1, a protein regulator of lipid synthesis." J Biol Chem 279(9): 8487-96. 
Fodil-Cornu, N. and S. M. Vidal (2008). "Type I interferon response to 
cytomegalovirus infection: the kick-start." Cell Host Microbe 3(2): 59-61. 
Foley, H. A., S. F. Ofori-Acquah, et al. (2002). "Stat3 beta inhibits gamma-globin 
gene expression in erythroid cells." J Biol Chem 277(18): 16211-9. 
Forde, K. A., C. Law, et al. (2009). "Do statins reduce hepatitis C RNA titers during 
routine clinical use?" World J Gastroenterol 15(40): 5020-7. 
Fortunato, E. A., A. K. McElroy, et al. (2000). "Exploitation of cellular signaling and 
regulatory pathways by human cytomegalovirus." Trends Microbiol 8(3): 
111-9. 
Gamadia, L. E., E. B. Remmerswaal, et al. (2003). "Primary immune responses to 
human CMV: a critical role for IFN-gamma-producing CD4+ T cells in 
protection against CMV disease." Blood 101(7): 2686-92. 
Gazit, R., R. Gruda, et al. (2006). "Lethal influenza infection in the absence of the 
natural killer cell receptor gene Ncr1." Nat Immunol 7(5): 517-23. 
Geelen, M. J., D. M. Gibson, et al. (1986). "Hydroxymethylglutaryl-CoA reductase--
the rate-limiting enzyme of cholesterol biosynthesis. A report of a meeting 
held at Nijenrode Castle, Breukelen, The Netherlands, August 24, 1985." 
FEBS Lett 201(2): 183-6. 
Georges, J. L., H. J. Rupprecht, et al. (2003). "Impact of pathogen burden in patients 
with coronary artery disease in relation to systemic inflammation and 
variation in genes encoding cytokines." Am J Cardiol 92(5): 515-21. 
Gerna, G., E. Percivalle, et al. (2000). "Human cytomegalovirus replicates abortively 
in polymorphonuclear leukocytes after transfer from infected endothelial cells 
via transient microfusion events." J Virol 74(12): 5629-38. 
Ghazal, P., M. Messerle, et al. (2003). "An essential role of the enhancer for murine 
cytomegalovirus in vivo growth and pathogenesis." J Virol 77(5): 3217-28. 
Gilman, A. G. (1987). "G proteins: transducers of receptor-generated signals." Annu 
Rev Biochem 56: 615-49. 
Glenn, J. S. (2006). "Prenylation of HDAg and antiviral drug development." Curr 
Top Microbiol Immunol 307: 133-49. 
Goldsmith, Z. G. and D. N. Dhanasekaran (2007). "G protein regulation of MAPK 
networks." Oncogene 26(22): 3122-42. 
177 
 
Goldstein, J. L. and M. S. Brown (1990). "Regulation of the mevalonate pathway." 
Nature 343(6257): 425-30. 
Gomez, E., A. Laures, et al. (2005). "Cytomegalovirus replication and "herpesvirus 
burden" as risk factor of cardiovascular events in the first year after renal 
transplantation." Transplant Proc 37(9): 3760-3. 
Gordon, S. (1998). "The role of the macrophage in immune regulation." Res 
Immunol 149(7-8): 685-8. 
Gordon, S. (2002). "Pattern recognition receptors: doubling up for the innate immune 
response." Cell 111(7): 927-30. 
Gower, T. L. and B. S. Graham (2001). "Antiviral activity of lovastatin against 
respiratory syncytial virus in vivo and in vitro." Antimicrob Agents 
Chemother 45(4): 1231-7. 
Grahame-Clarke, C., N. N. Chan, et al. (2003). "Human cytomegalovirus 
seropositivity is associated with impaired vascular function." Circulation 
108(6): 678-83. 
Grandvaux, N., M. J. Servant, et al. (2002). "Transcriptional profiling of interferon 
regulatory factor 3 target genes: direct involvement in the regulation of 
interferon-stimulated genes." J Virol 76(11): 5532-9. 
Granucci, F., I. Zanoni, et al. (2004). "A contribution of mouse dendritic cell-derived 
IL-2 for NK cell activation." J Exp Med 200(3): 287-95. 
Gschwentner, M., A. Susanna, et al. (1995). "Antiviral drugs from the nucleoside 
analog family block volume-activated chloride channels." Mol Med 1(4): 
407-17. 
Hahm, B., M. J. Trifilo, et al. (2005). "Viruses evade the immune system through 
type I interferon-mediated STAT2-dependent, but STAT1-independent, 
signaling." Immunity 22(2): 247-57. 
Hajjar, D. P., D. J. Falcone, et al. (1985). "Altered cholesteryl ester cycle is 
associated with lipid accumulation in herpesvirus-infected arterial smooth 
muscle cells." J Biol Chem 260(10): 6124-8. 
Hambleton, S., S. P. Steinberg, et al. (2007). "Cholesterol dependence of varicella-
zoster virion entry into target cells." J Virol 81(14): 7548-58. 
Hamilton, J. D. and B. J. Seaworth (1985). "Transmission of latent cytomegalovirus 
in a murine kidney tissue transplantation model." Transplantation 39(3): 290-
6. 
Hannah, B. P., T. M. Cairns, et al. (2009). "Herpes simplex virus glycoprotein B 
associates with target membranes via its fusion loops." J Virol 83(13): 6825-
36. 
Hanson, L. K., J. S. Slater, et al. (1999). "Replication of murine cytomegalovirus in 
differentiated macrophages as a determinant of viral pathogenesis." J Virol 
73(7): 5970-80. 
Hao, X. R., D. L. Cao, et al. (2009). "IFN-gamma down-regulates ABCA1 
expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-
dependent manner." Atherosclerosis 203(2): 417-28. 
Hardardottir, I., A. H. Moser, et al. (1994). "Effects of TNF, IL-1, and the 
combination of both cytokines on cholesterol metabolism in Syrian 
hamsters." Lymphokine Cytokine Res 13(3): 161-6. 
178 
 
Hegarty, B. D., A. Bobard, et al. (2005). "Distinct roles of insulin and liver X 
receptor in the induction and cleavage of sterol regulatory element-binding 
protein-1c." Proc Natl Acad Sci U S A 102(3): 791-6. 
Heise, M. T., M. Connick, et al. (1998). "Murine cytomegalovirus inhibits interferon 
gamma-induced antigen presentation to CD4 T cells by macrophages via 
regulation of expression of major histocompatibility complex class II-
associated genes." J Exp Med 187(7): 1037-46. 
Heise, M. T., J. L. Pollock, et al. (1998). "Murine cytomegalovirus infection inhibits 
IFN gamma-induced MHC class II expression on macrophages: the role of 
type I interferon." Virology 241(2): 331-44. 
Heise, M. T. and H. W. t. Virgin (1995). "The T-cell-independent role of gamma 
interferon and tumor necrosis factor alpha in macrophage activation during 
murine cytomegalovirus and herpes simplex virus infections." J Virol 69(2): 
904-9. 
Hemmi, H., O. Takeuchi, et al. (2000). "A Toll-like receptor recognizes bacterial 
DNA." Nature 408(6813): 740-5. 
Hengel, H., P. Lucin, et al. (1994). "Restoration of cytomegalovirus antigen 
presentation by gamma interferon combats viral escape." J Virol 68(1): 289-
97. 
Hers, H. G. and L. Hue (1983). "Gluconeogenesis and related aspects of glycolysis." 
Annu Rev Biochem 52: 617-53. 
Hill, J. M., I. Steiner, et al. (2005). "Statins lower the risk of developing Alzheimer's 
disease by limiting lipid raft endocytosis and decreasing the neuronal spread 
of Herpes simplex virus type 1." Med Hypotheses 64(1): 53-8. 
Ho (1995). Cytomegalovirus Biology and Infection. 2nd Ed. Plenum Medical 
Book Company, New York. 353 pp. 
Horne, B. D., J. B. Muhlestein, et al. (2003). "Statin therapy interacts with 
cytomegalovirus seropositivity and high C-reactive protein in reducing 
mortality among patients with angiographically significant coronary disease." 
Circulation 107(2): 258-63. 
Hornung, V., S. Rothenfusser, et al. (2002). "Quantitative expression of toll-like 
receptor 1-10 mRNA in cellular subsets of human peripheral blood 
mononuclear cells and sensitivity to CpG oligodeoxynucleotides." J Immunol 
168(9): 4531-7. 
Horton, J. D. (2002). "Sterol regulatory element-binding proteins: transcriptional 
activators of lipid synthesis." Biochem Soc Trans 30(Pt 6): 1091-5. 
Horton, J. D., J. L. Goldstein, et al. (2002). "SREBPs: transcriptional mediators of 
lipid homeostasis." Cold Spring Harb Symp Quant Biol 67: 491-8. 
Hsich, E., Y. F. Zhou, et al. (2001). "Cytomegalovirus infection increases 
development of atherosclerosis in Apolipoprotein-E knockout mice." 
Atherosclerosis 156(1): 23-8. 
Hsu, H. Y., A. C. Nicholson, et al. (1995). "Altered cholesterol trafficking in 
herpesvirus-infected arterial cells. Evidence for viral protein kinase-mediated 
cholesterol accumulation." J Biol Chem 270(33): 19630-7. 
Huang, Q., H. M. Shen, et al. (2006). "Emodin inhibits tumor cell adhesion through 
disruption of the membrane lipid Raft-associated integrin signaling pathway." 
Cancer Res 66(11): 5807-15. 
179 
 
Ikeda, M. and N. Kato (2007). "Life style-related diseases of the digestive system: 
cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: 
suppression of HCV replication by statins and synergistic action with 
interferon." J Pharmacol Sci 105(2): 145-50. 
Ikeda, M. and R. Longnecker (2007). "Cholesterol is critical for Epstein-Barr virus 
latent membrane protein 2A trafficking and protein stability." Virology 
360(2): 461-8. 
Imhoff, H., V. von Messling, et al. (2007). "Canine distemper virus infection requires 
cholesterol in the viral envelope." J Virol 81(8): 4158-65. 
Itabashi, S., H. Arai, et al. (1997). "Herpes simplex virus and risk of Alzheimer's 
disease." Lancet 349(9058): 1102. 
Itzhaki, R. F. and M. A. Wozniak (2006). "Herpes simplex virus type 1, 
apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease 
and other disorders." Prog Lipid Res 45(1): 73-90. 
Jonjic, S., W. Mutter, et al. (1989). "Site-restricted persistent cytomegalovirus 
infection after selective long-term depletion of CD4+ T lymphocytes." J Exp 
Med 169(4): 1199-212. 
Jonjic, S., I. Pavic, et al. (1990). "Efficacious control of cytomegalovirus infection 
after long-term depletion of CD8+ T lymphocytes." J Virol 64(11): 5457-64. 
Jonjic, S., I. Pavic, et al. (1994). "Antibodies are not essential for the resolution of 
primary cytomegalovirus infection but limit dissemination of recurrent virus." 
J Exp Med 179(5): 1713-7. 
Joseph, S. B., M. N. Bradley, et al. (2004). "LXR-dependent gene expression is 
important for macrophage survival and the innate immune response." Cell 
119(2): 299-309. 
Joseph, S. B., A. Castrillo, et al. (2003). "Reciprocal regulation of inflammation and 
lipid metabolism by liver X receptors." Nat Med 9(2): 213-9. 
Juckem, L. K., K. W. Boehme, et al. (2008). "Differential initiation of innate immune 
responses induced by human cytomegalovirus entry into fibroblast cells." J 
Immunol 180(7): 4965-77. 
Kadegowda, A. K., M. Bionaz, et al. (2009). "Peroxisome proliferator-activated 
receptor-gamma activation and long-chain fatty acids alter lipogenic gene 
networks in bovine mammary epithelial cells to various extents." J Dairy Sci 
92(9): 4276-89. 
Kanehisa, M. and S. Goto (2000). "KEGG: kyoto encyclopedia of genes and 
genomes." Nucleic Acids Res 28(1): 27-30. 
Kapadia, S. B. and F. V. Chisari (2005). "Hepatitis C virus RNA replication is 
regulated by host geranylgeranylation and fatty acids." Proc Natl Acad Sci U 
S A 102(7): 2561-6. 
Kavanagh, D. G., M. C. Gold, et al. (2001). "The multiple immune-evasion genes of 
murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen 
presentation in a complementary and cooperative fashion." J Exp Med 
194(7): 967-78. 
Kawabata, A., H. Tang, et al. (2009). "y Human herpesvirus 6 envelope components 
enriched in lipid rafts: evidence for virion-associated lipid rafts." Virol J 6: 
127. 
Kawai, T. and S. Akira (2006). "Innate immune recognition of viral infection." Nat 
Immunol 7(2): 131-7. 
180 
 
Kawai, T. and S. Akira (2006). "TLR signaling." Cell Death Differ 13(5): 816-25. 
Keay, S. and B. R. Baldwin (1996). "Evidence for the role of cell protein 
phosphorylation in human cytomegalovirus/host cell fusion." J Gen Virol 77 ( 
Pt 10): 2597-604. 
Keil, G. M., A. Ebeling-Keil, et al. (1984). "Temporal regulation of murine 
cytomegalovirus transcription and mapping of viral RNA synthesized at 
immediate early times after infection." J Virol 50(3): 784-95. 
Khovidhunkit, W., M. S. Kim, et al. (2004). "Effects of infection and inflammation 
on lipid and lipoprotein metabolism: mechanisms and consequences to the 
host." J Lipid Res 45(7): 1169-96. 
Kiefer, T. L., L. Lai, et al. (2005). "Differential regulation of estrogen receptor alpha, 
glucocorticoid receptor and retinoic acid receptor alpha transcriptional 
activity by melatonin is mediated via different G proteins." J Pineal Res 
38(4): 231-9. 
Kim, T. H., H. Kim, et al. (2009). "Interrelationship between liver X receptor alpha, 
sterol regulatory element-binding protein-1c, peroxisome proliferator-
activated receptor gamma, and small heterodimer partner in the 
transcriptional regulation of glucokinase gene expression in liver." J Biol 
Chem 284(22): 15071-83. 
Kinzler, E. R. and T. Compton (2005). "Characterization of human cytomegalovirus 
glycoprotein-induced cell-cell fusion." J Virol 79(12): 7827-37. 
Kleijnen, M. F., J. B. Huppa, et al. (1997). "A mouse cytomegalovirus glycoprotein, 
gp34, forms a complex with folded class I MHC molecules in the ER which 
is not retained but is transported to the cell surface." Embo J 16(4): 685-94. 
Klenovsek, K., F. Weisel, et al. (2007). "Protection from CMV infection in 
immunodeficient hosts by adoptive transfer of memory B cells." Blood 
110(9): 3472-9. 
Koszinowski, U. H., M. J. Reddehase, et al. (1991). "The role of CD4 and CD8 T 
cells in viral infections." Curr Opin Immunol 3(4): 471-5. 
Kovacs, A., M. Schluchter, et al. (1999). "Cytomegalovirus infection and HIV-1 
disease progression in infants born to HIV-1-infected women. Pediatric 
Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV 
Infection Study Group." N Engl J Med 341(2): 77-84. 
Kowalik, T. F., B. Wing, et al. (1993). "Multiple mechanisms are implicated in the 
regulation of NF-kappa B activity during human cytomegalovirus infection." 
Proc Natl Acad Sci U S A 90(3): 1107-11. 
Kristoffersen, A. K., K. Tasken, et al. (1994). "Expression of protein kinase A and 
protein kinase C during ongoing human cytomegalovirus infection." Arch 
Virol 138(1-2): 85-93. 
Krmpotic, A., D. H. Busch, et al. (2002). "MCMV glycoprotein gp40 confers virus 
resistance to CD8+ T cells and NK cells in vivo." Nat Immunol 3(6): 529-35. 
Kropp, K. A., C. O. Simon, et al. (2009). "Synergism between the components of the 
bipartite major immediate-early transcriptional enhancer of murine 
cytomegalovirus does not accelerate virus replication in cell culture and host 
tissues." J Gen Virol 90(Pt 10): 2395-401. 
Krug, A., A. R. French, et al. (2004). "TLR9-dependent recognition of MCMV by 
IPC and DC generates coordinated cytokine responses that activate antiviral 
NK cell function." Immunity 21(1): 107-19. 
181 
 
Kucic, N., H. Mahmutefendic, et al. (2005). "Inhibition of protein kinases C prevents 
murine cytomegalovirus replication." J Gen Virol 86(Pt 8): 2153-61. 
Kumar, H., T. Kawai, et al. (2009). "Toll-like receptors and innate immunity." 
Biochem Biophys Res Commun 388(4): 621-5. 
Kurzrock, R., M. F. Rohde, et al. (1986). "Recombinant gamma interferon induces 
hypertriglyceridemia and inhibits post-heparin lipase activity in cancer 
patients." J Exp Med 164(4): 1093-101. 
Lacaze, P., S. Raza, et al. (2009). "Combined genome-wide expression profiling and 
targeted RNA interference in primary mouse macrophages reveals 
perturbation of transcriptional networks associated with interferon 
signalling." BMC Genomics 10: 372. 
Le, V. T., M. Trilling, et al. (2008). "Mouse cytomegalovirus inhibits beta interferon 
(IFN-beta) gene expression and controls activation pathways of the IFN-beta 
enhanceosome." J Gen Virol 89(Pt 5): 1131-41. 
Lee, C. J., H. R. Lin, et al. (2008). "Cholesterol effectively blocks entry of 
flavivirus." J Virol 82(13): 6470-80. 
Lenac, T., J. Arapovic, et al. (2008). "Murine cytomegalovirus regulation of NKG2D 
ligands." Med Microbiol Immunol 197(2): 159-66. 
Lester, R. L., G. B. Wells, et al. (1993). "Mutant strains of Saccharomyces cerevisiae 
lacking sphingolipids synthesize novel inositol glycerophospholipids that 
mimic sphingolipid structures." J Biol Chem 268(2): 845-56. 
Liao, J. K. (2002). "Isoprenoids as mediators of the biological effects of statins." J 
Clin Invest 110(3): 285-8. 
Lilley, B. N., H. L. Ploegh, et al. (2001). "Human cytomegalovirus open reading 
frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein." J 
Virol 75(22): 11218-21. 
Lippmann, J., S. Rothenburg, et al. (2008). "IFNbeta responses induced by 
intracellular bacteria or cytosolic DNA in different human cells do not require 
ZBP1 (DLM-1/DAI)." Cell Microbiol 10(12): 2579-88. 
Liu, S., A. V. Rodriguez, et al. (2006). "Role of simvastatin and methyl-beta-
cyclodextrin [corrected] on inhibition of poliovirus infection." Biochem 
Biophys Res Commun 347(1): 51-9. 
Liu, Y. J. (2005). "IPC: professional type 1 interferon-producing cells and 
plasmacytoid dendritic cell precursors." Annu Rev Immunol 23: 275-306. 
Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method." 
Methods 25(4): 402-8. 
Lucin, P., S. Jonjic, et al. (1994). "Late phase inhibition of murine cytomegalovirus 
replication by synergistic action of interferon-gamma and tumour necrosis 
factor." J Gen Virol 75 ( Pt 1): 101-10. 
Ma, Z., M. J. Chang, et al. (2005). "Interferon-gamma-activated STAT-1alpha 
suppresses MMP-9 gene transcription by sequestration of the coactivators 
CBP/p300." J Leukoc Biol 78(2): 515-23. 
Mackenzie, J. M., A. A. Khromykh, et al. (2007). "Cholesterol manipulation by West 
Nile virus perturbs the cellular immune response." Cell Host Microbe 2(4): 
229-39. 
Malmgaard, L., T. P. Salazar-Mather, et al. (2002). "Promotion of alpha/beta 
interferon induction during in vivo viral infection through alpha/beta 
182 
 
interferon receptor/STAT1 system-dependent and -independent pathways." J 
Virol 76(9): 4520-5. 
Manie, S. N., S. de Breyne, et al. (2000). "Measles virus structural components are 
enriched into lipid raft microdomains: a potential cellular location for virus 
assembly." J Virol 74(1): 305-11. 
Marjomaki, V., V. Pietiainen, et al. (2002). "Internalization of echovirus 1 in 
caveolae." J Virol 76(4): 1856-65. 
Martin, S. and R. G. Parton (2005). "Caveolin, cholesterol, and lipid bodies." Semin 
Cell Dev Biol 16(2): 163-74. 
Matthews, T. and R. Boehme (1988). "Antiviral activity and mechanism of action of 
ganciclovir." Rev Infect Dis 10 Suppl 3: S490-4. 
McCormick, A. L., A. Skaletskaya, et al. (2003). "Differential function and 
expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and 
the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death 
suppressors conserved in primate and rodent cytomegaloviruses." Virology 
316(2): 221-33. 
McEwan, I. J. (2009). "Nuclear receptors: one big family." Methods Mol Biol 505: 3-
18. 
McLauchlan, J. (2009). "Hepatitis C virus: viral proteins on the move." Biochem Soc 
Trans 37(Pt 5): 986-90. 
McTaggart, S. J. (2006). "Isoprenylated proteins." Cell Mol Life Sci 63(3): 255-67. 
Medzhitov, R. and C. A. Janeway, Jr. (1998). "Innate immune recognition and 
control of adaptive immune responses." Semin Immunol 10(5): 351-3. 
Melnick, J. L., E. Adam, et al. (1996). "Cytomegalovirus and atherosclerosis." Arch 
Immunol Ther Exp (Warsz) 44(5-6): 297-302. 
Messerle, M., G. Hahn, et al. (2000). "Cytomegalovirus bacterial artificial 
chromosomes: a new herpesvirus vector approach." Adv Virus Res 55: 463-
78. 
Mettenleiter, T. C. (2002). "Brief overview on cellular virus receptors." Virus Res 
82(1-2): 3-8. 
Miller, D. M., B. M. Rahill, et al. (1998). "Human cytomegalovirus inhibits major 
histocompatibility complex class II expression by disruption of the Jak/Stat 
pathway." J Exp Med 187(5): 675-83. 
Miller, D. M., Y. Zhang, et al. (1999). "Human cytomegalovirus inhibits IFN-alpha-
stimulated antiviral and immunoregulatory responses by blocking multiple 
levels of IFN-alpha signal transduction." J Immunol 162(10): 6107-13. 
Mintern, J. D., E. J. Klemm, et al. (2006). "Viral interference with B7-1 
costimulation: a new role for murine cytomegalovirus fc receptor-1." J 
Immunol 177(12): 8422-31. 
Mitchell, B. M., A. Leung, et al. (1996). "Murine cytomegalovirus DNA in 
peripheral blood of latently infected mice is detectable only in monocytes and 
polymorphonuclear leukocytes." Virology 223(1): 198-207. 
Miyanari, Y., K. Atsuzawa, et al. (2007). "The lipid droplet is an important organelle 
for hepatitis C virus production." Nat Cell Biol 9(9): 1089-97. 
Mo, H. and C. E. Elson (2004). "Studies of the isoprenoid-mediated inhibition of 
mevalonate synthesis applied to cancer chemotherapy and chemoprevention." 
Exp Biol Med (Maywood) 229(7): 567-85. 
183 
 
Mocarski, E. S., Jr. (2002). "Immunomodulation by cytomegaloviruses: manipulative 
strategies beyond evasion." Trends Microbiol 10(7): 332-9. 
Mocarski, E. S., Jr. and G. W. Kemble (1996). "Recombinant cytomegaloviruses for 
study of replication and pathogenesis." Intervirology 39(5-6): 320-30. 
Mohan, K. V., J. Muller, et al. (2008). "Defective rotavirus particle assembly in 
lovastatin-treated MA104 cells." Arch Virol 153(12): 2283-90. 
Montoya, C. J., F. Jaimes, et al. (2009). "Antiretroviral effect of lovastatin on HIV-1-
infected individuals without highly active antiretroviral therapy (The LIVE 
study): a phase-II randomized clinical trial." Trials 10: 41. 
Morra, V. B., G. Coppola, et al. (2004). "Interferon-beta treatment decreases 
cholesterol plasma levels in multiple sclerosis patients." Neurology 62(5): 
829-30. 
Munger, J., S. U. Bajad, et al. (2006). "Dynamics of the cellular metabolome during 
human cytomegalovirus infection." PLoS Pathog 2(12): e132. 
Munger, J., B. D. Bennett, et al. (2008). "Systems-level metabolic flux profiling 
identifies fatty acid synthesis as a target for antiviral therapy." Nat Biotechnol 
26(10): 1179-86. 
Murphy, D. J. (2001). "The biogenesis and functions of lipid bodies in animals, 
plants and microorganisms." Prog Lipid Res 40(5): 325-438. 
Naiki, Y., R. Sorrentino, et al. (2008). "TLR/MyD88 and liver X receptor alpha 
signaling pathways reciprocally control Chlamydia pneumoniae-induced 
acceleration of atherosclerosis." J Immunol 181(10): 7176-85. 
Naor, Z. (2009). "Signaling by G-protein-coupled receptor (GPCR): studies on the 
GnRH receptor." Front Neuroendocrinol 30(1): 10-29. 
Ness, G. C., D. Lopez, et al. (1998). "Effects of 15-oxa-32-vinyl-lanost-8-ene-3 
beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase and low density lipoprotein receptor in rat liver." Arch Biochem 
Biophys 357(2): 259-64. 
Neuhaus, O., O. Stuve, et al. (2005). "Putative mechanisms of action of statins in 
multiple sclerosis--comparison to interferon-beta and glatiramer acetate." J 
Neurol Sci 233(1-2): 173-7. 
Neves, S. R., P. T. Ram, et al. (2002). "G protein pathways." Science 296(5573): 
1636-9. 
Nishi, K. and K. Saigo (2007). "Cellular internalization of green fluorescent protein 
fused with herpes simplex virus protein VP22 via a lipid raft-mediated 
endocytic pathway independent of caveolae and Rho family GTPases but 
dependent on dynamin and Arf6." J Biol Chem 282(37): 27503-17. 
Norkin, L. C., H. A. Anderson, et al. (2002). "Caveolar endocytosis of simian virus 
40 is followed by brefeldin A-sensitive transport to the endoplasmic 
reticulum, where the virus disassembles." J Virol 76(10): 5156-66. 
O'Leary, J. G., J. L. Chan, et al. (2007). "Atorvastatin does not exhibit antiviral 
activity against HCV at conventional doses: a pilot clinical trial." Hepatology 
45(4): 895-8. 
O'Toole, D. and W. C. Love (2002). "Interferon-beta-1b and interferon-gamma have 
similar inhibitory effects on apolipoprotein-E production in the 
monocyte/macrophage." Mult Scler 8(2): 124-9. 
Orange, J. S., B. Wang, et al. (1995). "Requirement for natural killer cell-produced 
interferon gamma in defence against murine cytomegalovirus infection and 
184 
 
enhancement of this defence pathway by interleukin 12 administration." J 
Exp Med 182(4): 1045-56. 
Osborne, T. F. (2000). "Sterol regulatory element-binding proteins (SREBPs): key 
regulators of nutritional homeostasis and insulin action." J Biol Chem 
275(42): 32379-82. 
Ostrowski, M. A., D. C. Krakauer, et al. (1998). "Effect of immune activation on the 
dynamics of human immunodeficiency virus replication and on the 
distribution of viral quasispecies." J Virol 72(10): 7772-84. 
Park, C. Y., H. J. Jun, et al. (2009). "Hepatitis C virus nonstructural 4B protein 
modulates sterol regulatory element-binding protein signaling via the AKT 
pathway." J Biol Chem 284(14): 9237-46. 
Paulus, C., S. Krauss, et al. (2006). "A human cytomegalovirus antagonist of type I 
IFN-dependent signal transducer and activator of transcription signaling." 
Proc Natl Acad Sci U S A 103(10): 3840-5. 
Peters, K. L., H. L. Smith, et al. (2002). "IRF-3-dependent, NFkappa B- and JNK-
independent activation of the 561 and IFN-beta genes in response to double-
stranded RNA." Proc Natl Acad Sci U S A 99(9): 6322-7. 
Pfeffer, L. M., B. C. Kwok, et al. (1985). "Interferon stimulates cholesterol and 
phosphatidylcholine synthesis but inhibits cholesterol ester synthesis in 
HeLa-S3 cells." Proc Natl Acad Sci U S A 82(8): 2417-21. 
Pinto, A. K. and A. B. Hill (2005). "Viral interference with antigen presentation to 
CD8+ T cells: lessons from cytomegalovirus." Viral Immunol 18(3): 434-44. 
Platanias, L. C. (2005). "Mechanisms of type-I- and type-II-interferon-mediated 
signalling." Nat Rev Immunol 5(5): 375-86. 
Popa, C., M. G. Netea, et al. (2007). "The role of TNF-alpha in chronic inflammatory 
conditions, intermediary metabolism, and cardiovascular risk." J Lipid Res 
48(4): 751-62. 
Porstmann, T., C. R. Santos, et al. (2008). "SREBP activity is regulated by mTORC1 
and contributes to Akt-dependent cell growth." Cell Metab 8(3): 224-36. 
Potena, L., G. Frascaroli, et al. (2004). "Hydroxymethyl-glutaryl coenzyme a 
reductase inhibition limits cytomegalovirus infection in human endothelial 
cells." Circulation 109(4): 532-6. 
Poulos, A. (1995). "Very long chain fatty acids in higher animals--a review." Lipids 
30(1): 1-14. 
Presti, R. M., J. L. Pollock, et al. (1998). "Interferon gamma regulates acute and 
latent murine cytomegalovirus infection and chronic disease of the great 
vessels." J Exp Med 188(3): 577-88. 
Price, P., J. G. Winter, et al. (1987). "Genetically determined resistance to murine 
cytomegalovirus: a role for lymphocytostatic macrophages." J Gen Virol 68 ( 
Pt 12): 2997-3008. 
Prunet, C., T. Montange, et al. (2006). "Multiplexed flow cytometric analyses of pro- 
and anti-inflammatory cytokines in the culture media of oxysterol-treated 
human monocytic cells and in the sera of atherosclerotic patients." Cytometry 
A 69(5): 359-73. 
Radhakrishnan, A., Y. Ikeda, et al. (2007). "Sterol-regulated transport of SREBPs 
from endoplasmic reticulum to Golgi: oxysterols block transport by binding 
to Insig." Proc Natl Acad Sci U S A 104(16): 6511-8. 
185 
 
Raghow, R., C. Yellaturu, et al. (2008). "SREBPs: the crossroads of physiological 
and pathological lipid homeostasis." Trends Endocrinol Metab 19(2): 65-73. 
Raghu, H., N. Sharma-Walia, et al. (2007). "Lipid rafts of primary endothelial cells 
are essential for Kaposi's sarcoma-associated herpesvirus/human herpesvirus 
8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for 
microtubule dynamics and nuclear delivery of viral DNA but dispensable for 
binding and entry." J Virol 81(15): 7941-59. 
Randolph-Habecker, J., M. Iwata, et al. (2002). "Interleukin-1-mediated inhibition of 
cytomegalovirus replication is due to increased IFN-beta production." J 
Interferon Cytokine Res 22(7): 765-72. 
Rawlings, J. S., K. M. Rosler, et al. (2004). "The JAK/STAT signaling pathway." J 
Cell Sci 117(Pt 8): 1281-3. 
Rawlinson, W. D., H. E. Farrell, et al. (1996). "Analysis of the complete DNA 
sequence of murine cytomegalovirus." J Virol 70(12): 8833-49. 
Reddehase, M. J. (2002). "Antigens and immunoevasins: opponents in 
cytomegalovirus immune surveillance." Nat Rev Immunol 2(11): 831-44. 
Reddehase, M. J., M. Balthesen, et al. (1994). "The conditions of primary infection 
define the load of latent viral genome in organs and the risk of recurrent 
cytomegalovirus disease." J Exp Med 179(1): 185-93. 
Reddehase, M. J., W. Mutter, et al. (1987). "CD8-positive T lymphocytes specific for 
murine cytomegalovirus immediate-early antigens mediate protective 
immunity." J Virol 61(10): 3102-8. 
Reddehase, M. J., J. Podlech, et al. (2002). "Mouse models of cytomegalovirus 
latency: overview." J Clin Virol 25 Suppl 2: S23-36. 
Reddehase, M. J., C. O. Simon, et al. (2008). "Murine model of cytomegalovirus 
latency and reactivation." Curr Top Microbiol Immunol 325: 315-31. 
Reddehase, M. J., F. Weiland, et al. (1985). "Interstitial murine cytomegalovirus 
pneumonia after irradiation: characterization of cells that limit viral 
replication during established infection of the lungs." J Virol 55(2): 264-73. 
Redpath, S., A. Angulo, et al. (1999). "Murine cytomegalovirus infection down-
regulates MHC class II expression on macrophages by induction of IL-10." J 
Immunol 162(11): 6701-7. 
Reiss, A. B., C. A. Patel, et al. (2004). "Interferon-gamma impedes reverse 
cholesterol transport and promotes foam cell transformation in THP-1 human 
monocytes/macrophages." Med Sci Monit 10(11): BR420-5. 
Reusch, U., W. Muranyi, et al. (1999). "A cytomegalovirus glycoprotein re-routes 
MHC class I complexes to lysosomes for degradation." Embo J 18(4): 1081-
91. 
Reyburn, H. T., O. Mandelboim, et al. (1997). "The class I MHC homologue of 
human cytomegalovirus inhibits attack by natural killer cells." Nature 
386(6624): 514-7. 
Reynolds, C. P., B. J. Maurer, et al. (2004). "Ceramide synthesis and metabolism as a 
target for cancer therapy." Cancer Lett 206(2): 169-80. 
Ringrose, J. H., R. E. Jeeninga, et al. (2008). "Proteomic studies reveal coordinated 
changes in T-cell expression patterns upon infection with human 
immunodeficiency virus type 1." J Virol 82(9): 4320-30. 
186 
 
Robinzon, S., A. Dafa-Berger, et al. (2009). "Impaired cholesterol biosynthesis in a 
neuronal cell line persistently infected with measles virus." J Virol 83(11): 
5495-504. 
Rothwell, C., A. Lebreton, et al. (2009). "Cholesterol biosynthesis modulation 
regulates dengue viral replication." Virology 389(1-2): 8-19. 
Ruzek, M. C., A. H. Miller, et al. (1997). "Characterization of early cytokine 
responses and an interleukin (IL)-6-dependent pathway of endogenous 
glucocorticoid induction during murine cytomegalovirus infection." J Exp 
Med 185(7): 1185-92. 
Sagedal, S., A. Hartmann, et al. (2005). "The impact of early cytomegalovirus 
infection and disease in renal transplant recipients." Clin Microbiol Infect 
11(7): 518-30. 
Sainz, B., Jr., H. L. LaMarca, et al. (2005). "Synergistic inhibition of human 
cytomegalovirus replication by interferon-alpha/beta and interferon-gamma." 
Virol J 2: 14. 
Samsa, M. M., J. A. Mondotte, et al. (2009). "Dengue virus capsid protein usurps 
lipid droplets for viral particle formation." PLoS Pathog 5(10): e1000632. 
Samuel, C. E. (2001). "Antiviral actions of interferons." Clin Microbiol Rev 14(4): 
778-809. 
Sanchez, V. and D. H. Spector (2008). "Subversion of cell cycle regulatory 
pathways." Curr Top Microbiol Immunol 325: 243-62. 
Sato, M., H. Suemori, et al. (2000). "Distinct and essential roles of transcription 
factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene 
induction." Immunity 13(4): 539-48. 
Scalzo, A. A., N. A. Fitzgerald, et al. (1990). "Cmv-1, a genetic locus that controls 
murine cytomegalovirus replication in the spleen." J Exp Med 171(5): 1469-
83. 
Schleiss, M. R. and T. C. Heineman (2005). "Progress toward an elusive goal: 
current status of cytomegalovirus vaccines." Expert Rev Vaccines 4(3): 381-
406. 
Schneider, K., A. Loewendorf, et al. (2008). "Lymphotoxin-mediated crosstalk 
between B cells and splenic stroma promotes the initial type I interferon 
response to cytomegalovirus." Cell Host Microbe 3(2): 67-76. 
Schneider, R. J. and I. Mohr (2003). "Translation initiation and viral tricks." Trends 
Biochem Sci 28(3): 130-6. 
Schultz, J. R., H. Tu, et al. (2000). "Role of LXRs in control of lipogenesis." Genes 
Dev 14(22): 2831-8. 
Scott, I. (2009). "Degradation of RIG-I following cytomegalovirus infection is 
independent of apoptosis." Microbes Infect 11(12): 973-9. 
Sears, A. E. and B. Roizman (1990). "Amplification by host cell factors of a 
sequence contained within the herpes simplex virus 1 genome." Proc Natl 
Acad Sci U S A 87(23): 9441-4. 
Shaw, S. M., J. E. Fildes, et al. (2009). "Pleiotropic effects and cholesterol-lowering 
therapy." Cardiology 112(1): 4-12. 
Sherman, B. T., W. Huang da, et al. (2007). "DAVID Knowledgebase: a gene-
centered database integrating heterogeneous gene annotation resources to 




Sherrill, J. D., M. P. Stropes, et al. (2009). "Activation of intracellular signaling 
pathways by the murine cytomegalovirus G protein-coupled receptor M33 
occurs via PLC-{beta}/PKC-dependent and -independent mechanisms." J 
Virol 83(16): 8141-52. 
Shibutani, T., T. M. Johnson, et al. (1997). "Pertussis toxin-sensitive G proteins as 
mediators of the signal transduction pathways activated by cytomegalovirus 
infection of smooth muscle cells." J Clin Invest 100(8): 2054-61. 
Shingai, M., M. Azuma, et al. (2008). "Soluble G protein of respiratory syncytial 
virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction." Int 
Immunol 20(9): 1169-80. 
Simon, C. O., R. Holtappels, et al. (2006). "CD8 T cells control cytomegalovirus 
latency by epitope-specific sensing of transcriptional reactivation." J Virol 
80(21): 10436-56. 
Simons, K. and E. Ikonen (2000). "How cells handle cholesterol." Science 
290(5497): 1721-6. 
Sinzger, C. and G. Jahn (1996). "Human cytomegalovirus cell tropism and 
pathogenesis." Intervirology 39(5-6): 302-19. 
Speir, E., T. Shibutani, et al. (1996). "Role of reactive oxygen intermediates in 
cytomegalovirus gene expression and in the response of human smooth 
muscle cells to viral infection." Circ Res 79(6): 1143-52. 
Speir, E., Z. X. Yu, et al. (1998). "Aspirin attenuates cytomegalovirus infectivity and 
gene expression mediated by cyclooxygenase-2 in coronary artery smooth 
muscle cells." Circ Res 83(2): 210-6. 
Spencer, J. V., K. M. Lockridge, et al. (2002). "Potent immunosuppressive activities 
of cytomegalovirus-encoded interleukin-10." J Virol 76(3): 1285-92. 
Stinski, M. F. and H. Isomura (2008). "Role of the cytomegalovirus major immediate 
early enhancer in acute infection and reactivation from latency." Med 
Microbiol Immunol 197(2): 223-31. 
Strobl, B., I. Bubic, et al. (2005). "Novel functions of tyrosine kinase 2 in the 
antiviral defence against murine cytomegalovirus." J Immunol 175(6): 4000-
8. 
Sun, L. P., J. Seemann, et al. (2007). "Sterol-regulated transport of SREBPs from 
endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap 
inaccessible to COPII proteins." Proc Natl Acad Sci U S A 104(16): 6519-26. 
Swiecki, M., S. Gilfillan, et al. (2010). "Plasmacytoid dendritic cell ablation impacts 
early interferon responses and antiviral NK and CD8(+) T cell accrual." 
Immunity 33(6): 955-66. 
Tabeta, K., P. Georgel, et al. (2004). "Toll-like receptors 9 and 3 as essential 
components of innate immune defence against mouse cytomegalovirus 
infection." Proc Natl Acad Sci U S A 101(10): 3516-21. 
Tailor, P., T. Tamura, et al. (2007). "The feedback phase of type I interferon 
induction in dendritic cells requires interferon regulatory factor 8." Immunity 
27(2): 228-39. 
Takai, Y., T. Sasaki, et al. (2001). "Small GTP-binding proteins." Physiol Rev 81(1): 
153-208. 
Tang-Feldman, Y. J., A. Wojtowicz, et al. (2006). "Use of quantitative real-time PCR 
(qRT-PCR) to measure cytokine transcription and viral load in murine 
cytomegalovirus infection." J Virol Methods 131(2): 122-9. 
188 
 
Tang, H., A. Kawabata, et al. (2008). "Human herpesvirus-6 infection induces the 
reorganization of membrane microdomains in target cells, which are required 
for virus entry." Virology 378(2): 265-71. 
Unutmaz, D., V. N. KewalRamani, et al. (1998). "G protein-coupled receptors in 
HIV and SIV entry: new perspectives on lentivirus-host interactions and on 
the utility of animal models." Semin Immunol 10(3): 225-36. 
Ushio-Fukai, M. (2009). "Vascular signaling through G protein-coupled receptors: 
new concepts." Curr Opin Nephrol Hypertens 18(2): 153-9. 
Vaidya, S., R. Bostedor, et al. (1998). "Massive production of farnesol-derived 
dicarboxylic acids in mice treated with the squalene synthase inhibitor 
zaragozic acid A." Arch Biochem Biophys 355(1): 84-92. 
Varani, S., M. Cederarv, et al. (2007). "Human cytomegalovirus differentially 
controls B cell and T cell responses through effects on plasmacytoid dendritic 
cells." J Immunol 179(11): 7767-76. 
Vassilatis, D. K., J. G. Hohmann, et al. (2003). "The G protein-coupled receptor 
repertoires of human and mouse." Proc Natl Acad Sci U S A 100(8): 4903-8. 
Vilkuna-Rautiainen, T., P. J. Pussinen, et al. (2006). "Serum antibody response to 
periodontal pathogens and herpes simplex virus in relation to classic risk 
factors of cardiovascular disease." Int J Epidemiol 35(6): 1486-94. 
Vliegen, I., A. Duijvestijn, et al. (2004). "Cytomegalovirus infection aggravates 
atherogenesis in apoE knockout mice by both local and systemic immune 
activation." Microbes Infect 6(1): 17-24. 
Wang, C., M. Gale, Jr., et al. (2005). "Identification of FBL2 as a geranylgeranylated 
cellular protein required for hepatitis C virus RNA replication." Mol Cell 
18(4): 425-34. 
Wang, G., S. J. Jones, et al. (2006). "Identification of genes targeted by the androgen 
and PKA signaling pathways in prostate cancer cells." Oncogene 25(55): 
7311-23. 
Wang, X., S. M. Huong, et al. (2003). "Epidermal growth factor receptor is a cellular 
receptor for human cytomegalovirus." Nature 424(6947): 456-61. 
Wang, X. Q., C. G. Panousis, et al. (2002). "Interferon-gamma-mediated 
downregulation of cholesterol efflux and ABC1 expression is by the Stat1 
pathway." Arterioscler Thromb Vasc Biol 22(5): e5-9. 
Ware, C. F. (2005). "Network communications: lymphotoxins, LIGHT, and TNF." 
Annu Rev Immunol 23: 787-819. 
Waris, G., D. J. Felmlee, et al. (2007). "Hepatitis C virus induces proteolytic 
cleavage of sterol regulatory element binding proteins and stimulates their 
phosphorylation via oxidative stress." J Virol 81(15): 8122-30. 
Welch, A. R., L. M. McGregor, et al. (1991). "Cytomegalovirus homologs of cellular 
G protein-coupled receptor genes are transcribed." J Virol 65(7): 3915-8. 
Welsh, R. M., J. O. Brubaker, et al. (1991). "Natural killer (NK) cell response to 
virus infections in mice with severe combined immunodeficiency. The 
stimulation of NK cells and the NK cell-dependent control of virus infections 
occur independently of T and B cell function." J Exp Med 173(5): 1053-63. 
Wenk, M. R. (2005). "The emerging field of lipidomics." Nat Rev Drug Discov 4(7): 
594-610. 




Wesoly, J., Z. Szweykowska-Kulinska, et al. (2007). "STAT activation and 
differential complex formation dictate selectivity of interferon responses." 
Acta Biochim Pol 54(1): 27-38. 
Wild, P., M. Engels, et al. (2005). "Impairment of nuclear pores in bovine 
herpesvirus 1-infected MDBK cells." J Virol 79(2): 1071-83. 
Wilson, N. S. and J. A. Villadangos (2005). "Regulation of antigen presentation and 
cross-presentation in the dendritic cell network: facts, hypothesis, and 
immunological implications." Adv Immunol 86: 241-305. 
Wong, A., K. H. Tan, et al. (2000). "Seroprevalence of cytomegalovirus, toxoplasma 
and parvovirus in pregnancy." Singapore Med J 41(4): 151-5. 
Wynn, K. K., Z. Fulton, et al. (2008). "Impact of clonal competition for peptide-
MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral 
infection." Blood 111(8): 4283-92. 
Xu, M., H. Zhou, et al. (2009). "ABCG1 mediated oxidized LDL-derived oxysterol 
efflux from macrophages." Biochem Biophys Res Commun 390(4): 1349-54. 
Ye, J., C. Wang, et al. (2003). "Disruption of hepatitis C virus RNA replication 
through inhibition of host protein geranylgeranylation." Proc Natl Acad Sci U 
S A 100(26): 15865-70. 
Yoneyama, M., W. Suhara, et al. (1998). "Direct triggering of the type I interferon 
system by virus infection: activation of a transcription factor complex 
containing IRF-3 and CBP/p300." EMBO J 17(4): 1087-95. 
Yvan-Charvet, L., N. Wang, et al. (2010). "Role of HDL, ABCA1, and ABCG1 
transporters in cholesterol efflux and immune responses." Arterioscler 
Thromb Vasc Biol 30(2): 139-43. 
Zheng, Y. H., A. Plemenitas, et al. (2003). "Nef increases the synthesis of and 
transports cholesterol to lipid rafts and HIV-1 progeny virions." Proc Natl 
Acad Sci U S A 100(14): 8460-5. 
Zhou, Y. F., E. Guetta, et al. (1996). "Human cytomegalovirus increases modified 
low density lipoprotein uptake and scavenger receptor mRNA expression in 
vascular smooth muscle cells." J Clin Invest 98(9): 2129-38. 
Zhu, X., J. Y. Lee, et al. (2008). "Increased cellular free cholesterol in macrophage-
specific Abca1 knock-out mice enhances pro-inflammatory response of 
macrophages." J Biol Chem 283(34): 22930-41. 
Zucchini, N., G. Bessou, et al. (2008). "Individual plasmacytoid dendritic cells are 
major contributors to the production of multiple innate cytokines in an organ-
specific manner during viral infection." Int Immunol 20(1): 45-56. 
Zucchini, N., G. Bessou, et al. (2008). "Cutting edge: Overlapping functions of 
TLR7 and TLR9 for innate defence against a herpesvirus infection." J 
Immunol 180(9): 5799-803. 
 
 
Appendix 1. - List of the 446 down regulated genes by mCMV in 
BMDMs after 24 hrs infection 
Probe Set 
ID Gene Symbol Gene Title FC P-Value 
94305_at Col1a1 collagen, type I, alpha 1 -4.48 4.30E-09 
160406_at Ctsk cathepsin K -3.73 3.66E-11 
160832_at Ldlr low density lipoprotein receptor -3.63 7.51E-10 
93100_at Acta2 actin, alpha 2, smooth muscle, aorta -3.32 1.80E-09 
92567_at Col5a2 collagen, type V, alpha 2 -3.31 1.62E-09 
94325_at Hmgcs1 
3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 1 -3.25 2.14E-10 
96269_at Idi1 isopentenyl-diphosphate delta isomerase -3.22 1.12E-10 
99098_at Fdps farnesyl diphosphate synthetase -3.06 4.73E-09 
94322_at Sqle squalene epoxidase -3.05 4.57E-10 
96049_at Bgn biglycan -2.94 2.48E-09 
95758_at Scd2 stearoyl-Coenzyme A desaturase 2 -2.79 1.18E-09 
103957_at Tfrc transferrin receptor -2.71 5.08E-10 
94769_at Mmp8 matrix metallopeptidase 8 -2.67 1.31E-08 
101160_at Cxcl2 chemokine (C-X-C motif) ligand 2 -2.61 6.84E-08 
101130_at Col1a2 collagen, type I, alpha 2 -2.60 6.14E-09 
99387_at Fpr1 formyl peptide receptor 1 -2.60 3.40E-08 
94916_at Cyp51 cytochrome P450, family 51 -2.54 7.77E-08 
160388_at Sc4mol sterol-C4-methyl oxidase-like -2.50 2.14E-09 
93294_at Ctgf connective tissue growth factor -2.50 4.32E-07 
94294_at Ccnb2 cyclin B2 -2.41 2.32E-09 
97203_at Marcksl1 MARCKS-like 1 -2.39 2.42E-08 
103958_g_at Tfrc transferrin receptor -2.39 1.05E-09 
103226_at Mrc1 mannose receptor, C type 1 -2.37 1.75E-07 
160118_at Mmp14 
matrix metallopeptidase 14 (membrane-
inserted) -2.36 2.47E-08 
160424_f_at Fdps farnesyl diphosphate synthetase -2.31 2.83E-09 
99457_at Mki67 
antigen identified by monoclonal antibody 
Ki 67 -2.29 2.14E-09 
94817_at Serpinh1 
serine (or cysteine) peptidase inhibitor, clade 
H, member 1 -2.23 3.71E-07 
92833_at Hal histidine ammonia lyase -2.20 2.38E-08 
96784_at Anln anillin, actin binding protein -2.19 1.55E-08 
94784_at Iqgap3 
IQ motif containing GTPase activating 
protein 3 -2.17 3.84E-09 
95348_at Cxcl1 chemokine (C-X-C motif) ligand 1 -2.17 1.10E-06 
97518_at Fdft1 farnesyl diphosphate farnesyl transferase 1 -2.17 6.34E-08 
97282_at Mela melanoma antigen -2.13 5.98E-08 
102629_at Tnf tumor necrosis factor -2.12 1.36E-08 
97320_at Slc39a4 solute carrier family 39 (zinc transporter), -2.11 3.88E-09 
member 4 
104333_at D17H6S56E-5 DNA segment, Chr 17, human D6S56E 5 -2.03 6.23E-08 
99979_at Cyp1b1 
cytochrome P450, family 1, subfamily b, 
polypeptide 1 -2.02 3.15E-07 
160544_at Fabp5 fatty acid binding protein 5, epidermal -1.98 3.02E-08 
96886_at Stab1 stabilin 1 -1.96 3.39E-08 
101073_at Lrp1 
low density lipoprotein receptor-related 
protein 1 -1.92 1.80E-07 
160280_at Cav1 caveolin 1, caveolae protein -1.92 4.44E-07 
104149_at Nfkbia 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha -1.92 1.33E-08 
160501_at Kif20a kinesin family member 20A -1.91 3.29E-07 
104451_at Slc11a2 
solute carrier family 11 (proton-coupled 
divalent metal ion transporters), member 2 -1.91 2.47E-08 
95032_at Prc1 protein regulator of cytokinesis 1 -1.90 5.52E-08 
93573_at Mt1 metallothionein 1 -1.89 1.00E-08 
99578_at Top2a topoisomerase (DNA) II alpha -1.87 9.50E-09 
103448_at S100a8 
S100 calcium binding protein A8 
(calgranulin A) -1.85 1.29E-07 
160770_at Mvd mevalonate (diphospho) decarboxylase -1.85 2.09E-08 
160159_at Ccnb1 cyclin B1 -1.85 2.44E-07 
97238_at Tacc3 
transforming, acidic coiled-coil containing 
protein 3 -1.85 4.26E-08 
160755_at Kif2c /// LOC631653 
kinesin family member 2C /// similar to 
Kinesin-like protein KIF2C (Mitotic 
centromere-associated kinesin) (MCAK) -1.82 2.42E-08 
94288_at Hist1h1c histone cluster 1, H1c -1.82 6.84E-08 
93273_at Snca synuclein, alpha -1.82 2.34E-07 
93777_at Golph3l golgi phosphoprotein 3-like -1.82 1.34E-08 
160901_at Fos FBJ osteosarcoma oncogene -1.81 6.66E-07 
99425_at Hmgcr 
3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase -1.81 3.41E-06 
92639_at Aurka aurora kinase A -1.81 1.55E-08 
101561_at Mt2 metallothionein 2 -1.81 4.92E-08 
162077_f_at Scd2 stearoyl-Coenzyme A desaturase 2 -1.80 2.89E-07 
101521_at Birc5 baculoviral IAP repeat-containing 5 -1.80 4.82E-08 
98773_s_at Irg1 immunoresponsive gene 1 -1.80 3.41E-07 
92593_at Postn periostin, osteoblast specific factor -1.80 3.33E-07 
103667_at Atp13a3 ATPase type 13A3 -1.78 2.76E-07 
161000_i_at Nusap1 nucleolar and spindle associated protein 1 -1.78 1.03E-06 
160973_at C330027C09Rik RIKEN cDNA C330027C09 gene -1.78 3.15E-07 
101571_g_at Igfbp4 insulin-like growth factor binding protein 4 -1.78 1.60E-07 
93574_at Serpinf1 
serine (or cysteine) peptidase inhibitor, clade 
F, member 1 -1.77 9.99E-07 
96319_at Cdc20 
cell division cycle 20 homolog (S. 
cerevisiae) -1.75 3.06E-08 
99186_at Ccna2 cyclin A2 -1.74 3.85E-07 
104314_r_at 1110032A03Rik RIKEN cDNA 1110032A03 gene -1.74 1.04E-04 
94211_at 6720460F02Rik RIKEN cDNA 6720460F02 gene -1.73 4.26E-08 
97160_at Sparc secreted acidic cysteine rich glycoprotein -1.73 1.48E-06 
100616_at Cenpa centromere protein A -1.71 7.10E-07 
100128_at Cdc2a cell division cycle 2 homolog A (S. pombe) -1.71 3.37E-08 
93541_at Tagln transgelin -1.70 7.21E-08 
93099_f_at Plk1 polo-like kinase 1 (Drosophila) -1.68 1.91E-06 
94910_at Nde1 
nuclear distribution gene E homolog 1 (A 
nidulans) -1.68 3.15E-07 
104056_at Ccdc50 coiled-coil domain containing 50 -1.67 1.28E-07 
100116_at 2810417H13Rik RIKEN cDNA 2810417H13 gene -1.65 5.68E-07 
104285_at Hmgcr 
3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase -1.65 3.21E-07 
160095_at Lox lysyl oxidase -1.65 1.18E-07 
161946_r_at Sorbs1 sorbin and SH3 domain containing 1 -1.65 3.51E-03 
92790_at Kpna2 karyopherin (importin) alpha 2 -1.65 1.29E-06 
98631_g_at Nsdhl 
NAD(P) dependent steroid dehydrogenase-
like -1.64 6.84E-08 
98575_at Fasn fatty acid synthase -1.64 3.20E-07 
93868_at Nsdhl 
NAD(P) dependent steroid dehydrogenase-
like -1.64 2.67E-07 
101393_at Anxa3 annexin A3 -1.64 3.55E-07 
160655_at Cpd carboxypeptidase D -1.63 1.27E-06 
98059_s_at Lmna lamin A -1.63 8.78E-07 
95062_at Cast calpastatin -1.63 1.51E-06 
101560_at Emb embigin -1.63 6.84E-08 
97105_at Zc3h12c zinc finger CCCH type containing 12C -1.62 1.23E-07 
98305_at Foxm1 forkhead box M1 -1.62 3.46E-07 
94971_at Cdkn3 cyclin-dependent kinase inhibitor 3 -1.62 7.86E-08 
104097_at Bub1 
budding uninhibited by benzimidazoles 1 
homolog (S. cerevisiae) -1.62 1.74E-07 
100885_at Nek2 
NIMA (never in mitosis gene a)-related 
expressed kinase 2 -1.62 3.84E-07 
94953_at Racgap1 Rac GTPase-activating protein 1 -1.62 3.71E-07 
102632_at Aspm 
asp (abnormal spindle)-like, microcephaly 
associated (Drosophila) -1.61 3.85E-07 
98982_at Tmpo thymopoietin -1.61 2.46E-07 
96551_at Clec4e C-type lectin domain family 4, member e -1.61 1.18E-06 
96168_at Kif23 kinesin family member 23 -1.60 2.76E-07 
99149_at Trim59 tripartite motif-containing 59 -1.60 3.83E-07 
100348_at --- --- -1.60 3.59E-07 
93833_s_at Hist1h2bc histone cluster 1, H2bc -1.59 6.82E-07 
94243_at Ckap5 cytoskeleton associated protein 5 -1.58 8.74E-07 
104522_at Itsn1 intersectin 1 (SH3 domain protein 1A) -1.58 4.48E-07 
94805_f_at 
Hist1h2ab /// Hist1h2ac 
/// Hist1h2ad /// 
Hist1h2ae /// Hist1h2af 
/// Hist1h2ag /// 
histone cluster 1, H2ab /// histone cluster 1, 
H2ac /// histone cluster 1, H2ad /// histone 
cluster 1, H2ae /// histone cluster 1, H2af /// 
histone cluster 1, H2ag /// histone cluster 1, -1.57 3.02E-07 
Hist1h2ah /// Hist1h2ai 
/// Hist1h2ak /// 
Hist1h2an /// Hist1h2ao 
/// Hist3h2a /// RP23-
480B19.10 
H2ah /// histone cluster 1, H2ai /// histone 
cluster 1, H2ak /// histone cluster 1, H2an /// 
histone cluster 1, H2ao /// histone cluster 3, 
H2a /// similar to histone 2a 
103978_at Zc3h11a zinc finger CCCH type containing 11A -1.57 5.28E-06 
99040_at Slc6a4 
solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 -1.57 1.57E-05 
97295_at Cdca8 cell division cycle associated 8 -1.57 3.76E-07 
99541_at Kif11 kinesin family member 11 -1.56 7.14E-07 
93019_at H2afx H2A histone family, member X -1.56 1.95E-06 
95721_at Mapkapk2 MAP kinase-activated protein kinase 2 -1.56 3.49E-07 
101676_at Gpx3 glutathione peroxidase 3 -1.56 7.91E-07 
96081_at Tk1 thymidine kinase 1 -1.56 3.14E-07 
103994_at Eif2c2 eukaryotic translation initiation factor 2C, 2 -1.55 2.19E-05 
103845_at Slc31a1 solute carrier family 31, member 1 -1.55 4.89E-07 
93990_at Hnrnph1 heterogeneous nuclear ribonucleoprotein H1 -1.55 5.00E-07 
92782_at Tmpo thymopoietin -1.55 4.49E-07 
92978_s_at Serpinb2 
serine (or cysteine) peptidase inhibitor, clade 
B, member 2 -1.54 3.84E-07 
104322_at Ckap2 cytoskeleton associated protein 2 -1.54 1.37E-06 
98968_at Myo5a myosin VA -1.54 2.51E-05 
92350_at Mapre1 
microtubule-associated protein, RP/EB 
family, member 1 -1.54 3.25E-06 
104320_at Pdxk pyridoxal (pyridoxine, vitamin B6) kinase -1.54 1.00E-05 
160479_at Cat catalase -1.54 9.04E-07 
93414_at Abcb1b 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1B -1.53 3.56E-07 
100884_at Akr1b8 aldo-keto reductase family 1, member B8 -1.53 6.23E-06 
100923_at Myo10 myosin X -1.53 3.56E-07 
103709_at Col1a1 collagen, type I, alpha 1 -1.52 5.68E-07 
161530_r_at Sema4a 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A -1.52 4.66E-06 
160546_at Aldoc aldolase C, fructose-bisphosphate -1.52 5.26E-07 
94177_at Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 -1.52 4.22E-07 
102768_i_at Sc5d 
sterol-C5-desaturase (fungal ERG3, delta-5-
desaturase) homolog (S. cerevisae) -1.52 6.29E-05 
160894_at CEbpd 
CCAAT/enhancer binding protein (C/EBP), 
delta -1.52 1.72E-06 
104214_at Slc7a8 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 8 -1.51 9.42E-07 
104059_at Chd8 
chromodomain helicase DNA binding 
protein 8 -1.51 3.29E-06 
95292_at Itga4 integrin alpha 4 -1.51 3.41E-06 
104467_at Cpd carboxypeptidase D -1.51 9.13E-07 
160461_f_at Tubb6 tubulin, beta 6 -1.51 1.10E-06 
102655_at Itga4 integrin alpha 4 -1.51 1.39E-05 
162379_r_at --- --- -1.51 3.77E-06 
104712_at Myc myelocytomatosis oncogene -1.51 7.74E-05 
100050_at Id1 inhibitor of DNA binding 1 -1.50 1.86E-04 
103914_at Pcyt2 
phosphate cytidylyltransferase 2, 
ethanolamine -1.50 9.25E-06 
97364_at Asf1b 
ASF1 anti-silencing function 1 homolog B 
(S. cerevisiae) -1.50 6.66E-07 
104644_at Kif4 kinesin family member 4 -1.50 3.79E-07 
95010_at Traf3 TNF receptor-associated factor 3 -1.50 4.27E-07 
104579_r_at Actn1 actinin, alpha 1 -1.50 1.75E-05 
92925_at CEbpb 
CCAAT/enhancer binding protein (C/EBP), 
beta -1.49 5.60E-07 
92984_g_at Ptprj protein tyrosine phosphatase, receptor type, J -1.49 1.25E-04 
99823_r_at D18Ertd232e 
DNA segment, Chr 18, ERATO Doi 232, 
expressed -1.49 3.44E-06 
161796_r_at Kcnq1 
potassium voltage-gated channel, subfamily 
Q, member 1 -1.48 2.48E-05 
97095_at Bub1 
budding uninhibited by benzimidazoles 1 
homolog (S. cerevisiae) -1.48 1.15E-05 
92280_at Actn1 actinin, alpha 1 -1.48 1.01E-05 
97421_at Smc2 structural maintenance of chromosomes 2 -1.48 7.18E-06 
161314_r_at Ubr4 
ubiquitin protein ligase E3 component n-
recognin 4 -1.47 6.32E-04 
101350_g_at Plk1 polo-like kinase 1 (Drosophila) -1.47 4.07E-06 
160489_at Tnfaip2 
tumor necrosis factor, alpha-induced protein 
2 -1.47 7.26E-06 
95542_at Tpm4 tropomyosin 4 -1.47 1.10E-06 
92412_s_at Spag5 sperm associated antigen 5 -1.47 6.79E-05 
92852_at Fn1 fibronectin 1 -1.47 7.42E-05 
98306_g_at Foxm1 forkhead box M1 -1.47 3.34E-06 
104578_f_at Actn1 actinin, alpha 1 -1.46 1.49E-06 
97527_at Cks2 CDC28 protein kinase regulatory subunit 2 -1.45 5.17E-06 
99392_at Tnfaip3 
tumor necrosis factor, alpha-induced protein 
3 -1.45 8.23E-07 
95731_at LOC100047324 /// Sesn1 similar to Sesn1 protein /// sestrin 1 -1.45 7.57E-06 
160737_at Lss lanosterol synthase -1.45 8.08E-05 
103201_at Ttk Ttk protein kinase -1.45 1.85E-05 
99621_s_at Sfpq 
splicing factor proline/glutamine rich 
(polypyrimidine tract binding protein 
associated) -1.45 6.89E-06 
102812_i_at Uba5 ubiquitin-like modifier activating enzyme 5 -1.45 1.67E-05 
98774_at Irg1 immunoresponsive gene 1 -1.45 2.48E-05 
98988_at Nfkbiz 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, zeta -1.45 1.22E-03 
93471_at Slc4a7 
solute carrier family 4, sodium bicarbonate 
cotransporter, member 7 -1.45 1.11E-05 
96930_at Ehd1 EH-domain containing 1 -1.45 4.76E-06 
100095_at Scarb1 scavenger receptor class B, member 1 -1.45 1.99E-06 
160762_at Abr active BCR-related gene -1.44 1.25E-06 
92301_at Ikbke inhibitor of kappaB kinase epsilon -1.44 5.99E-07 
100928_at Fbln2 fibulin 2 -1.44 1.80E-06 
93758_at Incenp inner centromere protein -1.44 8.69E-07 
93111_at Kpnb1 karyopherin (importin) beta 1 -1.43 1.74E-06 
93264_at Srebf1 
sterol regulatory element binding 
transcription factor 1 -1.43 1.40E-06 
103736_at Sash1 SAM and SH3 domain containing 1 -1.43 3.42E-06 
160255_at Ahnak AHNAK nucleoprotein (desmoyokin) -1.43 9.72E-06 
99073_at Ccnf cyclin F -1.43 4.66E-06 
161137_r_at Ube2c ubiquitin-conjugating enzyme E2C -1.43 5.66E-06 
94712_at Vegfc vascular endothelial growth factor C -1.43 1.28E-04 
95693_at Idh2 
isocitrate dehydrogenase 2 (NADP+), 
mitochondrial -1.43 1.06E-06 
101902_at Rbpj 
recombination signal binding protein for 
immunoglobulin kappa J region -1.42 1.31E-05 
160387_at Cd302 CD302 antigen -1.42 2.69E-06 
95625_at Slc6a8 
solute carrier family 6 (neurotransmitter 
transporter, creatine), member 8 -1.42 1.77E-06 
160101_at Hmox1 heme oxygenase (decycling) 1 -1.42 3.78E-06 
162402_r_at Hoxa4 homeo box A4 -1.42 3.10E-06 
161856_f_at Kif20a kinesin family member 20A -1.42 4.10E-05 
95543_at EG665825 /// Tpm4 predicted gene, EG665825 /// tropomyosin 4 -1.42 7.11E-05 
160369_at Dhcr24 24-dehydrocholesterol reductase -1.41 7.27E-06 
160335_at Gclm glutamate-cysteine ligase, modifier subunit -1.41 8.13E-06 
103720_at Rest RE1-silencing transcription factor -1.41 1.33E-03 
101554_at Nfkbia 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha -1.41 1.16E-06 
100530_at Ralgds 
ral guanine nucleotide dissociation 
stimulator -1.41 1.38E-05 
160885_at Nucks1 
nuclear casein kinase and cyclin-dependent 
kinase substrate 1 -1.41 4.38E-05 
100089_at Ppic peptidylprolyl isomerase C -1.41 4.21E-06 
160638_at Cdkn2c 
cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) -1.40 1.49E-06 
103614_at Nfkb2 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 2, p49/p100 -1.40 5.45E-06 
102642_at Slc11a2 
solute carrier family 11 (proton-coupled 
divalent metal ion transporters), member 2 -1.40 8.09E-06 
102934_s_at Cdc25c cell division cycle 25 homolog C (S. pombe) -1.40 1.99E-05 
97411_at Ect2 ect2 oncogene -1.40 2.91E-05 
95665_at Sec14l1 SEC14-like 1 (S. cerevisiae) -1.40 1.39E-05 
94362_at Nras neuroblastoma ras oncogene -1.40 6.43E-06 
97383_at Slc6a6 
solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 -1.40 1.04E-05 
98766_at Sh3bp5 
SH3-domain binding protein 5 (BTK-
associated) -1.40 8.75E-06 
97248_at Dbi diazepam binding inhibitor -1.40 1.56E-06 
160296_at Wsb2 WD repeat and SOCS box-containing 2 -1.39 4.11E-05 
95597_at Ptgs1 prostaglandin-endoperoxide synthase 1 -1.39 5.08E-06 
97148_at Kifc1 Kinesin family member C1 (Kifc1), mRNA -1.39 2.49E-05 
95466_at Cotl1 coactosin-like 1 (Dictyostelium) -1.39 1.57E-03 
103886_at Reep5 receptor accessory protein 5 -1.39 3.60E-05 
96042_at Sod2 superoxide dismutase 2, mitochondrial -1.39 5.77E-05 
94697_at Fgr 
Gardner-Rasheed feline sarcoma viral (Fgr) 
oncogene homolog -1.39 2.18E-05 
99009_at Nnt nicotinamide nucleotide transhydrogenase -1.39 4.93E-06 
98586_at Nap1l1 nucleosome assembly protein 1-like 1 -1.39 1.77E-04 
97556_at Anp32e 
acidic (leucine-rich) nuclear phosphoprotein 
32 family, member E -1.38 3.40E-05 
94217_f_at Cdca3 cell division cycle associated 3 -1.38 3.46E-06 
95349_g_at Cxcl1 chemokine (C-X-C motif) ligand 1 -1.38 4.73E-05 
162124_r_at Rusc1 RUN and SH3 domain containing 1 -1.38 7.34E-05 
160571_at Idh1 
isocitrate dehydrogenase 1 (NADP+), 
soluble -1.38 1.24E-04 
161524_r_at Gpi1 glucose phosphate isomerase 1 -1.38 2.74E-05 
102767_at Gng12 
guanine nucleotide binding protein (G 
protein), gamma 12 -1.38 4.17E-05 
101877_at Slc31a1 solute carrier family 31, member 1 -1.38 6.77E-05 
101982_at Vasp vasodilator-stimulated phosphoprotein -1.38 6.69E-06 
102337_s_at Fcgr2b Fc receptor, IgG, low affinity IIb -1.38 2.80E-03 
96885_at Nt5dc2 5'-nucleotidase domain containing 2 -1.37 3.77E-06 
93015_at Gsta3 glutathione S-transferase, alpha 3 -1.37 6.68E-05 
98828_at Itgam integrin alpha M -1.37 3.57E-04 
160580_at Man1a mannosidase 1, alpha -1.37 4.30E-05 
95117_at Igf2r insulin-like growth factor 2 receptor -1.37 3.69E-06 
95753_at Ncaph non-SMC condensin I complex, subunit H -1.37 4.80E-06 
92858_at Slpi secretory leukocyte peptidase inhibitor -1.37 1.33E-05 
93131_at Galc galactosylceramidase -1.37 9.65E-05 
160648_at Fignl1 fidgetin-like 1 -1.37 6.80E-06 
98053_at Ywhab 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide -1.37 8.95E-05 
160469_at LOC640441 /// Thbs1 
similar to thrombospondin 1 /// 




high mobility group box 2 /// predicted gene, 
OTTMUSG00000011058 -1.36 1.04E-04 
100949_at Fam20c 
family with sequence similarity 20, member 
C -1.36 3.92E-06 
98989_at Dhcr7 7-dehydrocholesterol reductase -1.36 1.14E-05 
103619_at Cyb5b cytochrome b5 type B -1.36 2.59E-05 
102334_at Dok2 docking protein 2 -1.36 6.38E-06 
93306_at Mapre1 
microtubule-associated protein, RP/EB 
family, member 1 -1.36 9.02E-06 
98060_at Lmna lamin A -1.36 1.25E-05 
101964_at Tkt transketolase -1.36 4.80E-05 
94361_at Ddx21 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
21 -1.36 4.66E-05 
103440_at Gabpa GA repeat binding protein, alpha -1.36 2.57E-06 
103091_at Relb 
avian reticuloendotheliosis viral (v-rel) 
oncogene related B -1.36 3.37E-06 
97273_at Srrt 
serrate RNA effector molecule homolog 
(Arabidopsis) -1.36 4.57E-06 
104735_at Kctd12 
potassium channel tetramerisation domain 
containing 12 -1.36 2.59E-05 
97468_at Cks1b CDC28 protein kinase 1b -1.36 4.22E-06 
95288_i_at Ccdc88a coiled coil domain containing 88A -1.36 1.21E-03 
160378_at Tmem109 transmembrane protein 109 -1.35 3.67E-05 
102209_at Nfatc1 
nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 1 -1.35 6.43E-06 
104755_at Tnip1 TNFAIP3 interacting protein 1 -1.35 2.30E-05 
97197_r_at AI506816 expressed sequence AI506816 -1.35 1.01E-03 
93298_at Papss1 
3'-phosphoadenosine 5'-phosphosulfate 
synthase 1 -1.35 2.63E-05 
162264_s_at Bub1 
budding uninhibited by benzimidazoles 1 
homolog (S. cerevisiae) -1.35 8.36E-06 
96215_f_at --- --- -1.35 7.59E-06 
98630_at Nsdhl 
NAD(P) dependent steroid dehydrogenase-
like -1.35 8.74E-06 
94963_at Vcl vinculin -1.35 2.63E-05 
101464_at Timp1 tissue inhibitor of metalloproteinase 1 -1.35 1.15E-05 
160111_at Eif1ay 
eukaryotic translation initiation factor 1A, Y-
linked -1.35 3.60E-05 
95596_at Foxk2 forkhead box K2 -1.35 2.36E-05 
99800_at L1cam L1 cell adhesion molecule -1.34 7.76E-06 
96677_at Setd8 
SET domain containing (lysine 
methyltransferase) 8 -1.34 8.78E-05 
98114_at Npc1 Niemann Pick type C1 -1.34 1.04E-05 
93676_at Rad51ap1 RAD51 associated protein 1 -1.34 3.41E-05 
102101_f_at --- --- -1.34 1.05E-03 
101029_f_at Actc1 /// LOC100048431 
actin, alpha, cardiac muscle 1 /// similar to 
alpha-actin (AA 27-375) -1.34 3.94E-05 
161684_r_at Lcn2 lipocalin 2 -1.34 1.44E-04 
160246_at Tnfaip8 
tumor necrosis factor, alpha-induced protein 
8 -1.34 1.01E-05 
102142_r_at OTTMUSG00000017864 predicted gene, OTTMUSG00000017864 -1.34 1.40E-04 
93860_i_at EG622147 predicted gene, EG622147 -1.34 2.99E-05 
99592_f_at Rdh11 retinol dehydrogenase 11 -1.34 1.04E-05 
162417_at 1500001M20Rik RIKEN cDNA 1500001M20 gene -1.33 4.77E-04 
160234_at Usp1 ubiquitin specific peptidase 1 -1.33 3.48E-05 
97967_at Plxnd1 plexin D1 -1.33 2.94E-05 
103499_at Vwf Von Willebrand factor homolog -1.33 2.15E-05 
92580_at Hars histidyl-tRNA synthetase -1.33 3.00E-05 
92845_at Oxct1 3-oxoacid CoA transferase 1 -1.33 1.02E-05 
103001_at Vegfb vascular endothelial growth factor B -1.33 3.43E-05 
161390_r_at Pou6f1 POU domain, class 6, transcription factor 1 -1.33 9.15E-04 
98489_at Dlgap5 
discs, large (Drosophila) homolog-associated 
protein 5 -1.33 8.74E-06 
160517_at Lmnb1 lamin B1 -1.33 7.76E-06 
102111_f_at Rpp30 
Ribonuclease P/MRP 30 subunit (human), 
mRNA (cDNA clone IMAGE:5010429) -1.33 7.91E-05 
103204_r_at E2f8 E2F transcription factor 8 -1.32 2.41E-04 
96674_at Tnpo3 transportin 3 -1.32 4.54E-05 
94504_at Slc48a1 
solute carrier family 48 (heme transporter), 
member 1 -1.32 7.50E-06 
101918_at Tgfb1 transforming growth factor, beta 1 -1.32 7.18E-05 
92354_at Maf 
avian musculoaponeurotic fibrosarcoma (v-





similar to putative /// hypothetical protein 
LOC100039914 /// similar to putative -1.32 1.95E-03 
98525_f_at Erdr1 erythroid differentiation regulator 1 -1.32 7.37E-05 
160916_at Eepd1 
endonuclease/exonuclease/phosphatase 
family domain containing 1 -1.32 9.72E-05 
93852_at Mef2a myocyte enhancer factor 2A -1.32 3.59E-05 




similar to solute carrier family 7 (cationic 
amino acid transporter, y+ system), member 
5 /// solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 5 -1.32 1.33E-05 
104725_at Rhoq ras homolog gene family, member Q -1.32 3.24E-05 
160698_s_at Prkcd protein kinase C, delta -1.32 3.00E-05 
96725_at Cic capicua homolog (Drosophila) -1.32 4.14E-04 
160338_at Ankrd13a ankyrin repeat domain 13a -1.32 3.55E-04 
93943_f_at Zfp36l2 zinc finger protein 36, C3H type-like 2 -1.32 2.33E-05 




similar to lymphocyte-specific adaptor 
protein Lnk /// SH2B adaptor protein 3 -1.31 1.71E-04 
99045_at Eno2 enolase 2, gamma neuronal -1.31 1.21E-03 
102944_at G3bp1 
Ras-GTPase-activating protein SH3-domain 
binding protein 1 -1.31 2.84E-05 
100569_at Anxa2 annexin A2 -1.31 1.07E-05 
97425_at Slc44a1 solute carrier family 44, member 1 -1.31 3.09E-05 
160377_at Tardbp TAR DNA binding protein -1.31 1.77E-05 
93507_at Timp2 tissue inhibitor of metalloproteinase 2 -1.31 1.16E-05 
160739_at Wnk1 WNK lysine deficient protein kinase 1 -1.31 5.31E-03 
100535_at Eif4g2 
eukaryotic translation initiation factor 4, 
gamma 2 -1.31 3.47E-05 
101589_at Hmgn2 
high mobility group nucleosomal binding 
domain 2 -1.31 1.03E-03 
98469_at Aurkb aurora kinase B -1.31 4.19E-05 
92762_at Clec4a2 C-type lectin domain family 4, member a2 -1.31 1.31E-05 
99329_at Abcc1 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 1 -1.31 1.09E-05 
92193_r_at Pcsk5 proprotein convertase subtilisin/kexin type 5 -1.31 6.00E-05 
160409_at Pitpna phosphatidylinositol transfer protein, alpha -1.31 8.44E-05 
96526_at D030029J20Rik RIKEN cDNA D030029J20 gene -1.31 1.14E-05 
161062_r_at Rufy3 RUN and FYVE domain containing 3 -1.31 4.10E-04 
92540_f_at Srm spermidine synthase -1.31 7.86E-06 
95435_at Arl8b ADP-ribosylation factor-like 8B -1.31 1.23E-04 
97885_at Tmem176b transmembrane protein 176B -1.31 7.90E-05 
92603_at Atp6v0d1 
ATPase, H+ transporting, lysosomal V0 
subunit D1 -1.31 6.79E-05 
99597_at Gnai2 
guanine nucleotide binding protein (G 
protein), alpha inhibiting 2 -1.31 7.11E-05 
103562_f_at LOC67527 murine leukemia retrovirus -1.31 3.91E-04 
95468_at Egln1 EGL nine homolog 1 (C. elegans) -1.30 3.84E-05 
99838_at Aoah acyloxyacyl hydrolase -1.30 9.50E-05 
99580_s_at 
Ugt1a1 /// Ugt1a10 /// 
Ugt1a2 /// Ugt1a5 /// 
Ugt1a6a /// Ugt1a6b /// 
Ugt1a7c /// Ugt1a9 
UDP glucuronosyltransferase 1 family, 
polypeptide A1 /// UDP glycosyltransferase 
1 family, polypeptide A10 /// UDP 
glucuronosyltransferase 1 family, 
polypeptide A2 /// UDP 
glucuronosyltransferase 1 family, 
polypeptide A5 /// UDP 
glucuronosyltransferase 1 family, 
polypeptide A6A /// UDP 
glucuronosyltransferase 1 family, 
polypeptide A6B /// UDP 
glucuronosyltransferase 1 family, 
polypeptide A7C /// UDP 
glucuronosyltransferase 1 family, 
polypeptide A9 -1.30 2.15E-05 
95156_g_at Znrf1 zinc and ring finger 1 -1.30 5.68E-05 
103065_at Slc20a1 solute carrier family 20, member 1 -1.30 1.12E-05 
99985_at Txnrd1 thioredoxin reductase 1 -1.30 1.52E-05 
160820_at Igsf8 immunoglobulin superfamily, member 8 -1.30 1.12E-04 
103370_at Lin7c lin-7 homolog C (C. elegans) -1.30 1.25E-04 
103642_at G3bp1 
Ras-GTPase-activating protein SH3-domain 
binding protein 1 -1.30 3.04E-05 
103270_at Gtse1 G two S phase expressed protein 1 -1.30 3.43E-05 
99448_at Tln1 talin 1 -1.30 1.11E-05 
93829_at Rod1 
ROD1 regulator of differentiation 1 (S. 
pombe) -1.30 6.06E-04 
101030_at Rhob ras homolog gene family, member B -1.30 1.72E-04 
101632_at Tnfrsf11a 
tumor necrosis factor receptor superfamily, 
member 11a -1.30 4.80E-05 





predicted gene, EG545743 /// similar to 
Pdlim1 protein /// PDZ and LIM domain 1 
(elfin) -1.30 2.39E-04 
97906_at Siah2 seven in absentia 2 -1.30 2.28E-04 
100915_at Myh9 myosin, heavy polypeptide 9, non-muscle -1.30 9.68E-05 
101882_s_at Col18a1 collagen, type XVIII, alpha 1 -1.30 7.06E-05 
94174_at Ctnnal1 
catenin (cadherin associated protein), alpha-
like 1 -1.29 2.00E-04 
98996_at Plk4 polo-like kinase 4 (Drosophila) -1.29 1.24E-04 
95493_at Col6a1 collagen, type VI, alpha 1 -1.29 2.22E-05 
100595_at Ptp4a2 protein tyrosine phosphatase 4a2 -1.29 6.68E-05 
98151_s_at Ctnnd1 catenin (cadherin associated protein), delta 1 -1.29 1.43E-04 
160167_at Nup62 nucleoporin 62 -1.29 1.86E-05 
98427_s_at Nfkb1 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1, p105 -1.29 3.92E-05 
94255_g_at Clic4 
chloride intracellular channel 4 
(mitochondrial) -1.29 8.65E-05 
95791_s_at Sfrs2 
splicing factor, arginine/serine-rich 2 (SC-
35) -1.29 6.76E-05 
93861_f_at EG622147 predicted gene, EG622147 -1.29 4.35E-05 
93193_at Adrb2 adrenergic receptor, beta 2 -1.29 1.20E-04 
94405_at Slc6a6 
solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 -1.28 2.78E-04 
94964_at Vcl vinculin -1.28 1.82E-04 
160579_at Man1a mannosidase 1, alpha -1.28 1.98E-04 
104501_at Vapb 
vesicle-associated membrane protein, 
associated protein B and C -1.28 1.74E-05 
99632_at Mad2l1 MAD2 mitotic arrest deficient-like 1 (yeast) -1.28 4.72E-05 
99120_f_at Chd4 
chromodomain helicase DNA binding 
protein 4 -1.28 1.07E-04 
162360_f_at Mtmr14 myotubularin related protein 14 -1.28 4.34E-04 
94004_at Cnn2 calponin 2 -1.28 2.95E-03 
93749_at Maoa monoamine oxidase A -1.28 1.16E-04 
102144_f_at --- --- -1.28 4.94E-04 
92256_at Ctsb cathepsin B -1.28 3.59E-04 
160353_i_at Mapkapk2 MAP kinase-activated protein kinase 2 -1.28 6.91E-05 
99638_at Col18a1 collagen, type XVIII, alpha 1 -1.28 3.95E-05 
102280_at Pcdh7 protocadherin 7 -1.28 8.50E-05 
94238_at Prss23 protease, serine, 23 -1.28 2.75E-04 
99138_at Rcc1 regulator of chromosome condensation 1 -1.28 4.54E-05 
160430_at Ctnnb1 catenin (cadherin associated protein), beta 1 -1.28 5.79E-05 
103713_at Usp9x 
ubiquitin specific peptidase 9, X 
chromosome -1.27 3.40E-05 
160785_at Arhgap21 Rho GTPase activating protein 21 -1.27 2.09E-04 
160988_r_at Fubp1 
far upstream element (FUSE) binding 
protein 1 -1.27 1.67E-04 
161931_r_at --- --- -1.27 3.04E-04 
103275_at Atp6v0a1 
ATPase, H+ transporting, lysosomal V0 
subunit A1 -1.27 3.08E-05 
100425_at Syk spleen tyrosine kinase -1.27 1.00E-04 
99439_at LOC100048871 /// Mas1 
similar to MAS1 oncogene /// MAS1 
oncogene -1.27 6.75E-05 
160682_at 6430706D22Rik RIKEN cDNA 6430706D22 gene -1.27 4.07E-05 
100020_at Slc4a2 
solute carrier family 4 (anion exchanger), 
member 2 -1.27 9.45E-05 
100548_at Pea15a phosphoprotein enriched in astrocytes 15A -1.27 3.69E-05 
102193_at Exod1 exonuclease domain containing 1 -1.27 2.33E-05 
101349_at Plk1 polo-like kinase 1 (Drosophila) -1.27 3.13E-04 
96811_at Rab31 RAB31, member RAS oncogene family -1.27 6.95E-05 
101040_at Capn2 calpain 2 -1.27 3.97E-05 
94548_at Mfsd1 
major facilitator superfamily domain 
containing 1 -1.27 2.13E-05 
95134_at Mid1ip1 
Mid1 interacting protein 1 (gastrulation 
specific G12-like (zebrafish)) -1.27 1.09E-03 
93604_f_at Cadm1 cell adhesion molecule 1 -1.27 3.00E-05 
102221_at Syngr1 synaptogyrin 1 -1.27 2.46E-05 
101546_at Neu1 neuraminidase 1 -1.27 1.67E-04 
103308_at C79407 expressed sequence C79407 -1.27 4.17E-05 
103855_at Plec1 plectin 1 -1.27 3.82E-03 
98552_at Pmf1 polyamine-modulated factor 1 -1.27 7.12E-05 
160091_at Pgam1 phosphoglycerate mutase 1 -1.27 3.68E-04 
98044_at Dab2 disabled homolog 2 (Drosophila) -1.27 8.39E-05 
96519_at Pdxk pyridoxal (pyridoxine, vitamin B6) kinase -1.27 2.31E-04 
94985_at Syncrip 
synaptotagmin binding, cytoplasmic RNA 






predicted gene, OTTMUSG00000014243 /// 
predicted gene, OTTMUSG00000014245 /// 
protein tyrosine phosphatase, receptor type, J -1.27 8.25E-05 
92773_at Nrp1 neuropilin 1 -1.27 1.36E-04 
94063_at Sema4a 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A -1.27 5.89E-05 
103529_at Tnfaip8l1 
tumor necrosis factor, alpha-induced protein 
8-like 1 -1.27 3.59E-05 
93803_at Psme3 
proteaseome (prosome, macropain) 28 
subunit, 3 -1.27 3.35E-04 
160568_at Eno1 enolase 1, alpha non-neuron -1.26 1.00E-04 
96285_at Myadm myeloid-associated differentiation marker -1.26 3.95E-05 
94768_at Rad21 RAD21 homolog (S. pombe) -1.26 2.81E-04 
94351_r_at Nqo1 NAD(P)H dehydrogenase, quinone 1 -1.26 3.50E-03 
93276_at Hn1 
hematological and neurological expressed 
sequence 1 -1.26 1.00E-04 
160462_f_at Tubb3 tubulin, beta 3 -1.26 2.96E-05 
94147_at Serpine1 
serine (or cysteine) peptidase inhibitor, clade 
E, member 1 -1.26 2.08E-04 
161172_f_at Ncaph non-SMC condensin I complex, subunit H -1.26 8.69E-03 
160676_at Lrrc58 leucine rich repeat containing 58 -1.26 1.18E-04 
96862_at 1110002B05Rik RIKEN cDNA 1110002B05 gene -1.26 3.75E-04 
94435_at LOC100047601 /// Nus1 
similar to DNA segment, Chr 10, ERATO 
Doi 438, expressed /// nuclear undecaprenyl 
pyrophosphate synthase 1 homolog (S. 
cerevisiae) -1.26 7.48E-03 
160970_at LOC100047199 /// Odf2 
similar to outer dense fiber of sperm tails 2 
/// outer dense fiber of sperm tails 2 -1.26 8.48E-05 
101913_at Clcn5 chloride channel 5 -1.26 5.55E-05 
101954_at H2afz H2A histone family, member Z -1.26 4.09E-04 
161161_r_at LOC100046344 /// Nme1 
similar to Nucleoside diphosphate kinase A 
(NDK A) (NDP kinase A) (Tumor metastatic 
process-associated protein) (Metastasis 
inhibition factor NM23) (NDPK-A) (nm23-
M1) /// non-metastatic cells 1, protein 
(NM23A) expressed in -1.26 1.05E-03 
98602_at Rangap1 RAN GTPase activating protein 1 -1.26 5.46E-05 
104531_at Prkcd protein kinase C, delta -1.26 7.59E-05 
102001_at Rrm2 ribonucleotide reductase M2 -1.26 8.13E-05 
93102_f_at Actg2 actin, gamma 2, smooth muscle, enteric -1.26 3.44E-05 
103553_at Mcm10 
minichromosome maintenance deficient 10 
(S. cerevisiae) -1.26 8.78E-05 
94511_at LOC636537 /// Ssr1 
similar to signal sequence receptor, alpha /// 
signal sequence receptor, alpha -1.26 1.43E-04 
160371_at Arl6ip1 
ADP-ribosylation factor-like 6 interacting 
protein 1 -1.26 3.50E-05 
94384_at Ier3 immediate early response 3 -1.26 1.36E-04 
95457_at Impad1 
inositol monophosphatase domain containing 
1 -1.26 3.52E-04 
160726_at Qk quaking -1.26 3.63E-03 
104036_at Dpp7 dipeptidylpeptidase 7 -1.25 7.79E-05 
97706_at --- --- -1.25 1.56E-04 
93850_at Iqgap1 
IQ motif containing GTPase activating 
protein 1 -1.25 1.59E-02 
103039_at Itga5 integrin alpha 5 (fibronectin receptor alpha) -1.25 2.22E-04 
162097_r_at Cdh3 cadherin 3 -1.25 1.91E-04 
98587_at Nap1l1 nucleosome assembly protein 1-like 1 -1.25 2.41E-04 
160326_at Cdv3 
carnitine deficiency-associated gene 
expressed in ventricle 3 -1.25 2.57E-04 
95137_at Tmem97 transmembrane protein 97 -1.25 2.92E-04 
96211_at Dpp8 dipeptidylpeptidase 8 -1.25 2.59E-04 
92637_at Pfkl phosphofructokinase, liver, B-type -1.25 3.07E-04 
102936_at B4galt6 
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 6, mRNA 
(cDNA clone MGC:19296 




Appendix 2. - List of the 630 up regulated genes by mCMV in 
BMDMs after 24 hrs infection 
Probe Set 
ID Gene Symbol Gene Title FC P-Value 
98406_at Ccl5 chemokine (C-C motif) ligand 5 10.61 1.97E-12 
100944_at AW112010 expressed sequence AW112010 7.04 3.29E-12 
98373_at Ms4a4c 
membrane-spanning 4-domains, subfamily 
A, member 4C 6.00 1.67E-11 
92315_at Slfn4 schlafen 4 4.84 5.15E-10 
102906_at Tgtp /// Tgtp2 
T-cell specific GTPase /// T-cell specific 
GTPase 2 4.51 3.11E-11 
102264_at Slfn1 schlafen 1 4.08 8.47E-10 
98299_s_at Slfn3 /// Slfn4 schlafen 3 /// schlafen 4 3.69 4.91E-09 
161968_f_at Ccr5 chemokine (C-C motif) receptor 5 3.68 8.02E-11 
103432_at Isg20 interferon-stimulated protein 3.36 5.09E-10 
96764_at Iigp1 interferon inducible GTPase 1 3.30 9.79E-11 
95303_at Ifitm6 
interferon induced transmembrane protein 
6 3.28 1.52E-09 
101793_at Fcgr1 Fc receptor, IgG, high affinity I 3.06 5.28E-10 
104669_at Irf7 interferon regulatory factor 7 3.02 8.02E-11 
93078_at Ly6a lymphocyte antigen 6 complex, locus A 2.99 5.15E-10 
103639_at Ifit2 
interferon-induced protein with 
tetratricopeptide repeats 2 2.95 9.89E-10 
95471_at Cdkn1c 
cyclin-dependent kinase inhibitor 1C 
(P57) 2.91 6.34E-08 
100484_at Mmp13 matrix metallopeptidase 13 2.90 8.36E-10 
92689_at Il18bp interleukin 18 binding protein 2.88 4.57E-10 
93397_at Ccr2 chemokine (C-C motif) receptor 2 2.84 9.57E-08 
93717_at Ccl12 chemokine (C-C motif) ligand 12 2.81 4.02E-09 
95508_at Nckap1 NCK-associated protein 1 2.74 2.63E-09 
102879_s_at Fcgr1 Fc receptor, IgG, high affinity I 2.73 4.57E-10 
94247_at Dsp desmoplakin 2.60 8.47E-10 
102718_at Ccr5 chemokine (C-C motif) receptor 5 2.56 1.26E-09 
161511_f_at 677168 /// Isg15 
predicted gene, 677168 /// ISG15 
ubiquitin-like modifier 2.49 1.10E-08 
101845_s_at 




component of Sp100-rs /// predicted gene, 
EG665317 /// predicted gene, EG665378 
/// similar to HSR /// similar to putative G-
protein coupled receptor 2.48 8.27E-08 
95743_at Paip2 
polyadenylate-binding protein-interacting 
protein 2 2.45 1.00E-08 
98417_at Mx1 myxovirus (influenza virus) resistance 1 2.44 6.00E-09 
93956_at Ifit3 
interferon-induced protein with 
tetratricopeptide repeats 3 2.42 2.32E-09 
102712_at Saa3 serum amyloid A 3 2.41 4.86E-08 
92406_at Cd7 CD7 antigen 2.41 3.11E-08 
93511_at Itm2a integral membrane protein 2A 2.41 8.59E-09 
101878_at Cd72 CD72 antigen 2.37 2.36E-09 
104606_at Cd52 CD52 antigen 2.36 8.65E-10 
93865_s_at 
H2-T10 /// H2-T17 /// 
H2-T22 /// H2-T9 
histocompatibility 2, T region locus 10 /// 
histocompatibility 2, T region locus 17 /// 
histocompatibility 2, T region locus 22 /// 
histocompatibility 2, T region locus 9 2.36 1.23E-09 
97322_at Ms4a6b 
membrane-spanning 4-domains, subfamily 
A, member 6B 2.30 1.09E-08 
95338_s_at Mmp12 matrix metallopeptidase 12 2.29 3.88E-09 
162202_f_at Irf7 interferon regulatory factor 7 2.27 1.78E-08 
102254_f_at LOC625360 
similar to 2-cell-stage, variable group, 
member 3 2.26 1.29E-07 
101876_s_at 
H2-T10 /// H2-T17 /// 
H2-T22 /// H2-T9 
histocompatibility 2, T region locus 10 /// 
histocompatibility 2, T region locus 17 /// 
histocompatibility 2, T region locus 22 /// 
histocompatibility 2, T region locus 9 2.26 2.32E-09 
93563_s_at Nid2 nidogen 2 2.26 7.82E-08 
99583_at Gstp1 glutathione S-transferase, pi 1 2.22 2.36E-09 
97844_at Rgs2 regulator of G-protein signaling 2 2.17 1.51E-08 
98092_at Plac8 placenta-specific 8 2.16 3.96E-08 
101658_f_at H2-Q8 histocompatibility 2, Q region locus 8 2.14 1.46E-08 
94158_f_at Ptafr platelet-activating factor receptor 2.14 2.52E-07 
93779_at 100039742 predicted gene, 100039742 2.14 4.66E-09 
103963_f_at Iigp1 interferon inducible GTPase 1 2.11 4.25E-08 




RIKEN cDNA C920025E04 gene /// 
histocompatibility 2, T region locus 23 2.10 5.07E-09 
101436_at Cxcl9 chemokine (C-X-C motif) ligand 9 2.10 7.08E-08 




similar to ubiquitin specific protease 
UBP43 /// ubiquitin specific peptidase 18 2.07 4.66E-09 
94425_at Ly86 lymphocyte antigen 86 2.07 8.59E-09 
92642_at Car2 carbonic anhydrase 2 2.06 1.55E-08 
92989_f_at Cadps Ca2+-dependent secretion activator 2.05 3.46E-07 
160150_f_at Cnn3 /// LOC100047856 
calponin 3, acidic /// similar to calponin 3, 
acidic 2.04 2.47E-08 
101429_at Ddit3 DNA-damage inducible transcript 3 2.02 3.21E-07 
95339_r_at Mmp12 matrix metallopeptidase 12 2.00 1.95E-08 
104464_s_at Kdelr3 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 2.00 1.08E-06 
160934_s_at Sgip1 
SH3-domain GRB2-like (endophilin) 
interacting protein 1 1.98 6.84E-08 
103029_at Pdcd4 programmed cell death 4 1.97 1.55E-08 
96766_s_at LOC100048488 /// Tyro3 
similar to Rse /// TYRO3 protein tyrosine 
kinase 3 1.96 1.59E-06 
160933_at Igtp interferon gamma induced GTPase 1.95 7.31E-08 
103517_at A530040E14Rik RIKEN cDNA A530040E14 gene 1.95 3.07E-08 
93497_at C3 complement component 3 1.95 3.15E-07 
94224_s_at 
100040462 /// Ifi203 /// 
Ifi204 /// Ifi205 /// 
LOC192690 /// 
LOC640890 /// Mnda 
predicted gene, 100040462 /// interferon 
activated gene 203 /// interferon activated 
gene 204 /// interferon activated gene 205 
/// similar to interferon activated gene 205 
/// similar to Interferon-activatable protein 
205 (IFI-205) (D3 protein) /// myeloid cell 
nuclear differentiation antigen 1.94 3.96E-08 
102330_at Aif1 allograft inflammatory factor 1 1.94 3.09E-08 
103446_at Ifih1 
interferon induced with helicase C domain 
1 1.93 2.42E-08 
104597_at Gbp2 guanylate binding protein 2 1.93 7.11E-09 
92786_at Efhd1 EF hand domain containing 1 1.91 1.36E-07 
103035_at Tap1 
transporter 1, ATP-binding cassette, sub-
family B (MDR/TAP) 1.90 1.34E-08 
93389_at Prom1 prominin 1 1.90 2.15E-06 
93268_at Glo1 glyoxalase 1 1.89 1.81E-07 
99378_f_at H2-gs10 MHC class I like protein GS10 1.87 8.36E-09 
102161_f_at 
EG630499 /// H2-D1 /// 
H2-K1 /// H2-L /// H2-
Q2 /// H2-T17 /// H2-T22 
/// H2-T23 /// H2-t9 /// 
LOC547349 /// 
LOC676708 
predicted gene, EG630499 /// 
histocompatibility 2, D region locus 1 /// 
histocompatibility 2, K1, K region /// 
histocompatibility 2, D region /// 
histocompatibility 2, Q region locus 2 /// 
histocompatibility 2, T region locus 17 /// 
histocompatibility 2, T region locus 22 /// 
histocompatibility 2, T region locus 23 /// 
MHC class Ib T9 /// similar to MHC class 
I antigen precursor /// similar to H-2 class 
I histocompatibility antigen, L-D alpha 
chain precursor 1.87 8.29E-09 
104750_at Ifi47 interferon gamma inducible protein 47 1.87 2.42E-08 
92988_i_at Cadps Ca2+-dependent secretion activator 1.87 4.83E-05 
99379_f_at LOC676689 
similar to H-2 class I histocompatibility 
antigen, L-D alpha chain precursor 1.86 5.31E-08 
97173_f_at LOC676708 
similar to H-2 class I histocompatibility 
antigen, L-D alpha chain precursor 1.86 2.60E-08 
93445_at Cd5l CD5 antigen-like 1.86 2.13E-08 
102208_at St3gal6 
ST3 beta-galactoside alpha-2,3-
sialyltransferase 6 1.86 5.02E-08 
93269_at Glo1 glyoxalase 1 1.85 4.37E-08 
103571_at Lst1 leukocyte specific transcript 1 1.85 7.38E-08 
103080_at Samhd1 SAM domain and HD domain, 1 1.85 1.24E-07 
97541_f_at 
H2-D1 /// H2-K1 /// 
LOC100044874 
histocompatibility 2, D region locus 1 /// 
histocompatibility 2, K1, K region /// 
similar to H-2K(d) antigen 1.84 1.55E-08 
96088_at Ndrg2 N-myc downstream regulated gene 2 1.83 8.01E-07 
94774_at Ifi202b interferon activated gene 202B 1.81 2.48E-07 
92644_s_at Myb myeloblastosis oncogene 1.81 3.69E-06 
94159_at Ptafr platelet-activating factor receptor 1.81 2.37E-07 
93898_at Sgcb 
sarcoglycan, beta (dystrophin-associated 
glycoprotein) 1.80 6.15E-08 
103202_at Gbp3 guanylate binding protein 3 1.79 6.33E-08 
94746_at H2-T24 histocompatibility 2, T region locus 24 1.78 3.93E-07 
97507_at Lgals3bp 
lectin, galactoside-binding, soluble, 3 
binding protein 1.77 1.55E-08 




RIKEN cDNA 2900062L11 gene /// 
RIKEN cDNA 6530401D17 gene 1.77 1.56E-05 
96055_at Cck cholecystokinin 1.77 7.07E-07 
98423_at Gjb2 gap junction protein, beta 2 1.77 2.10E-06 
96900_at Chchd10 
coiled-coil-helix-coiled-coil-helix domain 
containing 10 1.77 1.55E-06 
99956_at Kit kit oncogene 1.76 3.37E-08 
99607_at Skp1a S-phase kinase-associated protein 1A 1.75 2.20E-05 
160264_s_at Pcp4l1 Purkinje cell protein 4-like 1 1.74 1.37E-06 
92866_at H2-Aa 
histocompatibility 2, class II antigen A, 
alpha 1.72 3.02E-08 
103235_at Npy neuropeptide Y 1.71 3.70E-08 
103066_at Cmpk2 
cytidine monophosphate (UMP-CMP) 
kinase 2, mitochondrial 1.70 1.32E-06 
98465_f_at Ifi204 interferon activated gene 204 1.69 1.24E-07 
101510_at Psme1 
proteasome (prosome, macropain) 28 
subunit, alpha 1.69 5.80E-08 
97949_at Fgl2 fibrinogen-like protein 2 1.69 2.76E-05 
97125_f_at H2-K1 histocompatibility 2, K1, K region 1.69 8.23E-08 
93085_at Psmb9 
proteasome (prosome, macropain) subunit, 
beta type 9 (large multifunctional 
peptidase 2) 1.68 3.37E-08 
97772_at Plau plasminogen activator, urokinase 1.68 1.97E-04 
94085_at Srgn serglycin 1.68 1.31E-06 
161504_i_at Cisd1 CDGSH iron sulfur domain 1 1.68 2.36E-05 
93077_s_at 
LOC100045833 /// 
Ly6c1 /// Ly6c2 
similar to Lymphocyte antigen 6C 
precursor (Ly-6C) /// lymphocyte antigen 
6 complex, locus C1 /// lymphocyte 
antigen 6 complex, locus C2 1.68 5.90E-08 
100981_at Ifit1 
interferon-induced protein with 
tetratricopeptide repeats 1 1.68 7.86E-08 
101054_at Cd74 
CD74 antigen (invariant polypeptide of 
major histocompatibility complex, class II 
antigen-associated) 1.67 9.42E-07 
100154_at Tapbp TAP binding protein 1.67 6.33E-08 
95974_at Gbp1 guanylate binding protein 1 1.66 2.78E-07 
101424_at Nmi N-myc (and STAT) interactor 1.66 1.41E-07 
93871_at Il1rn interleukin 1 receptor antagonist 1.66 1.09E-06 
98801_at Klra2 
killer cell lectin-like receptor, subfamily 
A, member 2 1.66 6.66E-07 
102904_at H2-Ea 
histocompatibility 2, class II antigen E 
alpha 1.66 1.19E-06 
160108_at Nupr1 nuclear protein 1 1.66 1.60E-07 
102689_at Tapbp TAP binding protein 1.66 3.46E-07 
98438_f_at H2-Q7 histocompatibility 2, Q region locus 7 1.66 5.68E-07 
104696_at Ctse cathepsin E 1.65 3.29E-06 
103422_at Cd1d1 CD1d1 antigen 1.65 3.87E-05 
99816_at Hspa2 heat shock protein 2 1.64 7.09E-07 
103299_at Pld4 phospholipase D family, member 4 1.64 6.56E-08 
102237_at Cd28 CD28 antigen 1.64 6.86E-06 
96920_at Htra1 HtrA serine peptidase 1 1.63 1.98E-06 
93560_at Acyp1 
acylphosphatase 1, erythrocyte (common) 
type 1.63 1.24E-07 
99030_at Il7r interleukin 7 receptor 1.63 3.20E-07 
102104_f_at Ms4a6c membrane-spanning 4-domains, subfamily 1.63 2.28E-07 
A, member 6C 
97409_at Irgm1 
immunity-related GTPase family M 
member 1 1.63 1.36E-07 
102360_at Mthfr 5,10-methylenetetrahydrofolate reductase 1.63 9.13E-07 
103816_at F11r F11 receptor 1.63 3.29E-07 
96956_at Prdx5 peroxiredoxin 5 1.62 2.61E-06 
100127_at Crabp2 cellular retinoic acid binding protein II 1.62 3.09E-06 
100134_at Eng endoglin 1.62 2.49E-07 
92310_at Plk2 polo-like kinase 2 (Drosophila) 1.61 2.88E-05 
92472_f_at Slfn2 schlafen 2 1.61 3.74E-06 
92356_at Ptpn22 
protein tyrosine phosphatase, non-receptor 
type 22 (lymphoid) 1.61 2.50E-07 
101886_f_at H2-D1 histocompatibility 2, D region locus 1 1.60 1.60E-07 
160921_at Acss1 
acyl-CoA synthetase short-chain family 
member 1 1.59 2.17E-06 
104417_at Flt4 FMS-like tyrosine kinase 4 1.59 2.28E-04 
92459_at Ccl8 chemokine (C-C motif) ligand 8 1.59 6.23E-07 
97477_at Timm8b 
translocase of inner mitochondrial 
membrane 8 homolog b (yeast) 1.59 1.60E-06 
93909_f_at 
100043775 /// 
100043821 /// BC094435 
/// Ccrn4l /// LOC280487 
/// Sgip1 
predicted gene, 100043775 /// predicted 
gene, 100043821 /// cDNA sequence 
BC094435 /// CCR4 carbon catabolite 
repression 4-like (S. cerevisiae) /// pol 
polyprotein /// SH3-domain GRB2-like 
(endophilin) interacting protein 1 1.58 7.31E-07 
102279_at Ube1l ubiquitin-activating enzyme E1-like 1.58 3.46E-07 
97504_at Ccnd2 cyclin D2 1.58 2.04E-05 
92471_i_at Slfn2 schlafen 2 1.57 7.14E-07 
93908_f_at 
100043775 /// 
100043821 /// BC094435 
/// Ccrn4l /// LOC280487 
/// Sgip1 
predicted gene, 100043775 /// predicted 
gene, 100043821 /// cDNA sequence 
BC094435 /// CCR4 carbon catabolite 
repression 4-like (S. cerevisiae) /// pol 
polyprotein /// SH3-domain GRB2-like 
(endophilin) interacting protein 1 1.57 3.53E-06 
97297_at Pcp4l1 Purkinje cell protein 4-like 1 1.57 4.31E-05 
103043_at Mtcp1 mature T-cell proliferation 1 1.57 2.64E-06 
98410_at Irgm2 
immunity-related GTPase family M 
member 2 1.57 3.96E-07 
101486_at Psmb10 
proteasome (prosome, macropain) subunit, 
beta type 10 1.57 1.22E-07 
93893_f_at Klra3 
killer cell lectin-like receptor, subfamily 





predicted gene, EG545743 /// similar to 
Pdlim1 protein /// PDZ and LIM domain 1 
(elfin) 1.57 8.23E-07 
102873_at Tap2 
transporter 2, ATP-binding cassette, sub-
family B (MDR/TAP) 1.56 2.18E-06 
98758_at Alox15 arachidonate 15-lipoxygenase 1.56 4.54E-06 
101653_f_at H2-D4 histocompatibility 2, D region locus 4 1.56 1.10E-05 
96912_s_at Ctla2a /// Ctla2b 
cytotoxic T lymphocyte-associated protein 
2 alpha /// cytotoxic T lymphocyte- 1.55 6.74E-07 
associated protein 2 beta 
104155_f_at Atf3 activating transcription factor 3 1.55 3.56E-07 
97825_at Perp PERP, TP53 apoptosis effector 1.55 1.39E-05 
102831_s_at Cd86 CD86 antigen 1.55 5.03E-07 
98405_at Serpinb9 
serine (or cysteine) peptidase inhibitor, 
clade B, member 9 1.55 7.25E-07 
161173_f_at Ifi202b interferon activated gene 202B 1.54 8.01E-07 
160617_at Klf13 Kruppel-like factor 13 1.54 1.01E-06 
93894_f_at Klra3 
killer cell lectin-like receptor, subfamily 
A, member 3 1.53 9.08E-06 
94269_at Rabac1 Rab acceptor 1 (prenylated) 1.53 3.12E-07 
160774_at Entpd1 
ectonucleoside triphosphate 
diphosphohydrolase 1 1.53 9.74E-06 
100013_at Ifi35 interferon-induced protein 35 1.53 1.05E-06 
100998_at H2-Ab1 
histocompatibility 2, class II antigen A, 
beta 1 1.53 3.41E-07 
104063_at Tom1l1 target of myb1-like 1 (chicken) 1.53 1.04E-05 
95064_at Acaa2 
acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) 1.52 2.65E-07 
93324_at Zfp36l1 zinc finger protein 36, C3H type-like 1 1.52 1.07E-05 
98498_at Casp7 caspase 7 1.52 9.80E-07 
93838_at 2700038C09Rik RIKEN cDNA 2700038C09 gene 1.52 1.08E-06 
95019_at Gstt1 glutathione S-transferase, theta 1 1.52 2.28E-05 
97206_at Spint1 serine protease inhibitor, Kunitz type 1 1.52 1.59E-06 
102052_at Abhd5 abhydrolase domain containing 5 1.52 5.25E-06 
93321_at Ifi203 interferon activated gene 203 1.51 4.98E-07 
162172_f_at Nedd4 
neural precursor cell expressed, 
developmentally down-regulated 4 1.51 2.27E-06 
98108_at Crabp1 cellular retinoic acid binding protein I 1.51 2.12E-05 
160230_at Cox17 
cytochrome c oxidase, subunit XVII 
assembly protein homolog (yeast) 1.51 2.57E-06 
95662_at Amz2 archaelysin family metallopeptidase 2 1.51 5.68E-07 
101972_at Napsa napsin A aspartic peptidase 1.51 4.07E-07 
95796_g_at 100041294 /// Supt4h1 
predicted gene, 100041294 /// suppressor 
of Ty 4 homolog 1 (S. cerevisiae) 1.51 1.36E-06 
97336_at Ctsf cathepsin F 1.50 1.60E-06 
103025_at Mov10 Moloney leukemia virus 10 1.50 3.93E-07 
162198_f_at --- --- 1.50 3.62E-05 
104172_at Folr2 folate receptor 2 (fetal) 1.50 3.55E-07 
104713_at Prpf38a 
PRP38 pre-mRNA processing factor 38 
(yeast) domain containing A 1.50 6.92E-07 
103330_at Strbp 
spermatid perinuclear RNA binding 
protein 1.50 3.83E-05 
102791_at Psmb8 
proteasome (prosome, macropain) subunit, 
beta type 8 (large multifunctional 
peptidase 7) 1.49 5.47E-07 
93907_f_at 
100043775 /// 
100043821 /// BC094435 
predicted gene, 100043775 /// predicted 
gene, 100043821 /// cDNA sequence 1.49 8.87E-07 
/// Ccrn4l /// Cog6 /// 
Sgip1 
BC094435 /// CCR4 carbon catabolite 
repression 4-like (S. cerevisiae) /// 
component of oligomeric golgi complex 6 
/// SH3-domain GRB2-like (endophilin) 
interacting protein 1 
98478_at Ccng2 cyclin G2 1.49 1.40E-06 
101973_at Cited2 
Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 1.48 1.69E-06 
161666_f_at Gadd45b 
growth arrest and DNA-damage-inducible 
45 beta 1.48 5.52E-05 
161610_at --- --- 1.48 8.87E-07 
100564_at Ddt D-dopachrome tautomerase 1.48 7.52E-06 
93120_f_at H2-K1 histocompatibility 2, K1, K region 1.48 8.86E-07 
97181_f_at 
100043775 /// 
100043821 /// BC094435 
/// Ccrn4l /// Cog6 /// 
ENSMUSG00000075496 
/// Sgip1 
predicted gene, 100043775 /// predicted 
gene, 100043821 /// cDNA sequence 
BC094435 /// CCR4 carbon catabolite 
repression 4-like (S. cerevisiae) /// 
component of oligomeric golgi complex 6 
/// predicted gene, 
ENSMUSG00000075496 /// SH3-domain 
GRB2-like (endophilin) interacting 
protein 1 1.48 8.01E-07 
101846_r_at EG665317 predicted gene, EG665317 1.47 2.59E-05 
93714_f_at EG630499 predicted gene, EG630499 1.47 3.84E-07 
94643_at Pvr poliovirus receptor 1.47 1.25E-04 
101461_f_at Pja1 praja1, RING-H2 motif containing 1.47 2.24E-06 
101897_g_at Cd1d1 /// Cd1d2 CD1d1 antigen /// CD1d2 antigen 1.47 9.46E-06 
104412_at Gnai1 
guanine nucleotide binding protein (G 
protein), alpha inhibiting 1 1.47 2.13E-05 
93194_at Ly9 lymphocyte antigen 9 1.47 2.37E-06 
104158_at Snw1 SNW domain containing 1 1.47 6.54E-06 
97540_f_at H2-D1 histocompatibility 2, D region locus 1 1.47 2.96E-06 
96653_at Rnaset2a /// Rnaset2b ribonuclease T2A /// ribonuclease T2B 1.47 7.08E-06 
95607_at Stard3 START domain containing 3 1.47 6.55E-07 
100609_at Cfb complement factor B 1.46 2.36E-05 
100465_i_at Gm1673 gene model 1673, (NCBI) 1.46 4.48E-07 
96791_at Fam101b 
family with sequence similarity 101, 
member B 1.46 2.28E-05 
103875_at Ngrn neugrin, neurite outgrowth associated 1.46 3.05E-06 
98984_f_at Gpd2 
glycerol phosphate dehydrogenase 2, 
mitochondrial 1.46 8.01E-07 
160612_at Abcg1 
ATP-binding cassette, sub-family G 
(WHITE), member 1 1.46 3.95E-05 
160344_at Npc2 Niemann Pick type C2 1.46 1.64E-06 
99140_at Mrpl16 mitochondrial ribosomal protein L16 1.46 1.08E-06 
100629_at Gstm5 glutathione S-transferase, mu 5 1.46 1.27E-06 
98597_at Ube2l6 ubiquitin-conjugating enzyme E2L 6 1.46 1.49E-06 
100064_f_at Gja1 gap junction protein, alpha 1 1.46 1.23E-05 
95120_at Tspan13 tetraspanin 13 1.45 6.09E-05 
92384_at Xpa 
xeroderma pigmentosum, 
complementation group A 1.45 8.36E-06 
102859_at Reep1 receptor accessory protein 1 1.45 9.73E-07 
93697_at Cbx4 
chromobox homolog 4 (Drosophila Pc 
class) 1.45 3.45E-06 
97925_at Csnk1e casein kinase 1, epsilon 1.45 1.40E-06 
100880_at Gbp6 guanylate binding protein 6 1.45 6.24E-07 
99058_at Hmga2 high mobility group AT-hook 2 1.45 1.04E-05 
100407_at Gal galanin 1.45 1.34E-06 
96104_at Rnf145 ring finger protein 145 1.45 1.48E-05 
100571_at Laptm4b 
lysosomal-associated protein 
transmembrane 4B 1.45 1.60E-06 
100486_at Ezh1 enhancer of zeste homolog 1 (Drosophila) 1.44 2.19E-06 
99085_at Usp3 ubiquitin specific peptidase 3 1.44 5.99E-07 
97972_at Rnf103 ring finger protein 103 1.44 1.05E-06 
160253_at Ifitm3 
interferon induced transmembrane protein 
3 1.44 7.58E-07 
160666_at Actr6 
ARP6 actin-related protein 6 homolog 
(yeast) 1.44 1.49E-05 
92718_at Ifi27l2a 
interferon, alpha-inducible protein 27 like 
2A 1.44 1.59E-06 
102896_at Dok1 docking protein 1 1.44 1.51E-06 
101930_at Nfix nuclear factor I/X 1.44 7.03E-05 
95795_at 100041294 predicted gene, 100041294 1.44 1.01E-05 




LOC637605 /// Pyhin1 
cDNA sequence BC094916 /// 
hypothetical protein LOC100048304 /// 
similar to Gamma-interferon-inducible 
protein Ifi-16 (Interferon-inducible 
myeloid differentiation transcriptional 
activator) (IFI 16) /// pyrin and HIN 
domain family, member 1 1.43 2.18E-05 
96146_at Btg3 /// EG654432 
B-cell translocation gene 3 /// predicted 
gene, EG654432 1.43 8.44E-05 
94761_at Ccl7 chemokine (C-C motif) ligand 7 1.43 5.80E-05 
96670_at Gstk1 glutathione S-transferase kappa 1 1.43 1.52E-05 
98499_s_at Casp7 caspase 7 1.43 2.12E-06 
94952_at Igf2bp2 
insulin-like growth factor 2 mRNA 
binding protein 2 1.43 2.99E-05 
96899_at Ndufs3 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 3 1.43 6.54E-06 
97890_at Sgk1 serum/glucocorticoid regulated kinase 1 1.43 7.86E-07 
96894_at Tmed4 
transmembrane emp24 protein transport 
domain containing 4 1.42 5.45E-06 
103518_at Ctla2b 
cytotoxic T lymphocyte-associated protein 
2 beta 1.42 1.08E-06 
95675_at Map4k3 
mitogen-activated protein kinase kinase 
kinase kinase 3 1.42 1.19E-06 
160627_at Ddx52 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 52 1.42 4.33E-06 
93678_s_at Klrk1 killer cell lectin-like receptor subfamily K, 1.42 4.39E-06 
member 1 
160958_at 9430016H08Rik RIKEN cDNA 9430016H08 gene 1.42 5.73E-06 
95105_at Higd2a HIG1 domain family, member 2A 1.42 1.28E-06 
95477_at Tmem59 transmembrane protein 59 1.41 4.54E-05 
96747_at Rhou ras homolog gene family, member U 1.41 2.75E-04 
95518_at Fam134b 
family with sequence similarity 134, 
member B 1.41 8.20E-06 
94365_at Hint2 histidine triad nucleotide binding protein 2 1.41 3.05E-06 
102699_at Mx2 myxovirus (influenza virus) resistance 2 1.40 3.62E-05 
99579_at Atp1b3 
ATPase, Na+/K+ transporting, beta 3 
polypeptide 1.40 2.27E-06 
162262_f_at Gyg glycogenin 1.40 8.88E-05 
93312_at Ube2g1 
ubiquitin-conjugating enzyme E2G 1 
(UBC7 homolog, C. elegans) 1.40 1.12E-05 
104177_at Rsad2 
radical S-adenosyl methionine domain 
containing 2 1.40 3.41E-06 
93869_s_at 
Bcl2a1a /// Bcl2a1c /// 
Bcl2a1d 
B-cell leukemia/lymphoma 2 related 
protein A1a /// B-cell leukemia/lymphoma 
2 related protein A1c /// B-cell 
leukemia/lymphoma 2 related protein A1d 1.40 7.26E-06 
103508_at LOC100048247 /// Pcgf5 
similar to polycomb group ring finger 5 /// 
polycomb group ring finger 5 1.40 4.07E-05 
96711_at Znrd1 zinc ribbon domain containing, 1 1.40 3.84E-06 
101922_at Kdelr2 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 2 1.40 4.54E-05 
98937_at Tbrg1 
transforming growth factor beta regulated 
gene 1 1.40 1.04E-05 
99413_at Ccr1 chemokine (C-C motif) receptor 1 1.40 1.14E-05 
101525_at Ndufb10 
NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 10 1.39 2.03E-05 
102342_at Nsf N-ethylmaleimide sensitive fusion protein 1.39 1.79E-05 
93309_at Ddx3x 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 3, X-linked 1.39 4.73E-05 
102047_at LOC100045684 /// Nmt1 
similar to N-myristoyltransferase 1 /// N-
myristoyltransferase 1 1.39 7.57E-06 
94841_at Psma5 
proteasome (prosome, macropain) subunit, 
alpha type 5 1.39 3.16E-06 
98335_at Rfc1 replication factor C (activator 1) 1 1.39 1.20E-05 
94995_at Ggct gamma-glutamyl cyclotransferase 1.39 1.12E-05 
104343_f_at Pla2g12a phospholipase A2, group XIIA 1.38 3.92E-06 
96881_at Commd6 COMM domain containing 6 1.38 1.99E-06 
101933_at Rab10 RAB10, member RAS oncogene family 1.38 2.60E-05 
104680_at Ramp1 
receptor (calcitonin) activity modifying 
protein 1 1.38 5.73E-06 
95058_f_at Brp44 brain protein 44 1.38 1.80E-05 
102819_at Nap1l2 nucleosome assembly protein 1-like 2 1.38 1.10E-05 
94834_at Ctsh cathepsin H 1.38 2.72E-05 
97487_at Serpine2 
serine (or cysteine) peptidase inhibitor, 
clade E, member 2 1.38 5.37E-06 
160486_at Ccdc28b coiled coil domain containing 28B 1.38 1.10E-05 
92243_at Vprbp Vpr (HIV-1) binding protein 1.38 3.09E-05 
101475_at Bmi1 Bmi1 polycomb ring finger oncogene 1.37 4.69E-06 
101487_f_at Ly6e lymphocyte antigen 6 complex, locus E 1.37 5.84E-06 
94263_f_at Psmb7 
proteasome (prosome, macropain) subunit, 
beta type 7 1.37 7.00E-06 
98590_at Sdc4 syndecan 4 1.37 9.07E-06 
100398_at Kif3a kinesin family member 3A 1.37 4.59E-06 
93728_at Tsc22d1 TSC22 domain family, member 1 1.37 3.33E-05 
94339_at Slc46a1 solute carrier family 46, member 1 1.37 4.09E-05 
99086_g_at Usp3 ubiquitin specific peptidase 3 1.37 5.83E-06 
97211_at Armcx2 armadillo repeat containing, X-linked 2 1.37 2.29E-04 
98254_f_at 
100043775 /// 
100043821 /// BC094435 
/// Ccrn4l /// Cog6 /// 
ENSMUSG00000075496 
/// Sgip1 
predicted gene, 100043775 /// predicted 
gene, 100043821 /// cDNA sequence 
BC094435 /// CCR4 carbon catabolite 
repression 4-like (S. cerevisiae) /// 
component of oligomeric golgi complex 6 
/// predicted gene, 
ENSMUSG00000075496 /// SH3-domain 
GRB2-like (endophilin) interacting 
protein 1 1.37 8.93E-06 
96481_at Nhedc2 Na+/H+ exchanger domain containing 2 1.37 4.07E-05 
95448_at Psmc2 
proteasome (prosome, macropain) 26S 
subunit, ATPase 2 1.37 5.36E-05 
96771_at Erbb3 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (avian) 1.37 9.46E-05 
160589_at Ppig 
peptidyl-prolyl isomerase G (cyclophilin 
G) 1.37 1.40E-04 
92191_at Mettl5 methyltransferase like 5 1.36 3.85E-05 
93579_at Jagn1 jagunal homolog 1 (Drosophila) 1.36 1.51E-05 
103922_f_at Cyb5r1 cytochrome b5 reductase 1 1.36 3.67E-05 
96657_at Sat1 
spermidine/spermine N1-acetyl transferase 
1 1.36 3.46E-06 
99629_at Ei24 etoposide induced 2.4 mRNA 1.36 2.09E-05 
99327_at Klk8 kallikrein related-peptidase 8 1.36 3.47E-05 
161359_s_at Apoa1bp apolipoprotein A-I binding protein 1.36 5.51E-06 
102925_at Dusp9 dual specificity phosphatase 9 1.36 5.97E-05 
160237_at Ndufa6 
NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 6 (B14) 1.36 2.99E-05 
100030_at Upp1 uridine phosphorylase 1 1.36 2.67E-06 
101502_at Tgif1 TGFB-induced factor homeobox 1 1.36 3.14E-06 
101102_at Igbp1 
immunoglobulin (CD79A) binding protein 
1 1.36 2.77E-05 
99053_at Icam2 intercellular adhesion molecule 2 1.36 2.36E-05 
93522_at Rad9 RAD9 homolog (S. pombe) 1.36 2.51E-05 
100946_at Hspa1b heat shock protein 1B 1.36 1.31E-05 
100074_at Tmed9 
transmembrane emp24 protein transport 





predicted gene, 100043775 /// predicted 
gene, 100043821 /// RIKEN cDNA 
2700079J08 gene /// CCR4 carbon 1.36 2.30E-05 
Ccrn4l /// EG668525 /// 
ENSMUSG00000075496 
/// LOC674800 /// Sgip1 
catabolite repression 4-like (S. cerevisiae) 
/// predicted gene, EG668525 /// predicted 
gene, ENSMUSG00000075496 /// similar 
to IgE-binding protein /// SH3-domain 
GRB2-like (endophilin) interacting 
protein 1 
104301_at Fam128b 
family with sequence similarity 128, 
member B 1.36 1.39E-05 
103254_at Trafd1 
TRAF type zinc finger domain containing 
1 1.36 4.84E-06 
102860_at Serpina3g 
serine (or cysteine) peptidase inhibitor, 
clade A, member 3G 1.36 8.45E-06 
160621_at Mrps22 mitochondrial ribosomal protein S22 1.36 3.73E-05 
103218_at Slc10a3 
solute carrier family 10 (sodium/bile acid 
cotransporter family), member 3 1.35 1.46E-04 
96623_at Ugcg 
UDP-glucose ceramide 
glucosyltransferase 1.35 2.03E-05 
100592_at Ghitm 
growth hormone inducible transmembrane 
protein 1.35 4.56E-06 
99465_at Mecp2 methyl CpG binding protein 2 1.35 1.87E-04 
93261_at Lgmn legumain 1.35 5.98E-05 
97220_at Psmg1 
proteasome (prosome, macropain) 
assembly chaperone 1 1.35 1.01E-05 
98855_r_at A930001N09Rik RIKEN cDNA A930001N09 gene 1.35 3.31E-05 
98901_at Fcf1 /// LOC633406 
FCF1 small subunit (SSU) processome 
component homolog (S. cerevisiae) /// 
similar to Protein C14orf111 homolog 1.35 1.39E-05 
95586_at P2rx4 
purinergic receptor P2X, ligand-gated ion 
channel 4 1.35 7.57E-06 
96708_at Tmed3 
transmembrane emp24 domain containing 
3 1.35 1.41E-05 
161046_at Crlf1 cytokine receptor-like factor 1 1.35 7.96E-04 
160618_at Lgals8 lectin, galactose binding, soluble 8 1.35 2.36E-04 
92468_at Ankrd49 ankyrin repeat domain 49 1.35 1.83E-04 
100988_at Bcl2l11 BCL2-like 11 (apoptosis facilitator) 1.35 6.07E-06 
101585_at Pgrmc1 
progesterone receptor membrane 
component 1 1.34 2.19E-05 
102731_g_at H2-M3 histocompatibility 2, M region locus 3 1.34 1.11E-05 
95517_i_at BC004004 cDNA sequence BC004004 1.34 2.54E-05 
97869_at Etfdh 
electron transferring flavoprotein, 
dehydrogenase 1.34 1.40E-04 
96785_at Kank3 KN motif and ankyrin repeat domains 3 1.34 1.97E-04 
100957_at Ssbp1 single-stranded DNA binding protein 1 1.34 3.83E-05 
102255_at Osmr oncostatin M receptor 1.34 7.33E-04 
96688_at Tmem77 transmembrane protein 77 1.34 4.20E-06 
100878_at --- --- 1.34 7.76E-06 
93101_s_at Nedd4 
neural precursor cell expressed, 




similar to Nedd4 WW domain-binding 
protein 5 /// Nedd4 family interacting 
protein 1 1.34 4.07E-05 
160290_at Ide insulin degrading enzyme 1.34 3.80E-05 
97926_s_at Pparg 
peroxisome proliferator activated receptor 
gamma 1.34 1.53E-03 
104225_at Snx5 sorting nexin 5 1.34 8.38E-04 
102870_at 
Dynlt1 /// Dynlt1d /// 
Tmem181 
dynein light chain Tctex-type 1 /// dynein 
light chain Tctex-type 1D /// 
transmembrane protein 181 1.34 8.93E-06 
98030_at Trim30 tripartite motif-containing 30 1.34 1.61E-05 
103804_at Reck 
reversion-inducing-cysteine-rich protein 
with kazal motifs 1.34 3.09E-05 
104398_at Tspan33 tetraspanin 33 1.34 9.09E-04 
96125_at Daxx Fas death domain-associated protein 1.34 5.94E-06 
95146_at Tmem66 transmembrane protein 66 1.34 6.44E-06 
104509_at Ch25h cholesterol 25-hydroxylase 1.34 2.67E-05 
99015_at Pml promyelocytic leukemia 1.34 6.54E-06 
95442_at Tmem205 transmembrane protein 205 1.34 1.86E-05 
92282_at Rprd1b 
regulation of nuclear pre-mRNA domain 
containing 1B 1.34 3.78E-05 
160711_at Decr1 
2,4-dienoyl CoA reductase 1, 
mitochondrial 1.34 5.03E-04 
95103_at 2310065K24Rik RIKEN cDNA 2310065K24 gene 1.34 8.66E-06 
102754_at Birc6 baculoviral IAP repeat-containing 6 1.34 1.25E-05 
102798_at Adm adrenomedullin 1.33 2.21E-05 
102022_at Mcee methylmalonyl CoA epimerase 1.33 6.14E-05 
99532_at Tob1 transducer of ErbB-2.1 1.33 9.16E-06 
100979_at Rnf138 ring finger protein 138 1.33 2.73E-03 
94526_at Cisd1 CDGSH iron sulfur domain 1 1.33 3.57E-05 
95139_at Wipi2 
WD repeat domain, phosphoinositide 
interacting 2 1.33 2.90E-05 
104156_r_at Atf3 activating transcription factor 3 1.33 2.76E-05 
94469_at Mat2b methionine adenosyltransferase II, beta 1.33 7.54E-06 
103654_at Nsbp1 nucleosome binding protein 1 1.33 1.13E-04 




thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), beta subunit 1.33 4.79E-06 
104616_g_at Galt galactose-1-phosphate uridyl transferase 1.33 1.71E-04 
96341_at Syf2 
SYF2 homolog, RNA splicing factor (S. 
cerevisiae) 1.33 1.47E-05 
99994_at Cidea 
cell death-inducing DNA fragmentation 
factor, alpha subunit-like effector A 1.33 5.45E-05 
95531_at Amot angiomotin 1.33 2.62E-05 
101255_at Ubb ubiquitin B 1.33 4.87E-05 
96608_at Phyh phytanoyl-CoA hydroxylase 1.33 9.03E-06 
98124_at 0610011F06Rik RIKEN cDNA 0610011F06 gene 1.33 2.13E-05 
93988_at Psma7 
proteasome (prosome, macropain) subunit, 
alpha type 7 1.33 2.43E-04 
92222_f_at H2-Q1 histocompatibility 2, Q region locus 1 1.33 4.71E-04 
93815_at Chchd3 
coiled-coil-helix-coiled-coil-helix domain 
containing 3 1.33 2.97E-05 
103020_s_at Map3k1 
mitogen-activated protein kinase kinase 
kinase 1 1.33 6.47E-06 
103861_s_at Ubfd1 ubiquitin family domain containing 1 1.33 7.79E-06 
101507_at Scnm1 sodium channel modifier 1 1.33 2.98E-05 
104399_at Cstf2 
cleavage stimulation factor, 3' pre-RNA 
subunit 2 1.33 8.02E-06 
103344_at Dnajc1 
DnaJ (Hsp40) homolog, subfamily C, 
member 1 1.33 1.29E-04 
103222_at Eps8 /// LOC632638 
epidermal growth factor receptor pathway 
substrate 8 /// similar to Epidermal growth 
factor receptor kinase substrate 8 1.33 5.71E-04 
96743_at 1810035L17Rik RIKEN cDNA 1810035L17 gene 1.33 3.42E-05 
95460_at Cops5 
COP9 (constitutive photomorphogenic) 
homolog, subunit 5 (Arabidopsis thaliana) 1.33 1.16E-05 
97324_at 5133401N09Rik RIKEN cDNA 5133401N09 gene 1.33 2.68E-05 
160397_at Ik IK cytokine 1.33 6.04E-05 
102965_at Znfx1 zinc finger, NFX1-type containing 1 1.32 6.59E-05 
96035_at Bckdha 
branched chain ketoacid dehydrogenase 
E1, alpha polypeptide 1.32 3.50E-05 
99419_g_at Bcl2l11 BCL2-like 11 (apoptosis facilitator) 1.32 3.69E-05 
160905_s_at A030009H04Rik RIKEN cDNA A030009H04 gene 1.32 1.97E-05 
96020_at C1qb 
complement component 1, q 
subcomponent, beta polypeptide 1.32 1.78E-03 
103314_at Parp8 
poly (ADP-ribose) polymerase family, 
member 8 1.32 5.71E-04 
99188_at Use1 
unconventional SNARE in the ER 1 
homolog (S. cerevisiae) 1.32 1.42E-05 
160772_i_at Slu7 
SLU7 splicing factor homolog (S. 
cerevisiae) 1.32 2.99E-04 
93531_at Ndufa8 
NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 8 1.32 1.01E-05 
93042_at Tspo translocator protein 1.32 8.74E-06 
98067_at Cdkn1a 
cyclin-dependent kinase inhibitor 1A 
(P21) 1.32 1.58E-05 
95380_at Cd244 CD244 natural killer cell receptor 2B4 1.32 1.02E-03 
102914_s_at 
Bcl2a1a /// Bcl2a1b /// 
Bcl2a1c /// Bcl2a1d 
B-cell leukemia/lymphoma 2 related 
protein A1a /// B-cell leukemia/lymphoma 
2 related protein A1b /// B-cell 
leukemia/lymphoma 2 related protein A1c 
/// B-cell leukemia/lymphoma 2 related 
protein A1d 1.32 8.97E-05 
93088_at B2m beta-2 microglobulin 1.32 4.31E-05 
96649_at Txndc14 thioredoxin domain containing 14 1.32 5.79E-05 
92375_at Ascc1 
activating signal cointegrator 1 complex 
subunit 1 1.32 7.44E-05 
96921_at Ttc1 tetratricopeptide repeat domain 1 1.32 1.32E-05 
101883_s_at 
LOC630164 /// Xlr3a /// 
Xlr3b /// Xlr3c /// Xlr3d-
ps 
similar to X-LINKED LYMPHOCYTE-
REGULATED PROTEIN 3A (XLR 
RELATED PROTEIN A12) /// X-linked 
lymphocyte-regulated 3A /// X-linked 
lymphocyte-regulated 3B /// X-linked 1.32 3.02E-05 
lymphocyte-regulated 3C /// X-linked 
lymphocyte-regulated 3D, pseudogene 









predicted gene, 100043775 /// predicted 
gene, 100043821 /// RIKEN cDNA 
2610028J07 gene /// cDNA sequence 
BC094435 /// CCR4 carbon catabolite 
repression 4-like (S. cerevisiae) /// 
component of oligomeric golgi complex 6 
/// predicted gene, 
ENSMUSG00000075496 /// SH3-domain 
GRB2-like (endophilin) interacting 
protein 1 1.32 3.31E-05 
162399_f_at 
Atxn2 /// 
LOC100047323 ataxin 2 /// similar to ataxin 2 1.32 4.48E-04 
103501_at Pura purine rich element binding protein A 1.32 1.77E-05 
160383_at Cox7a2l 
cytochrome c oxidase subunit VIIa 
polypeptide 2-like 1.32 7.98E-05 
102370_at Hsd17b11 
hydroxysteroid (17-beta) dehydrogenase 
11 1.32 3.28E-04 
95416_at Usp15 ubiquitin specific peptidase 15 1.32 2.41E-05 
160966_at Zfp187 zinc finger protein 187 1.31 1.43E-04 
97318_at Dtd1 /// LOC100048650 
D-tyrosyl-tRNA deacylase 1 homolog (S. 
cerevisiae) /// similar to D-tyrosyl-tRNA 
deacylase 1 1.31 7.26E-05 
99577_at Kitl kit ligand 1.31 3.69E-04 
95490_at Kdelr1 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 1 1.31 1.53E-05 
92452_at Pik3ca 
phosphatidylinositol 3-kinase, catalytic, 
alpha polypeptide 1.31 6.96E-05 
94327_at Mrps18a mitochondrial ribosomal protein S18A 1.31 4.00E-05 
98849_at --- --- 1.31 3.74E-05 
160667_at Evl /// LOC100047333 
Ena-vasodilator stimulated 
phosphoprotein /// similar to Ena-VASP-
like 1.31 7.06E-05 
93672_at Eif2ak2 
eukaryotic translation initiation factor 2-
alpha kinase 2 1.31 1.20E-05 
94270_at Krt18 keratin 18 1.31 3.50E-05 
101971_at Rnf181 ring finger protein 181 1.31 1.00E-05 
100072_at Ciao1 
cytosolic iron-sulfur protein assembly 1 
homolog (S. cerevisiae) 1.31 2.22E-05 
102960_at Rag1ap1 
recombination activating gene 1 activating 
protein 1 1.31 3.91E-05 
104257_g_at Cytip cytohesin 1 interacting protein 1.31 1.32E-05 
101979_at Gadd45g 
growth arrest and DNA-damage-inducible 
45 gamma 1.31 3.47E-05 
99501_at Sec62 SEC62 homolog (S. cerevisiae) 1.31 2.90E-04 
104419_at Fndc3a fibronectin type III domain containing 3A 1.31 1.69E-04 
160240_at 1110003E01Rik RIKEN cDNA 1110003E01 gene 1.31 1.47E-05 
94929_at Ptpn1 
protein tyrosine phosphatase, non-receptor 
type 1 1.31 4.17E-05 
98113_at Psmb1 
proteasome (prosome, macropain) subunit, 
beta type 1 1.31 7.62E-06 
97496_f_at Prkcdbp protein kinase C, delta binding protein 1.31 2.26E-04 
103394_at Fxyd5 
FXYD domain-containing ion transport 
regulator 5 1.31 1.77E-05 
94275_at Urod uroporphyrinogen decarboxylase 1.31 1.05E-04 
95491_at Park7 
Parkinson disease (autosomal recessive, 
early onset) 7 1.30 3.05E-05 
103044_g_at Mtcp1 mature T-cell proliferation 1 1.30 1.23E-05 
97254_at Rbm8a RNA binding motif protein 8a 1.30 1.25E-05 
94025_at Psmb3 
proteasome (prosome, macropain) subunit, 
beta type 3 1.30 8.45E-06 
101019_at Ctsc cathepsin C 1.30 2.48E-05 
103596_at Dgka diacylglycerol kinase, alpha 1.30 8.33E-03 
94939_at Cd53 CD53 antigen 1.30 4.54E-05 
160361_at Trappc4 trafficking protein particle complex 4 1.30 5.17E-05 
101516_at Cd59a CD59a antigen 1.30 2.62E-05 
99667_at Cox6a2 
cytochrome c oxidase, subunit VI a, 
polypeptide 2 1.30 1.67E-04 
160705_at Cited1 
Cbp/p300-interacting transactivator with 
Glu/Asp-rich carboxy-terminal domain 1 1.30 1.03E-04 
102197_at Nucb2 nucleobindin 2 1.30 6.01E-04 
104116_at Stbd1 starch binding domain 1 1.30 1.39E-04 
99475_at Socs2 suppressor of cytokine signaling 2 1.30 1.60E-04 
92202_g_at Zbtb16 zinc finger and BTB domain containing 16 1.30 4.75E-04 
96298_f_at Dynll1 dynein light chain LC8-type 1 1.30 2.20E-04 
101484_at Nbr1 neighbor of Brca1 gene 1 1.30 2.76E-05 
95465_s_at Tmem37 transmembrane protein 37 1.30 4.56E-05 
104714_at Dock9 dedicator of cytokinesis 9 1.30 3.57E-05 




similar to long overlapping ORF; NH2 
terminus uncertain /// POU domain, class 
3, transcription factor 1 1.30 7.34E-05 
99624_at 9530068E07Rik RIKEN cDNA 9530068E07 gene 1.30 3.83E-05 
102009_at Cyfip2 cytoplasmic FMR1 interacting protein 2 1.29 1.32E-04 
99187_f_at Use1 
unconventional SNARE in the ER 1 
homolog (S. cerevisiae) 1.29 1.57E-05 
102678_at Trim21 tripartite motif-containing 21 1.29 8.23E-05 
95884_at TLR7 toll-like receptor 7 1.29 5.79E-05 
160345_at Mrpl34 mitochondrial ribosomal protein L34 1.29 1.80E-04 
98511_at Raly hnRNP-associated with lethal yellow 1.29 6.59E-04 
102292_at Gadd45a 
growth arrest and DNA-damage-inducible 
45 alpha 1.29 1.12E-04 
102318_at St8sia4 
ST8 alpha-N-acetyl-neuraminide alpha-
2,8-sialyltransferase 4 1.29 1.16E-04 
102710_at Apbb1ip 
amyloid beta (A4) precursor protein-
binding, family B, member 1 interacting 
protein 1.29 2.62E-05 
93219_at Acp1 acid phosphatase 1, soluble 1.29 3.54E-05 
95067_at Mrpl2 mitochondrial ribosomal protein L2 1.29 2.32E-05 
93538_at Ttrap 
TRAF and TNF receptor associated 
protein 1.29 3.22E-05 
102064_at Casp1 caspase 1 1.29 3.62E-05 
98980_at Cd37 CD37 antigen 1.29 1.44E-05 
98452_at Flt1 FMS-like tyrosine kinase 1 1.29 2.66E-04 
97551_at Hip1r huntingtin interacting protein 1 related 1.29 5.85E-05 
97460_at Ube2r2 ubiquitin-conjugating enzyme E2R 2 1.29 3.24E-05 
96629_at Nudt19 
nudix (nucleoside diphosphate linked 
moiety X)-type motif 19 1.28 7.08E-05 
104312_at Abhd14a abhydrolase domain containing 14A 1.28 4.74E-05 
104189_at Traf6 TNF receptor-associated factor 6 1.28 2.66E-05 
94982_f_at Nme3 
non-metastatic cells 3, protein expressed 
in 1.28 4.00E-05 
95480_at Vps25 vacuolar protein sorting 25 (yeast) 1.28 3.44E-05 
99160_s_at Grina 
glutamate receptor, ionotropic, N-methyl 
D-aspartate-associated protein 1 
(glutamate binding) 1.28 4.07E-05 
100931_at Arsa arylsulfatase A 1.28 1.83E-04 
93011_at Gabarapl1 
gamma-aminobutyric acid (GABA) A 
receptor-associated protein-like 1 1.28 5.74E-05 
98018_at Procr protein C receptor, endothelial 1.28 1.17E-04 
96774_at Fermt2 fermitin family homolog 2 (Drosophila) 1.28 1.77E-04 
94219_at Psmb2 
proteasome (prosome, macropain) subunit, 
beta type 2 1.28 4.07E-05 
92574_at Sdhd 
succinate dehydrogenase complex, subunit 
D, integral membrane protein 1.28 1.88E-04 
95590_at Alg5 
asparagine-linked glycosylation 5 
homolog (yeast, dolichyl-phosphate beta-
glucosyltransferase) 1.28 4.54E-05 
101481_at Rnf34 ring finger protein 34 1.28 4.39E-03 
160444_at Pigx 
phosphatidylinositol glycan anchor 
biosynthesis, class X 1.28 2.63E-04 
94241_at Coasy Coenzyme A synthase 1.28 7.81E-05 
97893_at Tbpl1 TATA box binding protein-like 1 1.28 4.88E-05 
95102_at Shisa5 shisa homolog 5 (Xenopus laevis) 1.28 2.13E-05 
104603_at Gstt2 glutathione S-transferase, theta 2 1.28 3.76E-05 
102421_at Lmf1 lipase maturation factor 1 1.28 2.98E-05 
100892_at Ndufaf1 
NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, assembly factor 1 1.28 1.39E-04 
95699_f_at Dnajc8 
DnaJ (Hsp40) homolog, subfamily C, 
member 8 1.28 4.99E-05 
161104_at Sep-10 septin 10 1.28 1.46E-03 
97933_at 2010111I01Rik RIKEN cDNA 2010111I01 gene 1.28 1.93E-05 
100405_at Cbx3 
chromobox homolog 3 (Drosophila HP1 
gamma) 1.28 1.11E-03 
95096_at LOC100046895 /// Qk similar to Quaking protein /// quaking 1.28 1.04E-04 
99586_at Cst3 cystatin C 1.28 3.62E-05 
95620_at Dhrs7 
dehydrogenase/reductase (SDR family) 
member 7 1.28 3.90E-05 
94453_at 1810046J19Rik RIKEN cDNA 1810046J19 gene 1.28 1.36E-04 
98936_at Sars seryl-aminoacyl-tRNA synthetase 1.28 3.54E-05 
103331_at C030006K11Rik RIKEN cDNA C030006K11 gene 1.28 1.04E-04 
100633_at Mosc2 
MOCO sulphurase C-terminal domain 
containing 2 1.28 1.77E-05 
104115_at Psme4 
proteasome (prosome, macropain) 
activator subunit 4 1.28 1.20E-04 
99147_at Znhit1 zinc finger, HIT domain containing 1 1.28 6.35E-05 
96728_at Wdr45 WD repeat domain 45 1.28 3.49E-05 
96822_at Eif2b5 
eukaryotic translation initiation factor 2B, 
subunit 5 epsilon 1.28 2.15E-05 
94438_at Pfkm phosphofructokinase, muscle 1.28 1.70E-04 




catenin (cadherin associated protein), delta 
2 /// similar to arm-repeat protein 
NPRAP/neurojungin 1.27 1.25E-04 
103231_at Rhoh ras homolog gene family, member H 1.27 2.12E-04 
101483_at Ccndbp1 cyclin D-type binding-protein 1 1.27 8.85E-05 
104188_at Notch2 Notch gene homolog 2 (Drosophila) 1.27 2.16E-03 
94530_at Eif2b2 
eukaryotic translation initiation factor 2B, 
subunit 2 beta 1.27 7.34E-05 
94843_at Pold4 polymerase (DNA-directed), delta 4 1.27 8.96E-05 
92206_at A430107D22Rik RIKEN cDNA A430107D22 gene 1.27 1.24E-04 
104328_at Aqp9 aquaporin 9 1.27 2.33E-04 
101976_at Cops4 
COP9 (constitutive photomorphogenic) 
homolog, subunit 4 (Arabidopsis thaliana) 1.27 2.41E-04 
160366_at BC031181 cDNA sequence BC031181 1.27 1.60E-04 
160305_at Psmd11 
proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 11 1.27 7.54E-05 
101298_g_at Ptprc 
protein tyrosine phosphatase, receptor 
type, C 1.27 2.20E-04 
102401_at Irf1 interferon regulatory factor 1 1.27 3.02E-05 
94078_at 1110020P15Rik RIKEN cDNA 1110020P15 gene 1.27 7.86E-05 
101045_at Hsd17b10 
hydroxysteroid (17-beta) dehydrogenase 
10 1.27 3.67E-05 
95730_at Mrps34 mitochondrial ribosomal protein S34 1.27 1.03E-04 
160668_at Ogfr opioid growth factor receptor 1.27 3.80E-05 
94924_at Prrg2 
proline-rich Gla (G-carboxyglutamic acid) 
polypeptide 2 1.27 1.01E-04 
101106_at G3bp2 
GTPase activating protein (SH3 domain) 
binding protein 2 1.27 5.38E-05 
96577_i_at Ubap2l ubiquitin associated protein 2-like 1.27 5.49E-05 
96658_at 2900010J23Rik RIKEN cDNA 2900010J23 gene 1.27 2.31E-04 
94860_at Timm17a 
translocase of inner mitochondrial 
membrane 17a 1.27 1.18E-04 
160320_at Sorbs1 sorbin and SH3 domain containing 1 1.27 1.60E-04 
103207_at Pola1 polymerase (DNA directed), alpha 1 1.27 8.11E-04 
160696_at Tia1 
cytotoxic granule-associated RNA binding 
protein 1 1.27 1.64E-04 
94032_at Apoa1bp apolipoprotein A-I binding protein 1.27 3.33E-05 
104250_at Lrrc8a leucine rich repeat containing 8A 1.27 1.23E-04 
103547_at Slc41a1 solute carrier family 41, member 1 1.27 4.44E-03 
160236_at Slain1 SLAIN motif family, member 1 1.27 3.30E-04 
98129_at Tmsb10 thymosin, beta 10 1.27 8.08E-05 
160138_at Mxi1 Max interacting protein 1 1.27 9.09E-04 
94505_at Peli1 pellino 1 1.27 6.76E-04 
97812_at Ranbp9 RAN binding protein 9 1.27 6.77E-03 
160176_at Nfu1 
NFU1 iron-sulfur cluster scaffold 
homolog (S. cerevisiae) 1.27 1.73E-04 
160271_at 0610007C21Rik RIKEN cDNA 0610007C21 gene 1.27 1.32E-04 
97918_at Rell1 RELT-like 1 1.27 1.03E-04 
96345_at Ergic3 ERGIC and golgi 3 1.27 9.72E-05 
95474_at F2r coagulation factor II (thrombin) receptor 1.27 4.75E-05 
98144_f_at Tspan31 tetraspanin 31 1.27 3.62E-04 
100608_at Sptlc1 
serine palmitoyltransferase, long chain 
base subunit 1 1.27 1.07E-04 
94488_at Vta1 
Vps20-associated 1 homolog (S. 
cerevisiae) 1.27 5.69E-05 
95049_at Snrpd2 small nuclear ribonucleoprotein D2 1.27 1.92E-04 
94396_at Ing1 inhibitor of growth family, member 1 1.26 2.79E-04 
101031_at Surf1 surfeit gene 1 1.26 4.83E-05 
94206_at Grcc10 gene rich cluster, C10 gene 1.26 6.53E-05 
100597_at Gyg glycogenin 1.26 4.17E-05 
93466_at Exoc4 exocyst complex component 4 1.26 3.96E-04 
92247_at Arhgap5 Rho GTPase activating protein 5 1.26 2.66E-04 
99194_at Pnpt1 
polyribonucleotide nucleotidyltransferase 
1 1.26 4.75E-05 
93994_at Chpt1 choline phosphotransferase 1 1.26 9.40E-04 
93039_at Pgcp plasma glutamate carboxypeptidase 1.26 8.39E-05 
98143_at Fut8 fucosyltransferase 8 1.26 6.31E-05 
104627_at Cds2 
CDP-diacylglycerol synthase 
(phosphatidate cytidylyltransferase) 2 1.26 2.68E-05 
102848_f_at 2610524H06Rik RIKEN cDNA 2610524H06 gene 1.26 1.04E-04 
96188_at Adar adenosine deaminase, RNA-specific 1.26 1.12E-04 
95110_at Ppil2 
peptidylprolyl isomerase (cyclophilin)-like 
2 1.26 8.18E-05 
98904_at Mrpl35 mitochondrial ribosomal protein L35 1.26 1.08E-04 
93949_at Gnb4 
guanine nucleotide binding protein (G 
protein), beta 4 1.26 2.19E-04 
101990_at Ldhb lactate dehydrogenase B 1.26 1.54E-04 
161060_i_at Ddx51 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 51 1.26 5.52E-03 
99935_at Tjp1 tight junction protein 1 1.26 5.15E-04 
103038_at Guca1a guanylate cyclase activator 1a (retina) 1.26 6.58E-05 
96300_f_at Rps27 ribosomal protein S27 1.26 4.56E-05 
161629_i_at Afp alpha fetoprotein 1.26 7.92E-03 
95282_at Hsp90aa1 heat shock protein 90, alpha (cytosolic), 1.26 7.37E-05 
class A member 1 
98514_at Tfpi tissue factor pathway inhibitor 1.26 8.10E-05 
95709_at Vkorc1 
vitamin K epoxide reductase complex, 
subunit 1 1.26 5.02E-05 
101064_at Plrg1 
pleiotropic regulator 1, PRL1 homolog 
(Arabidopsis) 1.26 1.03E-04 
94366_at 2310079N02Rik RIKEN cDNA 2310079N02 gene 1.26 1.37E-04 
93614_at Rragd Ras-related GTP binding D 1.26 3.67E-04 
104709_at Sec23a SEC23A (S. cerevisiae) 1.26 8.93E-05 
97195_at Gnai1 
guanine nucleotide binding protein (G 
protein), alpha inhibiting 1 1.26 4.83E-03 
98120_at Mrpl27 mitochondrial ribosomal protein L27 1.26 6.74E-05 
93735_f_at Psmc3 
proteasome (prosome, macropain) 26S 
subunit, ATPase 3 1.26 1.37E-04 
97380_at Zc3h14 zinc finger CCCH type containing 14 1.26 9.68E-05 
95046_s_at Eif2b4 
eukaryotic translation initiation factor 2B, 
subunit 4 delta 1.25 3.27E-04 
98544_at Guk1 guanylate kinase 1 1.25 7.79E-05 
98398_s_at Apobec1 
apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1 1.25 5.35E-05 
94073_at Polr2g 
polymerase (RNA) II (DNA directed) 
polypeptide G 1.25 9.65E-05 
103371_at Slc39a7 
solute carrier family 39 (zinc transporter), 
member 7 1.25 5.79E-05 
97292_at 2810407C02Rik RIKEN cDNA 2810407C02 gene 1.25 9.23E-05 
100450_r_at Acvrl1 activin A receptor, type II-like 1 1.25 8.54E-05 
93711_at Sec23a SEC23A (S. cerevisiae) 1.25 5.77E-04 
103762_at Gtf2f1 
general transcription factor IIF, 
polypeptide 1 1.25 1.81E-04 
94302_at Psmd4 
proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 4 1.25 6.35E-05 
100733_at Psma2 
proteasome (prosome, macropain) subunit, 
alpha type 2 1.25 1.80E-04 
102910_at Abcb1a 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1A 1.25 1.23E-03 
100772_g_at Blnk B-cell linker 1.25 3.85E-05 
93252_at Bcap31 B-cell receptor-associated protein 31 1.25 4.91E-05 
92958_at Foxo3 forkhead box O3 1.25 5.24E-05 
98026_g_at Evi2a ecotropic viral integration site 2a 1.25 1.36E-04 
100600_at Cd24a CD24a antigen 1.25 1.16E-03 
99623_s_at Olfm1 olfactomedin 1 1.25 3.93E-05 
94428_at Ilvbl ilvB (bacterial acetolactate synthase)-like 1.25 4.92E-05 
102056_f_at 2610002J02Rik RIKEN cDNA 2610002J02 gene 1.25 7.73E-04 
99544_at Dguok deoxyguanosine kinase 1.25 7.57E-04 
96076_at Stx5a syntaxin 5A 1.25 3.20E-05 
160149_at Rab10 RAB10, member RAS oncogene family 1.25 2.06E-04 
96773_at Erp44 endoplasmic reticulum protein 44 1.25 4.62E-04 
160455_s_at Zwint ZW10 interactor 1.25 1.33E-04 
160704_at 1110067D22Rik RIKEN cDNA 1110067D22 gene 1.25 4.65E-03 
103946_at Pstpip1 
proline-serine-threonine phosphatase-
interacting protein 1 1.25 2.13E-04 















Appendix 3: Micro array experiment and analysis 
Temporal gene expression analysis of BMDMs 
Experiment 
Briefly, BMDMs were either mock treated or infected with mCMV at a multiplicity of infection 
(MOI) of 1 or treated with 10 U IFNγ (Boelinger Manhaim Corp). Every 30 min for each 
treatment, cells were lysed with Trizol and stored at -80ºC (a full description of the experiment 
will be discussed elsewhere). 
RNA was extracted from each sample using Trizol RNA extraction protocol.  Mock samples 
were pooled and labeled with Cy3 while the lyzed or IFNγ treated samples were labeled with 
Cy5 using a modification of the Agilent Fluorescent protocol, using half of the standard Cy3/Cy5 
labeled dUTP concentration. The Cy3 labeled pooled control was hybridized with each of the 75 
Cy5 labeled samples according to the Agilent Low RNA Input protocol. The dual hybridizations 
were carried out on Mouse Agilent V2 array (G4121A, 20868 annotated probes), and were 
scanned on an Agilent Technologies scanner. Agilent feature extraction software (V.A7.5.1) was 
used to extract numeric data for further analysis. 
Processing microarray data 
Data of each sample was first background corrected, and then transformed to log (base 2) scale. 
Any non-positive values in the background corrected data were replaced with unity before 
performing the log-transformation. Exploratory plots do not suggest any intensity dependent 
non-linear trend in the data. Therefore subset median normalization based on 42 positive controls 
needed to be used to remove any chip-to-chip variation within the data. More specifically, 
suppose (m1, m2,..., m50) represent the medians of the positive controls for the 50 arrays, and m0 is 
their mean. Then the normalizing constants for the 50 samples are defined as (m0-m1, m0-m2 ..., 
m0-m50) . The data of each sample are adjusted by adding these constants to the log (base 2) 
intensity data of the respective samples. 
The normalised data was filtered using ROC analysis based on 42 positive and 111 negative 
controls. For each array, a threshold value was calculated corresponding to the 80% sensitivity 
level of the corresponding ROC curve. A gene is declared on in a particular sample (time point) 
if its log2 expression value exceeds that threshold. Genes are then selected for further analysis if 
they were found to be on in 5 or more consecutive time points in a particular experimental 
condition.  These genes were also selected for inclusion in Tabs. S4 and S5. 
Statistical analysis of time course 
The method below36 provides statistical test for identifying within condition temporal 
differential expression as well as test for identifying differential expression between conditions. 
The framework of the model is defined as 
                                                     yij = µi (tj) + εij                                                            (1) 
with yij  being the log (base 2) expression level of gene  i in sample j and the sample j is observed 
at time point  tj , where there are i = 1,2,...,M  genes on each array and J =1,2,...,N  time 
points/samples for each experimental conditions. The population average time curve is 
represented by a linear regression of a p-dimensional basis: 
                       µi (t) = αi + βi
T S(t) = αi + βi1S1 (t) + βi2S2 (t) + ... + βipSp(t)          (2) 
where αi is the gene-specific intercept term, βi = βi1, βi2,..., βip)
T  is a p-dimensional vector of 
regression parameters, and S(t) = S1 (t), S2(t), ..., Sp(t))
T  is a known p-dimensional basis.  
A polynomial of degree p or more flexible natural cubic splines has been suggested as a choice 
of basis. For identifying temporal differential expression, the null hypothesis, restricting µi (t) to 
be constant, can be tested against the alternative hypothesis that µi (t) is a curve. Thus, 
mathematically, the hypothesis of no temporal differential expression for gene i can be stated as 
                        H0: βi = 0, or equivalently, H0: µi = αi                                         . 
The observed statistics and null statistics were used to estimate a q-value for each gene, which 
estimate the false discovery rate for calling the gene significant. In order to select very highly 
significant temporal changes, we considered a q-value cutoff of 10-6. 
Cholesterol gene expression profiling of SFV HSV1 VV and AD infected macrophages 
Experiment: 
The avirulent Semliki Forest virus strain A774 (SFV A7), HSV1 (strain), Vaccinia virus and 
Adenovirus 2  were used to infect BMDMs and were kindly donated by Dr Hesper of the DPM. 
RNA was isolated from cultured macrophages using the TRIzol method according to the 
manufacturer’s instructions (Invitrogen, San Diego, CA, USA). RNA concentration and purity 
were obtained by spectrophotometry and RNA integrity monitored using the Agilent 2100 
bioanalyzer system (Agilent, Palo Alto, CA, USA).  Five micrograms of total RNA isolated from 
macrophage cultures were used to synthesise biotinylated cRNA target which was hybridised to 
the Mouse Genome 430 2.0 GeneChip (Affymetrix, Santa Clara, CA, USA). RNA was reverse 
transcribed using Superscript II reverse transcriptase (Invitrogen) into double stranded cDNA 
using oligo dT primers that contained a T7 promoter. cDNA was extracted with phenol-
chloroform and a Phase Lock Gel (Eppendorf, Hamburg, Germany) and precipitated with ethanol 
and ammonium acetate. Biotinylated cRNA was synthesised using the cDNA as a template in an 
in vitro transcription reaction using the BioArray HighYield RNA Transcript Labelling Kit 
(Enzo Life Sciences Inc., Farmingdale, NY, USA) as described by the manufacturer. The 
resulting biotinylated target cRNA was purified using RNeasy columns according to the 
manufacturers instructions (QIAgen Ltd., Crawley, UK) and quantified by spectrophotometry. 
15µg of purified biotinylated cRNA was fragmented by heating for 35 mins at 94oC in the 
presence of magnesium ions, spiked with eukaryotic hybridisation control and hybridised to 
Mouse Genome 430 2.0 microarrays overnight at 45oC. After hybridisation the array was 
washed, stained with phycoerythrin coupled streptavidin and processed on the Affymetrix 
GeneChip Fluidics Workstation 400 using the EukGE-Ws2v4 protocol. Microarrays were then 
scanned using the Agilent 2500A GeneArray Scanner (Agilent).  
Data processing and statistical analysis: 
Data from hybridised chips were acquired using proprietary Affymetrix platform scanners and 
GCOS software (Affymetrix). The numeric data were processed and subsequently analysed with 
the Bioconductor package for the R statistical programming environment. Raw data distributions 
and summary statistics were assessed for quality. Data were then background corrected, quantile 
normalised and probe-set summarised using the RMA algorithm. Prior to statistical analysis, a 
non-specific filter was applied to remove genes that were not expressed on any of the samples in 
the experiment. Null hypotheses for each gene were based on the comparison between mock 
arrays and each of the 3 biological conditions; they were tested using an empirical Bayes test, 
providing good robustness for small sample sizes. In order to adjust for multiple testing issues, 
the false discovery rate was controlled using the Benjamini-Hochberg p-value adjustment 
method. Genes were interpreted on the basis of differential expression between mock and each of 
the 3 groups, and the corresponding statistical significance. Visualisation of data was performed 














































ID Unigene ID David ID AffyID AgilentID Lipid Category  Full name 
LMP000004 
St6galnac
1  Q9QZ39  MM.383719   11828  #N/A  A_51_P504028  Sphingolipids (SP) 
ST6 (ALPHA‐N‐ACETYL‐NEURAMINYL‐2,3‐BETA‐
GALACTOSYL‐1,3)‐N‐ACETYLGALACT... 
LMP000007  St3gal5  O88829  MM.38248   39223  #N/A  A_51_P483473  Sphingolipids (SP) 
ST3 BETA‐GALACTOSIDE ALPHA‐2,3‐
SIALYLTRANSFERASE 5 
LMP000008  Skip  Q8C5L6  MM.1458   9636  #N/A  #N/A  Glycerophospholipids (GP)  PUTATIVE PHOSPHATASE 
LMP000009  Dgke  Q9R1C6  MM.153695   10953  #N/A  A_51_P410744 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  DIACYLGLYCEROL KINASE, EPSILON 
LMP000012  Pik4cb  Q8BKC8  MM.386837   149041  #N/A  A_51_P202320  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 4‐KINASE, CATALYTIC, 
BETA POLYPEPTIDE 





LMP000018  Lipa  Q9Z0M5  MM.157545   145282  #N/A  A_51_P459661  Sterol Lipids (ST)  LYSOSOMAL ACID LIPASE 1 
LMP000024  Flot1  O08917  MM.2931   117626  95095_at  A_51_P423088  Not classified  FLOTILLIN 1 
LMP000025  Tbxa2r  P30987  MM.4545   144071  92685_at  A_51_P473086  Fatty acids/Eicosanoids (FA)  THROMBOXANE A2 RECEPTOR 
LMP000026  Slc27a2  O35488  MM.290044   27168  100967_at  A_51_P484551  Fatty acids/Eicosanoids (FA) 
SOLUTE CARRIER FAMILY 27 (FATTY ACID 
TRANSPORTER), MEMBER 2 
LMP000043  Pik3r1  Q99LY6  MM.259333   37643  96592_at  #N/A  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 1 (P85 ... 
LMP000044  Anxa11  P97384  MM.294083   145144  102815_at  A_51_P280597  Glycerophospholipids (GP)  ANNEXIN A11 
LMP000049  Hsd17b7  Q8C5N9  MM.12882   4622  94177_at  A_51_P250934  Sterol Lipids (ST)  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 7 
LMP000057  Hsd17b1  P51656  MM.188939   4220  #N/A  A_51_P243435  Sterol Lipids (ST)  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 1 
LMP000059  Osbpl8  Q69ZJ4  MM.220204   144350  #N/A  A_51_P286551  Sterol Lipids (ST)  OXYSTEROL BINDING PROTEIN‐LIKE 8 
LMP000061  Hsd17b2  P51658  MM.276466   144377  101891_at  A_51_P441914  Sterol Lipids (ST)  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 2 





LMP000066  Ltb4r  O88855  MM.20853   11092  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  LEUKOTRIENE B4 RECEPTOR 1 
LMP000067  Osbp2  Q6PE09  MM.61022   10914  #N/A  A_51_P348636  Sterol Lipids (ST)  OXYSTEROL BINDING PROTEIN 2 
LMP000070  Mcat  Q8R3F5  MM.37560   6647  #N/A  A_51_P314852  Fatty acids/Eicosanoids (FA)  CDNA SEQUENCE BC025519 
LMP000074  Hsd17b4  P51660  MM.277857   3265  97515_at  A_51_P445662 
Sterol Lipids (ST) / Fatty 
acids/Eicosanoids (FA)  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 4 
LMP000076  Hsd11b2  P51661  MM.5079   149447 
100493_at;16
1517_at  A_51_P410205  Sterol Lipids (ST)  HYDROXYSTEROID 11‐BETA DEHYDROGENASE 2 
LMP000079  Pla2g4c  Q64GA5  MM.223639   3309  #N/A  #N/A  Not classified 
PHOSPHOLIPASE A2, GROUP IVC (CYTOSOLIC, 
CALCIUM‐INDEPENDENT) 
LMP000084  Lip1  Q6PDR1  MM.157545   145282  102123_at  #N/A  Sterol Lipids (ST)  LYSOSOMAL ACID LIPASE 1 










LMP000087  Pclo  Q9QYX7  MM.332218   144565  97753_at  A_51_P436669  Not classified  PICCOLO (PRESYNAPTIC CYTOMATRIX PROTEIN) 
LMP000089  Pbp2  Q8VIN1  MM.293018   37032  #N/A  A_51_P324450  Not classified 
PHOSPHATIDYLETHANOLAMINE BINDING 
PROTEIN 2 





LMP000093  Soat1  Q61263  MM.28099   149465 
160767_at,95
887_at  A_51_P391754  Sterol Lipids (ST)  STEROL O‐ACYLTRANSFERASE 1 
LMP000096  Pla2g2f  Q8CE14  MM.331989   37041  #N/A  A_51_P118255 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP IIF 
LMP000097  Apoc4  Q61268  MM.344270   13194  101463_at  A_51_P460332  Not classified  APOLIPOPROTEIN C‐IV 
LMP000099  Anxa9  Q9JHQ0  MM.218844   38836  #N/A  A_51_P451482  Not classified  ANNEXIN A9 
LMP000101  Cyp11a1  Q9QZ82  MM.302865   4084  #N/A  A_51_P309731  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 11, SUBFAMILY A, 
POLYPEPTIDE 1 






LMP000115  Alox12e  P55249  MM.274093   144032 
102269_at;16
1947_f_at  A_51_P471659  Fatty acids/Eicosanoids (FA)  ARACHIDONATE LIPOXYGENASE, EPIDERMAL 
LMP000116  Nr5a2  P45448  MM.16794   37660  102932_at  A_51_P514449  Sterol Lipids (ST) 
NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, 
MEMBER 2 
LMP000118  Cpt1a  P97742  MM.18522   37793 
161248_r_at;
93320_at  A_51_P427674  Fatty acids/Eicosanoids (FA)  CARNITINE PALMITOYLTRANSFERASE 1A, LIVER 





LMP000121  Elovl2  Q9JLJ4  MM.2567   27222  94393_r_at  A_51_P292582  Fatty acids/Eicosanoids (FA) 
ELONGATION OF VERY LONG CHAIN FATTY ACIDS 
(FEN1/ELO2, SUR4/ELO3, YEAST... 
LMP000122  Fads2  Q9Z0R9  MM.38901   12871  #N/A  A_51_P364609  Fatty acids/Eicosanoids (FA)  FATTY ACID DESATURASE 2 
LMP000127  Sphk1  O88885  MM.20944   11179  103839_at  A_51_P501248  Sphingolipids (SP)  SPHINGOSINE KINASE 1 
LMP000128  Sphk1  O88886  MM.20944   11179  103839_at  A_51_P501248  Sphingolipids (SP)  SPHINGOSINE KINASE 1 
LMP000131  Slco2a1  Q9CQU9  MM.207106   38158  #N/A  A_51_P315931  Fatty acids/Eicosanoids (FA) 
SOLUTE CARRIER ORGANIC ANION 
TRANSPORTER FAMILY, MEMBER 2A1 
LMP000135  Aldh8a1  Q8BH00  MM.90181   16565  #N/A  A_51_P509384  Not classified 
ALDEHYDE DEHYDROGENASE 8 FAMILY, 
MEMBER A1 





LMP000139  Apoa2  P09813  MM.288374   144830 
161924_f_at;
99648_at  A_51_P128973  Sterol Lipids (ST)  APOLIPOPROTEIN A‐II 
LMP000141  Hexa  P29416  MM.2284   27886 
162488_at;94
840_at  A_51_P282663  Sphingolipids (SP)  HEXOSAMINIDASE A 
LMP000142  Bpnt1  Q9Z0S1  MM.227549   36023  103336_r_at  A_51_P512503  Glycerophospholipids (GP)  BISPHOSPHATE 3'‐NUCLEOTIDASE 1 
LMP000144  Apoc1  P34928  MM.182440   7402  93354_at  A_51_P164504  Not classified  APOLIPOPROTEIN C‐I 
LMP000155  Ednra  Q61614  MM.283168   15439  #N/A  A_51_P457734  Not classified  ENDOTHELIN RECEPTOR TYPE A 
LMP000160  Pctp  P53808  MM.5062   9516  101173_at  A_51_P113477  Not classified  PHOSPHATIDYLCHOLINE TRANSFER PROTEIN 





LMP000164  Cyp2j5  O54749  MM.12838   16763  92814_at  A_51_P307872  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY J, 
POLYPEPTIDE 5 
LMP000169  Hexb  P20060  MM.27816   14150  97232_at  A_51_P453111  Sphingolipids (SP)  HEXOSAMINIDASE B 
LMP000177  Hlcs  Q920N2  MM.30921   9998  #N/A  A_51_P176912  Fatty acids/Eicosanoids (FA) 
HOLOCARBOXYLASE SYNTHETASE (BIOTIN‐ 
[PROPRIONY‐COENZYME A‐CARBOXYLASE ... 
LMP000180  Pitpna  P53810  NA     149711  #N/A  A_51_P466371  Not classified 
PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, 
ALPHA  
LMP000181  Rxra  P28700  MM.24624   145920 
92234_at,922
35_g_at  A_51_P307370  Sterol Lipids (ST)  RETINOID X RECEPTOR ALPHA 
LMP000185  Cyp2j6  O54750  MM.98200   8098  92813_at  A_51_P506328  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY J, 
POLYPEPTIDE 6 
LMP000187  Rxrb  P28704  MM.1243   144990  102398_at  A_51_P314830  Sterol Lipids (ST)  RETINOID X RECEPTOR BETA 
LMP000188  Rxrg  P28705  MM.3475   149387  92237_at  A_51_P513311  Sterol Lipids (ST)  RETINOID X RECEPTOR GAMMA 
LMP000191  Lipc  P27656  MM.30056   150635  98962_at  A_51_P263993  Glycerophospholipids (GP)  LIPASE, HEPATIC 
LMP000195  Cept1  Q8BGS7  MM.14816   145071  #N/A  A_51_P313460  Not classified 
CHOLINE/ETHANOLAMINEPHOSPHOTRANSFERAS
E 1 





LMP000197  Osbp  Q52KH7  MM.291279   35712  #N/A  A_51_P393768  Sterol Lipids (ST)  OXYSTEROL BINDING PROTEIN 
LMP000200  ND2  Q9MD59  NA     10664  #N/A  #N/A  Not classified  NADH DEHYDROGENASE SUBUNIT 2  
LMP000202  Isyna1  Q9JHU9  MM.29357   13815  #N/A  #N/A  Not classified  MYO‐INOSITOL 1‐PHOSPHATE SYNTHASE A1 
LMP000203  Acsl4  Q8BW44  MM.143689   17019  #N/A  A_51_P268154  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE LONG‐CHAIN FAMILY 
MEMBER 4 
LMP000213  Slc10a3  P21129  MM.3979   38063  #N/A  A_51_P423041  Not classified  UBIQUITIN‐LIKE 4 
LMP000218  Pik3r3  Q64143  MM.253819   148193  #N/A  A_51_P222863  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3 KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 3 (P55) 
LMP000219  Rarg  P18911  MM.383991   5803  102419_at  A_51_P372853 
Prenol Lipids (PR) / Sterol 
Lipids (ST)  RETINOIC ACID RECEPTOR, GAMMA 








LMP000225  Msr1  P30204  MM.239291   149493 
94140_at;947
92_at  A_51_P404846  Not classified  MACROPHAGE SCAVENGER RECEPTOR 1 
LMP000226  Paqr7  Q80ZE4  MM.142343   145415  #N/A  A_51_P430973  Sterol Lipids (ST) 
PROGESTIN AND ADIPOQ RECEPTOR FAMILY 
MEMBER VII 
LMP000227  Paqr8  Q80ZE5  MM.40780   20294  #N/A  A_51_P422540  Sterol Lipids (ST) 
PROGESTIN AND ADIPOQ RECEPTOR FAMILY 
MEMBER VIII 




LMP000237  Pla2g7  Q8BKM3  MM.9277   17346  101923_at  A_51_P447835  Glycerophospholipids (GP) 
PHOSPHOLIPASE A2, GROUP VII (PLATELET‐
ACTIVATING FACTOR ACETYLHYDROLAS... 
LMP000239  Mecr  Q9DCS3  MM.192706   31172  #N/A  A_51_P386080  Fatty acids/Eicosanoids (FA) 
MITOCHONDRIAL TRANS‐2‐ENOYL‐COA 
REDUCTASE 
LMP000242  Acot5  Q6Q2Z6  MM.123934   27213  #N/A  A_51_P355996  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 5 









LMP000252  mt‐Nd4  Q9MD77  NA     27202  #N/A  #N/A  Not classified 
ACTIVATED SPLEEN CDNA, RIKEN FULL‐LENGTH 
ENRICHED LIBRARY, CLONE:F8302  





LMP000255  Cyp4f14  Q9EP75  MM.10976   19282  #N/A  A_51_P452768  Not classified 
CYTOCHROME P450, FAMILY 4, SUBFAMILY F, 
POLYPEPTIDE 14 
LMP000256  Agpat3  Q9D517  MM.141230   145440  160807_at  A_51_P425490  Not classified 
1‐ACYLGLYCEROL‐3‐PHOSPHATE O‐
ACYLTRANSFERASE 3 
LMP000265  Atp8b3  Q6UQ17  MM.52511   16782  #N/A  A_51_P371500  Not classified  ATPASE, CLASS I, TYPE 8B, MEMBER 3 
LMP000266  Akr1e1  Q9DCT1  MM.251908   8656  103068_at  A_51_P195316 
Glycerophospholipids (GP) / 
Sterol Lipids (ST)  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER E1 
LMP000269  Acot8  P58137  MM.277878   4064  #N/A  A_51_P454078  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 8 
LMP000270  Ggt1  Q60928  MM.4559   7923  100085_at  A_51_P468071  Fatty acids/Eicosanoids (FA)  GAMMA‐GLUTAMYLTRANSFERASE 1 
LMP000275  A4galt  Q67BJ4  MM.323805   144170  #N/A  #N/A  Sphingolipids (SP)  ALPHA 1,4‐GALACTOSYLTRANSFERASE 
LMP000276  mt‐Nd5  Q9MD82  NA     10662  #N/A  #N/A  Not classified  NADH DEHYDROGENASE SUBUNIT 5  
LMP000278  Nqo2  Q9JI75  MM.264036   11348  #N/A  A_51_P229536  Sterol Lipids (ST)  NAD(P)H DEHYDROGENASE, QUINONE 2 





LMP000288  Paqr5  Q9DCU0  MM.273267   37896  #N/A  A_51_P258768  Sterol Lipids (ST) 
PROGESTIN AND ADIPOQ RECEPTOR FAMILY 
MEMBER V 
LMP000291  Sphk1  Q8CI15  MM.20944   11179  103839_at  A_51_P501248  Sphingolipids (SP)  SPHINGOSINE KINASE 1 
LMP000292  Nr1h5  Q811W9  MM.331269   13241  #N/A  A_51_P226667  Not classified 
NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, 
MEMBER 5 
LMP000293  Pnliprp2  P17892  MM.212333   146794  160070_at  A_51_P314669  Glycerophospholipids (GP)  PANCREATIC LIPASE‐RELATED PROTEIN 2 
                 
LMP000295  Pla2g1b  Q9Z0Y2  MM.20190   22565  160120_i_at  A_51_P280893 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP IB, PANCREAS 
LMP000296  Nr1h3  Q9Z0Y9  MM.22690   144164  104381_at  A_51_P448778  Sterol Lipids (ST) 
NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, 
MEMBER 3 
LMP000300  Apoa1  Q00623  MM.26743   18836  96094_at  A_51_P408082  Sterol Lipids (ST)  APOLIPOPROTEIN A‐I 
LMP000309  Itpka  Q8R071  MM.65337   27434  #N/A  A_51_P273609  Glycerophospholipids (GP)  INOSITOL 1,4,5‐TRISPHOSPHATE 3‐KINASE A 
LMP000310  Nr1h5  Q811X0  MM.331269   13241  #N/A  A_51_P226667  Not classified 
NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, 
MEMBER 5 
LMP000312  Nr1h5  Q811X1  MM.331269   13241  #N/A  A_51_P226667  Not classified 
NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, 
MEMBER 5 
LMP000313  Nr1h5  Q811X2  MM.331269   13241  #N/A  A_51_P226667  Not classified 
NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, 
MEMBER 5 
LMP000314  Syt16  Q7TN83  MM.311393   148305  #N/A  A_51_P122866  Not classified  SYNAPTOTAGMIN XVI 
LMP000315  Cyp7a1  Q64505  MM.57029   17149  99404_at  A_51_P290981  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 7, SUBFAMILY A, 
POLYPEPTIDE 1 
LMP000317  Syt14  Q7TN84  MM.170401   147194  #N/A  A_51_P372565  Not classified  SYNAPTOTAGMIN XIV 
LMP000320  Dgat2  Q9DCV3  MM.180189   45478  #N/A  A_51_P396003  Glycerolipids (GL)  DIACYLGLYCEROL O‐ACYLTRANSFERASE 2 
LMP000321  Plcxd1  Q8CHS4  MM.297057   19242  #N/A  A_51_P322658  Not classified 
PHOSPHATIDYLINOSITOL‐SPECIFIC 
PHOSPHOLIPASE C, X DOMAIN CONTAINING 1 
LMP000328  Scp2  P32020  MM.379011   143786  93278_at  A_51_P444052  Sterol Lipids (ST)  STEROL CARRIER PROTEIN 2, LIVER 
LMP000330  Acot8  Q8BZR4  MM.277878   4064  #N/A  A_51_P454078  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 8 
LMP000331  Prkca  P20444  MM.222178   31943  102299_at  A_51_P118007 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  PROTEIN KINASE C, ALPHA 
LMP000332  Sgpp1  Q9JI99  MM.280199   147197  94501_at  A_51_P469992  Sphingolipids (SP)  SPHINGOSINE‐1‐PHOSPHATE PHOSPHATASE 1 
LMP000338  Gk  Q64516  MM.246682   144099  #N/A  #N/A  Glycerophospholipids (GP)  GLYCEROL KINASE 











LMP000343  Slc25a29  Q8BL03  MM.266264   145827  #N/A  A_51_P288479  Fatty acids/Eicosanoids (FA) 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL 
CARRIER, PALMITOYLCARNITINE TR... 
LMP000357  Egln2  Q91YE2  MM.29978   146982  96338_at  A_51_P385415  Not classified  EXPRESSED SEQUENCE C85656 
LMP000361  Impa1  Q80ZJ2  MM.183042   145170  101498_at  A_51_P242056  Glycerophospholipids (GP)  INOSITOL (MYO)‐1(OR 4)‐MONOPHOSPHATASE 1 





LMP000370  Pla2g7  Q60963  MM.9277   17346  101923_at  A_51_P447835  Glycerophospholipids (GP) 
PHOSPHOLIPASE A2, GROUP VII (PLATELET‐
ACTIVATING FACTOR ACETYLHYDROLAS... 
LMP000371  Hsd3b5  Q61694  MM.17910   12345  94795_at  A_51_P496162  Sterol Lipids (ST) 
HYDROXYSTEROID DEHYDROGENASE‐5, 
DELTA<5>‐3‐BETA 
LMP000373  Cyb5a  P56395  MM.31018   33638  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  RIKEN CDNA 0610009N12 GENE 
LMP000374  Liph  Q8CI45  MM.33192   16830  #N/A  A_51_P122660  Not classified  LIPASE, MEMBER H 
LMP000375  Echs1  Q8BH95  MM.24452   19848  95426_at  A_51_P409039  Fatty acids/Eicosanoids (FA) 
ENOYL COENZYME A HYDRATASE, SHORT CHAIN, 
1, MITOCHONDRIAL 
LMP000379  Fads3  Q6IQY1  MM.253875   144010  #N/A  A_51_P464029  Fatty acids/Eicosanoids (FA)  FATTY ACID DESATURASE 3 





LMP000390  Crabp1  P62965  MM.34797   27997  98108_at  A_51_P378978  Prenol Lipids (PR)  CELLULAR RETINOIC ACID BINDING PROTEIN I 




LMP000394  Cerk  Q52KP2  MM.222685   146813  101426_at  A_51_P146360 
Glycerolipids (GL) / 
Sphingolipids (SP)  CERAMIDE KINASE 





LMP000409  Inpp1  P49442  MM.917   147030 
161407_i_at;
93942_at  A_51_P361465  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE‐1‐PHOSPHATASE 
LMP000424  Mulk  Q9ESW4  MM.32840   146910  #N/A  #N/A  Sphingolipids (SP)  MULTIPLE SUBSTRATE LIPID KINASE 





t  A_51_P408569  Fatty acids/Eicosanoids (FA)  STEAROYL‐COENZYME A DESATURASE 1 
LMP000432  Fcer1a  P20489  MM.5266   14709  101209_at  A_51_P429770  Fatty acids/Eicosanoids (FA) 
FC RECEPTOR, IGE, HIGH AFFINITY I, ALPHA 
POLYPEPTIDE 
LMP000433  Crls1  Q80ZM8  MM.357342   37126  #N/A  A_51_P373187  Not classified  RIKEN CDNA 0610009I22 GENE 





LMP000437  Alox12l  P39654  MM.4584   9805  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  ARACHIDONATE 15‐LIPOXYGENASE 
LMP000439  Alox12  P39655  MM.12286   148931  102290_at  A_51_P520306  Fatty acids/Eicosanoids (FA)  ARACHIDONATE 12‐LIPOXYGENASE 
LMP000440  Adipoq  Q60994  MM.3969   147321  #N/A  A_51_P458451  Fatty acids/Eicosanoids (FA) 
ADIPONECTIN, C1Q AND COLLAGEN DOMAIN 
CONTAINING 
LMP000457  Sc4mol  Q9CRA4  MM.30119   22983  160388_at  A_51_P209372 
Fatty acids/Eicosanoids (FA) / 
Sterol Lipids (ST)  STEROL‐C4‐METHYL OXIDASE‐LIKE 
LMP000463  Pisd  Q8BSF4  MM.273765   6970  #N/A  A_51_P461947  Glycerophospholipids (GP)  PHOSPHATIDYLSERINE DECARBOXYLASE 
LMP000470  Zdhhc2  P59267  MM.34326   146241  #N/A  A_51_P117226  Fatty acids/Eicosanoids (FA)  ZINC FINGER, DHHC DOMAIN CONTAINING 2 
LMP000474  Plcb3  Q8CI86  MM.273204   148650  101358_at  A_51_P236042  Glycerophospholipids (GP)  PHOSPHOLIPASE C, BETA 3 
LMP000483  Rarb  P22605  MM.259318   20242  #N/A  A_51_P202440 
Prenol Lipids (PR) / Sterol 
Lipids (ST)  RETINOIC ACID RECEPTOR, BETA 
LMP000486  Ggta1  P23336  MM.281124   7347  102993_at  A_51_P349988  Glycerolipids (GL) 
GLYCOPROTEIN GALACTOSYLTRANSFERASE 
ALPHA 1, 3 
LMP000489  Acot7  Q91V12  MM.296191   3939  #N/A  A_51_P328652  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 7 
LMP000501  Calm4  Q9JM83  MM.21075   8375  93744_at  A_51_P460613  Glycerophospholipids (GP)  RIKEN CDNA 2310037J09 GENE 
LMP000503  Lep  P41160  MM.277072   22348 
98443_at;984
44_g_at  A_51_P225546  Sterol Lipids (ST)  LEPTIN 




LMP000511  Prkce  P16054  MM.24614   145670  94161_at 
A_51_P352782;A_
51_P436429  Glycerolipids (GL)  PROTEIN KINASE C, EPSILON 





LMP000523  Pla2g3  Q8BL71  MM.100476   43776  #N/A  A_51_P402868  Not classified  PHOSPHOLIPASE A2, GROUP III 
LMP000524  Cbr1  P48758  MM.26940   37417  96110_at  A_51_P262739  Fatty acids/Eicosanoids (FA)  CARBONYL REDUCTASE 1 
LMP000526  Ocrl  Q6NVF0  MM.210343   38837  #N/A  A_51_P159492  Not classified  OCULOCEREBRORENAL SYNDROME OF LOWE 
LMP000529  Auh  Q9JLZ3  MM.252034   9232  96650_at  A_51_P372472  Fatty acids/Eicosanoids (FA) 
AU RNA BINDING PROTEIN/ENOYL‐COENZYME A 
HYDRATASE 
LMP000538  Sphk2  Q9JIA7  MM.24222   26770  162381_f_at  A_51_P119302 
Glycerolipids (GL) / 
Sphingolipids (SP)  SPHINGOSINE KINASE 2 
LMP000544  Mlycd  Q99J39  MM.255499   45373  103622_at  A_51_P222283  Fatty acids/Eicosanoids (FA)  MALONYL‐COA DECARBOXYLASE 
LMP000549  Cav1  P49817  MM.28278   147850  #N/A  A_51_P107302 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  CAVEOLIN, CAVEOLAE PROTEIN 1 
LMP000554  Plcb1  Q9Z1B3  MM.378986   146620 
92465_at;924
66_at;92467_
g_at  A_51_P284665  Glycerophospholipids (GP)  PHOSPHOLIPASE C, BETA 1 
LMP000556  Plcd1  Q9Z1B4  MM.23963   16634  #N/A  A_51_P239766  Glycerophospholipids (GP)  PHOSPHOLIPASE C, DELTA 1 
LMP000558  Stat5a  P42230  MM.277403   15573  #N/A  A_51_P152765  Sterol Lipids (ST) 
SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION 5A 
LMP000559  Pnlip  Q9D950  MM.20407   17651  #N/A  A_51_P520552  Sterol Lipids (ST)  PANCREATIC LIPASE 





LMP000572  Rbp7  Q9EPC5  MM.46023   17791  #N/A  A_51_P508902  Prenol Lipids (PR)  RETINOL BINDING PROTEIN 7, CELLULAR 




LMP000577  Mogat2  Q80W94  MM.208030   13083  #N/A  A_51_P411345  Glycerolipids (GL)  MONOACYLGLYCEROL O‐ACYLTRANSFERASE 2 
LMP000583  Pdhx  Q8BKZ9  MM.315011   146520  #N/A  A_51_P149944  Not classified 
PYRUVATE DEHYDROGENASE COMPLEX, 
COMPONENT X 
LMP000591  St3gal5  Q9CZ65  MM.38248   39223  #N/A  A_51_P483473  Sphingolipids (SP) 
ST3 BETA‐GALACTOSIDE ALPHA‐2,3‐
SIALYLTRANSFERASE 5 
LMP000595  Prkab2  Q6PAM0  MM.31175   9154  #N/A  #N/A  Not classified 
PROTEIN KINASE, AMP‐ACTIVATED, BETA 2 NON‐
CATALYTIC SUBUNIT 
LMP000596  Pccb  Q99MN9  MM.335385   19392  160128_at  A_51_P418259  Fatty acids/Eicosanoids (FA) 
PROPIONYL COENZYME A CARBOXYLASE, BETA 
POLYPEPTIDE 
LMP000607  Mttp  O08601  MM.2941   144926  104448_at  A_51_P178887  Glycerolipids (GL)  MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN 
LMP000610  Cbr2  P08074  MM.21454   14431  93808_at  A_51_P238425  Fatty acids/Eicosanoids (FA)  CARBONYL REDUCTASE 2 
LMP000613  Pmvk  Q9D1G2  MM.34242   146543  #N/A  A_51_P492408  Sterol Lipids (ST)  PHOSPHOMEVALONATE KINASE 
LMP000614  Ihpk3  Q8BWD2  MM.209679   12680  #N/A  A_51_P163238  Not classified  INOSITOL HEXAPHOSPHATE KINASE 3 
LMP000616  Pib5pa  P59644  MM.24313   144173  103732_at  A_51_P180669  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL (4,5) BISPHOSPHATE 5‐
PHOSPHATASE, A 
LMP000626  Anxa2  P07356  MM.238343   16639  100569_at  A_51_P165335  Not classified  ANNEXIN A2 
LMP000631  Cpt1b  Q924X2  MM.358582   34408  #N/A  A_51_P232913  Fatty acids/Eicosanoids (FA) 
CARNITINE PALMITOYLTRANSFERASE 1B, 
MUSCLE 
LMP000634  Lrp8  Q924X6  MM.331760   143820  #N/A  A_51_P145041  Not classified 
LOW DENSITY LIPOPROTEIN RECEPTOR‐RELATED 
PROTEIN 8, APOLIPOPROTEIN E R... 
LMP000638  Akr1c13  Q8VC28  NA     20604  95015_at  #N/A 
Glycerophospholipids (GP) / 
Sterol Lipids (ST)  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER C13  
LMP000642  Prmt1  Q9JIF0  MM.27545   147345  #N/A  A_51_P389531  Sterol Lipids (ST)  PROTEIN ARGININE N‐METHYLTRANSFERASE 1 
LMP000644  Clc  P97400  NA     22164  #N/A  #N/A  Not classified  CHARCOT‐LEYDEN CRYSTAL PROTEIN  
LMP000645  Cyp2d10  P24456  NA     3215  98612_at  A_51_P111192  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY D, 
POLYPEPTIDE 10  





LMP000652  Acot5  Q91YQ6  MM.123934   27213  #N/A  A_51_P355996  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 5 
LMP000653  Hhat  Q8BWF5  MM.145857   26910  #N/A  A_51_P445677  Fatty acids/Eicosanoids (FA)  HEDGEHOG ACYLTRANSFERASE 
LMP000660  Apob48r  Q8VBT6  MM.170665   18796  #N/A  #N/A  Not classified  APOLIPOPROTEIN B48 RECEPTOR 
LMP000663  Atp6v0a1  Q9Z1G4  MM.340818   17112  103275_at  A_51_P142080  Not classified 
ATPASE, H+ TRANSPORTING, LYSOSOMAL V0 
SUBUNIT A1 
LMP000665  Itpr3  P70227  MM.328900   3786  #N/A  A_51_P104897  Glycerophospholipids (GP)  INOSITOL 1,4,5‐TRIPHOSPHATE RECEPTOR 3 
LMP000668  Cyp26a1  O55127  MM.42230   146537  #N/A  A_51_P401568  Prenol Lipids (PR) 
CYTOCHROME P450, FAMILY 26, SUBFAMILY A, 
POLYPEPTIDE 1 
LMP000670  Cyp2a4  P15392  MM.154643   16767  102847_s_at  A_51_P377154  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY A, 
POLYPEPTIDE 4 
LMP000672  Mfge8  P21956  MM.1451   37289  92880_at  A_51_P255682  Glycerophospholipids (GP)  MILK FAT GLOBULE‐EGF FACTOR 8 PROTEIN 
LMP000675  Plcb4  Q91UZ1  MM.38009   148146  #N/A 
A_51_P211659;A_
51_P225695  Glycerophospholipids (GP)  PHOSPHOLIPASE C, BETA 4 
LMP000679  Lass2  Q924Z4  MM.181009   7967  160396_at  A_51_P517375  Not classified 
LONGEVITY ASSURANCE HOMOLOG 2 (S. 
CEREVISIAE) 
LMP000684  Lipc  Q8VC44  MM.30056   31093  98962_at  A_51_P263993  Glycerolipids (GL)  LIPASE, HEPATIC 
LMP000685  Sec14l4  Q8R0F9  MM.337476   37247  #N/A  A_51_P194853  Not classified  SEC14‐LIKE 4 (S. CEREVISIAE) 
LMP000691  Acot1  O55137  MM.1978   143852  #N/A  A_51_P451574  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 1 





LMP000699  Lrp8  Q921B5  MM.331760   143820  #N/A  A_51_P145041  Not classified 
LOW DENSITY LIPOPROTEIN RECEPTOR‐RELATED 
PROTEIN 8, APOLIPOPROTEIN E R... 
LMP000706  Fads1  Q8R0G8  MM.30158   3941  #N/A  A_51_P358112  Fatty acids/Eicosanoids (FA)  FATTY ACID DESATURASE 1 
LMP000709  Dgkb  Q6NS52  MM.242576   146614  #N/A  A_51_P515612  Glycerolipids (GL)  DIACYLGLYCEROL KINASE, BETA 
LMP000710  Ebp  P70245  MM.27183   38190  96627_at  A_51_P429682  Sterol Lipids (ST) 
PHENYLALKYLAMINE CA2+ ANTAGONIST 
(EMOPAMIL) BINDING PROTEIN 
LMP000714  Gpaa1  Q9WTK3  MM.5903   5313 
100911_at;16
1682_f_at  A_51_P273203  Glycerophospholipids (GP)  GPI ANCHOR ATTACHMENT PROTEIN 1 
LMP000715  Rbm14  Q62019  MM.276338   25411 
100138_f_at,
100546_at,16
2067_at  A_51_P116616  Not classified  RNA BINDING MOTIF PROTEIN 14 
LMP000721  Inpp5e  Q9JII1  MM.250359   17140  #N/A  A_51_P136324  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE‐5‐PHOSPHATASE E 
LMP000724  Cyp3a41  Q9JMA7  MM.379071   7396  #N/A  A_51_P341203  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 3, SUBFAMILY A, 
POLYPEPTIDE 41 
LMP000725  Akr1a1  Q9JII6  MM.30085   32755  #N/A  #N/A  Glycerolipids (GL) 
ALDO‐KETO REDUCTASE FAMILY 1, MEMBER A4 
(ALDEHYDE REDUCTASE) 
LMP000729  Sult1e1  P49891  MM.89655   149873  #N/A  A_51_P493649  Sterol Lipids (ST)  SULFOTRANSFERASE FAMILY 1E, MEMBER 1 
LMP000732  Rbm14  Q8C2Q3  MM.276338   25411 
100138_f_at,
100546_at,16
2067_at  A_51_P116616  Not classified  RNA BINDING MOTIF PROTEIN 14 
LMP000735  Cyp51  Q8BSQ7  MM.140158   6612  94916_at  A_51_P485791  Sterol Lipids (ST)  CYTOCHROME P450, FAMILY 51 
LMP000738  Cept1  Q8VC64  MM.14816   145071  #N/A  A_51_P313460  Not classified 
CHOLINE/ETHANOLAMINEPHOSPHOTRANSFERAS
E 1 










LMP000746  Lypla2  Q9WTL7  MM.34302   7014  98429_at  A_51_P520084 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  LYSOPHOSPHOLIPASE 2 
LMP000747  Dbi  P31786  MM.2785   26248  97248_at  A_51_P399697  Not classified  DIAZEPAM BINDING INHIBITOR 
LMP000752  Soat2  O88908  MM.358862   39251 
97132_at;994
31_at  A_51_P196995   / Sterol Lipids (ST)  STEROL O‐ACYLTRANSFERASE 2 





LMP000757  Ppt1  Q8VBX5  MM.277719   147223  99646_at  A_51_P114307  Fatty acids/Eicosanoids (FA)  PALMITOYL‐PROTEIN THIOESTERASE 1 






LMP000759  Ptgdr  P70263  MM.5105   36867  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN D RECEPTOR 
LMP000769  Gpihbp1  Q9D1N2  MM.46367   145573  #N/A  #N/A  Sterol Lipids (ST)  GPI‐ANCHORED HDL‐BINDING PROTEIN 1 





4  Q9R2B6  MM.27446   6968  #N/A  A_51_P284891  Sphingolipids (SP) 
ST6 (ALPHA‐N‐ACETYL‐NEURAMINYL‐2,3‐BETA‐
GALACTOSYL‐1,3)‐N‐ACETYLGALACT... 
LMP000780  Pla2g12b  Q8VC81  MM.30268   37683  #N/A  A_51_P184385 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP XIIB 





















LMP000786  Srebf1  Q9WTN3  MM.278701   17082  93264_at  A_51_P401921  Sterol Lipids (ST) 
STEROL REGULATORY ELEMENT BINDING 
FACTOR 1 
LMP000792  Cds1  P98191  MM.46764   3318  #N/A  A_51_P479688 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  CDP‐DIACYLGLYCEROL SYNTHASE 1 
LMP000793  Pla2g2f  Q9QZT4  MM.331989   37041  #N/A  A_51_P118255 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP IIF 
LMP000794  Gnpat  P98192  MM.29114   107088  94562_at  A_51_P224575  Glycerophospholipids (GP)  GLYCERONEPHOSPHATE O‐ACYLTRANSFERASE 
LMP000799  Lcn5  Q9R2C6  MM.12867   8935  99236_at  A_51_P191875  Prenol Lipids (PR)  LIPOCALIN 5 
LMP000802  Ptger2  Q62053  MM.4630   31104  98768_at  A_51_P249215  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN E RECEPTOR 2 (SUBTYPE EP2) 
LMP000805  Tbxas1  P36423  MM.4054   22953 
162136_r_at;
92387_at  A_51_P448667  Fatty acids/Eicosanoids (FA)  THROMBOXANE A SYNTHASE 1, PLATELET 
LMP000806  Plekha4  Q8VC98  MM.274158   147078  #N/A  A_51_P501858  Not classified 
PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, 
FAMILY A (PHOSPHOINOSITIDE BIND... 





LMP000809  Prkcg  P63318  MM.368265   28552  #N/A  #N/A 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  PROTEIN KINASE C, GAMMA 
LMP000812  Ptger1  P35375  MM.347482   13051  99998_at  A_51_P144303  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN E RECEPTOR 1 (SUBTYPE EP1) 
LMP000813  Ldlr  Q8CAV5  MM.3213   8818  160832_at  A_51_P274173  Sterol Lipids (ST)  LOW DENSITY LIPOPROTEIN RECEPTOR 
LMP000816  Ptgs2  Q05769  MM.292547   37761  104647_at  A_51_P254855  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN‐ENDOPEROXIDE SYNTHASE 2 





LMP000820  Coq7  P97478  MM.20634   26734  93582_at  A_51_P161682  Prenol Lipids (PR)  DEMETHYL‐Q 7 
LMP000822  Cxcl16  Q8BSU2  MM.359802   16564  #N/A  A_51_P374198  Not classified  CHEMOKINE (C‐X‐C MOTIF) LIGAND 16 





LMP000833  Pebp1  P70296  MM.195898   27999  #N/A  A_51_P171700  Not classified 
PHOSPHATIDYLETHANOLAMINE BINDING 
PROTEIN 1 
LMP000841  Acot4  Q8BWN8  MM.219001   12942  #N/A  A_51_P396141  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 4 
LMP000847  Acaa1a  Q921H8  MM.205266   27176  #N/A  A_51_P327075 
Fatty acids/Eicosanoids (FA) / 
Sterol Lipids (ST)  ACETYL‐COENZYME A ACYLTRANSFERASE 1A 
LMP000852  Cyp1a2  P00186  MM.15537   36875  102998_at  A_51_P450140  Fatty acids/Eicosanoids (FA)  CYTOCHROME P450, FAMILY 1, SUBFAMILY A,  
LMP000856  Plcg2  Q8CIH5  MM.192699   59878  #N/A  A_51_P279163  Glycerophospholipids (GP)  PHOSPHOLIPASE C, GAMMA 2 
LMP000859  Apoa2  Q60615  MM.288374   144830 
161924_f_at;
99648_at  A_51_P128973  Sterol Lipids (ST)  APOLIPOPROTEIN A‐II 
LMP000862  Prkci  Q62074  MM.291554   145800  #N/A 
A_51_P387713;A_
51_P406671  Glycerolipids (GL)  PROTEIN KINASE C, IOTA 





LMP000867  Ppard  P35396  MM.328914   37622  94198_at  A_51_P271556  Sterol Lipids (ST) 
PEROXISOME PROLIFERATOR ACTIVATOR 
RECEPTOR DELTA 
LMP000871  Pld2  P97813  MM.260177   146888  94371_at  A_51_P357759  Not classified  PHOSPHOLIPASE D2 
LMP000873  Pecr  Q99MZ7  MM.281738   9938  #N/A  A_51_P291749  Fatty acids/Eicosanoids (FA)  RIKEN CDNA 2400003B18 GENE 
LMP000875  Cysltr1  Q99JA4  MM.287166   19380  #N/A  A_51_P140017  Fatty acids/Eicosanoids (FA)  CYSTEINYL LEUKOTRIENE RECEPTOR 1 
LMP000876  Acsm1  Q91VA0  MM.135543   4182  #N/A  A_51_P376139  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE MEDIUM‐CHAIN FAMILY 
MEMBER 1 
LMP000877  Pla2g6  P97819  MM.155620   12642  97965_at  A_51_P464860 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP VI 
LMP000878  Carkl  Q9D5J6  MM.200905   33612  #N/A  A_51_P318804  Glycerophospholipids (GP)  CARBOHYDRATE KINASE‐LIKE 
LMP000879  Srd5a2  Q99N99  MM.38933   144889  #N/A  A_51_P497006  Sterol Lipids (ST)  STEROID 5 ALPHA‐REDUCTASE 2 
LMP000880  Shbg  P97497  MM.1431   19648  100702_at  A_51_P423549  Sterol Lipids (ST)  SEX HORMONE BINDING GLOBULIN 
LMP000881  Cpne3  Q8BT60  MM.38390   31109  104274_at  A_51_P175146  Not classified  COPINE III 
LMP000887  Zdhhc1  Q8R0N9  MM.100917   13100  #N/A  A_51_P514898  Fatty acids/Eicosanoids (FA)  ZINC FINGER, DHHC DOMAIN CONTAINING 1 
LMP000889  Chka  O54804  NA     146571  #N/A  A_51_P142923  Glycerophospholipids (GP)  CHOLINE KINASE ALPHA  





LMP000892  Samd8  Q9DA37  MM.102765   15663  #N/A  A_51_P246077  Sphingolipids (SP)  STERILE ALPHA MOTIF DOMAIN CONTAINING 8 
LMP000895  Alox15b  O35936  MM.289672   28220  99848_at  #N/A  Fatty acids/Eicosanoids (FA)  ARACHIDONATE 8‐LIPOXYGENASE 
LMP000897  Neu2  Q9JMH3  MM.45670   3707  #N/A  A_51_P460143  Sphingolipids (SP)  NEURAMINIDASE 2 
LMP000898  Acat2  Q8CAY6  MM.360538   3712  101006_at  #N/A  Fatty acids/Eicosanoids (FA)  T‐COMPLEX PROTEIN 1, RELATED SEQUENCE 1 









LMP000902  Neu3  Q9JMH7  MM.103703   28706  #N/A  A_51_P210106  Sphingolipids (SP)  NEURAMINIDASE 3 
LMP000910  Stard5  Q9EPQ7  MM.357953   25400  #N/A  A_51_P319141  Sterol Lipids (ST) 
DNA SEGMENT, CHR 7, ERATO DOI 152, 
EXPRESSED 
LMP000911  Ttpa  Q8BWP5  MM.379065   26891  #N/A  A_51_P258817  Prenol Lipids (PR)  TOCOPHEROL (ALPHA) TRANSFER PROTEIN 
LMP000913  Olr1  Q9EQ09  MM.293626   4873  93167_f_at  A_51_P462192  Not classified 
OXIDIZED LOW DENSITY LIPOPROTEIN (LECTIN‐
LIKE) RECEPTOR 1 
LMP000915  Acsl5  Q8JZR0  MM.292056   26342  #N/A  A_51_P472173  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE LONG‐CHAIN FAMILY 
MEMBER 5 
LMP000926  Cpt2  P52825  MM.307620   148638 
161978_r_at;
95646_at  A_51_P403388  Fatty acids/Eicosanoids (FA)  CARNITINE PALMITOYLTRANSFERASE 2 
LMP000928  Elovl3  O35949  MM.21806   3845  103469_at  A_51_P324636  Fatty acids/Eicosanoids (FA) 
ELONGATION OF VERY LONG CHAIN FATTY ACIDS 
(FEN1/ELO2, SUR4/ELO3, YEAST... 
LMP000929  Pla2g12a  Q9EPR2  MM.151951   148707  #N/A  A_51_P207550 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP XIIA 
LMP000934  Nr1h4  Q60641  MM.3095   135585  97969_at  A_51_P464669  Sterol Lipids (ST) 
NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, 
MEMBER 4 





LMP000941  Amacr  Q543Q9  MM.2787   145128  95588_at  A_51_P118885  Prenol Lipids (PR)  ALPHA‐METHYLACYL‐COA RACEMASE 
LMP000942  Gm2a  Q60648  MM.287807   4322  99141_at  A_51_P466180  Sphingolipids (SP)  GM2 GANGLIOSIDE ACTIVATOR PROTEIN 
LMP000943  Atp10a  O54827  MM.135129   24608  #N/A  A_51_P320022  Not classified  ATPASE, CLASS V, TYPE 10A 
LMP000945  Apom  Q9Z1R3  MM.2161   143971 
162148_r_at;
93840_at  A_51_P461178  Not classified  APOLIPOPROTEIN M 
LMP000946  Sdha  Q8K2B3  MM.158231   12673  94080_at  A_51_P410823  Prenol Lipids (PR) 
SUCCINATE DEHYDROGENASE COMPLEX, 
SUBUNIT A, FLAVOPROTEIN (FP) 
LMP000951  Prkcq  Q02111  MM.329993   146652 
104431_at;16
1853_f_at  A_51_P338935  Glycerolipids (GL)  PROTEIN KINASE C, THETA 
LMP000954  Pigw  Q8C398  MM.288689   146505  #N/A  A_51_P414927  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASS W 
LMP000956  Rbp2  Q08652  MM.12825   145779  92811_at  A_51_P399143  Prenol Lipids (PR)  RETINOL BINDING PROTEIN 2, CELLULAR 












LMP000970  Slco2a1  Q9EPT5  MM.207106   38158  #N/A  A_51_P315931  Fatty acids/Eicosanoids (FA) 
SOLUTE CARRIER ORGANIC ANION 
TRANSPORTER FAMILY, MEMBER 2A1 
LMP000975  Fabp3  P11404  MM.22220   145246  94214_at  A_51_P167535  Glycerophospholipids (GP) 
FATTY ACID BINDING PROTEIN 3, MUSCLE AND 
HEART 
LMP000977  Fabp4  P04117  MM.582   27888  100567_at  A_51_P336830  Not classified  FATTY ACID BINDING PROTEIN 4, ADIPOCYTE 
LMP000984  Plcxd3  Q8BLJ3  MM.308996   9062  #N/A  #N/A  Not classified 
PHOSPHATIDYLINOSITOL‐SPECIFIC 
PHOSPHOLIPASE C, X DOMAIN CONTAINING 3 






LMP000989  Pla2g2c  P48076  MM.5189   99994  99326_at  A_51_P427052 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP IIC 
                 




LMP000995  Acaa2  Q8BWT1  MM.245724   29019  95064_at  A_51_P125260  Fatty acids/Eicosanoids (FA) 
ACETYL‐COENZYME A ACYLTRANSFERASE 2 
(MITOCHONDRIAL 3‐OXOACYL‐COENZYME ... 
LMP000997  Mvd  Q99JF5  MM.28146   145978  160770_at  A_51_P355943 
Prenol Lipids (PR) / Sterol 
Lipids (ST)  MEVALONATE (DIPHOSPHO) DECARBOXYLASE 
LMP000999  St3gal2  Q11204  MM.200388   13089  #N/A  A_51_P305537  Sphingolipids (SP) 
ST3 BETA‐GALACTOSIDE ALPHA‐2,3‐
SIALYLTRANSFERASE 2 
LMP001001  Rara  P11416  MM.103336   26670  92901_at  A_51_P389724 
Prenol Lipids (PR) / Sterol 
Lipids (ST)  RETINOIC ACID RECEPTOR, ALPHA 
LMP001003  Mlstd1  Q7TNT2  MM.322130   146460  #N/A  A_51_P285986  Fatty acids/Eicosanoids (FA)  MALE STERILITY DOMAIN CONTAINING 1 
LMP001011  Gk2  Q9WU65  MM.61206   8004  #N/A  A_51_P194658  Not classified  GLYCEROL KINASE 2 





6  Q8JZW3  MM.88831   4643  #N/A  A_51_P284997  Sphingolipids (SP) 
ST6 (ALPHA‐N‐ACETYL‐NEURAMINYL‐2,3‐BETA‐
GALACTOSYL‐1,3)‐N‐ACETYLGALACT... 
LMP001019  Ugt1  P70691  NA     3809  #N/A  #N/A  Sterol Lipids (ST) 
UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, 
POLYPEPTIDE A2  
LMP001024  Akr1c6  P70694  MM.196666   6796  92556_at  A_51_P189082  Sterol Lipids (ST)  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 5 





LMP001033  Pnpla5  Q9D603  MM.159565   3627  #N/A  A_51_P334804  Not classified 
PATATIN‐LIKE PHOSPHOLIPASE DOMAIN 
CONTAINING 5 
LMP001036  Adipor1  Q91VH1  MM.259976   21906  #N/A  A_51_P485243  Fatty acids/Eicosanoids (FA)  ADIPONECTIN RECEPTOR 1 










LMP001057  Lss  Q8BLN5  MM.55075   4544  160737_at  A_51_P296487  Sterol Lipids (ST)  LANOSTEROL SYNTHASE 





LMP001064  Ptdss2  Q9Z1X2  MM.293591   37986  160853_at  A_51_P185713 
Glycerophospholipids (GP) / 
Sphingolipids (SP)  PHOSPHATIDYLSERINE SYNTHASE 2 
LMP001065  Mbtps1  Q9WTZ2  MM.206934   18084  95754_at  A_51_P382588  Sterol Lipids (ST) 
MEMBRANE‐BOUND TRANSCRIPTION FACTOR 
PEPTIDASE, SITE 1 
LMP001066  Rlbp1  Q9Z275  MM.41653   36177  92435_at  A_51_P211798  Prenol Lipids (PR)  RETINALDEHYDE BINDING PROTEIN 1 
LMP001068 
2310016
F22Rik  Q6PF90  MM.243758   145658  #N/A  A_51_P500215  Not classified  RIKEN CDNA 2310016F22 GENE 
LMP001071  Pik3c3  Q6PF93  MM.194127   3591  #N/A  #N/A  Glycerophospholipids (GP)  PHOSPHOINOSITIDE‐3‐KINASE, CLASS 3 





LMP001085  Hsd3b4  Q61767  MM.14309   20317  92869_at  A_51_P352005  Sterol Lipids (ST) 
HYDROXYSTEROID DEHYDROGENASE‐4, 
DELTA<5>‐3‐BETA 




_g_at  A_51_P159203  Glycerophospholipids (GP)  PHOSPHOLIPASE D1 
LMP001098  Rbp4  Q00724  MM.2605   146821  96047_at  A_51_P374752  Prenol Lipids (PR)  RETINOL BINDING PROTEIN 4, PLASMA 
LMP001101  Stard4  Q80SX0  MM.127058   10716  #N/A  A_51_P105445  Sterol Lipids (ST)  RIKEN CDNA 4632419C16 GENE 
LMP001103  Zdhhc3  Q8R173  MM.28300   9165  97857_at  A_51_P258432  Fatty acids/Eicosanoids (FA)  ZINC FINGER, DHHC DOMAIN CONTAINING 3 
LMP001106  Sgpl1  Q8R0X7  MM.200373   144501 
96126_at,961
27_at  A_51_P391694  Sphingolipids (SP)  SPHINGOSINE PHOSPHATE LYASE 1 








at  A_51_P474658  Sterol Lipids (ST)  ESTROGEN RECEPTOR 1 (ALPHA) 
LMP001113  Plcd3  Q8K2J0  MM.264743   9346  #N/A  A_51_P278163  Glycerophospholipids (GP)  PHOSPHOLIPASE C, DELTA 3 
LMP001115  Apoc2  Q05020  MM.28394   37971  97887_at  A_51_P334979  Not classified  APOLIPOPROTEIN C‐II 
LMP001119  Degs1  O09005  MM.29648   18914  #N/A  A_51_P498890  Sphingolipids (SP) 
DEGENERATIVE SPERMATOCYTE HOMOLOG 1 
(DROSOPHILA) 
LMP001129  Cckbr  P56481  MM.44513   22183  101344_at  A_51_P506201  Not classified  CHOLECYSTOKININ B RECEPTOR 
LMP001130  Acadm  P45952  MM.10530   32812  92581_at  A_51_P319879  Fatty acids/Eicosanoids (FA) 
ACETYL‐COENZYME A DEHYDROGENASE, 
MEDIUM CHAIN 
LMP001135  Plcb2  Q8BI81  MM.379966   6990  #N/A 
A_51_P260350;A_
51_P429382  Glycerophospholipids (GP)  PHOSPHOLIPASE C, BETA 2 








LMP001139  Prkcd  P28867  MM.2314   9520 
104531_at;16
0698_s_at  A_51_P460734  Glycerolipids (GL)  PROTEIN KINASE C, DELTA 
LMP001143  Alox5ap  P30355  MM.19844   3373  #N/A  A_51_P235687  Fatty acids/Eicosanoids (FA) 
ARACHIDONATE 5‐LIPOXYGENASE ACTIVATING 
PROTEIN 








LMP001150  Acaa1b  Q8VCH0  NA     147437  #N/A  #N/A 
Fatty acids/Eicosanoids (FA) / 
Sterol Lipids (ST)  ACETYL‐COENZYME A ACYLTRANSFERASE 1B  
LMP001151  Olah  Q8R197  MM.13808   27450  #N/A  A_51_P369906  Fatty acids/Eicosanoids (FA)  THIOESTERASE DOMAIN CONTAINING 1 
LMP001159  Bcdo2  Q99NF1  MM.379309   7224  #N/A  A_51_P424168  Not classified  BETA‐CAROTENE 9', 10'‐DIOXYGENASE 2 
LMP001167  Gc  P21614  MM.196595   17654  99197_at  A_51_P349961  Sterol Lipids (ST)  GROUP SPECIFIC COMPONENT 





LMP001177  Prkcb1  P68404  NA     35234  #N/A  A_51_P485098 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  PROTEIN KINASE C, BETA 1  
LMP001181  Scd4  Q6T707  MM.313583   108193  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  STEAROYL‐COENZYME A DESATURASE 4 
LMP001185  Liph  Q8CIV3  MM.33192   16830  #N/A  A_51_P122660  Not classified  LIPASE, MEMBER H 
LMP001204  Pdss1  Q9CZQ1  MM.249752   148145  #N/A  A_51_P127841  Not classified 
PRENYL (SOLANESYL) DIPHOSPHATE SYNTHASE, 
SUBUNIT 1 





LMP001232  Ggtla1  Q80WV0  MM.257927   20280  102968_at  A_51_P201709  Fatty acids/Eicosanoids (FA) 
GAMMA‐GLUTAMYLTRANSFERASE‐LIKE ACTIVITY 
1 
LMP001238  Nqo1  Q64669  MM.252   149538 
100725_at;94
350_f_at;943
51_r_at  A_51_P424338  Sterol Lipids (ST)  NAD(P)H DEHYDROGENASE, QUINONE 1 
LMP001242  Plcz1  Q9DAC8  MM.50808   37226  #N/A  A_51_P297441  Glycerophospholipids (GP)  PHOSPHOLIPASE C, ZETA 1 
LMP001252  Itpkc  Q7TS72  MM.30963   145969  #N/A  A_51_P507622  Not classified  INOSITOL 1,4,5‐TRISPHOSPHATE 3‐KINASE C 
LMP001255  Atp8b1  Q6R964  MM.270043   144899  #N/A 
A_51_P192329;A_
51_P494297  Sterol Lipids (ST)  ATPASE, CLASS I, TYPE 8B, MEMBER 1 
LMP001257  Ugt8  Q64676  MM.306021   146732  98872_at  #N/A 
Glycerolipids 
(GL)/Sphingolipids (SP)  UDP GALACTOSYLTRANSFERASE 8A 
LMP001259  Dgat2l4  Q6E1M8  MM.118171   4847  #N/A  A_51_P474151  Fatty acids/Eicosanoids (FA)  DIACYLGLYCEROL O‐ACYLTRANSFERASE 2‐LIKE 4 








LMP001273  Asah3  Q8R4X1  MM.218784   4147  #N/A  A_51_P510239  Sphingolipids (SP)  RIKEN CDNA 2310024P18 GENE 



















LMP001286  Inpp5d  Q9WUC2  MM.15105   3846  #N/A  A_51_P337125  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE‐5‐PHOSPHATASE D 
LMP001287  Cyp2e1  Q05421  MM.21758   4103  93996_at  A_51_P283456  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY E, 
POLYPEPTIDE 1 
LMP001288  Dgat1  Q9Z2A7  MM.22633   6880 
104371_at;16
2316_f_at  A_51_P510059  Glycerolipids (GL)  DIACYLGLYCEROL O‐ACYLTRANSFERASE 1 
LMP001290  Ggtla1  Q9Z2A9  MM.257927   20280  102968_at  A_51_P201709  Fatty acids/Eicosanoids (FA) 
GAMMA‐GLUTAMYLTRANSFERASE‐LIKE ACTIVITY 
1 
LMP001296  Esrrb  Q8C7A6  MM.235550   26436  100301_at  A_51_P419047  Sterol Lipids (ST)  ESTROGEN RECEPTOR RELATED 2 
LMP001311  Pik3cb  Q8BTI9  MM.213128   10735  #N/A  A_51_P479914  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, CATALYTIC, 
BETA POLYPEPTIDE 
LMP001316  Eif2ak3  Q9Z2B5  MM.247167   113355  103537_at  A_51_P253642  Glycerophospholipids (GP) 
EUKARYOTIC TRANSLATION INITIATION FACTOR 
2 ALPHA KINASE 3 
LMP001317  Pip5k1c  O70161  NA     6253  94119_at  A_51_P149852  Glycerophospholipids (GP)  PIP5KIGAMMA  





LMP001327  Itpr1  P11881  MM.227912   43495 
161661_i_at;
93895_s_at;9
4977_at  A_51_P269663  Glycerophospholipids (GP)  INOSITOL 1,4,5‐TRIPHOSPHATE RECEPTOR 1 
LMP001328  Pik3ca  P42337  MM.260521   19965  92452_at  A_51_P166682  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, CATALYTIC, 
ALPHA POLYPEPTIDE 
LMP001329  Hsd3b7  Q9EQC1  MM.157103   18865  160104_at  A_51_P435911  Sterol Lipids (ST) 
HYDROXY‐DELTA‐5‐STEROID DEHYDROGENASE, 3 
BETA‐ AND STEROID DELTA‐ISOME... 
LMP001331  Pik3c2g  O70167  MM.333471   23796  94108_at  A_51_P191077  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, C2 DOMAIN 
CONTAINING, GAMMA POLYPEPTIDE 
LMP001341  Ggtla1  Q8C7B4  MM.257927   20280  102968_at  A_51_P201709  Fatty acids/Eicosanoids (FA) 
GAMMA‐GLUTAMYLTRANSFERASE‐LIKE ACTIVITY 
1 
LMP001344  Ehhadh  Q91W49  MM.28100   146125  #N/A  A_51_P462918  Fatty acids/Eicosanoids (FA) 
ENOYL‐COENZYME A, HYDRATASE/3‐
HYDROXYACYL COENZYME A DEHYDROGENASE 











at;96848_at  A_51_P166695  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE‐5‐PHOSPHATASE B 
LMP001356  Acsl3  Q9CZW4  NA     29539  #N/A  A_51_P511560  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE LONG‐CHAIN FAMILY 
MEMBER 3  
LMP001363  Lta4h  P24527  MM.271071   14994  100540_at  A_51_P101955  Fatty acids/Eicosanoids (FA)  LEUKOTRIENE A4 HYDROLASE 
LMP001365  Stard4  Q99JV5  MM.127058   10716  #N/A  A_51_P105445  Sterol Lipids (ST)  RIKEN CDNA 4632419C16 GENE 
LMP001371  Chpt1  Q8C025  MM.288897   30110  #N/A  A_51_P240857  Not classified  CHOLINE PHOSPHOTRANSFERASE 1 





LMP001377  Tmem23  Q8VCQ6  MM.171256   15383  #N/A  #N/A  Sphingolipids (SP)  TRANSMEMBRANE PROTEIN 23 
LMP001382 
Hsd17b1





LMP001384  Ncf1  Q09014  MM.4149   144386  97763_at  A_51_P207031  Fatty acids/Eicosanoids (FA)  NEUTROPHIL CYTOSOLIC FACTOR 1 
LMP001385  Hexdc  Q6NSQ8  MM.386870   13666  #N/A  #N/A  Not classified 
HEXOSAMINIDASE (GLYCOSYL HYDROLASE 
FAMILY 20, CATALYTIC DOMAIN) CONTAI... 






LMP001393  Prdx6  O08709  MM.186185   3244 
100332_s_at;
100622_at  A_51_P496023  Fatty acids/Eicosanoids (FA)  PEROXIREDOXIN 6 










LMP001405  Abca4  O35600  MM.3918   37684  97730_at  A_51_P413614  Not classified 
ATP‐BINDING CASSETTE, SUB‐FAMILY A (ABC1), 
MEMBER 4 
LMP001407  Pik3r1  P70304  MM.259333   37643  96592_at  #N/A  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 1 (P85 ... 
LMP001408  Plcb3  P51432  MM.273204   148650  101358_at  A_51_P236042  Glycerophospholipids (GP)  PHOSPHOLIPASE C, BETA 3 
LMP001409  Ltc4s  Q8K355  MM.245151   45402  92401_at  A_51_P354792  Fatty acids/Eicosanoids (FA)  LEUKOTRIENE C4 SYNTHASE 
LMP001410  Npc1  O35604  MM.3484   17029  98114_at  A_51_P349341  Sterol Lipids (ST)  NIEMANN PICK TYPE C1 
LMP001416  Fabp9  O08716  MM.26654   36000 
160729_f_at;
94927_at  A_51_P234996  Not classified  FATTY ACID BINDING PROTEIN 9, TESTIS 
LMP001419  Prkcz  Q02956  MM.28561   27837 
161964_r_at;
96198_at;965
71_at  A_51_P314631  Glycerolipids (GL)  PROTEIN KINASE C, ZETA 
LMP001420  Apoa4  P06728  MM.4533   147861  100078_at  A_51_P327496  Sterol Lipids (ST)  APOLIPOPROTEIN A‐IV 
LMP001422  Lpin1  Q91ZP3  MM.153625   12995  98892_at  A_51_P394984  Not classified  LIPIN 1 
LMP001423 
4632408
A20Rik  Q8BXE0  MM.49245   145642  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  RIKEN CDNA 4632408A20 GENE 





LMP001432  Pparg  Q6TQE4  MM.3020   148555  97926_s_at  A_51_P106799  Sterol Lipids (ST) 
PEROXISOME PROLIFERATOR ACTIVATED 
RECEPTOR GAMMA 
LMP001442  Acsm3  Q9Z2F3  MM.334199   37109  #N/A  A_51_P487175  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE MEDIUM‐CHAIN FAMILY 
MEMBER 3 
LMP001444  Apoc3  P33622  MM.178973   15124  #N/A  A_51_P310629  Not classified  APOLIPOPROTEIN C‐III 




LMP001457  Ppap2b  Q99JY8  MM.348326   12962  #N/A 
A_51_P452997;A_
51_P503433  Glycerophospholipids (GP)  PHOSPHATIDIC ACID PHOSPHATASE TYPE 2B 
LMP001458  Acads  Q91W85  MM.18759   14602  103401_at  A_51_P452807  Fatty acids/Eicosanoids (FA) 
ACYL‐COENZYME A DEHYDROGENASE, SHORT 
CHAIN 
LMP001459  Gba2  Q8BTN9  MM.229444   9138  92784_at  A_51_P261359  Not classified  GLUCOSIDASE BETA 2 






LMP001461  Zdhhc17  Q8BIE0  MM.339281   15248  #N/A  A_51_P348672  Fatty acids/Eicosanoids (FA)  HUNTINGTIN INTERACTING PROTEIN 14 
LMP001465  Acad10  Q8K370  MM.45423   27723  #N/A  A_51_P187507  Fatty acids/Eicosanoids (FA) 
ACYL‐COENZYME A DEHYDROGENASE FAMILY, 
MEMBER 10 






LMP001478  Chkb  O55229  MM.227738   4925  #N/A  A_51_P159771  Glycerophospholipids (GP)  CHOLINE KINASE BETA 
LMP001483  Chpt1  Q91W91  MM.288897   30110  #N/A  A_51_P240857  Not classified  CHOLINE PHOSPHOTRANSFERASE 1 
LMP001484  Apoa5  Q8C7G5  MM.29738   37790 
95727_at;957
28_g_at;9572
9_at  A_51_P259930  Not classified  APOLIPOPROTEIN A‐V 
LMP001491  Prkd1  Q62101  MM.386771   20045  #N/A  #N/A  Glycerolipids (GL)  PROTEIN KINASE C, MU 
LMP001492  Fabp9  Q9DAL2  MM.26654   36000 
160729_f_at;
94927_at  A_51_P234996  Not classified  FATTY ACID BINDING PROTEIN 9, TESTIS 
LMP001494  Vamp2  P63044  MM.28643   146844 
98925_at;989
26_at  A_51_P446927  Not classified  VESICLE‐ASSOCIATED MEMBRANE PROTEIN 2 
LMP001499  Fabp5  Q05816  MM.741   35192  160544_at  A_51_P387764  Glycerophospholipids (GP)  FATTY ACID BINDING PROTEIN 5, EPIDERMAL 
LMP001500  Anxa3  O35639  MM.7214   36967  101393_at  A_51_P451032  Not classified  ANNEXIN A3 
LMP001503  Dld  O08749  MM.3131   147715  97502_at  A_51_P184282  Not classified  DIHYDROLIPOAMIDE DEHYDROGENASE 
LMP001505  Cyp2r1  Q6VVW9  MM.108037   148005  #N/A  A_51_P118046  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY R, 
POLYPEPTIDE 1 
LMP001507  Asah3l  Q8VD53  MM.266817   16613  #N/A 
A_51_P244408;A_
51_P249305  Not classified  RIKEN CDNA 2410116I05 GENE 
LMP001508  Rdh5  O55240  MM.378996   148291  101431_at  A_51_P479618  Prenol Lipids (PR)  RETINOL DEHYDROGENASE 5 
LMP001516  Plcl2  Q8K394  MM.217362   132312  #N/A  A_51_P219444  Glycerophospholipids (GP)  PHOSPHOLIPASE C‐LIKE 2 
LMP001521  Hadh2  O08756  NA     13192  101045_at  #N/A  Fatty acids/Eicosanoids (FA)  3‐HYDROXYACYL‐COA DEHYDROGENASE TYPE II  
LMP001523  Pigo  Q9JJI6  MM.143738   147400  #N/A  A_51_P469545  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASS O 
LMP001524  Dgka  O88673  MM.291235   25737  103596_at  A_51_P319093 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  DIACYLGLYCEROL KINASE, ALPHA 





LMP001534  Nmt2  Q8CFK1  MM.65021   8003  102229_at  A_51_P465512  Fatty acids/Eicosanoids (FA)  N‐MYRISTOYLTRANSFERASE 2 
LMP001542  Gpr44  Q9Z2J6  MM.353637   7375  101282_at  A_51_P406315  Fatty acids/Eicosanoids (FA)  G PROTEIN‐COUPLED RECEPTOR 44 
LMP001546  Neu1  O35657  MM.8856   3440  #N/A  A_51_P428032  Sphingolipids (SP)  NEURAMINIDASE 1 
LMP001553  Dgkg  Q8C413  MM.379296   26711  #N/A  A_51_P494037 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  DIACYLGLYCEROL KINASE, GAMMA 
LMP001555  Akr1d1  Q8VCX1  MM.262635   16140  #N/A  A_51_P391626  Sterol Lipids (ST)  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER D1 
LMP001557  Fabp2  P55050  MM.28398   35211  97889_at  A_51_P313581  Not classified  FATTY ACID BINDING PROTEIN 2, INTESTINAL 
LMP001563  Pdk4  O70571  MM.235547   32788  102049_at  A_51_P350453  Not classified 
PYRUVATE DEHYDROGENASE KINASE, 
ISOENZYME 4 
LMP001564  Slc10a5  Q5PT54  MM.358910   145580  #N/A  #N/A  Not classified 
SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID 
COTRANSPORTER FAMILY), MEMB... 
LMP001565  Smpd2  O70572  MM.953   27591  101940_at  A_51_P234421  Sphingolipids (SP) 
SPHINGOMYELIN PHOSPHODIESTERASE 2, 
NEUTRAL 
LMP001566  Ar  P19091  MM.39005   149722  92667_at  A_51_P496031  Sterol Lipids (ST)  ANDROGEN RECEPTOR 
LMP001573  Pparg  P37238  MM.3020   148555  97926_s_at  A_51_P106799  Sterol Lipids (ST) 
PEROXISOME PROLIFERATOR ACTIVATED 
RECEPTOR GAMMA 
LMP001577  Fasn  P19096  MM.236443   100298  98575_at  A_51_P321126  Fatty acids/Eicosanoids (FA)  FATTY ACID SYNTHASE 
LMP001583  Pik3cg  Q9EQL1  MM.101369   34398  #N/A  A_51_P507832  Glycerophospholipids (GP) 
PHOSPHOINOSITIDE‐3‐KINASE, CATALYTIC, 
GAMMA POLYPEPTIDE 
LMP001584  Mogat1  Q91ZV4  MM.41325   148046  #N/A  A_51_P112151  Glycerolipids (GL)  MONOACYLGLYCEROL O‐ACYLTRANSFERASE 1 







LMP001590  Pcyt2  Q922E4  MM.21439   4597  #N/A  A_51_P432504  Glycerophospholipids (GP) 
PHOSPHATE CYTIDYLYLTRANSFERASE 2, 
ETHANOLAMINE 
LMP001597  Alox12b  O70582  MM.340329   30278  102216_at  A_51_P447258  Fatty acids/Eicosanoids (FA)  ARACHIDONATE 12‐LIPOXYGENASE, 12R TYPE 
LMP001598  Pltp  P55065  MM.6105   27082  100927_at  A_51_P226655  Not classified  PHOSPHOLIPID TRANSFER PROTEIN 
LMP001599  Aldh1a2  Q62148  MM.42016   8489  101707_at  A_51_P166824  Prenol Lipids (PR) 
ALDEHYDE DEHYDROGENASE FAMILY 1, 
SUBFAMILY A2 
LMP001602  Mgll  O35678  MM.272197   38143 
97510_at;975
11_at  A_51_P139923  Glycerolipids (GL)  MONOGLYCERIDE LIPASE 
LMP001606  Ltb4r2  Q9JJL9  MM.159670   36058  #N/A  A_51_P282210  Fatty acids/Eicosanoids (FA)  LEUKOTRIENE B4 RECEPTOR 2 





LMP001613  Hadh  Q61425  MM.260164   7444  #N/A  A_51_P196590  Fatty acids/Eicosanoids (FA) 
L‐3‐HYDROXYACYL‐COENZYME A 
DEHYDROGENASE, SHORT CHAIN 
LMP001616  Hsd17b3  P70385  MM.5109   13867  101184_at  A_51_P275207  Sterol Lipids (ST)  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 3 
LMP001623  Scap  Q6GQT6  MM.288741   149121  #N/A  #N/A 
Fatty acids/Eicosanoids (FA) / 
Sterol Lipids (ST)  SREBP CLEAVAGE ACTIVATING PROTEIN 
LMP001649  Prkaa1  Q5EG47  MM.207004   145495  #N/A  A_51_P158922  Fatty acids/Eicosanoids (FA) 
PROTEIN KINASE, AMP‐ACTIVATED, ALPHA 1 
CATALYTIC SUBUNIT 
LMP001654  Plcl4  Q8BXN5  MM.379458   27196  #N/A  #N/A  Not classified  PHOSPHOLIPASE C‐LIKE 4 
LMP001655  Prmt3  Q922H1  MM.33202   37373  #N/A  A_51_P101316  Sterol Lipids (ST)  RIKEN CDNA 2010005E20 GENE 
LMP001656  Pdk3  Q922H2  MM.12775   40814  92810_at  A_51_P392293  Not classified 
PYRUVATE DEHYDROGENASE KINASE, 
ISOENZYME 3 
LMP001661  Slc27a1  Q60714  MM.38165   38056  93486_at  A_51_P117477  Fatty acids/Eicosanoids (FA) 
SOLUTE CARRIER FAMILY 27 (FATTY ACID 
TRANSPORTER), MEMBER 1 
LMP001670  Aloxe3  Q9WV07  MM.41989   25401  97784_at  A_51_P136143  Fatty acids/Eicosanoids (FA)  ARACHIDONATE LIPOXYGENASE 3 
LMP001672  Lass4  Q9D6J1  MM.35511   11305  #N/A  A_51_P296528  Sphingolipids (SP) 
LONGEVITY ASSURANCE HOMOLOG 4 (S. 
CEREVISIAE) 
LMP001677  Aacs  Q9D2R0  MM.296918   10113  #N/A  A_51_P453043  Not classified  ACETOACETYL‐COA SYNTHETASE 
LMP001681  Zdhhc17  Q80TN5  MM.339281   15248  #N/A  A_51_P348672  Fatty acids/Eicosanoids (FA)  HUNTINGTIN INTERACTING PROTEIN 14 





LMP001685  Plch1  Q8CFQ2  MM.316391   147017  #N/A  #N/A  Not classified  PHOSPHOLIPASE C‐LIKE 3 





LMP001688  Peci  Q9WUR2  MM.28883   145921  94485_at  A_51_P394665  Fatty acids/Eicosanoids (FA) 
PEROXISOMAL DELTA3, DELTA2‐ENOYL‐
COENZYME A ISOMERASE 
LMP001693  Pik3r1  Q8C7P2  MM.259333   37643  96592_at  #N/A  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 1 (P85 ... 
LMP001695  Lass5  Q9D6K9  MM.9550   3879  #N/A  A_51_P481546  Sphingolipids (SP) 
LONGEVITY ASSURANCE HOMOLOG 5 (S. 
CEREVISIAE) 
LMP001697  Lpl  P11152  MM.1514   144445 
160083_at;95
611_at  A_51_P259296  Glycerophospholipids (GP)  LIPOPROTEIN LIPASE 
LMP001700  Nr1i2  O54915  MM.8509   146098  93696_at  A_51_P266958  Sterol Lipids (ST) 
NUCLEAR RECEPTOR SUBFAMILY 1, GROUP I, 
MEMBER 2 






LMP001708  Etnk1  Q8BXQ0  MM.272548   144874  #N/A  A_51_P229600  Not classified  ETHANOLAMINE KINASE 1 
LMP001711  Pigt  Q8BXQ2  MM.28228   3997  #N/A  A_51_P338803  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASS T 
LMP001712  Apol6  Q9D6L7  MM.34173   149208  #N/A  A_51_P404815  Not classified  APOLIPOPROTEIN L, 6 
LMP001715  Daglb  Q91WC9  MM.332549   35027  #N/A  A_51_P122582  Not classified  RIKEN CDNA E330036I19 GENE 
LMP001716  Pnpla7  Q8BTY7  MM.29046   17154  #N/A  A_51_P276235  Not classified  CDNA SEQUENCE BC027342 






LMP001725  Fabp7  P51880  MM.3644   15073  98967_at  A_51_P290074  Not classified  FATTY ACID BINDING PROTEIN 7, BRAIN 
LMP001727  Picalm  Q7M6Y3  MM.235175   148598  #N/A  A_51_P183400  Not classified 
PHOSPHATIDYLINOSITOL BINDING CLATHRIN 
ASSEMBLY PROTEIN 
LMP001731  Chka  Q99KD4  MM.225505   27079  #N/A  A_51_P142923  Glycerophospholipids (GP)  CHOLINE KINASE ALPHA 
LMP001735  Gpr6  Q6YNI2  MM.290693   146015  #N/A  #N/A 
Glycerophospholipids (GP) / 
Sphingolipids (SP)  G PROTEIN‐COUPLED RECEPTOR 6 
LMP001737  Pip5k2b  Q80XI4  MM.39700   3280  #N/A  A_51_P267375  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL‐4‐PHOSPHATE 5‐
KINASE, TYPE II, BETA 
LMP001743  Mvk  Q9R008  MM.28088   37172 
95632_f_at;9
5633_r_at  A_51_P169527  Sterol Lipids (ST)  MEVALONATE KINASE 
LMP001747  Lbp  Q61805  MM.218846   90678  96123_at  A_51_P454008  Not classified  LIPOPOLYSACCHARIDE BINDING PROTEIN 
LMP001751  Gcdh  Q60759  MM.2475   28290 
160194_at;16
2189_r_at;95
561_at  A_51_P260098  Fatty acids/Eicosanoids (FA)  GLUTARYL‐COENZYME A DEHYDROGENASE 
LMP001756  Itpr2  Q9Z329  MM.333496   18040 
101441_i_at;
101442_f_at;  #N/A     INOSITOL 1,4,5‐TRIPHOSPHATE RECEPTOR 2 
LMP001757  Akr1b7  P21300  MM.90151   17178 
102826_at;16
1918_at  A_51_P331288  Glycerolipids (GL)  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER B7 
LMP001758  Bcmo1  Q9JJS6  MM.174133   34393  #N/A  A_51_P374137  Prenol Lipids (PR)  BETA,BETA‐CAROTENE 15,15'‐DIOXYGENASE 
LMP001759  Fvt1  Q6GV12  MM.284775   20232  #N/A  A_51_P107782  Sphingolipids (SP) 
FOLLICULAR LYMPHOMA VARIANT 
TRANSLOCATION 1 
LMP001760  Fn3k  Q9ER35  MM.266448   10634  #N/A  A_51_P398525  Glycerophospholipids (GP)  FRUCTOSAMINE 3 KINASE 
LMP001766  Piga  Q64323  MM.3781   149597 
161433_f_at;
92304_at  A_51_P458839  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASS A 
LMP001771  Ppap2c  Q9DAX2  MM.28873   147433  #N/A  A_51_P361812  Glycerophospholipids (GP)  PHOSPHATIDIC ACID PHOSPHATASE TYPE 2C 
LMP001772  Adfp  P43883  MM.381   39259 
161443_r_at;
98589_at  A_51_P258150  Fatty acids/Eicosanoids (FA)  ADIPOSE DIFFERENTIATION RELATED PROTEIN 
LMP001774 
St6galnac
3  Q9WUV2  MM.296453   22157  #N/A  A_51_P479724  Sphingolipids (SP) 
ST6 (ALPHA‐N‐ACETYL‐NEURAMINYL‐2,3‐BETA‐
GALACTOSYL‐1,3)‐N‐ACETYLGALACT... 
LMP001776  Asah1  Q9WV54  MM.22547   33203  94282_at  A_51_P509098  Sphingolipids (SP)  N‐ACYLSPHINGOSINE AMIDOHYDROLASE 1 
LMP001781  Hsd3b3  Q5FW73  MM.158717   3543  98401_at  A_51_P397056  Sterol Lipids (ST) 
HYDROXYSTEROID DEHYDROGENASE‐3, 
DELTA<5>‐3‐BETA 
LMP001783  Prkag1  O54950  MM.6670   144449  100632_at  A_51_P121818  Fatty acids/Eicosanoids (FA) 
PROTEIN KINASE, AMP‐ACTIVATED, GAMMA 1 
NON‐CATALYTIC SUBUNIT 
LMP001796  Pdk2  Q9JK42  MM.29768   17110  #N/A  A_51_P426274  Not classified 
PYRUVATE DEHYDROGENASE KINASE, 
ISOENZYME 2 
LMP001799  Acox2  Q9QXD1  MM.28700   3284  #N/A  A_51_P206704  Fatty acids/Eicosanoids (FA) 
ACYL‐COENZYME A OXIDASE 2, BRANCHED 
CHAIN 










LMP001806  Dgkg  Q91WG7  MM.379296   26711  #N/A  A_51_P494037 
Glycerolipids (GL) / 
Glycerophospholipids (GP)  DIACYLGLYCEROL KINASE, GAMMA 
LMP001811  Acad11  Q80XL6  MM.347362   13037  #N/A  A_51_P299260  Not classified 
ACYL‐COENZYME A DEHYDROGENASE FAMILY, 
MEMBER 11 
LMP001813  St3gal1  P54751  MM.371457   37431  #N/A  A_51_P301804  Sphingolipids (SP) 
ST3 BETA‐GALACTOSIDE ALPHA‐2,3‐
SIALYLTRANSFERASE 1 
LMP001816  Zdhhc17  Q8BIT5  MM.339281   15248  #N/A  A_51_P348672  Fatty acids/Eicosanoids (FA)  HUNTINGTIN INTERACTING PROTEIN 14 
LMP001823  Hacl1  Q9QXE0  MM.38887   36032  #N/A  A_51_P314065  Not classified  PHYTANOYL‐COA 2‐HYDROXYLASE 2 
LMP001824 
9130022
K13Rik  Q9D2Y0  MM.232636   17766  #N/A  #N/A  Not classified  RIKEN CDNA 9130022K13 GENE 
LMP001827  Osbpl5  Q9ER64  MM.21199   22790  103311_at  A_51_P200309  Sterol Lipids (ST)  OXYSTEROL BINDING PROTEIN‐LIKE 5 
LMP001828  Mlycd  Q9QXE6  MM.255499   45373  103622_at  A_51_P222283  Fatty acids/Eicosanoids (FA)  MALONYL‐COA DECARBOXYLASE 
LMP001842  Acsm3  Q91WI1  MM.334199   37109  #N/A  A_51_P487175  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE MEDIUM‐CHAIN FAMILY 
MEMBER 3 
LMP001847  Plin  Q8C0F5  MM.254917   37305  #N/A  A_51_P244497  Not classified  PERILIPIN 
LMP001851  Hnf4a  Q8CFY1  MM.202383   16277  #N/A  A_51_P198473  Sterol Lipids (ST)  HEPATIC NUCLEAR FACTOR 4, ALPHA 
LMP001855  Scd4  Q8CFY4  MM.313583   108193  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  STEAROYL‐COENZYME A DESATURASE 4 
LMP001856  Cox10  Q8CFY5  MM.340211   144335  #N/A  A_51_P276198  Prenol Lipids (PR) 
COX10 HOMOLOG, CYTOCHROME C OXIDASE 
ASSEMBLY PROTEIN, HEME A: FARNESYL... 
LMP001857  Cyp39a1  Q8CFY8  MM.17991   10876  #N/A  A_51_P515446  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 39, SUBFAMILY A, 
POLYPEPTIDE 1 
LMP001858  Pla2g4f  Q50L41  MM.24880   19813  #N/A  #N/A  Not classified  PHOSPHOLIPASE A2, GROUP IVF 
LMP001859  Pla2g4e  Q50L42  MM.330505   147200  #N/A  A_51_P362498  Not classified  PHOSPHOLIPASE A2, GROUP IVE 
LMP001861  Pla2g4d  Q50L43  NA     13717  #N/A  #N/A  Not classified  PHOSPHOLIPASE A2, GROUP IVD  
LMP001863  Chm  Q9QXG2  MM.257316   26939  #N/A  A_51_P296512  Prenol Lipids (PR)  CHOROIDERMIA 
LMP001873  Npc1l1  Q6T3U4  MM.212492   19653  #N/A  A_51_P262645  Sterol Lipids (ST)  NPC1‐LIKE 1 





at;96848_at  A_51_P166695  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE‐5‐PHOSPHATASE B 
LMP001883  smpd3  Q9JJY3  MM.23298   27939  #N/A  A_51_P383459  Sphingolipids (SP) 
SPHINGOMYELIN PHOSPHODIESTERASE 3, 
NEUTRAL 





LMP001899  Prkab1  Q9R078  MM.200912   148605  160808_at  #N/A  Fatty acids/Eicosanoids (FA) 
PROTEIN KINASE, AMP‐ACTIVATED, BETA 1 NON‐
CATALYTIC SUBUNIT 
LMP001903  Acbd3  Q8BMP6  MM.272981   3381  #N/A  A_51_P326762  Sterol Lipids (ST) 
ACYL‐COENZYME A BINDING DOMAIN 
CONTAINING 3 
LMP001906  Pigf  O09101  MM.219685   149069  101466_at  A_51_P264053  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASS F 





LMP001915  Ipmk  Q7TT16  MM.245867   148510  #N/A  A_51_P472799  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE MULTIKINASE 
LMP001922  Stard6  P59096  MM.83623   19307  #N/A  A_51_P397152  Sterol Lipids (ST) 
STAR‐RELATED LIPID TRANSFER (START) DOMAIN 
CONTAINING 6 
LMP001925  Pafah2  Q8VDG7  MM.22116   4648  #N/A  A_51_P345896  Glycerophospholipids (GP) 
PLATELET‐ACTIVATING FACTOR 
ACETYLHYDROLASE 2 
LMP001930  Akr1c18  Q8K023  MM.41337   4187  #N/A  A_51_P256170  Sterol Lipids (ST)  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER C18 






LMP001933  Ptgds  O09114  MM.1008   147644 
102105_f_at;
92545_f_at;9
2546_r_at  A_51_P157403  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN D2 SYNTHASE (BRAIN) 
LMP001934  Ptgs1  P22437  MM.275434   18555 
161694_f_at,
95597_at  A_51_P279100  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN‐ENDOPEROXIDE SYNTHASE 1 
LMP001944  Azgp1  Q64726  MM.30061   8857  96867_at  A_51_P456721  Not classified  ALPHA‐2‐GLYCOPROTEIN 1, ZINC 
LMP001948  Ptger4  P32240  MM.18509   144520  103362_at  A_51_P207988  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN E RECEPTOR 4 (SUBTYPE EP4) 
LMP001957  Pla2g3  Q6AXH0  MM.100476   43776  #N/A  A_51_P402868  Not classified  PHOSPHOLIPASE A2, GROUP III 
LMP001961  Coq3  Q8BMS4  MM.5662   22118  99365_at  A_51_P378336  Prenol Lipids (PR) 
COENZYME Q3 HOMOLOG, 
METHYLTRANSFERASE (YEAST) 





LMP001985  Hdlbp  Q8VDJ3  MM.30012   35186  96359_at  A_51_P416591  Sterol Lipids (ST) 
DNA SEGMENT, CHR 1, ERATO DOI 101, 
EXPRESSED 





LMP001990  Hhat  Q8BMT9  MM.145857   26910  #N/A  A_51_P445677  Fatty acids/Eicosanoids (FA)  HEDGEHOG ACYLTRANSFERASE 
LMP001998  Sftpb  P50405  MM.46033   13393  160891_at  A_51_P269134  Sphingolipids (SP)  SURFACTANT ASSOCIATED PROTEIN B 
LMP002000  Ptgfr  P43117  MM.331442   146259 
161713_f_at;
97769_at  A_51_P511329  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN F RECEPTOR 
LMP002005  Vdr  Q922X0  MM.245084   5037 
99964_at;999
65_at  A_51_P506843  Sterol Lipids (ST)  VITAMIN D RECEPTOR 
LMP002010  Acsl4  Q5D071  MM.143689   17019  #N/A  A_51_P268154  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE LONG‐CHAIN FAMILY 
MEMBER 4 
LMP002026  Ptgs1  Q6QDC8  MM.275434   18555 
161694_f_at,
95597_at  A_51_P279100  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN‐ENDOPEROXIDE SYNTHASE 1 
LMP002033  Fut1  O09160  MM.56933   15895  99381_at  A_51_P222604 
Glycerolipids (GL) / 
Sphingolipids (SP)  FUCOSYLTRANSFERASE 1 
LMP002034  Nr2f2  P43135  MM.158143   29270  103052_r_at  A_51_P147684  Sterol Lipids (ST) 
NUCLEAR RECEPTOR SUBFAMILY 2, GROUP F, 
MEMBER 2 
LMP002036  Apoe  P08226  MM.305152   15454 
161321_i_at;
95356_at  A_51_P171999  Not classified  APOLIPOPROTEIN E 
LMP002037  Sts  P50427  MM.5129   19966 
98860_at;988
61_at  A_51_P377526  Sterol Lipids (ST)  STEROID SULFATASE 
LMP002038  Arsa  P50428  MM.620   38094 
100931_at;16
1286_f_at  A_51_P310649  Sphingolipids (SP)  ARYLSULFATASE A 
LMP002042  Dgkd  Q80Y60  MM.277217   9628  #N/A  #N/A  Glycerolipids (GL)  DIACYLGLYCEROL KINASE, DELTA 





LMP002055  Cyp21  P03940  MM.57192   144658  #N/A  #N/A  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 21, SUBFAMILY A, 
POLYPEPTIDE 1 
LMP002056  Adfp  Q8K3Q8  MM.381   39259 
161443_r_at;
98589_at  A_51_P258150  Fatty acids/Eicosanoids (FA)  ADIPOSE DIFFERENTIATION RELATED PROTEIN 
LMP002059  Amacr  O09174  NA     24913  95588_at  A_51_P118885  Prenol Lipids (PR)  2‐METHYLACYL‐COA RACEMASE  
LMP002067  Chpt1  Q6SXV1  MM.288897   30110  #N/A  A_51_P240857  Not classified  CHOLINE PHOSPHOTRANSFERASE 1 
LMP002070  Mtmr12  Q8C0P1  MM.54460   4003  #N/A  A_51_P308308  Not classified  VMYOTUBULARIN RELATED PROTEIN 12 
LMP002075  Plcd4  Q8K3R3  MM.290731   149111  #N/A  #N/A  Glycerophospholipids (GP)  PHOSPHOLIPASE C, DELTA 4 
                 
LMP002080  Acadl  P51174  MM.2445   144354  95425_at  A_51_P149455  Fatty acids/Eicosanoids (FA) 
ACETYL‐COENZYME A DEHYDROGENASE, LONG‐
CHAIN 






LMP002085  Pon1  Q91X30  MM.237657   17183  96895_at  A_51_P108659  Sterol Lipids (ST)  PARAOXONASE 1 
LMP002089  Cyp11b2  P15539  MM.377079   146066  #N/A  A_51_P508159  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 11, SUBFAMILY B, 
POLYPEPTIDE 2 
LMP002095  Akr1c14  Q91WT7  MM.26838   7965  #N/A  A_51_P284177  Sterol Lipids (ST)  RIKEN CDNA 9030611N15 GENE 
LMP002097  Hnf4a  P49698  MM.202383   16277  #N/A  A_51_P198473  Sterol Lipids (ST)  HEPATIC NUCLEAR FACTOR 4, ALPHA 














LMP002113  Zdhhc7  Q91WU6  MM.240076   7125  #N/A  A_51_P154933  Fatty acids/Eicosanoids (FA)  ZINC FINGER, DHHC DOMAIN CONTAINING 7 




LMP002132  Acox1  Q8BYC3  MM.383812   16948 
101515_at;16
2158_r_at  A_51_P366704  Fatty acids/Eicosanoids (FA)  ACYL‐COENZYME A OXIDASE 1, PALMITOYL 










LMP002140  Adipor2  Q8BQS5  MM.291826   6586  #N/A  A_51_P257151  Fatty acids/Eicosanoids (FA)  EST AI115388 










LMP002148  Pla2g2d  Q9WVF6  MM.71913   66677  #N/A  A_51_P232281 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP IID 
LMP002151  Rara  Q5BLJ8  MM.103336   149784  92901_at  A_51_P389724 
Prenol Lipids (PR) / / Sterol 
Lipids (ST)  RETINOIC ACID RECEPTOR, ALPHA 
LMP002153  Thrap5  Q6PGF3  MM.260089   13263  #N/A  A_51_P297552  Not classified 
THYROID HORMONE RECEPTOR ASSOCIATED 
PROTEIN 5 
LMP002154  Dapp1  Q9QXT1  MM.254835   148780  #N/A  A_51_P244824  Glycerophospholipids (GP) 
DUAL ADAPTOR FOR PHOSPHOTYROSINE AND 3‐
PHOSPHOINOSITIDES 1 
LMP002157  Acat1  Q8QZT1  MM.293233   19679  #N/A  A_51_P319449  Fatty acids/Eicosanoids (FA)  ACETYL‐COENZYME A ACETYLTRANSFERASE 1 





7  MM.86557   14518  #N/A  A_51_P389265  Glycerolipids (GL)  ADIPONUTRIN 
                 
LMP002163  Plekha1  Q8BUL6  MM.323554   145652  #N/A  A_51_P237367  Not classified 
PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, 
FAMILY A (PHOSPHOINOSITIDE BIND... 
LMP002167  Alox5  P48999  MM.41072   14970  #N/A 
A_51_P247249;A_
51_P473051  Fatty acids/Eicosanoids (FA)  ARACHIDONATE 5‐LIPOXYGENASE 
LMP002169  Ppargc1b  Q8VHJ7  MM.32269   145357  #N/A  A_51_P294891  Not classified 
PEROXISOME PROLIFERATIVE ACTIVATED 
RECEPTOR, GAMMA, COACTIVATOR 1 BETA 
LMP002170  Slc10a4  Q8BJC7  MM.253661   9142  #N/A  A_51_P448479  Not classified 
SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID 
COTRANSPORTER FAMILY), MEMB... 





LMP002173  Lipg  Q9WVG5  MM.299647   17095  #N/A  A_51_P354782  Glycerolipids (GL)  LIPASE, ENDOTHELIAL 
LMP002175  Grk6  O70293  MM.10193   144592  #N/A  #N/A  Glycerophospholipids (GP)  G PROTEIN‐COUPLED RECEPTOR KINASE 6 
LMP002178  Phyh  O35386  MM.27066   148871  96608_at  A_51_P276063 
Fatty acids/Eicosanoids (FA) / 
Prenol Lipids (PR)  PHYTANOYL‐COA HYDROXYLASE 
LMP002179  Ttpa  Q8QZU5  MM.379065   26891  #N/A  A_51_P258817  Prenol Lipids (PR)  TOCOPHEROL (ALPHA) TRANSFER PROTEIN 
LMP002181  Hsd17b7  O88736  MM.12882   4622  94177_at  A_51_P250934  Sterol Lipids (ST)  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 7 
LMP002183  Lipf  Q9CPP7  MM.329816   3503  #N/A  A_51_P201174  Glycerolipids (GL)  LIPASE, GASTRIC 







LMP002198  Dci  Q8QZV3  MM.291743   7147  98527_at  A_51_P105589  Fatty acids/Eicosanoids (FA) 
DODECENOYL‐COENZYME A DELTA ISOMERASE 
(3,2 TRANS‐ENOYL‐COENYME A ISOME... 
LMP002199  Dgkb  Q8BUN1  MM.242576   146614  #N/A  A_51_P515612  Glycerolipids (GL)  DIACYLGLYCEROL KINASE, BETA 





LMP002204  Anxa1  P10107  MM.248360   13826 
161703_f_at;
93037_i_at;9
3038_f_at  A_51_P283590  Not classified  ANNEXIN A1 
LMP002205  Acot12  Q9DBK0  MM.275963   145958  #N/A  A_51_P414305  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 12 
LMP002214  Star  P51557  MM.293314   40769 
161784_f_at;
92213_at  A_51_P274436  Sterol Lipids (ST)  STEROIDOGENIC ACUTE REGULATORY PROTEIN 
LMP002216  Slc10a6  Q9CXB2  MM.7446   59888  #N/A  A_51_P173678  Not classified 
SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID 
COTRANSPORTER FAMILY), MEMB... 










F22Rik  Q8VDU3  MM.379359   144986  #N/A  A_51_P500215  Not classified  CDNA SEQUENCE BC020489 
LMP002223  Acox1  Q8C168  MM.383812   16948 
101515_at;16
2158_r_at  A_51_P366704  Fatty acids/Eicosanoids (FA)  ACYL‐COENZYME A OXIDASE 1, PALMITOYL 





LMP002227  Pik3r1  P26450  MM.259333   37643  96592_at  #N/A  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 1 (P85 ... 
LMP002228  Abhd5  Q9DBL9  MM.280254   144532  #N/A  A_51_P407165  Not classified  ABHYDROLASE DOMAIN CONTAINING 5 
LMP002232  Gla  P51569  MM.1114   14848  102341_at  A_51_P153265 
Glycerolipids (GL) / 
Sphingolipids (SP)  GALACTOSIDASE, ALPHA 
LMP002236  Pla2g12b  Q99P27  MM.30268   37683  #N/A  A_51_P184385 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP XIIB 





LMP002240  Pla2g10  Q9QXX3  MM.4214   4590  161034_at  A_51_P380451 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP X 
LMP002242  Lass6  Q8C172  MM.222222   22082  #N/A  A_51_P335269  Not classified 
LONGEVITY ASSURANCE HOMOLOG 6 (S. 
CEREVISIAE) 
LMP002245  Acox3  Q8C178  MM.291503   146997  #N/A  A_51_P252768 
Fatty acids/Eicosanoids (FA) / 
Sterol Lipids (ST)  ACYL‐COENZYME A OXIDASE 3, PRISTANOYL 





LMP002250  Ehhadh  Q9DBM2  MM.28100   146125  #N/A  A_51_P462918  Fatty acids/Eicosanoids (FA) 
ENOYL‐COENZYME A, HYDRATASE/3‐
HYDROXYACYL COENZYME A DEHYDROGENASE 






LMP002262  Ugt2b5  P17717  MM.29157   146553  96796_f_at  #N/A  Sterol Lipids (ST) 
UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, 
POLYPEPTIDE B5 





A20Rik  Q8BYI3  MM.49245   145642  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  RIKEN CDNA 4632408A20 GENE 
LMP002273  Pigs  Q6PD26  MM.295908   14415  #N/A  #N/A  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASS S 
LMP002274  Acox1  Q9R0H0  MM.383812   16948 
101515_at;16
2158_r_at  A_51_P366704  Fatty acids/Eicosanoids (FA)  ACYL‐COENZYME A OXIDASE 1, PALMITOYL 
LMP002276  Tnr  Q8BYI9  MM.383195   147060  #N/A  #N/A  Sphingolipids (SP)  TENASCIN R 
LMP002282  Shh  Q62226  MM.57202   6746  101831_at  A_51_P350419  Sterol Lipids (ST)  SONIC HEDGEHOG 
LMP002287  Apobec1  P51908  MM.3333   35220  98398_s_at  A_51_P160754  Not classified  APOLIPOPROTEIN B EDITING COMPLEX 1 
LMP002290  Pdk1  Q8BFP9  MM.34411   147286  #N/A  A_51_P406429  Not classified 
PYRUVATE DEHYDROGENASE KINASE, 
ISOENZYME 1 
LMP002294  Cyp39a1  Q9JKJ9  MM.17991   10876  #N/A  A_51_P515446  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 39, SUBFAMILY A, 
POLYPEPTIDE 1 
LMP002299  Ddhd1  Q80YA3  MM.121918   22102  #N/A  A_51_P454441  Not classified  DDHD DOMAIN CONTAINING 1 
LMP002301  Srd5a1  Q8BUR8  MM.315983   12273  #N/A  A_51_P420415  Sterol Lipids (ST)  STEROID 5 ALPHA‐REDUCTASE 1 
LMP002302  Pik3r1  Q80UI5  MM.259333   37643  96592_at  #N/A  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 1 (P85 ... 
LMP002303  Apod  P51910  MM.2082   144426  93592_at  A_51_P366811  Not classified  APOLIPOPROTEIN D 





LMP002306  Inpp5d  Q61181  MM.15105   3846  #N/A  A_51_P337125  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE‐5‐PHOSPHATASE D 
LMP002309  Gpr68  Q8BFQ3  MM.32160   16856  #N/A  A_51_P296815  Not classified  G PROTEIN‐COUPLED RECEPTOR 68 
LMP002321  Rdh12  Q8BYK4  MM.274373   144082  #N/A  A_51_P141960  Not classified  RETINOL DEHYDROGENASE 12 
LMP002323  Pla2g3  Q8BV23  MM.100476   43776  #N/A  A_51_P402868  Not classified  PHOSPHOLIPASE A2, GROUP III 
LMP002328  Acot11  Q8VHQ9  MM.274924   23811  #N/A 
A_51_P141741;A_
51_P226453  Not classified  THIOESTERASE, ADIPOSE ASSOCIATED 





LMP002340  Syt1  P46096  MM.336111   108131  93005_at 
A_51_P297896;A_
51_P298873  Not classified  SYNAPTOTAGMIN I 
LMP002342  Cyp7a1  Q8BFR7  MM.57029   17149  99404_at  A_51_P290981  Sterol Lipids (ST) 
CYTOCHROME P450, FAMILY 7, SUBFAMILY A, 
POLYPEPTIDE 1 












LMP002355  Plin  Q8CGN5  MM.254917   37305  #N/A  A_51_P244497  Not classified  PERILIPIN 
LMP002356  Dbt  P53395  MM.3636   17113  98966_at  A_51_P350883  Glycerophospholipids (GP) 
DIHYDROLIPOAMIDE BRANCHED CHAIN 
TRANSACYLASE E2 
LMP002357  Akr1b1  P45376  MM.451   3746  #N/A  #N/A  Glycerolipids (GL) 
ALDO‐KETO REDUCTASE FAMILY 1, MEMBER B3 
(ALDOSE REDUCTASE) 
LMP002358  Inppl1  Q6P549  MM.5028   16981  102988_at  A_51_P142334  Glycerophospholipids (GP)  INOSITOL POLYPHOSPHATE PHOSPHATASE‐LIKE 1 
LMP002360  Akr1b8  P45377  MM.5378   17166  100884_at  A_51_P128987  Glycerolipids (GL)  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER B8 






LMP002382  Esrrb  Q61539  MM.235550   149415  100301_at  A_51_P419047  Sterol Lipids (ST)  ESTROGEN RECEPTOR RELATED 2 
LMP002389  Oxsm  Q9D404  MM.197960   23143  #N/A  A_51_P312749  Fatty acids/Eicosanoids (FA)  3‐OXOACYL‐ACP SYNTHASE, MITOCHONDRIAL 
LMP002390  Scd2  P13011  MM.193096   4054 
162077_f_at,
95758_at  A_51_P129464  Fatty acids/Eicosanoids (FA)  STEAROYL‐COENZYME A DESATURASE 2 
LMP002394  Atp8b3  Q9CPY8  MM.52511   16782  #N/A  A_51_P371500  Not classified  ATPASE, CLASS I, TYPE 8B, MEMBER 3 
LMP002396  Pgr  Q00175  MM.12798   146799  98726_at  A_51_P213476  Sterol Lipids (ST)  PROGESTERONE RECEPTOR 
LMP002398  Pnpla8  Q9DC20  MM.54126   14954  #N/A  A_51_P201104  Not classified  RIKEN CDNA 1200006O19 GENE 
LMP002399  Gbgt1  Q8VI38  MM.213199   26263  #N/A  A_51_P394281  Sphingolipids (SP) 
GLOBOSIDE ALPHA‐1,3‐N‐
ACETYLGALACTOSAMINYLTRANSFERASE 1 
LMP002400  Stard3  Q61542  MM.265546   30268 
162228_f_at;
95607_at  A_51_P154973  Sterol Lipids (ST)  START DOMAIN CONTAINING 3 





LMP002416  Phca  Q9D099  MM.334041   144791  #N/A  A_51_P130757  Sphingolipids (SP)  PHYTOCERAMIDASE, ALKALINE 





LMP002423  Chpt1  Q8K0H2  MM.288897   30110  #N/A  A_51_P240857  Not classified  CHOLINE PHOSPHOTRANSFERASE 1 
LMP002430  Acox3  Q7TPP6  MM.291503   146997  #N/A  A_51_P252768 
Fatty acids/Eicosanoids (FA) / 
Prenol Lipids (PR)  ACYL‐COENZYME A OXIDASE 3, PRISTANOYL 






LMP002440  Cyp19a1  P28649  MM.5199   7249  101200_at  A_51_P474555  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 19, SUBFAMILY A, 
POLYPEPTIDE 1 
LMP002441  Esr2  Q8BG65  MM.2561   10899  96514_at  A_51_P279803  Sterol Lipids (ST)  ESTROGEN RECEPTOR 2 (BETA) 
LMP002442  Lpin1  Q8CD95  MM.153625   12995  98892_at  A_51_P394984  Not classified  LIPIN 1 






LMP002447  Nsddr  Q6WQJ1  MM.329718   31996  #N/A  #N/A  Not classified  5'‐NUCLEOTIDASE DOMAIN CONTAINING 3 
LMP002450  Plch1  Q7TPQ1  MM.316391   147017  #N/A  #N/A  Not classified  PHOSPHOLIPASE C‐LIKE 3 
LMP002451  Fads3  Q8C4Y5  MM.253875   144010  #N/A  A_51_P464029  Fatty acids/Eicosanoids (FA)  FATTY ACID DESATURASE 3 
LMP002452  Star  Q6P910  MM.293314   40769 
161784_f_at;
92213_at  A_51_P274436  Sterol Lipids (ST)  STEROIDOGENIC ACUTE REGULATORY PROTEIN 
LMP002453  Dgkz  Q80UP3  MM.314923   27299  #N/A 
A_51_P226049;A_
51_P505156  Glycerolipids (GL)  DIACYLGLYCEROL KINASE ZETA 
LMP002456  Crot  Q9DC50  MM.28197   28137  #N/A  A_51_P489153  Fatty acids/Eicosanoids (FA)  CARNITINE O‐OCTANOYLTRANSFERASE 
LMP002458  Galc  P54818  MM.5120   15929 
161732_at;93
131_at  A_51_P428688  Sphingolipids (SP)  GALACTOSYLCERAMIDASE 
LMP002464  Plekha3  Q9ERS4  MM.41636   34426  #N/A  A_51_P108525  Glycerophospholipids (GP) 
PLECKSTRIN HOMOLOGY DOMAIN‐CONTAINING, 
FAMILY A (PHOSPHOINOSITIDE BIND... 





LMP002467  Ncoa6  Q9JL19  MM.27592   11429 
95351_at;955
25_at  A_51_P521128  Not classified  NUCLEAR RECEPTOR COACTIVATOR 6 
LMP002473  Ptges3  Q9R0Q7  MM.22421   14581  #N/A 
A_51_P165960;A_
51_P474367  Not classified  PROSTAGLANDIN E SYNTHASE 3 (CYTOSOLIC) 
LMP002475  Pla1a  Q8VI78  MM.279805   145809  #N/A  A_51_P381618  Not classified  PHOSPHOLIPASE A1 MEMBER A 
LMP002476  Ldlr  P35951  MM.3213   8818  160832_at  A_51_P274173  Sterol Lipids (ST)  LOW DENSITY LIPOPROTEIN RECEPTOR 











LMP002490  Fut2  Q9JL27  MM.290046   17765  101760_at  A_51_P393098 
Glycerolipids (GL) / 
Sphingolipids (SP)  FUCOSYLTRANSFERASE 2 
LMP002494  Pgr  Q8BZ29  MM.12798   146799  98726_at  A_51_P213476  Sterol Lipids (ST)  PROGESTERONE RECEPTOR 
LMP002495  Acsl4  Q9QUJ7  MM.143689   17019  #N/A  A_51_P268154  Fatty acids/Eicosanoids (FA) 
ACYL‐COA SYNTHETASE LONG‐CHAIN FAMILY 
MEMBER 4 
LMP002498  Pnpla2  Q643S0  MM.29998   26846  #N/A  A_51_P197213  Not classified 
PATATIN‐LIKE PHOSPHOLIPASE DOMAIN 
CONTAINING 2 
LMP002499  Pnpla6  Q9R114  MM.23085   4926  #N/A  A_51_P301891  Not classified  NEUROPATHY TARGET ESTERASE 
LMP002502  Ltc4s  Q60860  MM.245151   45402  92401_at  A_51_P354792  Fatty acids/Eicosanoids (FA)  LEUKOTRIENE C4 SYNTHASE 
LMP002514 
4833405
L16Rik  Q8BFZ6  MM.313743   37398  #N/A  #N/A  Prenol Lipids (PR)  RIKEN CDNA 4833405L16 GENE 
LMP002515  Plcz1  Q8K4D7  MM.50808   37226  #N/A  A_51_P297441  Glycerophospholipids (GP)  PHOSPHOLIPASE C, ZETA 1 
LMP002524  Tlr4  Q9QUK6  MM.38049   12229  #N/A  A_51_P300806  Not classified  TOLL‐LIKE RECEPTOR 4 
LMP002528  Nat6  Q9R123  MM.10305   9303  104439_at  A_51_P268145  Glycerophospholipids (GP)  N‐ACETYLTRANSFERASE 6 
LMP002533  Vdr  P48281  MM.245084   5037 
99964_at;999
65_at  A_51_P506843  Sterol Lipids (ST)  VITAMIN D RECEPTOR 
LMP002534  Ugt1a6  Q64435  MM.300095   146268  #N/A  #N/A  Sterol Lipids (ST) 
UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, 
POLYPEPTIDE A6A 





LMP002536  Inpp5a  Q8BNK3  MM.277096   5838  #N/A  A_51_P364014  Not classified  INOSITOL POLYPHOSPHATE‐5‐PHOSPHATASE A 






LMP002539  Pnlip  Q6P8U6  MM.20407   17651  #N/A  A_51_P520552  Sterol Lipids (ST)  PANCREATIC LIPASE 
LMP002542  Acaca  Q705X8  MM.352014   36995  #N/A 
A_51_P191939;A_
51_P439426  Fatty acids/Eicosanoids (FA)  ACETYL‐COENZYME A CARBOXYLASE ALPHA 
LMP002543  Rdh1  Q8CGV4  MM.235814   8096  #N/A  #N/A 
Prenol Lipids (PR) / Sterol 
Lipids (ST)  RETINOL DEHYDROGENASE 1 (ALL TRANS) 










LMP002553  Pla2g2e  Q9QUL3  MM.296007   14170  #N/A  A_51_P311159 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP IIE 





LMP002560  Ncoa2  Q7TPU7  MM.2537   12954  96508_at  A_51_P478593  Not classified  NUCLEAR RECEPTOR COACTIVATOR 2 
                 





LMP002565  Ptdss1  Q99LH2  MM.281464   3506 
101931_at;16
1864_f_at  A_51_P442056  Glycerophospholipids (GP)  PHOSPHATIDYLSERINE SYNTHASE 1 
LMP002573  Prmt2  Q9R144  MM.32020   149274  #N/A  A_51_P219064  Sterol Lipids (ST)  PROTEIN ARGININE N‐METHYLTRANSFERASE 2 
LMP002581  Cyp2c29  Q64458  MM.20764   147212  93585_at  A_51_P103706  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY C, 
POLYPEPTIDE 29 
LMP002582  Pgrmc2  Q80UU9  MM.40321   22116  #N/A  A_51_P413916  Sterol Lipids (ST) 
PROGESTERONE RECEPTOR MEMBRANE 
COMPONENT 2 
LMP002583  Dgkq  Q8BK42  MM.260921   20152  #N/A  A_51_P329869  Glycerolipids (GL)  DIACYLGLYCEROL KINASE, THETA 
LMP002584  Cyp3a11  Q64459  MM.332844   98682  93770_at  A_51_P355301  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 3, SUBFAMILY A, 
POLYPEPTIDE 11 





LMP002589  Gltp  Q9JL62  MM.275766   26293  #N/A  A_51_P255271  Not classified  GLYCOLIPID TRANSFER PROTEIN 





LMP002591  Rdh11  Q9QYF1  MM.291799   16643 
99591_i_at;9
9592_f_at  A_51_P469160  Not classified  RETINOL DEHYDROGENASE 11 
LMP002592  Pigc  Q9CXR4  MM.45106   12872  #N/A  A_51_P307800  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASSC 
LMP002598  Sdhb  Q9CQA3  MM.246965   5189  95053_s_at  A_51_P234853  Prenol Lipids (PR) 
SUCCINATE DEHYDROGENASE COMPLEX, 
SUBUNIT B, IRON SULFUR (IP) 
LMP002608  Cyp3a13  Q64464  MM.289886   19495  99463_at  A_51_P114941  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 3, SUBFAMILY A, 
POLYPEPTIDE 13 
LMP002609  Cyp2c37  P56654  MM.220317   148321  99083_at  A_51_P498882  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2. SUBFAMILY C, 
POLYPEPTIDE 37 
LMP002611  Cyp2c38  P56655  MM.42100   8638  102084_f_at  A_51_P342207  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY C, 
POLYPEPTIDE 38 
LMP002612  Cyp2c39  P56656  MM.42101   147076  98295_at  A_51_P304111  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY C, 
POLYPEPTIDE 39 
LMP002614  Cyp2c40  P56657  MM.358585   37664  96334_f_at  A_51_P502599  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY C, 
POLYPEPTIDE 40 
LMP002621  Wbscr22  Q9CY21  MM.347936   4185  #N/A  A_51_P456590  Sterol Lipids (ST) 
WILLIAMS BEUREN SYNDROME CHROMOSOME 
REGION 22 
LMP002624  Gyk  Q8C8X0  MM.246682   144099  97525_at  A_51_P297671  Glycerolipids (GL)  GLYCEROL KINASE 
LMP002630  Rbp1  Q00915  MM.279741   20055  104716_at  A_51_P423484  Prenol Lipids (PR)  RETINOL BINDING PROTEIN 1, CELLULAR 
LMP002633  Ptger2  Q8BZ75  MM.4630   31104  98768_at  A_51_P249215  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN E RECEPTOR 2 (SUBTYPE EP2) 
LMP002636  Apol2  Q8BZ78  MM.125650   5737  #N/A  A_51_P115471  Not classified  APOLIPOPROTEIN L, 2 
LMP002642  Osbp  Q570Y8  MM.291279   35712  #N/A  A_51_P393768  Sterol Lipids (ST)  OXYSTEROL BINDING PROTEIN 
LMP002644  Srd5a1  Q68FF9  MM.315983   12273  #N/A  A_51_P420415  Sterol Lipids (ST)  STEROID 5 ALPHA‐REDUCTASE 1 
LMP002646  Fabp1  P12710  MM.22126   21351 
162342_at;94
075_at  A_51_P487818  Fatty acids/Eicosanoids (FA)  FATTY ACID BINDING PROTEIN 1, LIVER 
LMP002655  Clk1  P22518  MM.1761   144442  #N/A  A_51_P193573  Glycerophospholipids (GP)  CDC‐LIKE KINASE 1 
LMP002656  Clps  Q9CQC2  MM.21160   13665  160132_at  A_51_P164459  Not classified  RIKEN CDNA 2200003J09 GENE 





LMP002662  Ihpk2  Q80V72  MM.276336   9692  #N/A  A_51_P257058  Not classified  INOSITOL HEXAPHOSPHATE KINASE 2 
LMP002670  Ptges  Q8BNP8  MM.28768   59852  104406_at  A_51_P312328  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN E SYNTHASE 
LMP002673  Dci  P42125  MM.291743   7147  98527_at  A_51_P105589  Fatty acids/Eicosanoids (FA) 
DODECENOYL‐COENZYME A DELTA ISOMERASE 
(3,2 TRANS‐ENOYL‐COENYME A ISOME... 
LMP002684  Angptl3  Q9R182  MM.28341   31181  #N/A  A_51_P481679  Not classified  ANGIOPOIETIN‐LIKE 3 
LMP002688  Crat  P47934  MM.20396   24681 
103646_at;16
1989_f_at  A_51_P440807  Fatty acids/Eicosanoids (FA)  CARNITINE ACETYLTRANSFERASE 
LMP002691  Coq6  Q8BJY5  MM.280062   144323  #N/A  A_51_P116479  Prenol Lipids (PR)  COENZYME Q6 HOMOLOG (YEAST) 
LMP002693 
St6galnac





5  Q9QYJ1  MM.40915   37257  #N/A  A_51_P421724  Sphingolipids (SP) 
ST6 (ALPHA‐N‐ACETYL‐NEURAMINYL‐2,3‐BETA‐
GALACTOSYL‐1,3)‐N‐ACETYLGALACT... 
LMP002698  Ptger3  P30557  MM.30424   146974 
96588_at;965
89_at  A_51_P520718  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN E RECEPTOR 3 (SUBTYPE EP3) 
LMP002709  Pla2g10  Q8K130  MM.4214   4590  161034_at  A_51_P380451 
Fatty acids/Eicosanoids (FA) / 
Glycerophospholipids (GP)  PHOSPHOLIPASE A2, GROUP X 





LMP002711  Osbp2  Q5QNQ6  MM.61022   10914  #N/A  A_51_P348636  Sterol Lipids (ST)  OXYSTEROL BINDING PROTEIN 2 





LMP002725  Aadac  Q99PG0  MM.24547   34406  95439_at  A_51_P394115  Not classified  ARYLACETAMIDE DEACETYLASE (ESTERASE) 
LMP002728  Hsd17b8  P50171  MM.275452   146466  #N/A  #N/A  Sterol Lipids (ST)  H2‐K REGION EXPRESSED GENE 6 
LMP002729  Hsd11b1  P50172  MM.28328   37378  97867_at  A_51_P127297  Sterol Lipids (ST)  HYDROXYSTEROID 11‐BETA DEHYDROGENASE 1 
LMP002731  Ptgis  O35074  MM.2339   27536  104538_at  A_51_P372819  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN I2 (PROSTACYCLIN) SYNTHASE 
LMP002732  Ptger3  Q6PDF2  MM.30424   146974 
96588_at;965
89_at  A_51_P520718  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN E RECEPTOR 3 (SUBTYPE EP3) 
LMP002742  Dgkq  Q6P5E8  MM.260921   20152  #N/A  A_51_P329869  Glycerolipids (GL)  DIACYLGLYCEROL KINASE, THETA 
LMP002743  Nmt1  O70310  MM.10265   30273 
102047_at;10
2980_at  A_51_P180825  Fatty acids/Eicosanoids (FA)  N‐MYRISTOYLTRANSFERASE 1 
LMP002744  Nmt2  O70311  MM.65021   8003  102229_at  A_51_P465512  Fatty acids/Eicosanoids (FA)  N‐MYRISTOYLTRANSFERASE 2 
LMP002745  Sult2b1  O35400  MM.271634   9560  101406_at  A_51_P403170  Sterol Lipids (ST) 
SULFOTRANSFERASE FAMILY, CYTOSOLIC, 2B, 
MEMBER 1 
                 




LMP002755  Scgb1a1  Q06318  MM.2258   14448  94291_at  A_51_P128575  Sterol Lipids (ST) 
SECRETOGLOBIN, FAMILY 1A, MEMBER 1 
(UTEROGLOBIN) 
LMP002757  Ache  P21836  MM.255464   16860  104650_at  A_51_P117627  Glycerophospholipids (GP)  ACETYLCHOLINESTERASE 
LMP002761  Gal3st1  Q9JHE4  MM.103414   3839  #N/A  A_51_P354354 
Glycerolipids (GL) / 
Sphingolipids (SP)  GALACTOSE‐3‐O‐SULFOTRANSFERASE 1 
LMP002763  Pigk  Q9CXY9  MM.331447   8124  #N/A  A_51_P197174  Glycerophospholipids (GP)  RIKEN CDNA 3000001O05 GENE 
LMP002764  Prkch  P23298  MM.341677   107086  99916_at  A_51_P355852  Glycerolipids (GL)  PROTEIN KINASE C, ETA 
LMP002765  Rarg  P20787  MM.1273   5803  102419_at  A_51_P372853 
Prenol Lipids (PR) / Sterol 
Lipids (ST)  RETINOIC ACID RECEPTOR, GAMMA 
LMP002772  B3galt4  Q9Z0F0  MM.11132   144732  102267_at  A_51_P167105  Sphingolipids (SP) 
UDP‐GAL:BETAGALNAC BETA 1,3‐
GALACTOSYLTRANSFERASE, POLYPEPTIDE 4 
LMP002774  Cpt1c  Q8BGD5  MM.231465   26746  #N/A  A_51_P177562  Fatty acids/Eicosanoids (FA)  CARNITINE PALMITOYLTRANSFERASE 1C 
LMP002781  Gpx4  O70325  NA     28391  94897_at  A_51_P462448  Not classified 
PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE 
PEROXIDASE, MITOCHONDRIAL PRECU  
LMP002785  Lias  Q99M04  MM.195776   16736  98909_at  A_51_P430644  Not classified  LIPOIC ACID SYNTHETASE 
LMP002789  Plcb1  Q6PDH1  MM.378986   146620 
92465_at;924
66_at;92467_
g_at  A_51_P284665  Glycerophospholipids (GP)  PHOSPHOLIPASE C, BETA 1 
LMP002790  Nr3c1  P06537  MM.129481   143770  98818_at  A_51_P355693  Sterol Lipids (ST) 
NUCLEAR RECEPTOR SUBFAMILY 3, GROUP C, 
MEMBER 1 
LMP002797  Ptgds2  Q9JHF7  MM.143720   37483  #N/A  A_51_P416315  Fatty acids/Eicosanoids (FA) 
PROSTAGLANDIN D2 SYNTHASE 2, 
HEMATOPOIETIC 





LMP002803  Pccb  Q7TMF4  MM.335385   19392  160128_at  A_51_P418259  Fatty acids/Eicosanoids (FA) 
PROPIONYL COENZYME A CARBOXYLASE, BETA 
POLYPEPTIDE 
LMP002808  Pgrmc1  O55022  MM.9052   148833  101585_at  A_51_P144581  Sterol Lipids (ST) 
PROGESTERONE RECEPTOR MEMBRANE 
COMPONENT 1 
LMP002809  Impa1  O55023  MM.183042   145170  101498_at  A_51_P242056  Glycerophospholipids (GP)  INOSITOL (MYO)‐1(OR 4)‐MONOPHOSPHATASE 1 










LMP002812  Dgkk  Q6DIC8  MM.335953   5408  #N/A  #N/A  Not classified  DIACYLGLYCEROL KINASE KAPPA 





LMP002817  Bckdk  O55028  MM.8903   7830  101557_at  A_51_P404413  Not classified 
BRANCHED CHAIN KETOACID DEHYDROGENASE 
KINASE 
LMP002819  Sgms2  Q9D4B1  MM.273360   12698  #N/A  A_51_P211998  Sphingolipids (SP)  RIKEN CDNA 4933405A16 GENE 
LMP002821  Hsd3b2  P26149  MM.196405   37169  101659_at  A_51_P226567  Sterol Lipids (ST) 
HYDROXYSTEROID DEHYDROGENASE‐2, 
DELTA<5>‐3‐BETA 
LMP002822  Esr2  O08537  NA     45332  96514_at  A_51_P279803  Sterol Lipids (ST)  ER‐BETA  
LMP002828  Pik3cg  Q9JHG7  MM.101369   34398  #N/A  A_51_P507832  Glycerophospholipids (GP) 
PHOSPHOINOSITIDE‐3‐KINASE, CATALYTIC, 
GAMMA POLYPEPTIDE 
LMP002830  Dhcr7  O88455  MM.249342   27932  98989_at  A_51_P290986  Sterol Lipids (ST)  7‐DEHYDROCHOLESTEROL REDUCTASE 
LMP002831  Cysltr2  Q920A1  MM.158324   27684  #N/A  A_51_P132013  Fatty acids/Eicosanoids (FA)  CYSTEINYL LEUKOTRIENE RECEPTOR 2 
LMP002832  Gpx4  Q91XR9  MM.332810   144833  94897_at  A_51_P462448  Not classified  GLUTATHIONE PEROXIDASE 4 
LMP002839  Ppargc1a  O70343  MM.259072   13095  #N/A  A_51_P279038  Not classified 
PEROXISOME PROLIFERATIVE ACTIVATED 
RECEPTOR, GAMMA, COACTIVATOR 1 ALPH... 
LMP002842  Cerk  Q8K4Q7  MM.222685   146813  101426_at  A_51_P146360 
Glycerolipids (GL) / 
Sphingolipids (SP)  CERAMIDE KINASE 
LMP002845  Lipe  Q8CDI9  MM.349647   9071  103083_at  A_51_P435366 
Glycerolipids (GL) / Sterol 
Lipids (ST)  LIPASE, HORMONE SENSITIVE 
LMP002847  Cyp2b9  P12790  MM.14413   12602  101862_at  A_51_P467076  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY B, 
POLYPEPTIDE 9 
LMP002849  Cyp2b10  P12791  MM.218749   34409  #N/A  A_51_P182370  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY B, 
POLYPEPTIDE 10 
LMP002855  St3gal3  P97325  MM.251002   16664  #N/A  A_51_P496551  Glycerolipids (GL) 
ST3 BETA‐GALACTOSIDE ALPHA‐2,3‐
SIALYLTRANSFERASE 3 
LMP002856  Oxct1  Q9D0K2  MM.13445   17968  #N/A  A_51_P107321  Fatty acids/Eicosanoids (FA)  3‐OXOACID COA TRANSFERASE 1 
LMP002857  Fut1  P97327  MM.56933   15895  99381_at  A_51_P222604 
Glycerolipids (GL) / 
Sphingolipids (SP)  FUCOSYLTRANSFERASE 1 
LMP002864  Ptgir  P43252  MM.287572   26885  98811_at  A_51_P202408  Fatty acids/Eicosanoids (FA)  PROSTAGLANDIN I RECEPTOR (IP) 







LMP002871  Scd3  Q99PL7  MM.371599   27373  #N/A  A_51_P446045  Fatty acids/Eicosanoids (FA)  STEAROYL‐COENZYME A DESATURASE 3 
LMP002873  Ppt2  O35448  MM.358666   7298  98426_at  A_51_P391885  Fatty acids/Eicosanoids (FA)  PALMITOYL‐PROTEIN THIOESTERASE 2 
LMP002880  Plce1  Q8K4S1  MM.34031   28123  #N/A 
A_51_P137029;A_
51_P451529  Glycerophospholipids (GP)  PHOSPHOLIPASE C‐LIKE PROTEIN 
LMP002881  Pnpla2  Q9DCF6  MM.29998   26846  #N/A  A_51_P197213  Not classified 
PATATIN‐LIKE PHOSPHOLIPASE DOMAIN 
CONTAINING 2 





LMP002888  Acads  Q07417  MM.18759   14602  103401_at  A_51_P452807  Fatty acids/Eicosanoids (FA) 
ACYL‐COENZYME A DEHYDROGENASE, SHORT 
CHAIN 
LMP002889  Crabp2  P22935  MM.4757   14840  100127_at  A_51_P521283  Not classified  CELLULAR RETINOIC ACID BINDING PROTEIN II 
LMP002895  Ech1  O35459  MM.291776   7668  93754_at  A_51_P421846  Fatty acids/Eicosanoids (FA) 
ENOYL COENZYME A HYDRATASE 1, 
PEROXISOMAL 





LMP002900  Acot3  Q9QYR7  MM.202331   8835  #N/A  A_51_P420489  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 3 
LMP002901  Acot2  Q9QYR9  MM.371675   10787  #N/A  #N/A  Fatty acids/Eicosanoids (FA)  ACYL‐COA THIOESTERASE 2 





LMP002905  Scd3  Q8BNZ5  MM.371599   27373  #N/A  A_51_P446045  Fatty acids/Eicosanoids (FA)  STEAROYL‐COENZYME A DESATURASE 3 
LMP002907  B4galnt1  Q09200  MM.386762   146222  #N/A  A_51_P233928  Sphingolipids (SP) 
BETA‐1,4‐N‐ACETYL‐GALACTOSAMINYL 
TRANSFERASE 1 
LMP002908  St8sia6  Q8K4T1  MM.330004   149022  #N/A  A_51_P471791  Glycerolipids (GL) 
ST8 ALPHA‐N‐ACETYL‐NEURAMINIDE ALPHA‐2,8‐
SIALYLTRANSFERASE 6 












LMP002912  Psap  Q61207  MM.277498   37075 
161476_at;97
114_at;97560
_at  A_51_P136820  Sphingolipids (SP)  PROSAPOSIN 
LMP002919  Gba  P17439  MM.5031   37752 
100488_at;16
2295_at  A_51_P423119  Sphingolipids (SP)  GLUCOSIDASE, BETA, ACID 
LMP002923  Hsd3b6  O35469  MM.14435   10683  102729_f_at  A_51_P466312  Sterol Lipids (ST) 
HYDROXYSTEROID DEHYDROGENASE‐6, 
DELTA<5>‐3‐BETA 
LMP002929  Plcd1  Q8R3B1  MM.23963   16634  #N/A  A_51_P239766  Glycerophospholipids (GP)  PHOSPHOLIPASE C, DELTA 1 




098_at  A_51_P379801  Sterol Lipids (ST)  FARNESYL DIPHOSPHATE SYNTHETASE 
LMP002932  Nr3c2  Q8VII8  MM.324393   35995  #N/A  #N/A  Sterol Lipids (ST) 
NUCLEAR RECEPTOR SUBFAMILY 3, GROUP C, 
MEMBER 2 
LMP002934  Itpkb  Q8BKB2  MM.383297   38142  #N/A  A_51_P250307  Not classified  INOSITOL 1,4,5‐TRISPHOSPHATE 3‐KINASE B 
LMP002936  Zdhhc15  Q8BGJ0  MM.30574   144594  #N/A  A_51_P405375  Fatty acids/Eicosanoids (FA)  ZINC FINGER, DHHC DOMAIN CONTAINING 15 





LMP002939  Slc10a2  P70172  MM.3500   147628  97150_at  A_51_P243755  Sterol Lipids (ST)  SOLUTE CARRIER FAMILY 10, MEMBER 2 
LMP002940  Cyp2b19  O55071  MM.14098   7650  102690_at  A_51_P352763  Fatty acids/Eicosanoids (FA) 
CYTOCHROME P450, FAMILY 2, SUBFAMILY B, 
POLYPEPTIDE 19 
LMP002944  Esrra  O08580  NA     13011 
102145_f_at;
103964_at  A_51_P248580  Sterol Lipids (ST)  ERR‐ALPHA  
LMP002949  Pik3r2  O08908  MM.12945   15466  102759_at  A_51_P417725  Glycerophospholipids (GP) 
PHOSPHATIDYLINOSITOL 3‐KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 2 (P85 ... 
LMP002953  Pten  O08586  MM.245395   145820 
160614_at;94
988_at  A_51_P275350  Glycerophospholipids (GP)  PHOSPHATASE AND TENSIN HOMOLOG 
LMP002954  Sc5dl  O88822  MM.32700   147456  #N/A  #N/A  Sterol Lipids (ST) 
STEROL‐C5‐DESATURASE (FUNGAL ERG3, DELTA‐
5‐DESATURASE) HOMOLOG (S. CER... 
                 





LMP002959  Pigq  Q9QYT7  MM.362054   12583 
100594_at;10
1646_at;1620
27_f_at  A_51_P232107  Glycerophospholipids (GP)  PHOSPHATIDYLINOSITOL GLYCAN, CLASS Q 
LMP002961  Pdss2  Q33DR3  MM.363225   11230  #N/A  A_51_P513181  Not classified 
PRENYL (SOLANESYL) DIPHOSPHATE SYNTHASE, 
SUBUNIT 2 
LMP002965  Rarres1  Q8BVL6  MM.38002   13381  #N/A  A_51_P401184  Not classified 
RETINOIC ACID RECEPTOR RESPONDER 
(TAZAROTENE INDUCED) 1 
LMP002969  Arsg  Q3TYD4  MM.211850   145084  #N/A  A_51_P221263  Not classified  ARYLSULFATASE G 
LMP002970  Rdh1  Q8VIJ7  MM.235814   8096  #N/A  #N/A  Not classified  RETINOL DEHYDROGENASE 1 (ALL TRANS) 
LMP002974  Pip5k1b  P70181  MM.217214   34377  104663_at  A_51_P410260  Not classified 
PHOSPHATIDYLINOSITOL‐4‐PHOSPHATE 5‐
KINASE, TYPE 1 ALPHA 
LMP002980  Faah  O08914  MM.256025   3449  96795_at  A_51_P386660  Not classified  FATTY ACID AMIDE HYDROLASE 
LMP002991  Slc22a16  Q3LVC1  MM.332570   4792  #N/A  A_51_P144134  Not classified 
SOLUTE CARRIER FAMILY 22 (ORGANIC CATION 
TRANSPORTER), MEMBER 16 





LMP002996  St3gal4  Q91Y74  MM.275973   148317  #N/A  A_51_P135132  Not classified 
ST3 BETA‐GALACTOSIDE ALPHA‐2,3‐
SIALYLTRANSFERASE 4 
LMP003000  Acsbg1  Q6ZQ79  MM.20592   147390  #N/A  A_51_P457636  Not classified 
ACYL‐COA SYNTHETASE BUBBLEGUM FAMILY 
MEMBER 1 
LMP003004  Slc18a2  Q8BRU6  MM.268797   4891  #N/A  A_51_P469551  Not classified 
SOLUTE CARRIER FAMILY 18 (VESICULAR 
MONOAMINE), MEMBER 2 
LMP003007  Gdpd5  Q640M6  MM.286317   144041  #N/A  A_51_P468463  Not classified 
GLYCEROPHOSPHODIESTER 
PHOSPHODIESTERASE DOMAIN CONTAINING 5 
LMP003017  Acsm3  Q3UNX5  MM.334199   37109  #N/A  A_51_P487175  Not classified 
ACYL‐COA SYNTHETASE MEDIUM‐CHAIN FAMILY 
MEMBER 3 
LMP003018  Fnta  Q61239  MM.3496   36170  98121_at  A_51_P112114  Not classified  FARNESYLTRANSFERASE, CAAX BOX, ALPHA 
LMP003023  Gdpd3  Q99LY2  MM.246881   16918  #N/A  A_51_P426872  Not classified 
GLYCEROPHOSPHODIESTER 
PHOSPHODIESTERASE DOMAIN CONTAINING 3 
LMP003037  Wipi1  Q8R3E3  MM.35817   145763  #N/A  A_51_P158044  Not classified 
WD REPEAT DOMAIN, PHOSPHOINOSITIDE 
INTERACTING 1 
LMP003044  Prkag3  Q8BGM7  MM.166501   147675  #N/A  A_51_P327129  Not classified 
PROTEIN KINASE, AMP‐ACTIVATED, GAMMA 3 
NON‐CATATLYTIC SUBUNIT 




LMP003067  Plekha6  Q7TQG1  MM.253559   145922  #N/A  A_51_P310850  Not classified  HYPOTHETICAL PROTEIN BC031133 
LMP003072  Enpp6  Q8BGN3  MM.211429   27969  #N/A  A_51_P359806  Not classified 
ECTONUCLEOTIDE 
PYROPHOSPHATASE/PHOSPHODIESTERASE 6 
LMP003096  Plaa  P27612  MM.22724   14412 
160169_at;94
825_at  A_51_P378348  Not classified  PHOSPHOLIPASE A2, ACTIVATING PROTEIN 
LMP003111  Inpp4b  Q6P1Y8  NA     11030  #N/A  #N/A  Not classified 
INOSITOL POLYPHOSPHATE‐4‐PHOSPHATASE, 
TYPE II  
LMP003113  Oxct2b  Q2HJ06  MM.189660     #N/A  #N/A  Not classified    
LMP003117  Abpd  Q9JI02  MM.296883   36043  #N/A  A_51_P491627  Not classified  ANDROGEN BINDING PROTEIN DELTA 
LMP003122  Dhrs3  O88876  MM.14063   6980  102797_at  A_51_P282947  Not classified 
DEHYDROGENASE/REDUCTASE (SDR FAMILY) 
MEMBER 3 










LMP003133  Hs2st1  Q8R3H7  MM.12863   27100  102306_at  A_51_P469522  Not classified  HEPARAN SULFATE 2‐O‐SULFOTRANSFERASE 1 
LMP003136  Nudt12  Q9DCN1  MM.36507   31775  #N/A  A_51_P136441  Not classified 
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED 
MOIETY X)‐TYPE MOTIF 12 




at  A_51_P189905  Not classified  DEFENDER AGAINST CELL DEATH 1 
LMP003146  Ephx2  P34914  MM.15295   26589  93051_at  A_51_P116940  Not classified  EPOXIDE HYDROLASE 2, CYTOPLASMIC 
LMP003156  Aldh9a1  Q9JLJ2  MM.330055   17185  96243_f_at  A_51_P106211  Not classified  ALDEHYDE DEHYDROGENASE 9, SUBFAMILY A1 




LMP003172  Mboat2  Q8R3I2  MM.167671   23850  #N/A  A_51_P433281  Not classified 
O‐ACYLTRANSFERASE (MEMBRANE BOUND) 
DOMAIN CONTAINING 2 





LMP003186  Pcyt1b  Q811Q9  MM.166467   31075  #N/A  A_51_P353125  Not classified 
PHOSPHATE CYTIDYLYLTRANSFERASE 1, 
CHOLINE, BETA ISOFORM 





LMP003188  Acsm2  Q3US47  MM.268448   147809  #N/A  A_51_P331732  Not classified 
ACYL‐COA SYNTHETASE MEDIUM‐CHAIN FAMILY 
MEMBER 2 
LMP003204  Rchy1  Q9CR50  MM.159453   9660  #N/A  A_51_P374306  Not classified 
RING FINGER AND CHY ZINC FINGER DOMAIN 
CONTAINING 1 
LMP003209  Sra1  Q80VJ2  MM.29058   12945  160323_at  A_51_P226053  Not classified  STEROID RECEPTOR RNA ACTIVATOR 1 
LMP003225  Neu4  Q8BZL1  MM.214565   145694  #N/A  A_51_P507709  Not classified  SIALIDASE 4 
LMP003228  Inppl1  Q9JLL7  MM.5028   16981  102988_at  A_51_P142334  Not classified  INOSITOL POLYPHOSPHATE PHOSPHATASE‐LIKE 1 
LMP003230  Gdpd2  Q9ESM6  MM.283495   145944  #N/A  A_51_P355954  Not classified 
GLYCEROPHOSPHODIESTER 
PHOSPHODIESTERASE DOMAIN CONTAINING 2 






LMP003243  Ffar1  Q76JU9  MM.347605   35188  #N/A  #N/A  Not classified  FREE FATTY ACID RECEPTOR 1 
                 
LMP003246  Rarres2  Q9DD06  MM.28231   12587  #N/A  A_51_P350311  Not classified 
RETINOIC ACID RECEPTOR RESPONDER 
(TAZAROTENE INDUCED) 2 
LMP003254  Plch1  Q4KWH5  MM.316391   147017  #N/A  #N/A  Not classified  PHOSPHOLIPASE C‐LIKE 3 
LMP003256  Nudt3  Q9JI46  MM.144699   146076  101977_at  A_51_P440657  Not classified 
NUDIX (NUCLEOTIDE DIPHOSPHATE LINKED 
MOIETY X)‐TYPE MOTIF 3 
LMP003296  Mmd  Q9CQY7  MM.277518   37579  #N/A  A_51_P431470  Not classified 
MONOCYTE TO MACROPHAGE 
DIFFERENTIATION‐ASSOCIATED 
LMP003303  Echdc2  Q3U553  MM.270783   28069  #N/A  A_51_P477414  Not classified 
ENOYL COENZYME A HYDRATASE DOMAIN 
CONTAINING 2 
LMP003324  Aldh1a3  Q9JHW9  MM.140988   18871  98372_at  A_51_P499482  Not classified 
ALDEHYDE DEHYDROGENASE FAMILY 1, 
SUBFAMILY A3 
LMP003334  Apoh  Q01339  MM.2266   19219  94318_at  A_51_P342387  Not classified  APOLIPOPROTEIN H 
LMP003356  Gpx1  P11352  MM.1090   3915  94132_at  A_51_P119725  Not classified  GLUTATHIONE PEROXIDASE 1 
LMP003363  Pllp  Q9DCU2  MM.279977   36199  #N/A 
A_51_P154867;A_
51_P201187  Not classified  PLASMA MEMBRANE PROTEOLIPID 
LMP003369  Cyp2b20  Q62397  MM.218749   34409  102701_at  #N/A  Not classified 
CYTOCHROME P450, FAMILY 2, SUBFAMILY B, 
POLYPEPTIDE 10 
LMP003393  Slc37a1  Q8R070  MM.311395   26509  #N/A  A_51_P215489  Not classified 
SOLUTE CARRIER FAMILY 37 (GLYCEROL‐3‐
PHOSPHATE TRANSPORTER), MEMBER 1 





L09Rik  Q8BVZ1  MM.254985   143951  #N/A  A_51_P262757  Not classified  RIKEN CDNA 2310076L09 GENE 
LMP003421  Plp2  Q9R1Q7  MM.18565   40189  93323_at  A_51_P243525  Not classified  PROTEOLIPID PROTEIN 2 
LMP003423  Lcn5  Q3UW42  MM.12867   8935  99236_at  A_51_P191875  Not classified  LIPOCALIN 5 




LMP003427  Plscr2  Q9DCW2  MM.10306   144912  102053_at  A_51_P251023  Not classified  PHOSPHOLIPID SCRAMBLASE 2 
LMP003430 
AB11235
0  Q8BH82  MM.153292   144088  #N/A  A_51_P392943  Not classified  CDNA SEQUENCE AB112350 
LMP003467  Mboat1  Q8BH98  MM.89682   146319  #N/A  A_51_P349495  Not classified 
O‐ACYLTRANSFERASE (MEMBRANE BOUND) 
DOMAIN CONTAINING 1 
LMP003475  Pla2g3  Q8BZT7  MM.100476   43776  #N/A  A_51_P402868  Not classified  PHOSPHOLIPASE A2, GROUP III 
LMP003477  Pign  Q9R1S3  MM.268911   4140  92296_at  A_51_P221274  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS N 
LMP003478  b3galnt1  Q920V1  MM.153710   17009  #N/A  A_51_P318637  Not classified 
UDP‐GAL:BETAGLCNAC BETA 1,3‐
GALACTOSYLTRANSFERASE, POLYPEPTIDE 3 
LMP003488  Ncor1  Q60974  MM.271814   27157  101536_at 
A_51_P457744;A_
51_P489043  Not classified  NUCLEAR RECEPTOR CO‐REPRESSOR 1 
LMP003516  Plscr4  P58196  MM.55289   145369  #N/A  A_51_P111049  Not classified  EXPRESSED SEQUENCE AV245873 
LMP003520  Ptges  Q9JM51  MM.28768   59852  104406_at  A_51_P312328  Not classified  PROSTAGLANDIN E SYNTHASE 
LMP003532  Lcn8  Q924P3  MM.196708   4961  #N/A  A_51_P379873  Not classified  LIPOCALIN 8 






4  Q80W54  MM.34399   16150  #N/A  A_51_P467720  Not classified 
ZINC METALLOPEPTIDASE, STE24 HOMOLOG (S. 
CEREVISIAE) 
LMP003572  Zdhhc9  P59268  MM.207367   12723  #N/A  A_51_P131514  Not classified  ZINC FINGER, DHHC DOMAIN CONTAINING 9 
LMP003574  Pla2g4b  Q4QQM1  MM.41467   143633  #N/A  A_51_P288549  Not classified  PHOSPHOLIPASE A2, GROUP IVB (CYTOSOLIC) 
LMP003575  Pag1  Q3U1F9  MM.214484   146141  #N/A  A_51_P335945  Not classified 
PHOSPHOPROTEIN ASSOCIATED WITH 
GLYCOSPHINGOLIPID MICRODOMAINS 1 
LMP003591  Phb2  O35129  MM.36241   35216  #N/A  A_51_P205833  Not classified  PROHIBITIN 2 
LMP003604  Plcl1  Q3USB7  NA     15791  #N/A  A_51_P422457  Not classified  PHOSPHOLIPASE C‐LIKE 1  
LMP003612  Vkorc1  Q9CRC0  MM.29703   45498  #N/A  A_51_P395555  Not classified 
VITAMIN K EPOXIDE REDUCTASE COMPLEX, 
SUBUNIT 1 
LMP003617  Prey  Q9D1C3  MM.44201   28365  #N/A  #N/A  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS Y 
LMP003618  Dhcr24  Q6ZQK9  MM.133370   27995  160369_at 
A_51_P242043;A_
51_P482711  Not classified  24‐DEHYDROCHOLESTEROL REDUCTASE 
LMP003619  Slc33a1  Q99J27  MM.135619   14637  160201_r_at  A_51_P164400  Not classified 
SOLUTE CARRIER FAMILY 33 (ACETYL‐COA 
TRANSPORTER), MEMBER 1 
LMP003623  Plekha8  Q80W71  MM.35416   15309  #N/A  A_51_P288756  Not classified 
PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, 
FAMILY A (PHOSPHOINOSITIDE BIND... 




LMP003644  Ang1  P21570  NA     13832  #N/A  A_51_P391159  Not classified 
ANGIOGENIN, RIBONUCLEASE A FAMILY, 
MEMBER 1  
LMP003653  Serinc1  Q9QZI8  MM.29344   129009  #N/A  A_51_P358225  Not classified  SERINE INCORPORATOR 1 
LMP003654  Prmt8  Q6PAK3  MM.39750   37978  #N/A  #N/A  Not classified  PROTEIN ARGININE N‐METHYLTRANSFERASE 8 
LMP003662  Agpat7  Q6NVG1        #N/A  #N/A  Not classified    
LMP003676  Grlf1  Q91YM2  MM.28646   15184  #N/A  A_51_P506748  Not classified 
GLUCOCORTICOID RECEPTOR DNA BINDING 
FACTOR 1 
LMP003705  Pla1a  Q99J51  MM.279805   145809  #N/A  A_51_P381618  Not classified  PHOSPHOLIPASE A1 MEMBER A 





LMP003723  Apon  Q8VC08  MM.30121   6041  #N/A  A_51_P100625  Not classified  APOLIPOPROTEIN N 





LMP003738  Apbh  O35176  MM.6205   45473  #N/A  A_51_P151211  Not classified  ANDROGEN‐BINDING PROTEIN ETA 
LMP003749  Prmt6  Q6NZB1  MM.36115   147034  #N/A  A_51_P331212  Not classified  PROTEIN ARGININE N‐METHYLTRANSFERASE 6 
LMP003778  Ppt1  O88531  MM.358818   147223  99646_at  A_51_P114307  Not classified  PALMITOYL‐PROTEIN THIOESTERASE 1 
LMP003784  Slc27a6  Q14C50  MM.258517     #N/A  A_51_P211616  Not classified    
LMP003786  Acp6  Q8BP40  MM.101368   8370  162336_r_at;  A_51_P444335  Not classified  LYSOPHOSPHATIDIC ACID PHOSPHATASE 





LMP003795  Osbp  Q3B7Z2  MM.291279   35712  #N/A  A_51_P393768  Not classified  OXYSTEROL BINDING PROTEIN 
LMP003816  Cyp2d11  P24457  NA        101287_s_at  #N/A  Not classified 
CYTOCHROME P450, FAMILY 2, SUBFAMILY D, 
POLYPEPTIDE 11  
LMP003821  Apof  Q91V80  MM.26513   4028  96074_at  A_51_P495825  Not classified  APOLIPOPROTEIN F 
LMP003823  Mcee  Q9D1I5  MM.10093   19896  #N/A  A_51_P320481  Not classified  METHYLMALONYL COA EPIMERASE 
LMP003824  Liph  Q3UWA2  MM.33192   16830  #N/A  A_51_P122660  Not classified  LIPASE, MEMBER H 
LMP003828  Calm1  P62204  MM.288630   7000  96522_at 
A_51_P465023;A_
51_P503933  Not classified  CALMODULIN 1 
LMP003829  Pigh  Q5M9N4  MM.281044   145839  101443_at  #N/A  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS H 
LMP003838  Cyp4f3  Q99N16  MM.160020   6807  #N/A  #N/A  Not classified 
CYTOCHROME P450, FAMILY 4, SUBFAMILY F, 
POLYPEPTIDE 18 
LMP003840  Mccc1  Q99MR8  MM.249016   6991  94940_at  A_51_P282974  Not classified 
METHYLCROTONOYL‐COENZYME A 
CARBOXYLASE 1 (ALPHA) 
LMP003841  Cyp4f13  Q99N19  MM.254838   145867  162058_f_at  A_51_P210603  Not classified  RIKEN CDNA 0610030I10 GENE 
LMP003844  Egln3  Q91UZ4  MM.133037   4004  #N/A  A_51_P274852  Not classified  EGL NINE HOMOLOG 3 (C. ELEGANS) 
LMP003846  Ltb4dh  Q91YR9  MM.34497   17035  98440_at  A_51_P444437  Not classified  LEUKOTRIENE B4 12‐HYDROXYDEHYDROGENASE 
LMP003848  Impa2  Q91UZ5  MM.34079   18883  98420_at  A_51_P299287  Not classified  INOSITOL (MYO)‐1(OR 4)‐MONOPHOSPHATASE 2 
LMP003860  Prkd3  Q8K1Y2  MM.252776   9184  #N/A  #N/A  Not classified  PROTEIN KINASE C, NU 
LMP003861  Pgs1  Q8BHF7  MM.28864   7791  #N/A  A_51_P515349  Not classified  RIKEN CDNA 2610019F11 GENE 
LMP003876  Slc27a3  O88561  NA     7439  92686_at  A_51_P133247  Not classified  LONG‐CHAIN FATTY ACID TRANSPORT PROTEIN 3  
LMP003883  Coq9  Q8K1Z0  MM.169234   12511  #N/A  A_51_P134542  Not classified  COENZYME Q9 HOMOLOG (YEAST) 
LMP003885  Esco2  Q8CIB9  MM.249280   10638  #N/A  A_51_P195034  Not classified 
ESTABLISHMENT OF COHESION 1 HOMOLOG 2 
(S. CEREVISIAE) 
LMP003908  Pon1  P52430  MM.237657   17183  96895_at  A_51_P108659  Not classified  PARAOXONASE 1 
LMP003912  Pla2r1  Q62028  MM.5092   144395  #N/A  A_51_P451335  Not classified  PHOSPHOLIPASE A2 RECEPTOR 1 
LMP003927  Pigm  Q8C2R7  MM.26612   148214 
162405_at;96
527_at  A_51_P219822  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS M 
LMP003932  Akr1c20  Q8VC77  MM.37605   37054  #N/A 
A_51_P276800;A_
51_P382764  Not classified  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER C20 
LMP003937  Elovl5  Q8BHI7  MM.19130   148870  93496_at  A_51_P505493  Not classified 
ELOVL FAMILY MEMBER 5, ELONGATION OF 
LONG CHAIN FATTY ACIDS (YEAST) 
LMP003961  Centg1  Q3UHD9  NA     143809  #N/A  A_51_P488118  Not classified  CENTAURIN, GAMMA 1  
LMP003977  Pitpnm3  Q3UHE1  NA     9374  #N/A  A_51_P118527  Not classified  EXPRESSED SEQUENCE AI848332  
LMP003983  Slc22a21  Q9WTN6  MM.154284   24671  #N/A  A_51_P407774  Not classified 
SOLUTE CARRIER FAMILY 22 (ORGANIC CATION 
TRANSPORTER), MEMBER 21 
LMP003995  Hnrpll  Q921F4  MM.64579   8251  #N/A  A_51_P390676  Not classified 
HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN L‐LIKE 
LMP004000  Dhrsx  Q8VBZ0  MM.358892   26684  93238_at  #N/A  Not classified 
DEHYDROGENASE/REDUCTASE (SDR FAMILY) X 
CHROMOSOME 
LMP004002  Btd  Q8CIF4  MM.282679   4746  95469_at  A_51_P196158  Not classified  BIOTINIDASE 





0  MM.28048   144328  160765_at  A_51_P349008  Not classified  PROSTAGLANDIN E SYNTHASE 2 
LMP004033  Prmt5  Q8CIG8  MM.196585   9358  #N/A  #N/A  Not classified  PROTEIN ARGININE N‐METHYLTRANSFERASE 5 





LMP004045  Dpm3  Q9D1Q4  MM.272927   19465  101084_f_at  A_51_P518566  Not classified 
DOLICHYL‐PHOSPHATE MANNOSYLTRANSFERASE 
POLYPEPTIDE 3 
LMP004092  Pon3  Q62087  MM.9122   16861  93940_at  A_51_P256665  Not classified  PARAOXONASE 3 
LMP004100  Cyp8b1  O88962  MM.20889   148953  103284_at  A_51_P266618  Not classified 
CYTOCHROME P450, FAMILY 8, SUBFAMILY B, 
POLYPEPTIDE 1 
LMP004105  Cyp51  Q9JIP8  MM.140158   6612  94916_at  A_51_P485791  Not classified  CYTOCHROME P450, FAMILY 51 
LMP004109  Dhrs8  Q9EQ06  MM.46019   27061  102370_at  #N/A  Not classified 
DEHYDROGENASE/REDUCTASE (SDR FAMILY) 
MEMBER 8 






LMP004120  Gpr23  Q8BLG2  MM.90147   6868  #N/A  #N/A  Not classified  G PROTEIN‐COUPLED RECEPTOR 23 
LMP004129  Plscr1  Q9JJ00  MM.14627   145307  102839_at  A_51_P229676  Not classified  PHOSPHOLIPID SCRAMBLASE 1 
LMP004132  B4galt4  Q9JJ04  MM.182377   26462  #N/A  A_51_P238383  Not classified 
UDP‐GAL:BETAGLCNAC BETA 1,4‐
GALACTOSYLTRANSFERASE, POLYPEPTIDE 4 
LMP004136  Srebf2  Q925C2  MM.38016   32779  #N/A  A_51_P377514  Not classified 
STEROL REGULATORY ELEMENT BINDING 
FACTOR 2 
LMP004151  Pitpnm1  O35954  MM.1860   23007  #N/A  A_51_P103000  Not classified 
PHOSPHATIDYLINOSITOL MEMBRANE‐
ASSOCIATED 1 
LMP004170  Hemk1  Q921L7  MM.259467   9425  #N/A  A_51_P475244  Not classified  HEMK METHYLTRANSFERASE FAMILY MEMBER 1 
LMP004186  B3gnt2  Q9Z222  MM.258094   27086  #N/A  A_51_P335653  Not classified 
UDP‐GLCNAC:BETAGAL BETA‐1,3‐N‐
ACETYLGLUCOSAMINYLTRANSFERASE 1 
LMP004193  Mccc2  Q3ULD5  MM.137327   42151  #N/A  A_51_P211880  Not classified 
METHYLCROTONOYL‐COENZYME A 
CARBOXYLASE 2 (BETA) 
LMP004196  Agpat6  Q8K2C8  MM.200898   147434  #N/A  A_51_P335710  Not classified 
PUTATIVE LYSOPHOSPHATIDIC ACID 
ACYLTRANSFERASE 





B18Rik  Q9D258  MM.99733   4406  #N/A  #N/A  Not classified  RIKEN CDNA 9230116B18 GENE 
LMP004234  Elovl7  Q8BX38  MM.286127   8496  #N/A  A_51_P189594  Not classified 
ELOVL FAMILY MEMBER 7, ELONGATION OF 
LONG CHAIN FATTY ACIDS (YEAST) 
LMP004241  Ugt1  Q62452  NA     3809  #N/A  #N/A  Not classified 
UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, 
POLYPEPTIDE A2  
LMP004243  Gpbar1  Q80SS6  MM.246587   27649  #N/A  A_51_P175311  Not classified  G PROTEIN‐COUPLED BILE ACID RECEPTOR 1 
LMP004249  Clu  Q06890  MM.200608   149786 
161294_f_at;
95286_at  A_51_P367720  Not classified  CLUSTERIN 
LMP004294  Gdpd1  Q9CRY7  MM.281887   6797  95470_at  A_51_P487439  Not classified 
GLYCEROPHOSPHODIESTER 
PHOSPHODIESTERASE DOMAIN CONTAINING 1 
LMP004297  Hpgd  Q8VCC1  MM.18832   6998  93351_at  A_51_P458778  Not classified 
HYDROXYPROSTAGLANDIN DEHYDROGENASE 15 
(NAD) 
LMP004298  Abpg  Q8JZX1  MM.155750   7323  #N/A  #N/A  Not classified  ANDROGEN BINDING PROTEIN GAMMA 
LMP004300  Ces1  Q8VCC2  MM.22720   144720  103519_at  A_51_P253484  Not classified  CARBOXYLESTERASE 1 
LMP004304  Pdia3  P27773  MM.263177   30857  #N/A  A_51_P168412  Not classified  PROTEIN DISULFIDE ISOMERASE ASSOCIATED 3 
LMP004314  Pcca  Q91ZA3  MM.23876   3471  #N/A  A_51_P484254  Not classified  EXPRESSED SEQUENCE C79630 
LMP004322  Alg1  Q921Q3  MM.34581   144280  #N/A  A_51_P329795  Not classified 
ASPARAGINE‐LINKED GLYCOSYLATION 1 
HOMOLOG (YEAST, BETA‐1,4‐MANNOSYLTRA... 
LMP004346  Pi4k2a  Q2TBE6  MM.117037     #N/A  A_51_P345467  Not classified    
LMP004347  Ahcyl1  Q80SW1  MM.220328   147253  97217_at 
A_51_P206243;A_
51_P296328  Not classified  S‐ADENOSYLHOMOCYSTEINE HYDROLASE‐LIKE 1 
LMP004348  Smpdl3b  P58242  MM.287187   27147  #N/A  A_51_P422839  Not classified 
SPHINGOMYELIN PHOSPHODIESTERASE, ACID‐
LIKE 3B 
LMP004358  Fntb  Q8K2I1  MM.151174   4883  96218_at  A_51_P517680  Not classified  EXPRESSED SEQUENCE AA409500 
LMP004374  Rxrip110  Q5U5Q9  MM.259301   3384  99464_at  #N/A  Not classified 
RETINOID X RECEPTOR INTERACTING PROTEIN 
110 
LMP004382  Bckdhb  Q6P3A8  MM.12819   7352  102302_at  A_51_P102782  Not classified 
BRANCHED CHAIN KETOACID DEHYDROGENASE 
E1, BETA POLYPEPTIDE 
LMP004388  Ncoa3  O09000  MM.1011   3245  102024_at  A_51_P454207  Not classified  NUCLEAR RECEPTOR COACTIVATOR 3 
LMP004394  Plscr3  Q9JIZ9  MM.28874   3366  #N/A  A_51_P302456  Not classified  PHOSPHOLIPID SCRAMBLASE 3 
LMP004404  Rbp3  P49194  MM.151562   27112  #N/A  A_51_P331690  Not classified  RETINOL BINDING PROTEIN 3, INTERSTITIAL 
LMP004426  Cnr1  P47746  MM.7992   26801  99892_at  A_51_P403378  Not classified  CANNABINOID RECEPTOR 1 (BRAIN) 
LMP004429  Rdh10  Q8VCH7  MM.274376   21146  #N/A  A_51_P184261  Not classified  RETINOL DEHYDROGENASE 10 (ALL‐TRANS) 
LMP004430  Nrip1  Q8CBD1  MM.74711   37797  #N/A  A_51_P152747  Not classified  NUCLEAR RECEPTOR INTERACTING PROTEIN 1 
LMP004448  Rad54l2  Q99NG0  MM.246689   149135  #N/A  A_51_P162812  Not classified  RAD54 LIKE 2 (S. CEREVISIAE) 





LMP004462  Sdpr  Q63918  MM.255909   19312  160373_i_at  A_51_P277336  Not classified  SERUM DEPRIVATION RESPONSE 
LMP004479  Ggtl3  Q99JP7  MM.41757   3520  #N/A  A_51_P265303  Not classified  GAMMA‐GLUTAMYLTRANSFERASE‐LIKE 3 
LMP004483  Acsbg2  Q2XU92  MM.179421   31538  #N/A  #N/A  Not classified 
ACYL‐COA SYNTHETASE BUBBLEGUM FAMILY 
MEMBER 2 
LMP004490  Ffar2  Q8VCK6  MM.97338   11914  #N/A  A_51_P176083  Not classified  FREE FATTY ACID RECEPTOR 2 
LMP004523  Tinagl1  Q99JR5  MM.15801   26882  #N/A  #N/A  Not classified  TUBULOINTERSTITIAL NEPHRITIS ANTIGEN‐LIKE 
LMP004550  Dpm1  O70152  MM.370658   7766  92828_at  A_51_P397834  Not classified 
DOLICHOL‐PHOSPHATE (BETA‐D) 
MANNOSYLTRANSFERASE 1 





LMP004564  Acat3  Q80X81  MM.229342   4898  #N/A  A_51_P139745  Not classified  ACETYL‐COENZYME A ACETYLTRANSFERASE 3 
LMP004573  Rdh9  Q76LB8  MM.379285   5481  #N/A  A_51_P177764  Not classified  RETINOL DEHYDROGENASE 9 
LMP004592  Naga  Q9QWR8  MM.20325   31946  103637_at  A_51_P117130  Not classified  N‐ACETYL GALACTOSAMINIDASE, ALPHA 
LMP004594  Acbd4  Q80X94  MM.225881   25421  #N/A  A_51_P292757  Not classified 
ACYL‐COENZYME A BINDING DOMAIN 
CONTAINING 4 
LMP004596  Mtmr12  Q80TA6  MM.54460   4003  #N/A  A_51_P308308  Not classified  VMYOTUBULARIN RELATED PROTEIN 12 
LMP004603  Tm7sf2  Q71KT5  MM.380396   5863 
92437_at;953
83_at  A_51_P246568  Not classified  TRANSMEMBRANE 7 SUPERFAMILY MEMBER 2 
LMP004625  Dhrs9  Q58NB6  MM.211655   26489  #N/A  A_51_P149126  Not classified 
DEHYDROGENASE/REDUCTASE (SDR FAMILY) 
MEMBER 9 






a  Q9CZX7  MM.279158   19676  #N/A  A_51_P495485  Not classified  TRANSMEMBRANE PROTEIN 55A 
LMP004641  Nrk1  Q91W63  MM.211595   15822  #N/A  #N/A  Not classified  CDNA SEQUENCE BC016495 
LMP004645 
Hsd17b1
3  Q8VCR2  MM.284944   146945  #N/A  #N/A  Not classified 
HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 
13 
LMP004658  Ncoa2  Q61026  MM.2537   12954  96508_at  A_51_P478593  Not classified  NUCLEAR RECEPTOR COACTIVATOR 2 
LMP004667  Rragc  Q99K70  MM.220922   144004  #N/A  A_51_P346826  Not classified  RAS‐RELATED GTP BINDING C 





A20Rik  Q32Q92  MM.49245   145642  #N/A  #N/A  Not classified  RIKEN CDNA 4632408A20 GENE 
LMP004690  Gpr65  Q61038  MM.378924   146191  #N/A  A_51_P108459  Not classified  G‐PROTEIN COUPLED RECEPTOR 65 
LMP004697  Aoah  O35298  MM.314046   143944  99838_at  A_51_P517105  Not classified  ACYLOXYACYL HYDROLASE 
LMP004699  Psat1  Q99K85  MM.289936   146132  96295_at  A_51_P317428  Not classified  PHOSPHOSERINE AMINOTRANSFERASE 1 





LMP004709  Ces3  Q8VCT4  MM.292803   148789 
101538_i_at;
101539_f_at  A_51_P375969  Not classified  CARBOXYLESTERASE 3 
LMP004721  Dnaja1  P63037  MM.27897   5439  97261_at  A_51_P303353  Not classified 
DNAJ (HSP40) HOMOLOG, SUBFAMILY A, 
MEMBER 1 
LMP004732  Zdhhc18  Q5Y5T2  NA     5284  #N/A  #N/A  Not classified  ZINC FINGER, DHHC DOMAIN CONTAINING 18  
LMP004768  Pigz  Q8BTP0  MM.347625   12682  #N/A  A_51_P285673  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS Z 
LMP004782  Suclg2  Q9Z2I8  MM.371585   18366  160428_at  A_51_P478672  Not classified 
SUCCINATE‐COENZYME A LIGASE, GDP‐
FORMING, BETA SUBUNIT 







F22Rik  Q8C7I4  MM.243758   145658  #N/A  A_51_P500215  Not classified  RIKEN CDNA 2310016F22 GENE 
LMP004799  Nat5  P61600  MM.151168   16805  #N/A  A_51_P424828  Not classified 
N‐ACETYLTRANSFERASE 5 (ARD1 HOMOLOG, S. 
CEREVISIAE) 
LMP004801  Lipe  P54310  MM.349647   9071  103083_at  A_51_P435366  Not classified  LIPASE, HORMONE SENSITIVE 
LMP004802  Pik3r4  Q8VD65  MM.274830   16591  #N/A  A_51_P110029  Not classified 
PHOSPHATIDYLINOSITOL 3 KINASE, REGULATORY 
SUBUNIT, POLYPEPTIDE 4, P150 
LMP004803  Abhd4  Q8VD66  MM.28771   19407  #N/A  A_51_P406020  Not classified  ABHYDROLASE DOMAIN CONTAINING 4 
LMP004805 
4930544
G21Rik  Q6NSW3  MM.154303   27566  #N/A  A_51_P482398  Not classified  RIKEN CDNA 4930544G21 GENE 
LMP004806 
Cyp4a12
b  O35650  NA     36002  #N/A  #N/A  Not classified  CDNA SEQUENCE BC060945  
LMP004818  Icmt  Q9EQK7  MM.277464   8390  160336_at  A_51_P283464  Not classified 
ISOPRENYLCYSTEINE CARBOXYL 
METHYLTRANSFERASE 
LMP004831  Pigr  O70570  MM.276414   146814  99926_at  A_51_P239737  Not classified  POLYMERIC IMMUNOGLOBULIN RECEPTOR 
LMP004832  Ncoa1  P70365  MM.301039   17056  103229_at  A_51_P502888  Not classified  NUCLEAR RECEPTOR COACTIVATOR 1 
LMP004839  Suclg1 
Q9WUM
5  MM.29845   144589  96268_at  A_51_P491227  Not classified 
SUCCINATE‐COA LIGASE, GDP‐FORMING, ALPHA 
SUBUNIT 






LMP004850  Acbd5  Q7TSC2  MM.181973   15148  #N/A  A_51_P279308  Not classified 
ACYL‐COENZYME A BINDING DOMAIN 
CONTAINING 5 
LMP004863  Coq2  Q66JT7  MM.260661   137823  #N/A  A_51_P447752  Not classified 
COENZYME Q2 HOMOLOG, 
PRENYLTRANSFERASE (YEAST) 
LMP004865  Atp6v0c  P63082  MM.30155   27977  96919_at  A_51_P127107  Not classified 
ATPASE, H+ TRANSPORTING, LYSOSOMAL V0 
SUBUNIT C 





b  Q3TWL2  MM.239117   6316  #N/A  A_51_P232508  Not classified  TRANSMEMBRANE PROTEIN 55B 
LMP004886  Rabggtb  P53612  MM.277831   25461  95077_at  A_51_P314763  Not classified 
RAB GERANYLGERANYL TRANSFERASE, B 
SUBUNIT 
LMP004896  Fprl1  O08790  MM.378919   30565  100741_at  A_51_P510982  Not classified  FORMYL PEPTIDE RECEPTOR‐LIKE 1 
LMP004917  Abpz  Q7M747  MM.261648   144524  #N/A  #N/A  Not classified  ANDROGEN BINDING PROTEIN ZETA 
LMP004923  Srd5a2l  Q9WUP4  MM.289446   105184  #N/A  A_51_P334730  Not classified  STEROID 5 ALPHA‐REDUCTASE 2‐LIKE 
LMP004928  Oxct2a  Q9JJN4  MM.270287   26829  #N/A  A_51_P125062  Not classified  3‐OXOACID COA TRANSFERASE 2A 
LMP004946  Phyhd1  Q9DB26  MM.297949   37282  #N/A  A_51_P357606  Not classified 
PHYTANOYL‐COA DIOXYGENASE DOMAIN 
CONTAINING 1 
LMP004969  B3galt1  O54904  MM.226435   21347  101725_at  A_51_P342916  Not classified 
UDP‐GAL:BETAGLCNAC BETA 1,3‐
GALACTOSYLTRANSFERASE, POLYPEPTIDE 1 
LMP004971  B3galt2  O54905  MM.285580   26626  92341_at  A_51_P148216  Not classified 
UDP‐GAL:BETAGLCNAC BETA 1,3‐
GALACTOSYLTRANSFERASE, POLYPEPTIDE 2 
LMP004979  Rdh16  O54909  MM.100276   147819  #N/A  A_51_P455256  Not classified  RETINOL DEHYDROGENASE 16 
LMP004985  Cyp2g1  Q9WV19  MM.102312   32101  #N/A  A_51_P137448  Not classified 
CYTOCHROME P450, FAMILY 2, SUBFAMILY G, 
POLYPEPTIDE 1 
LMP004990  Ppapdc3  Q91WB2  MM.257236   16065  #N/A  A_51_P321374  Not classified 
PHOSPHATIDIC ACID PHOSPHATASE TYPE 2 
DOMAIN CONTAINING 3 
LMP004993  Abpa  Q91WB5  MM.8025   15299  94628_r_at  A_51_P344136  Not classified  ANDROGEN BINDING PROTEIN ALPHA 
LMP005002  Mlstd2  Q922J9  MM.206919   15015  #N/A  A_51_P186092  Not classified  MALE STERILITY DOMAIN CONTAINING 2 
LMP005013  Slc22a4  Q9Z306  MM.274590   32849  92497_at  #N/A    
SOLUTE CARRIER FAMILY 22 (ORGANIC CATION 
TRANSPORTER), MEMBER 4 
LMP005015  Pigb  Q9JJQ0  MM.139905   147667  #N/A  A_51_P427483  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS B 





LMP005028  Pik3r6  Q3U6Q4  MM.234573   32759  #N/A  #N/A  Not classified  EXPRESSED SEQUENCE BB220380 
LMP005074  Dpm2  Q9Z324  MM.22001   25680  94052_at  #N/A    
DOLICHOL‐PHOSPHATE (BETA‐D) 
MANNOSYLTRANSFERASE 2 
LMP005075  Gdpd4  Q3TT99  MM.358889   143835  #N/A  A_51_P241690  Not classified 
GLYCEROPHOSPHODIESTER 
PHOSPHODIESTERASE DOMAIN CONTAINING 4 
LMP005117  Coq6  Q8R1S0  MM.280062   144323  #N/A  A_51_P116479  Not classified  COENZYME Q6 HOMOLOG (YEAST) 
LMP005122  Mettl2  Q8BMK1  MM.270091   22972  #N/A  A_51_P401745  Not classified  METHYLTRANSFERASE LIKE 2 
LMP005131  B3gnt3  Q5JCS9  MM.290837   5751  #N/A  A_51_P240760  Not classified 
UDP‐GLCNAC:BETAGAL BETA‐1,3‐N‐
ACETYLGLUCOSAMINYLTRANSFERASE 3 
LMP005137  Decr2  Q9WV68  MM.292869   37132  #N/A  A_51_P443293  Not classified 
2‐4‐DIENOYL‐COENZYME A REDUCTASE 2, 
PEROXISOMAL 
LMP005147  Ces2  Q91WG0  MM.28191   19326  #N/A  A_51_P513571  Not classified  CARBOXYLESTERASE 2 
LMP005150  Lsr  Q99KG5  MM.4067   146044  #N/A  A_51_P436839  Not classified  LIPOLYSIS STIMULATED LIPOPROTEIN RECEPTOR 
LMP005152  Prkag2  Q91WG5  MM.33649   5057  #N/A  A_51_P460872  Not classified  RIKEN CDNA 2410051C13 GENE 
LMP005157  Gcnt3  Q5JCT0  MM.195555   31071  #N/A  A_51_P412369  Not classified 
GLUCOSAMINYL (N‐ACETYL) TRANSFERASE 3, 
MUCIN TYPE 
LMP005176  Gusb  P12265  MM.371672   17517  #N/A  A_51_P211491  Not classified  BETA‐GLUCURONIDASE STRUCTURAL 
LMP005181  Pik3r5  Q5SW28  MM.244960   11284  #N/A  A_51_P173331  Not classified 
PHOSPHOINOSITIDE‐3‐KINASE, REGULATORY 
SUBUNIT 5, P101 
LMP005187  Akr7a2  Q8CG76  MM.287397   26238  #N/A  #N/A  Not classified 
ALDO‐KETO REDUCTASE FAMILY 7, MEMBER A5 
(AFLATOXIN ALDEHYDE REDUCTASE) 
LMP005197  Fkbp4  P30416  MM.12758   45371 
92808_f_at;9
2809_r_at  A_51_P185175  Not classified  FK506 BINDING PROTEIN 4 
LMP005206 
4833424
O15Rik  Q8BJ52  MM.72187   144924  #N/A  A_51_P128786  Not classified  RIKEN CDNA 4833424O15 GENE 
LMP005211  Pnpla2  Q8BJ56  MM.29998   26846  #N/A  A_51_P197213  Not classified 
PATATIN‐LIKE PHOSPHOLIPASE DOMAIN 
CONTAINING 2 
LMP005214  Ptgfrn  Q9WV91  MM.24807   36916  99894_at  A_51_P354062  Not classified 
PROSTAGLANDIN F2 RECEPTOR NEGATIVE 
REGULATOR 
LMP005223  Acss2  Q9QXG4  MM.255026   6835  #N/A  A_51_P488399  Not classified  ACETYL‐COA SYNTHETASE 
LMP005241  B4galt2  Q9Z2Y2  MM.123843   7411  104005_at  #N/A    
UDP‐GAL:BETAGLCNAC BETA 1,4‐ 
GALACTOSYLTRANSFERASE, POLYPEPTIDE 2 
LMP005250  Slc10a4  Q3UEZ8  MM.253661   9142  #N/A  A_51_P448479  Not classified 
SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID 
COTRANSPORTER FAMILY), MEMB... 
LMP005269  Slc25a20  Q9Z2Z6  MM.29666   147040  95695_at  #N/A    
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL 
CARNITINE/ACYLCARNITINE TRANSL... 
LMP005280  Cyp4a12  Q91WL5  MM.276106   22145  101307_at  A_51_P433360  Not classified 
SIMILAR TO CYTOCHROME P450 4A8 (CYPIVA8) 
(P450‐KP1) (P450‐PP1) 
LMP005283  Agps  Q8C0I1  MM.31227   12617  #N/A  A_51_P399504  Not classified  ALKYLGLYCERONE PHOSPHATE SYNTHASE 
LMP005318  Hsd17b9  Q9R092  MM.26719   7364  #N/A  #N/A  Not classified  HYDROXYSTEROID (17‐BETA) DEHYDROGENASE 9 
LMP005329  Nr2c1  Q505F1  MM.107483   147601  92190_at  A_51_P197849  Not classified 
NUCLEAR RECEPTOR SUBFAMILY 2, GROUP C, 
MEMBER 1 
LMP005339  Acot10  Q32MW2  MM.352763   145870  #N/A  #N/A  Not classified  ACYL‐COA THIOESTERASE 10 
LMP005340 
AY05357
3  Q8K3L9  MM.331466   30297  #N/A  #N/A  Not classified  CDNA SEQUENCE AY053573 
LMP005355  Fads6  Q810B5  MM.21995   14041  #N/A  #N/A  Not classified 
FATTY ACID DESATURASE DOMAIN FAMILY, 
MEMBER 6 
LMP005370  Ywhah  P68510  MM.332314   28860  97535_at  A_51_P306527  Not classified 
TYROSINE 3‐MONOOXYGENASE/TRYPTOPHAN 5‐
MONOOXYGENASE ACTIVATION PROTEIN... 
LMP005377  Nudt10  P0C027  MM.41198   146851  #N/A  #N/A  Not classified 
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED 
MOIETY X)‐TYPE MOTIF 11 
LMP005378  Nudt11  P0C028  MM.41198   146851  #N/A  A_51_P490217  Not classified 
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED 
MOIETY X)‐TYPE MOTIF 11 
LMP005391  Plp1  P60202  MM.1268   16768  #N/A  A_51_P127392  Not classified  PROTEOLIPID PROTEIN (MYELIN) 1 
LMP005403  Prmt7  Q922X9  MM.251804   149196  #N/A  A_51_P298538  Not classified  PROTEIN ARGININE N‐METHYLTRANSFERASE 7 
LMP005410  Cyp11b1  Q3UQH5  NA     28328  #N/A  #N/A  Not classified 
CYTOCHROME P450, FAMILY 11, SUBFAMILY B, 
POLYPEPTIDE 1  
LMP005416  Dhrs1  Q99L04  MM.21623   6294  93843_at  A_51_P293901  Not classified 
DEHYDROGENASE/REDUCTASE (SDR FAMILY) 
MEMBER 1 
LMP005421  Miox  Q9QXN5  MM.158200   127058  #N/A  A_51_P385258  Not classified  MYO‐INOSITOL OXYGENASE 
LMP005422  Cyp3a25  O09158  MM.301900   17429  104024_at  A_51_P489367  Not classified 
CYTOCHROME P450, FAMILY 3, SUBFAMILY A, 
POLYPEPTIDE 25 
LMP005440  Abpe  Q6UGQ3  MM.333771   37224  #N/A  #N/A  Not classified  ANDROGEN BINDING PROTEIN EPSILON 
LMP005442  Lycat  Q3UN02  MM.329194   10462  #N/A  #N/A  Not classified  LYSOCARDIOLIPIN ACYLTRANSFERASE 
LMP005450  Apol6  Q3UN08  MM.34173   149208  #N/A  A_51_P404815  Not classified  APOLIPOPROTEIN L, 6 
LMP005459  Akr1c21  Q91WR5  MM.27085   26838  160733_at  A_51_P208472  Not classified  ALDO‐KETO REDUCTASE FAMILY 1, MEMBER C21 
LMP005462  Gpx6  Q91WR8  MM.46195   144846  #N/A  A_51_P299149  Not classified  GLUTATHIONE PEROXIDASE 6 
LMP005471  Srd5a1  Q505K7  MM.315983   12273  #N/A  A_51_P420415  Not classified  STEROID 5 ALPHA‐REDUCTASE 1 
LMP005479  Gpx5  P21765  MM.1332   149254 
161986_f_at;
94692_at  A_51_P267644  Not classified  GLUTATHIONE PEROXIDASE 5 





16Rik  Q3TPQ0  NA     147591  #N/A  #N/A  Not classified  RIKEN CDNA D030013I16 GENE  
LMP005524  Mall  Q91X49  MM.133036   13736  #N/A  A_51_P221441  Not classified  MAL, T‐CELL DIFFERENTIATION PROTEIN‐LIKE 
LMP005529  Cyp27a1  Q9DBG1  MM.85083   37251  #N/A  A_51_P112821  Not classified  RIKEN CDNA 1300013A03 GENE 
LMP005530  Atp8b1  Q3U010  MM.270043   144899  #N/A 
A_51_P192329;A_
51_P494297  Not classified  ATPASE, CLASS I, TYPE 8B, MEMBER 1 
LMP005543  Hibch  Q8QZS1  MM.222063   37162  #N/A  A_51_P178735  Not classified 
3‐HYDROXYISOBUTYRYL‐COENZYME A 
HYDROLASE 
LMP005546  Ffar3  Q3UFD7  MM.291167   18381  #N/A  #N/A  Not classified  G PROTEIN‐COUPLED RECEPTOR 41 
LMP005549  Plcl4  Q3LUA7  MM.379458   27196  #N/A  #N/A  Not classified  PHOSPHOLIPASE C‐LIKE 4 
LMP005558  Ptpmt1  Q66GT5  MM.23926   15355  #N/A  A_51_P226341  Not classified 
PROTEIN TYROSINE PHOSPHATASE, 
MITOCHONDRIAL 1 
LMP005573  Abcb11  Q9QY30  MM.303187   7543  #N/A  A_51_P309338  Not classified 
ATP‐BINDING CASSETTE, SUB‐FAMILY B 
(MDR/TAP), MEMBER 11 
LMP005576  Sgk3  Q9ERE3  MM.336410   43494  #N/A  A_51_P306151  Not classified  SERUM/GLUCOCORTICOID REGULATED KINASE 3 
LMP005578  Abcc1  O35379  MM.196634   143756  99329_at  A_51_P152633  Not classified 
ATP‐BINDING CASSETTE, SUB‐FAMILY C 
(CFTR/MRP), MEMBER 1 
LMP005582  Sgpp2  Q810K3  MM.276248   148455  #N/A  A_51_P267169  Not classified  SPHINGOSINE‐1‐PHOSPHATE PHOSPHOTASE 2 
LMP005596  Carm1  Q9WVG6  MM.230844   23321  99169_at  A_51_P370390  Not classified  PROTEIN ARGININE N‐METHYLTRANSFERASE 4 
LMP005609  Ldlrap1  Q8C142  MM.27486   3956  #N/A  A_51_P404644  Not classified 
LOW DENSITY LIPOPROTEIN RECEPTOR ADAPTOR 
PROTEIN 1 
LMP005610  Slc37a2  Q8C144  MM.325350   15004  #N/A  A_51_P259773  Not classified 
SOLUTE CARRIER FAMILY 37 (GLYCEROL‐3‐
PHOSPHATE TRANSPORTER), MEMBER 2 
LMP005653  Cyp4a14  O35728  MM.250901   36636  101103_at  A_51_P238576  Not classified 
CYTOCHROME P450, FAMILY 4, SUBFAMILY A, 
POLYPEPTIDE 14 
LMP005660  Cyp2c44  Q8QZW4  MM.329866   16956  #N/A  A_51_P209782  Not classified 
CYTOCHROME P450, FAMILY 2, SUBFAMILY C, 
POLYPEPTIDE 44 
LMP005674  Ppapdc1  Q3UMZ3  MM.217337   11389  #N/A  A_51_P281593  Not classified 
PHOSPHATIDIC ACID PHOSPHATASE TYPE 2 
DOMAIN CONTAINING 1 
LMP005684  Ptdsr  Q9ERI5  MM.348004   146930  95486_at  #N/A  Not classified  PHOSPHATIDYLSERINE RECEPTOR 
LMP005685  Rdh14  Q9ERI6  MM.119343   37882  #N/A  A_51_P370380  Not classified  RIKEN CDNA 3110030G19 GENE 
LMP005686  Itgb1bp3  Q9D7C9  MM.81562   14672  #N/A  A_51_P369766  Not classified  INTEGRIN BETA 1 BINDING PROTEIN 3 
LMP005704  Paqr9  Q6TCG2  MM.151485   27619  #N/A  #N/A  Not classified 
PROGESTIN AND ADIPOQ RECEPTOR FAMILY 
MEMBER IX 
LMP005707  Paqr6  Q6TCG5  MM.267521   148920  #N/A  A_51_P475628  Not classified 
PROGESTIN AND ADIPOQ RECEPTOR FAMILY 
MEMBER VI 
LMP005709  Paqr3  Q6TCG8  MM.332505   37307  #N/A  A_51_P418749  Not classified 
PROGESTIN AND ADIPOQ RECEPTOR FAMILY 
MEMBER III 





1  Q8R2H9  MM.133075   27481  #N/A  A_51_P149257  Not classified  PHOSPHATASE, ORPHAN 1 
LMP005721  Ldlrad3  Q8CCS0  MM.35116   146405  #N/A  A_51_P283826  Not classified  EXPRESSED SEQUENCE AI194318 
LMP005729  Fpr1  P33766  MM.56951   32253  99387_at  A_51_P312485  Not classified  FORMYL PEPTIDE RECEPTOR 1 
LMP005741  Acacb  Q6JIZ0  MM.81793   37148  #N/A  A_51_P239236  Not classified  ACETYL‐COENZYME A CARBOXYLASE BETA 
LMP005747  Slc27a5  Q4LDG0  MM.10984   19519  92612_at  A_51_P289742  Not classified 
SOLUTE CARRIER FAMILY 27 (FATTY ACID 
TRANSPORTER), MEMBER 5 
LMP005757  Pld4  Q8BG07  MM.203915   16896  #N/A  A_51_P506148  Not classified  PHOSPHOLIPASE D FAMILY, MEMBER 4 
LMP005762  Pdhb  Q9D051  MM.301527   146539  94806_at  A_51_P321921  Not classified  PYRUVATE DEHYDROGENASE (LIPOAMIDE) BETA 
LMP005773  Gpx3  P46412  MM.200916   26447  101676_at  A_51_P292008  Not classified  GLUTATHIONE PEROXIDASE 3 
LMP005784  Syt2  P46097  MM.5102   4628  101183_at  A_51_P330749  Not classified  SYNAPTOTAGMIN II 
LMP005789  Acbd6  Q9D061  MM.288249   13166  104346_at  A_51_P208919  Not classified  RIKEN CDNA 0610010G04 GENE 
LMP005791  Decr1  Q9CQ62  MM.24395   16636  160711_at  A_51_P208555  Not classified 
2,4‐DIENOYL COA REDUCTASE 1, 
MITOCHONDRIAL 
LMP005820  Pi4k2b  Q9D072  MM.248647   149242  #N/A  A_51_P230987  Not classified  PHOSPHATIDYLINOSITOL 4‐KINASE TYPE 2 BETA 
LMP005837  Coq5  Q9CXI0  MM.290142   147239  #N/A  A_51_P125183  Not classified 
COENZYME Q5 HOMOLOG, 
METHYLTRANSFERASE (YEAST) 
LMP005842  Itpk1  Q8BYN3  MM.347546   37298  #N/A  #N/A  Not classified  INOSITOL 1,3,4‐TRIPHOSPHATE 5/6 KINASE 
LMP005848  B3gnt4  Q923H4  MM.373617   22165  #N/A  A_51_P225565  Not classified 
UDP‐GLCNAC:BETAGAL BETA‐1,3‐N‐
ACETYLGLUCOSAMINYLTRANSFERASE 4 
LMP005850  Pigv  Q7TPN3  MM.217004   144457  #N/A  A_51_P116427  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS V 
LMP005853 
Cyp21a2‐
p  Q60810  NA     16694  #N/A  #N/A  Not classified 
SIMILAR TO CYTOCHROME P450 XXI (STEROID 
21‐HYDROXYLASE) (21‐OHASE) (P4  
LMP005870  Pnpla7  Q3UFP1  MM.29046   17154  #N/A  A_51_P276235  Not classified  CDNA SEQUENCE BC027342 
LMP005876  Echdc3  Q9D7J9  MM.38342   37628  #N/A  A_51_P475378  Not classified 
ENOYL COENZYME A HYDRATASE DOMAIN 
CONTAINING 3 
LMP005904  Dhrs4  Q99LB2  MM.27427   5440  96678_at  A_51_P352374  Not classified 
DEHYDROGENASE/REDUCTASE (SDR FAMILY) 
MEMBER 4 
LMP005922  Fads3  Q3U3X6  MM.253875   144010  #N/A  A_51_P464029  Not classified  FATTY ACID DESATURASE 3 
LMP005931  Cryz  P47199  MM.347513   37139  98131_at  A_51_P435198  Not classified  CRYSTALLIN, ZETA 
LMP005936  Prkd2  Q8BZ03  MM.1881   27297  #N/A  A_51_P499441  Not classified  PROTEIN KINASE D2 
LMP005942  Pggt1b  Q8BUY9  MM.262096   39624  #N/A  A_51_P184477  Not classified 
PROTEIN GERANYLGERANYLTRANSFERASE TYPE I, 
BETA SUBUNIT 
LMP005945  Plb1  Q3TTY0  MM.160067   11097  #N/A 
A_51_P108031;A_
51_P238803  Not classified  PHOSPHOLIPASE B1 
LMP005986  Ubiad1  Q9DC60  MM.292503   9131  #N/A  A_51_P331661  Not classified 
UBIA PRENYLTRANSFERASE DOMAIN 
CONTAINING 1 
LMP005996  Fads1  Q3U494  MM.30158   3941  #N/A  A_51_P358112  Not classified  FATTY ACID DESATURASE 1 
LMP006002  Cd36  Q08857  MM.18628   20611 
161704_r_at,
93332_at  A_51_P375138  Not classified  CD36 ANTIGEN 
LMP006007  Plcd3  Q69Z55  MM.264743   9346  #N/A  A_51_P278163  Not classified  PHOSPHOLIPASE C, DELTA 3 
LMP006009  Myst3  Q8BZ21  MM.182776   3650  #N/A  A_51_P295277  Not classified 
MYST HISTONE ACETYLTRANSFERASE 
(MONOCYTIC LEUKEMIA) 3 
LMP006016  Chat  Q03059  MM.190503   27416  #N/A  A_51_P285243  Not classified  CHOLINE ACETYLTRANSFERASE 
LMP006027  Ippk  Q6P1C1  NA     8772  #N/A  A_51_P100361  Not classified 
INOSITOL 1,3,4,5,6‐PENTAKISPHOSPHATE 2‐
KINASE  
LMP006035  Esco1  Q69Z69  MM.210996   37260  #N/A  A_51_P270350  Not classified 
ESTABLISHMENT OF COHESION 1 HOMOLOG 1 
(S. CEREVISIAE) 





LMP006065  Pigl  Q5SX19  MM.374899   24617  #N/A  #N/A  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS L 
LMP006077  Gde1  Q9JL56  MM.273142   27496  #N/A  #N/A  Not classified  MEMBRANE INTERACTING PROTEIN OF RGS16 
LMP006085  Nudt4  Q8R2U6  MM.24397   144575  #N/A  A_51_P189418  Not classified 
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED 
MOIETY X)‐TYPE MOTIF 4 
LMP006098  Dhrs7  Q9CXR1  MM.289653   9210  95620_at  A_51_P312437  Not classified 
DEHYDROGENASE/REDUCTASE (SDR FAMILY) 
MEMBER 7 
LMP006108  Med4  Q9CQA5  MM.282888   7517  #N/A  A_51_P373369  Not classified 
MEDIATOR OF RNA POLYMERASE II 
TRANSCRIPTION, SUBUNIT 4 HOMOLOG (YEAST) 





LMP006123  Ogt  Q8CGY8  MM.259191   38165  94818_at  A_51_P261107  Not classified 
O‐LINKED N‐ACETYLGLUCOSAMINE (GLCNAC) 
TRANSFERASE (UDP‐N‐ACETYLGLUCOSA... 
LMP006131  Gpx7  Q99LJ6  MM.20164   26861  #N/A  A_51_P461364  Not classified  GLUTATHIONE PEROXIDASE 7 
LMP006146  Acaca  Q5SWU9  MM.31374   36995  #N/A 
A_51_P191939;A_
51_P439426  Not classified  ACETYL‐COENZYME A CARBOXYLASE ALPHA 
LMP006151  Plekha5  Q6ZPK1  MM.247670   14771  #N/A  A_51_P500862  Not classified  EST AI428202 
LMP006152  Bckdha  P50136  MM.25848   37474  96035_at  A_51_P466148  Not classified 
BRANCHED CHAIN KETOACID DEHYDROGENASE 
E1, ALPHA POLYPEPTIDE 
LMP006153  Enpp7  Q3TIW9  NA     146231  #N/A  #N/A  Not classified 
ECTONUCLEOTIDE 
PYROPHOSPHATASE/PHOSPHODIESTERASE 7  
LMP006163  Acot9  Q9R0X4  MM.268710   136320  #N/A  A_51_P280165  Not classified  ACYL‐COA THIOESTERASE 9 
LMP006175  Chst12  Q99LL3  MM.28934   8923  #N/A  A_51_P464021  Not classified  CARBOHYDRATE SULFOTRANSFERASE 12 
LMP006194  Cnr2  P47936  MM.297251   16881  102674_at  A_51_P208511  Not classified  CANNABINOID RECEPTOR 2 (MACROPHAGE) 
LMP006197  Pnpla1  Q3V1D5  MM.328925   148364  #N/A  #N/A  Not classified 
SIMILAR TO PATATIN‐LIKE PHOSPHOLIPASE 
DOMAIN CONTAINING 1 
LMP006200  Phyhip  Q8K0S0  MM.192598   37122  #N/A  A_51_P368210  Not classified 
PHYTANOYL‐COA HYDROXYLASE INTERACTING 
PROTEIN 





G03Rik  Q3U4B4  MM.75602   16174  #N/A  #N/A  Not classified  RIKEN CDNA 2210418G03 GENE 
LMP006250  Gpx2  Q9JHC0  MM.371561   27037  99810_at  A_51_P486810  Not classified  GLUTATHIONE PEROXIDASE 2 




LMP006257  Pcyox1  Q9CQF9  MM.30849   15472  #N/A  A_51_P508029  Not classified  PRENYLCYSTEINE OXIDASE 1 
LMP006266  Pld5  Q3UNN8  MM.338001   36834  #N/A  #N/A  Not classified  PHOSPHOLIPASE D FAMILY, MEMBER 5 
LMP006267  Hoxa1  P09022  MM.197   14559  95297_at  A_51_P351975  Not classified  HOMEO BOX A1 
LMP006283  St3gal6  Q8VIB3  MM.212742   3529  #N/A  A_51_P281333  Not classified 
ST3 BETA‐GALACTOSIDE ALPHA‐2,3‐
SIALYLTRANSFERASE 6 
LMP006292  Ugcgl1  Q6P5E4  MM.261022   9195  #N/A 
A_51_P148838;A_
51_P236775  Not classified  RIKEN CDNA 0910001L17 GENE 
LMP006298  Retsat  Q64FW2  MM.305108   26782  #N/A  A_51_P319070  Not classified  RIKEN CDNA 0610039N19 GENE 
LMP006300  Fa2h  Q5RL53  MM.41083   36913  #N/A  A_51_P477692  Not classified  HYPOTHETICAL PROTEIN LOC234737 
LMP006309  Pld3  O35405  MM.6483   37501  100607_at  A_51_P361478  Not classified  PHOSPHOLIPASE D FAMILY, MEMBER 3 
LMP006310  Slc22a5  Q9Z0E8  MM.42253   5874  98322_at  A_51_P165060  Not classified 
SOLUTE CARRIER FAMILY 22 (ORGANIC CATION 
TRANSPORTER), MEMBER 5 
LMP006313  Cyp27b1  O35084  MM.6216   3409  99836_at  A_51_P287221  Not classified 
CYTOCHROME P450, FAMILY 27, SUBFAMILY B, 
POLYPEPTIDE 1 
LMP006314  Asah2  Q9JHE3  MM.104900   16288  #N/A  A_51_P305708  Not classified  N‐ACYLSPHINGOSINE AMIDOHYDROLASE 2 
LMP006329  Ch25h  Q9Z0F5  MM.30824   145585  104509_at  A_51_P112966  Not classified  CHOLESTEROL 25‐HYDROXYLASE 
LMP006330  Mut  P16332  MM.259884   144428  99613_at  A_51_P193935  Not classified  METHYLMALONYL‐COENZYME A MUTASE 
LMP006338  Aytl2  Q3TFD2  MM.284649   3869  #N/A  A_51_P405089  Not classified  RIKEN CDNA 2900035H07 GENE 
LMP006340  Pitpnm2  Q6ZPQ6  MM.44261   11278  #N/A  A_51_P112529  Not classified 
PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, 
MEMBRANE‐ASSOCIATED 2 
LMP006357  Wisp2  Q9Z0G4  MM.13828   148069  94704_at  A_51_P390804  Not classified 
WNT1 INDUCIBLE SIGNALING PATHWAY 
PROTEIN 2 
LMP006364  Pigp  Q9JHG1  MM.328717   32992  #N/A  A_51_P182144  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS P 
LMP006370  Smpd4  Q6ZPR5  MM.34659   148099  #N/A  A_51_P159813  Not classified  RIKEN CDNA 4122402O22 GENE 
LMP006373  Rdh7  O88451  MM.6696   23037  100634_at  A_51_P122170  Not classified  RETINOL DEHYDROGENASE 7 
LMP006375  Inpp5f  Q6ZQ16  MM.58882   41244  #N/A  A_51_P176054  Not classified  INOSITOL POLYPHOSPHATE‐5‐PHOSPHATASE F 
LMP006407  Psph  Q99LS3  MM.271784   30317  92589_at  A_51_P430263  Not classified  PHOSPHOSERINE PHOSPHATASE 
LMP006411 
4933403
G17Rik  Q9D4C4  MM.158548   149013  #N/A  A_51_P174133  Not classified  RIKEN CDNA 4933403G17 GENE 
LMP006418  Mettl6  Q8BVH9  MM.291731   148873  #N/A  A_51_P288961  Not classified  METHYLTRANSFERASE LIKE 6 
LMP006424  Pak1ip1  Q9DCE5  MM.24789   6977  #N/A  A_51_P200151  Not classified  PAK1 INTERACTING PROTEIN 1 
LMP006425  Hexdc  Q3U4H6  MM.386870   13666  #N/A  #N/A  Not classified 
HEXOSAMINIDASE (GLYCOSYL HYDROLASE 
FAMILY 20, CATALYTIC DOMAIN) CONTAI... 
LMP006446  Ivd  Q9JHI5  MM.6635   14962  #N/A  A_51_P425674  Not classified  ISOVALERYL COENZYME A DEHYDROGENASE 
LMP006461 
Ppapdc1
a  Q0VBU9        #N/A  #N/A  Not classified    
LMP006469  Dgkd  Q6A0B7  MM.277217   9628  #N/A  #N/A  Not classified  DIACYLGLYCEROL KINASE, DELTA 
LMP006481  Smpdl3a  P70158  MM.2379   26391  #N/A  A_51_P153053  Not classified 
SPHINGOMYELIN PHOSPHODIESTERASE, ACID‐
LIKE 3A 





L16Rik  Q4FZF0  MM.313743   37398  #N/A  #N/A  Not classified  RIKEN CDNA 4833405L16 GENE 
LMP006508  Gba2  Q69ZF3  MM.229444   9138  92784_at  A_51_P261359  Not classified  GLUCOSIDASE BETA 2 
LMP006516  Ppapdc2  Q9D4F2  NA     14242  #N/A  A_51_P433026  Not classified 
PHOSPHATIDIC ACID PHOSPHATASE TYPE 2 
DOMAIN CONTAINING 2  
LMP006518  Rabggta  Q9JHK4  MM.87216   28273  #N/A  A_51_P481832  Not classified 
RAB GERANYLGERANYL TRANSFERASE, A 
SUBUNIT 
LMP006519  Pigx  Q99LV7  MM.37613   19984  #N/A  A_51_P399217  Not classified  PHOSPHATIDYLINOSITOL GLYCAN, CLASS X 
LMP006522  Nsd1  O88491  MM.386965   3641  #N/A  A_51_P477809  Not classified 
NUCLEAR RECEPTOR‐BINDING SET‐DOMAIN 
PROTEIN 1 
LMP006525  Fut9  O88819  MM.39101   148200  #N/A 
A_51_P250733;A_
51_P417758  Not classified  FUCOSYLTRANSFERASE 9 
LMP006536  Rftn1  Q6A0D4  MM.41854   5341  #N/A  A_51_P408800  Not classified  RIKEN CDNA 2310015N21 GENE 
LMP006537  A3galt2  Q3V1N9  MM.300900   19569  #N/A  #N/A  Not classified 
ALPHA 1,3‐GALACTOSYLTRANSFERASE 2 
(ISOGLOBOTRIAOSYLCERAMIDE SYNTHASE) 
LMP006548  Pdss1  Q33DR2  MM.249752   148145  #N/A  A_51_P127841  Not classified 
PRENYL (SOLANESYL) DIPHOSPHATE SYNTHASE, 
SUBUNIT 1 
                 
                 
 
